

# AUTHOR INDEX\*

## Volume 51

### A

Aalders, J. G., 116  
 Aapro, M., 294  
 Abbott, B. J., 2837  
 Abdiu, A., 3585  
 Abe, K., 2223  
 Abe, K., 4631  
 Abe, K., 6656  
 Abe, O., 1504, 2199, 6656  
 Abe, T., 3327  
 Abidi, T. F., 813  
 Abraham, B. A., 4107  
 Abrahams, C., 5608  
 Abrams, P. G., 676  
 Acevedo, J., 3153  
 Achten, S., 3702  
 Acker, H., 1039  
 Ackerman, J. J. H., 3108  
 Ackermann, R., 1811  
 Adachi, H., 5951, 5956  
 Adami, H.-O., 3696  
 Adams, J., 2531  
 Adamson, P. C., 6079  
 Adenis, L., 5384  
 Aderka, D., 5602  
 Adi, S., 2803  
 Adlakha, H., 3411  
 Afshari, C. A., 6010  
 Agarwal, C., 3982  
 Agarwal, M. L., 5993  
 Agarwal, S. C., 5198  
 Aggarwal, B. B., 4266  
 Aherne, G. W., 2346  
 Ahlem, C. N., 6650  
 Ahluwalia, G. S., 3733  
 Ahmad, M., 857  
 Ahmed, K. J., 1866  
 Ahn, D. K., 1014, 1370  
 Aisenberg, A. C., 6103  
 Aitokallio-Tallberg, A. M., 4146  
 Akao, Y., 1574, 6708  
 Aki, M., 6677  
 Akinaga, S., 4888  
 Akita, H. D., 6346  
 Akita, R. W., 2593  
 Akiyama, F., 5794  
 Akiyama, T., 990  
 Akslen, L. A., 1234  
 Alaoui-Jamali, M. A., 3946  
 Alauddin, M., 2694  
 Albeck, M., 1499, 5614  
 Alberti, D., 1099, 1105, 1651  
 Albertini, A., 4470  
 Albertini, R. J., 6001, 6603  
 Albini, A., 2670  
 Albino, A. P., 4815, 5881  
 Albright, K. D., 3677  
 Aldaz, C. M., 1045  
 Alewood, P. F., 5826  
 Alexander, J., 4199

Alfthan, H., 222  
 Alfthan, O., 222  
 Alini, M., 1443  
 Allavena, A., 2273  
 Allegra, C. J., 6668  
 Allen, L., 5461  
 Allen-Hoffmann, B. L., 5967  
 Alley, M. C., 1247  
 Alsina, M. M., 2438, 4430  
 Alterman, A. L., 2444  
 Altermatt, H.-J., 2092  
 Altschuler, E., 4729, 6704  
 Amano, T., 1472  
 Amemiya, K., 5322, 5951, 5956  
 Amin, S. G., 1846  
 Amlot, P., 4052  
 Ammigan, N., 3018  
 Amos, C. I., 1793  
 Amoss, M. S., Jr., 2025  
 Amundsen, A. R., 1866  
 Anderson, K., 4757  
 Anderson, L. D., 6650  
 Anderson, M. W., 1148  
 Anderson, P., 6084  
 Anderson, P. M., 2127  
 Anderson, R. D., 3930  
 Anderson, R. L., 2636  
 Anderson, T. D., 1318  
 Anderson, W. K., 4581  
 Andersson, C., 880  
 Ando, N., 1504  
 Andoh, T., 4903, 4909  
 Andresen, S., 857  
 Andrew, S. M., 5716  
 Andrews, A. F., 549  
 Andrews, P. A., 3677, 5903  
 Andrews, P. E., 3748  
 Andrusis, I. L., 985  
 Angeles, S. M., 3420  
 Anglard, P., 1071, 2490  
 Anichini, A., 2239  
 Annab, L. A., 6010  
 Antal, J., 857  
 Antman, K. H., 5060s  
 Antoniadis, H. N., 1345  
 Antoniono, R. J., 4455  
 Antunez, A. R., 5993  
 Anzai, K., 5392  
 Anzai, Y., 5476  
 Aoki, T., 318  
 Aoki, Y., 1934  
 Aonuma, M., 4187  
 Appelbaum, F. R., 5921  
 Appella, E., 4090  
 Applegate, L. A., 974  
 Applegate, L. A., 6539  
 Arai, H., 110  
 Araki, A., 3212  
 Arao, T., 1726  
 Arase, Y., 2842  
 Arce, C., 3391  
 Archibald, B.-L., 1904  
 Argon, Y., 5361  
 Arita, M., 2319  
 Ariyoshi, Y., 2416  
 Arkin, H., 55  
 Arlinghaus, R. B., 3048  
 Arlow, F. L., 3416  
 Armour, E. P., 3088  
 Arndt, C. A., 6079  
 Arthur, K., 4476  
 Arzooanian, R. Z., 1099, 1105, 1651  
 Asa, S. L., 6351  
 Asamoto, M., 2548  
 Asano, K., 3710  
 Asano, T., 4450  
 Asanuma, F., 4631  
 Ascari, E., 536  
 Ashar, B., 4360  
 Ashendel, C. L., 4624  
 Ashizawa, T., 110  
 Ashmun, R. A., 6286  
 Ashton, W. S., 1564  
 Asina, S., 2706  
 Asou, N., 6084  
 Assaraf, Y. G., 2949  
 Asselin, B. L., 6568  
 Aston, D. A., 1370  
 Atassi, G., 2312  
 Athas, W. F., 5786  
 Atlante, G., 3001  
 Atlas, E., 612  
 Atzpodien, J., 6312  
 Au, J. L.-S., 3849, 4347, 5144  
 Aubin, F., 5893  
 Aubry, J., 1537  
 Auger, M., 718  
 August, E. M., 1586  
 Augustin-Voss, H. G., 394  
 Ault, J. G., 4942  
 Aurbach, G. D., 1154  
 Austin, D. F., 3044  
 Austin, E. B., 5425  
 Austin, H., 568  
 Austin, J. M., Jr., 568  
 Avanzi, G. C., 1741  
 Avis, I., 1798  
 Awwad, B. H., 1959  
 Azuma, I., 22  
 Azuma, M., 110

### B

Baba, H., 2994, 3559, 3568  
 Baba, I., 1286  
 Baba, M., 785, 2863, 3493, 6150  
 Bachor, R., 4410  
 Backmann, R., 4712  
 Badalament, R. A., 3849, 4347, 5144  
 Badger, C. C., 5921  
 Baer, A. R., 2069  
 Bagges, R. B., 3311  
 Baguley, B. C., 77  
 Bailey, G. S., 2362  
 Bailey, H., 1099, 1105  
 Bailey, J. R., 4371  
 Baillie, R., 4685  
 Bak, M., 4102  
 Baker, M. A., 1257, 4955  
 Baker, T. S., 5461  
 Bakhshi, R., 1817  
 Bakj, W., 2098  
 Baldwin, B., 3925  
 Baldwin, D. M., 492  
 Baldwin, J. K., 5642  
 Baldwin, N. J., 1384  
 Baldwin, R. W., 1990, 5425  
 Bale, A. E., 1154  
 Balis, F. M., 5467, 6079  
 Balkwill, F. R., 4020, 6643  
 Ball, E. D., 2451  
 Ballejo, G., 5476  
 Ballinari, D., 199  
 Balmain, A., 4097  
 Ballos, J., 3204  
 Baltzer, L., 3096  
 Bamberg, M., 4762  
 Bamias, A., 724, 3251  
 Banáth, J. P., 4671  
 Band, V., 3602  
 Bando, Y., 3153  
 Banerjee, A., 4481  
 Banerjee, S., 1092  
 Banez, M., 2002, 5687  
 Bannasch, P., 1952  
 Bano, M., 3590  
 Barber, D. C., 1836  
 Barber, S. R., 4423  
 Barbey, S., 5712  
 Barcos, M. P., 2985  
 Bardeel, A., 1020  
 Barkai, I. S., 5614  
 Barker, E., 144  
 Barletta, C., 3821  
 Barna, B. P., 836, 857  
 Barnd, D. L., 2908  
 Barnett, T., 1851  
 Barone, E., 301  
 Baroni, C. D., 2456  
 Barr, L. F., 5514  
 Barrett, J. C., 6010  
 Barrett, J. S., 3434  
 Barrow, B. J., 1564  
 Barth, R. F., 2373  
 Bartholomew, M., 4149  
 Bartolazzi, A., 3001  
 Barton, R. L., 5774  
 Bartram, H.-P., 4238  
 Baserga, R., 1465, 5997

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Basse, P. H., 4931  
 Bassin, R. H., 324  
 Bast, R. C., Jr., 468, 2908, 2979, 5361  
 Bastid, C., 5679  
 Basu, A., 893, 2511, 5903  
 Basu, A., 5626  
 Bataille, R., 3224  
 Batist, G., 1434  
 Battifora, H., 3802  
 Bauer, K. D., 2403  
 Bauer, L., 836, 857, 4199  
 Baum, E. S., 2885  
 Baumal, R., 1619  
 Bautch, V. L., 4917  
 Baxter, J., 3930  
 Baxter, L. T., 3119  
 Baylin, S. B., 5514  
 Bazer, F. W., 5304  
 Beardsley, G. P., 2291  
 Beattie, C. W., 2025, 3768  
 Beatty, B. G., 2335  
 Beatty, J. D., 2335, 3802, 5704  
 Beauchamp, R. D., 5253  
 Beaumier, P. L., 676  
 Bechtel, D., 907  
 Beck, S. A., 6089  
 Beck, W. T., 4213, 4665  
 Beckitt, M. A., 521, 6393  
 Beckett, M. L., 1326  
 Bedford, J. S., 2740  
 Beex, L. V. A. M., 4544  
 Begović, M., 1521, 5153  
 Behn-Krappa, A., 3702  
 Behrens, J., 6328  
 Bei, R., 5378  
 Bélanger, P. M., 3946  
 Belizario, J. E., 2379  
 Bell, R., 5565  
 Bell, S. C., 3030  
 Bellamy, W. T., 995  
 Bellocq, J.-P., 624  
 Bellon, S. F., 1866  
 Bellot, F., 2438  
 Beltran, L., 1398  
 Belury, M. A., 907  
 Bem, W. T., 6558  
 Benabid, A. L., 2566  
 Bénard, J., 33  
 Benasutti, M., 2268  
 Bendt, K. M., 2908  
 Benedict, W. F., 2735, 4481, 5736  
 Benenati, S. V., 4395  
 Benítez, J., 2098  
 Benjamin, H., 2940  
 Benjamin, S. A., 2740  
 Benjamin, W. R., 1823  
 Bennett, L. L., Jr., 2386  
 Bennett, R. C., 3059  
 Bennett, W. P., 4090, 5370  
 Bennicelli, J. L., 3334, 4853  
 Benraad, T. J., 4544  
 Bensaadi, N., 3633  
 Benson, R. W., 4371  
 Benvenuto, J. A., 935  
 Beran, M., 935  
 Berchuck, A., 2979  
 Berd, D., 2731, 4937  
 Berdel, W. E., 43, 3862  
 Berens, M. E., 1713  
 Berg, R. H., 6286  
 Berg, S. L., 5467  
 Bergamaschi, G., 536  
 Berger, U., 239  
 Bergeron, R. J., 3715  
 Bergholz, M., 3243  
 Berhane, K., 94  
 Berko-Flint, Y., 612  
 Berline, J., 1014  
 Berlion, M., 2312  
 Bermudez, E., 4059  
 Bernasconi, S., 2239  
 Berns, A., 958  
 Bernstein, I. D., 5921  
 Berrino, F., 2572  
 Berry, N., 1990  
 Bertino, J. R., 789  
 Bertone, A., 1917  
 Bertrand, R., 6280  
 Beshah, K., 3289  
 Betsholtz, C., 1553  
 Beyaert, R., 2469  
 Bhandal, A. K., 3451  
 Bhargava, M., 5315  
 Bhide, S. V., 3018  
 Bi, N., 372  
 Bianchi, A., 1045, 6615  
 Bianchini, F., 3721  
 Bianco, A. R., 1294, 4898  
 Biedler, J. L., 1596  
 Biesma, B., 73, 116  
 Bigner, D. D., 3339, 3906, 4164, 4643, 4721  
 Bigner, S. H., 4721  
 Bigos, D., 1561  
 Bigotti, A., 3001  
 Bilhartz, D. L., 3748  
 Billings, P. C., 5539  
 Billingsley, M., 4149  
 Biocca, M. E., 4603  
 Biondi, A., 6358  
 Biondi, D. A., 1823  
 Birch, M., 6660  
 Birchmeier, W., 6328  
 Bird, R. P., 5270  
 Birrell, G. W., 5826  
 Birt, D. F., 1851  
 Bissery, M.-C., 4845  
 Bistrain, A., 4994  
 Bizzari, J.-P., 2312  
 Bjerkvig, R., 1713, 4643  
 Blakely, R. L., 6568  
 Blanz, J., 3427  
 Blasi, F., 3690  
 Blättler, W. A., 6236  
 Blazar, B. R., 1883, 1891  
 Bleehen, N. M., 5205  
 Bloom, S. R., 5205  
 Bloomer, W. D., 6695  
 Blot, W. J., 3044, 3068  
 Blottiére, H. M., 1537  
 Blount, P. L., 5482, 5766  
 Blum, M. R., 3906  
 Blumberg, P. M., 5355  
 Blumenenson, L. E., 4701  
 Boccon-Gibod, L., 33  
 Bock, S. N., 2649  
 Bodell, W. J., 1568  
 Bodmer, M., 181  
 Boesch, D., 4226  
 Bogdanowski, M., 310  
 Bogdanowicz, J. F. A. T., 3445  
 Bogden, A., 1798  
 Bohoslawec, O., 1318  
 Bohr, V. A., 775, 6550  
 Boice, J. D., Jr., 2885  
 Boileau, M. A., 1373  
 Boiron, J.-M., 3224  
 Bok, R. A., 672  
 Boland, C. R., 657  
 Bolhuis, R. L. H., 2324  
 Bolling, T. J., 1876  
 Bollinger, P., 4226  
 Bols, B. L. M. C., 1177  
 Bolton, M. G., 2410  
 Bolz, I., 3243  
 Boman, B. M., 1452  
 Bondada, V., 1973  
 Bongcam-Rudloff, E., 1553  
 Bonner, R. B., 2762  
 Bookland, E. A., 3323  
 Boone, C. W., 3069  
 Boonstra, H., 5915  
 Boonstra, J., 4028  
 Boothman, D. A., 5587  
 Borden, E. C., 1651, 4155  
 Borst, P., 2628  
 Bosia, A., 1741  
 Bossola, P. C., 2456  
 Botta, E., 3965  
 Boucheix, C., 3224  
 Boucher, Y., 6691, 6695  
 Bouffard, P., 5384  
 Boukamp, P., 4402  
 Bourhis, J., 33  
 Bowden, P. E., 3793  
 Bowler, J., 3867  
 Bowlin, T. L., 62  
 Bowman, D., 365  
 Boyd, D., 3690  
 Boyd, J., 6010  
 Boyd, M. R., 1247, 2515, 2837  
 Boyer, C. M., 2908, 5361  
 Boyer, J. C., 2960  
 Boyett, J., 4199  
 Boyle, L. A., 3164  
 Boynton, R. F., 5766  
 Braakhuis, B. J. M., 211  
 Brachman, D. G., 6393  
 Brady, J. F., 1509  
 Brambilla, C., 2566  
 Brambilla, E., 2566  
 Brambilla, G., 2273  
 Branda, R. F., 6603  
 Brandi, M. L., 1154  
 Brandt, D., 294  
 Brandt, M. E., 3663  
 Brantom, P., 6415, 6452, 6470  
 Brasitus, T. A., 4305, 5608  
 Brattain, M. G., 1452, 5275  
 Brauch, H., 1071  
 Braunschweiger, P. G., 5454  
 Breillout, F., 2073  
 Breit, P., 2478  
 Breikreutz, D., 4402  
 Brem, H., 672  
 Brenes, M. M., 4785  
 Brennan, J., 1708  
 Brennan, M. F., 863  
 Brent, T. P., 3339  
 Breuer, M., 958  
 Briggs, S. L., 2965, 5471  
 Brill, A. B., 255  
 Brinton, L. A., 4785  
 Brizzi, M. F., 1741  
 Brockenbrough, J. S., 130  
 Brockhausen, I., 1257, 3136  
 Brockman, R. W., 2386  
 Broder, S., 4743  
 Brodeur, G. M., 1596, 4721, 5435  
 Brodie, A. M. H., 3663  
 Brodt, P., 3578  
 Broggin, M., 199  
 Bromberg, W. D., 2780  
 Bronstein, S. M., 5188  
 Brooks, G., 3281  
 Brother, M. B., 1596  
 Brouckaert, P., 2366  
 Broussoud, A., 5370  
 Brown, E. J., 3726  
 Brown, J. M., 3768  
 Brown, J. M., 4463  
 Brown, M., 5579  
 Brown, R., 2242  
 Brown, R. R., 1651  
 Brown, T. D., 6268  
 Brown, T. R., 841  
 Brojde, S., 3482  
 Brubaker, P. L., 1196  
 Bruchelt, G., 6066  
 Bruggink, J., 1105  
 Bruskin, A. M., 5361  
 Bryce, W., 4149  
 Brynes, R. K., 2015  
 Buble, G., 1086  
 Bucana, C. D., 3062, 3741  
 Buchmann, A., 4097  
 Buchsbaum, D. J., 1883, 1891  
 Buchsbaum, R., 6695  
 Buckley, J. D., 3617  
 Budd, G. T., 836, 4199  
 Buddenbaum, W. E., 573  
 Budillon, A., 1294  
 Budnick, R. M., 595  
 Bukowski, R. M., 836, 857, 4199  
 Bull, J. M. C., 2994, 3559, 3568  
 Bull, R., 6596  
 Bumol, T. F., 2286  
 Bunn, P. A., 688, 3274  
 Bunni, M., 789  
 Buras, R. R., 2335  
 Buresh, C. M., 2302  
 Burghardt, R. C., 696  
 Burgua, W. D., 676  
 Burill, C., 487  
 Burke, P. J., 3534  
 Burkhart, B. A., 6010  
 Burrows, F. J., 4768

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Bursch, W., 2478  
 Burstyn, J. N., 1866  
 Busch, H., 1973  
 Busch, R., 43  
 Busch, R. K., 1973  
 Buser, K., 2092  
 Bussemakers, M. J. G., 606  
 Butel, J. S., 49  
 Butler, M. A., 4371  
 Buzard, G. S., 5308  
 Byars, N., 6045  
 Byers, V. S., 1990  
 Byrd, J. C., 1026  
 Bystry, J.-C., 3643, 5003  
 Byus, C. V., 2932
- C**
- Caamano, J., 6615  
 Caballes, L., 886  
 Cabrera, T., 2463  
 Caderni, G., 3721  
 Cagle, P. T., 2735  
 Cai, R.-Z., 5980  
 Cairoli, V., 753  
 Calabretta, B., 2897, 3821, 4505  
 Calabrò, A. M., 652  
 Calderone, C., 400  
 Callahan, A. P., 4594  
 Callahan, R., 181, 2490, 6194  
 Callé, A., 405  
 Calvert, A. H., 5579  
 Cameron, G. S., 850, 5642  
 Cameron, I. L., 6388  
 Cameron, R. B., 2649  
 Campbell, I. G., 5329  
 Campbell, T. C., 3826  
 Campen, C. A., 1823  
 Campo, E., 4436  
 Campos, R. V., 1196, 6351  
 Canaani, E., 6712  
 Canaani, O., 6712  
 Candelaresi, G., 1917  
 Candrian, U., 1148  
 Cannizzaro, L. A., 3818, 6712  
 Cantaloube, J.-F., 3224  
 Canuto, R. A., 4603  
 Cao, J. D., 1515  
 Capizzi, R. L., 2559  
 Caporaso, N. E., 5219  
 Cappa, A. P. M., 6194  
 Cara, A., 1733  
 Caraglia, M., 1294  
 Caramia, F., 5378  
 Carayannopoulos, L., 6125  
 Carbone, D. P., 6142  
 Cardesa, A., 4436  
 Cardona, C., 5205  
 Cardona, S., 964  
 Carey, T. E., 2395  
 Carinhas, J., 3669  
 Carlhom, E., 1684  
 Carlsson, J., 1039  
 Carmi, P., 2173  
 Carmona, R., 422  
 Carnes, B. A., 4125  
 Carney, D. N., 3296  
 Carralero, D., 387  
 Carrasquillo, J. A., 688  
 Carroll, P. R., 3807  
 Carroll, S. F., 1990, 4219  
 Carson, D. A., 3193  
 Carson, D. D., 1910  
 Carson, L., 4012  
 Carter, B. S., 4716  
 Carter, C. A., 499  
 Casalaro, A., 1733, 4342  
 Casazza, A. M., 5275  
 Cashmore, A. R., 2291  
 Casley, W. L., 1668  
 Caspers, J. I., 3990  
 Casson, A. G., 4495  
 Castonguay, A., 2009, 3946  
 Castro, V. M., 94  
 Castronovo, V., 5672  
 Catapano, C. V., 1829  
 Cathignol, D., 3024  
 Caty, A., 5384  
 Caulfield, M. J., 2521  
 Cavalleri, A., 2572  
 Cavender, A. C., 1744  
 Cavenee, W. K., 1684, 2164, 5100, 5435  
 Cavener, D. R., 3405  
 Cazzola, M., 536  
 Ceriani, R. L., 4994  
 Cerny, T., 2092  
 Cerutti, P., 5370  
 Chabner, B. A., 6668  
 Chagnovich, D., 6338  
 Chambon, P., 624, 3972  
 Chamness, G. C., 105  
 Chan, D., 2151  
 Chan, T., 4575  
 Chanda, E. R., 3345  
 Chander, S. K., 5851  
 Chandler, K. B., 1829  
 Chandrasekar, B., 6243  
 Chaney, S. G., 969  
 Chang, A.-S., 5621  
 Chang, C., 1898  
 Chang, C.-H., 2386  
 Chang, C.-H., 4594  
 Chang, C. N., 465  
 Chang, J.-Y., 1755  
 Chang, P.-L., 2144  
 Chang, Z.-F., 4724  
 Chao, C.-C., 3938  
 Chao, C. C.-K., 601  
 Chao, L. A., 2593  
 Chapelon, J. Y., 3024  
 Chapin, C., 6286  
 Chaplin, D. J., 2251  
 Chappel, C. I., 1766  
 Char, D. H., 1370  
 Charak, B. S., 2015, 2694  
 Chatal, J.-F., 1537  
 Chattopadhyay, P., 3183, 6045  
 Chaudhuri, A., 2552  
 Chauffert, B., 3024  
 Chauhan, S. S., 1478  
 Chauvin, C., 2566  
 Chen, A., 1045  
 Chen, A. Y., 6039  
 Chen, B. M., 4001  
 Chen, C.-J., 1720, 5621  
 Chen, J., 3826  
 Chen, P.-L., 6381  
 Chen, P. P., 3193  
 Chen, Q., 1544  
 Chen, R.-H., 2587  
 Chen, S., 4131  
 Chen, S.-C., 1898  
 Chen, S.-C., 2015  
 Chen, Y.-F., 657  
 Chen, Z. J., 4790  
 Cheng, A.-L., 6629  
 Cheng, P.-W., 601  
 Cheng, R., 2889  
 Cheng, Y.-C., 1755  
 Chengde, L., 2307  
 Cherif, A., 6704  
 Chernajovsky, Y., 6292  
 Cheung, N.-K. V., 1117, 4865  
 Chiarodo, A., 2498  
 Chiba, I., 6194  
 Chidambaram, A., 6385  
 Chikkala, N. F., 6133  
 Chin, S. F., 6118  
 Chin, T., 2101  
 Ching, L.-M., 77  
 Chiolerio, F., 5960  
 Chisari, F. V., 1278  
 Cerny, T., 2092  
 Chizzonite, R., 415  
 Chmiel, J. S., 2403  
 Cho, J.-M., 4250  
 Cho, K. R., 4135  
 Cho, Y. L., 2848  
 Cho-Chung, Y. S., 6206, 6263  
 Choi, C.-I., 1846  
 Cholon, A., 4463  
 Chong, Y. C., 2047  
 Chou, C.-K., 1898  
 Chou, J. Y., 2058  
 Choux, R., 5679  
 Chovnick, A., 465  
 Chresta, C. M., 6592  
 Chrétien, P., 5245  
 Christensen, C., 2848  
 Chu, H., 3274  
 Chubb, S., 6110  
 Chun, H. G., 1803  
 Chung, F.-L., 137, 1846  
 Chung, L. W. K., 1910, 3753  
 Chung, R. T., 2280  
 Ciardiello, F., 1051  
 Cimino, G., 6712  
 Cimino, L., 5491  
 Cincotta, L., 1109, 2710  
 Cioce, V., 439  
 Citron, M., 4131  
 Civil, C. I., 4279  
 Clapper, M. L., 6059  
 Clark, B. A., 5826  
 Clark, G., 1391  
 Clark, G. M., 944  
 Clark, P., 4052  
 Clarke, R., 1638  
 Clarke-Pearson, D. L., 2979  
 Clarkson, B. D., 2084, 4828  
 Clausen, H., 2879  
 Clay, M. E., 5993  
 Cleary, K. R., 387, 4495, 5728  
 Clemente, F., 3633  
 Clerc, P., 3633  
 Clezardin, P., 2621  
 Clodfelter, K., 897  
 Cochran, C. G., 6066  
 Cochran, J. E., 5188  
 Codd, M. B., 3296  
 Coffey, D. S., 6514  
 Coffey, R. J., Jr., 5253  
 Cohen, H. J., 6568  
 Cohen, J. S., 1638  
 Cohen, M. B., 521  
 Cohen, M. B., 3807  
 Cohen, N. A., 4360  
 Cohen, S. M., 1766, 1778, 3471, 6493  
 Cohn, S. L., 6338  
 Colburn, N. H., 1158  
 Colcher, D., 181, 2889, 5461  
 Coldman, A. J., 1904  
 Cole, D., 3171  
 Cole, R. W., 4942  
 Cole, S. P. C., 3345  
 Coleman, C. N., 1086  
 Collins, A. R., 3965  
 Collins, J. A., 255  
 Collins, R., 4052  
 Collins, V. P., 1684, 2164, 4295  
 Collinson, A. R., 6236  
 Colnaghi, M. I., 6125  
 Colombo, M. P., 2897  
 Colston, K., 239  
 Colucci-D'Amato, G. L., 4234  
 Colvin, O. M., 2410  
 Comis, R. L., 2041, 3080, 3171, 6059  
 Comstock, G. W., 1366  
 Conaway, C. C., 3143  
 Concha, A., 2463, 4948  
 Coney, L. R., 6125  
 Conney, A. H., 813  
 Connor, J., 3062  
 Constantinidis, I., 3378  
 Conti, C. J., 737, 1045, 4859, 6615  
 Contreras, E., 6388  
 Cook, J. A., 1606, 4287  
 Cooksley, W. G. E., 4367  
 Coombes, R. C., 239, 1817, 4685, 5851  
 Coon, J. S., 897, 2720  
 Cooney, D. A., 3733  
 Cooper, D. L., 1586  
 Coppola, D. J., 6568  
 Corbelli, R. M., 5704  
 Cordeiro-Stone, M., 2960  
 Cordell, J., 123  
 Cordon-Cardo, C., 5405, 6372  
 Cornaglia-Ferraris, P., 4342  
 Cornelisse, C. J., 1020, 4028  
 Cornelius, A. S., 6025  
 Cornil, I., 4486  
 Corominas, M., 5129  
 Correa, P., 190  
 Corry, P. M., 3088  
 Corsi, C., 301

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Coscia, C. J., 6558  
 Costantini, V., 349, 354  
 Cote, R. J., 2706, 5410  
 Cotelingam, J. D., 688  
 Coulombe, B., 2138  
 Courtenay, A. E., 2353  
 Coverlizza, S., 1917  
 Cowan, J., 6338  
 Cowan, K. H., 587  
 Cowen, M. E., 3274  
 Cox, L. R., 4810  
 Cox, R. S., 2280  
 Coy, D., 1798  
 Craft, T. R., 5188  
 Cragoe, E. J., Jr., 3212  
 Craig, R. W., 4279, 6304  
 Crenshaw, M. C., 2593  
 Crist, S. A., 1373, 1378  
 Crist, W. M., 6712  
 Croce, C. M., 1553, 1574, 3818, 3821, 5015s, 6712  
 Croisy, A., 5770  
 Cropp, C. S., 2490  
 Cros, S., 2312  
 Crouch, G. D., 4882  
 Crowe, D. L., 3972  
 Crum, C. P., 4423  
 Crum, E. D., 875  
 Cuddy, M., 6529  
 Cueto, A., 4948  
 Cullen, K. J., 4978  
 Culouscou, J.-M., 2813  
 Cunha, G. R., 4924  
 Cunningham, D., 4052  
 Curti, S., 6163  
 Curtin, N. J., 2346  
 Cuttitta, F., 1798  
 Czajkowski, C. A., 3420  
 Czerwinski, M., 4636
- D**
- Daddona, P. E., 5716  
 D'Aleo, C. J., 5744  
 Dallmann, I., 6312  
 Dallner, G., 3774  
 Dalton, J. T., 4347, 5144  
 Dalton, W. S., 995  
 Damon, L. E., 4141  
 Danels, Y. J., 1452  
 Danforth, D. N., Jr., 1488  
 Danforth, L., 2021  
 d'Anglebermes, M., 1270  
 Danhauser-Riedl, S., 43  
 Daniel, E. M., 2063  
 Danks, J. A., 3059  
 Danks, M. K., 4213  
 Danø, K., 4067  
 Danyluk, J., 556  
 Darzynkiewicz, Z., 1165, 3682, 4828  
 Das Gupta, T. K., 3768  
 Dashwood, R. H., 2362  
 Daugherty, J. P., 2041  
 Dauvois, S., 2797, 3131  
 D'Avanzo, B., 629  
 Davidoff, A. M., 2605, 2979  
 Davidson, K., 6273  
 Davidson, N. E., 162  
 Davidson, N. O., 4305  
 Davies, R. J., 4492  
 Davies, S. M., 6592  
 Davis, B. B., 514  
 Davis, B. H., 1334  
 Davis, B. M., 4815  
 Davis, J., 5921  
 Davis, M. A., 3900  
 Davis, W. L., 5744  
 Dawley, R. M., 514  
 Dawson, M. I., 4804  
 Day, N. K., 5123  
 Dean, C. J., 123  
 Dean, P. J., 5482  
 DeAngelis, P., 336  
 Deans, R. J., 1418  
 de Belle, I., 528  
 De Benedetti, F., 1158  
 de Brauw, L. M., 1694  
 de Britton, R. C., 4785  
 de Bruijn, E. A., 1694, 4523  
 Debruyne, F. M. J., 606, 2329  
 Decker, R., 4131  
 DeClerck, Y. A., 2151  
 De Clue, J. E., 712  
 Deerenberg, I. M., 6138  
 de Francis, V., 4234  
 de Goeij, C. C. J., 1930, 3843  
 De Graff, W., 4287, 6622  
 de Groot, T. J., 1930  
 de Gruilj, F. R., 979  
 DeHerd, S. V., 2286  
 Deisseroth, K., 4729  
 Dejana, E., 2239  
 de Jong, F. H., 3445  
 de Jong, S., 5915  
 de la Calle-Martin, O., 4436  
 de la Chapelle, A., 4135  
 DeLap, R. J., 3171  
 de Launoit, Y., 2797, 4336, 5165  
 Del Bino, G., 1165  
 DeLeo, A., 5212  
 Della Porta, G., 400, 6299  
 Della Ragione, F., 3193  
 Delmas, P. D., 2621  
 Delmoro, C. M., 3814  
 Delobelle, A., 5384  
 Delsite, R., 3304  
 DeLuca, H. F., 2021  
 de Luise, M., 1750  
 Demant, E. J. F., 5093  
 Demetrio, M., 718  
 Demuth, L., 807  
 Deng-ao, J., 2307  
 Denko, N. C., 4463  
 Dennis, J. W., 718  
 Denton, G. W. L., 5425  
 De Pooter, C. M. J., 4523  
 Deppe, G., 2848  
 Dervan, P. A., 3296  
 Desai, D. H., 1846  
 Desantis, M., 6691  
 Deschauer, B., 3590  
 Detrisac, C. J., 481  
 DeVathaire, F., 33  
 Devilee, P., 1020  
 Devine, P. L., 5826  
 DeVito, J., 3171  
 de Vries, E. G. E., 73, 116, 5915  
 Dewhurst, M. W., 3906  
 Dezza, L., 536  
 Dianzani, M. U., 4603  
 Diaz-Rubio, M., 2098  
 Dicke, F. P., 3345  
 Dickson, R. B., 3590  
 Diehl, V., 3702  
 Dietrich, D. R., 3512  
 Dietrich, K. D., 556  
 Di Filippo, F., 652  
 DiGiovanni, J., 1045, 1398  
 Dilley, G. G., 3814  
 Di Lorenzo, D., 4470  
 Di Martino, D., 1733  
 Dimitroff, K., 1851  
 Dinarello, C. A., 2379, 2803  
 D'Incalci, M., 199  
 Dinney, C. P. N., 3741  
 DiPette, D. J., 3612  
 Di Pietro, S., 2572  
 DiRado, M., 6615  
 Discifani, C. M., 1339, 3762  
 Dive, C., 799  
 Dixit, V. M., 1645, 3648  
 Dizdaroglu, M., 5837  
 Djakiew, D., 3304  
 Dlugosz, A. A., 4677  
 Dobyns, K. A., 3733  
 Dodd, S. W., 6363  
 Dodge, R. K., 2979  
 Doerfler, W., 3702  
 Doherty, G. M., 2302  
 Doi, S., 3544  
 Dolan, M. E., 3367  
 Dolara, P., 3721  
 Dols, S., 3289  
 Dominguez, J. M., 2720  
 Don, A. L., 573  
 Donahoe, P. K., 2101  
 Donawho, C. K., 4176, 5893  
 Donehower, R. C., 5781  
 Dong, K.-W., 2577  
 Dong, Q., 1581  
 Dono, R., 1051  
 Donovan, M. A., 5315  
 Donowitz, M., 359  
 Dooley, K. L., 4371  
 Dooley, T. P., 3281  
 Doppler, W., 5821  
 Dorwin, S. A., 1876  
 Dotzlaw, H., 2051  
 Douillard, J.-Y., 1537  
 Downs, E. C., 1339  
 Dowsett, M., 5851  
 Drabkin, H., 3821  
 Dragani, T. A., 6299  
 Drago, J. R., 4347, 5144  
 Dray, S., 4516  
 Dreyfus, M. G., 6094  
 Drivsholm, L., 2879  
 Drobnjak, M., 6372  
 Drouin, J., 2621  
 Druck, T., 3821  
 Drucker, D. J., 1196, 6351  
 Dubeau, L., 4045  
 Dufau, E., 1039  
 Dufour, M., 2797, 5165  
 Dugan, M., 3643  
 Dukes, M., 3867  
 Dulhanty, A. M., 1860  
 Dumanski, J. P., 4295  
 Dumenco, L. L., 3391  
 Dunnill, M. S., 261  
 Dunsford, H. A., 1278, 1308  
 Duong, M., 1434  
 Duperray, C., 3224  
 Durrant, L. G., 5425  
 Dutlow, C., 2577  
 Duty, L., 1521  
 D'Uva, R., 536  
 Dykes, D. J., 1979, 2837
- E**
- Eader, L. A., 6596  
 Earley, K., 5198  
 Earp, H. S., 5238  
 Eary, J. F., 5921  
 East, C. J., 4701  
 East, N., 4020, 6643  
 Eastin, W. C., Jr., 1398  
 Eastman, A., 5903  
 Easton, D., 239  
 Ebade, P., 3938  
 Ebisuzaki, K., 1668  
 Ecker, J., 4090  
 Eckert, R. L., 3982  
 Eddy, J., 688  
 Edelstein, P. S., 4492  
 Eder, J. P., 510, 1086  
 Edgerton, S. M., 624  
 Edler, L., 3456  
 Edwards, C. L., 4257  
 Edwards, M. L., 62  
 Eggensperger, D., 2889  
 Egle, A., 5821  
 Egorin, M. J., 4360  
 Eguchi, F., 4639  
 Eguchi, K., 1472  
 Eguchi, M., 341  
 Ehlen, T., 4045  
 Ehninger, G., 3427  
 Ehsan, M. N., 5181  
 Eibl, R. H., 6202  
 Eick, S., 3243  
 Eidne, K., 2577  
 Eisenbach, L., 6372  
 Eisenhauer, E., 6318  
 Eisenkraft, B. L., 5881  
 Ekimoto, H., 3229  
 Ekland, K. I., 1846  
 Ekstrand, A. J., 2164  
 El-Bayoumy, K., 2826  
 Elg, S., 4012  
 Elion, G. B., 3906  
 Elkind, M. M., 573, 2740  
 Elliott, W. L., 4581  
 Ellis, N. K., 1984  
 Ellis, P. A., 5929  
 Ellison, D. J., 3267  
 Ellwein, L. B., 1766, 6493  
 Elmore, L. W., 5752

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Elsinga, P. H., 1930  
 Elson, C. E., 37  
 Elst, H. J., 4523  
 El-Tahtawy, A., 5806  
 Embleton, M. J., 1990  
 Embleton, M. J., 5433  
 Emerson, J. L., 1766  
 Emonard, H. P., 405  
 Endo, K., 990  
 Endo, K., 1613  
 Endo, T., 1701  
 Endou, Y., 1034  
 Engebraaten, O., 1713, 4643  
 Engelhardt, R., 2524  
 Engelman, R. W., 5123  
 Engelmann, H., 5602  
 English, H. F., 162, 1760  
 Engstrom, P. F., 3171  
 Enomoto, T., 5308  
 Ensminger, W. D., 870, 3900  
 Epelbaum, R., 780  
 Epenetos, A. A., 724, 3251  
 Epstein, A. L., 2694  
 Epszteyn, S., 2179  
 Erba, E., 199  
 Erber, E., 1143, 2478  
 Erickson, L. C., 1581, 1984  
 Ericson, A., 3696  
 Eriksen, B. L., 2403  
 Eriksen, J., 4067  
 Eriksson, L. C., 3774  
 Erkelens, C., 1694  
 Erlichman, C., 6318  
 Esa, A. H., 682  
 Esselink, M., 73  
 Esteban, J. M., 2335, 3802, 5704  
 Esterbauer, H., 1789  
 Estey, E., 935  
 Estival, A., 3633  
 Esumi, N., 1185, 4549  
 Ettenson, D., 1619  
 Ettinger, D. S., 5781  
 Eva, A., 4234  
 Evans, A. E., 1426  
 Evans, H. H., 5993  
 Evans, J. W., 2636, 4463  
 Evelhoch, J. L., 3108  
 Even, J., 612  
 Everitt, J., 2973, 4059, 4415  
 Everson, P., 1883, 1891  
 Ewart, K. L., 1515  
 Ewing, C. M., 4716
- F**
- Fabbro, D., 632  
 Fabian, C., 4238  
 Fabregat, V., 4436  
 Faderl, M., 3217  
 Fair, W. R., 1544, 5405  
 Fairchild, C. R., 1638  
 Fairchild, R. G., 4588  
 Falcioni, R., 1529  
 Falk, L., 1158  
 Fallavollita, L., 3578  
 Faltynek, C. R., 1158  
 Falvey, S., 4367  
 Fan, D., 4549  
 Farber, E., 2751  
 Farid, N. R., 2690  
 Faris, R. A., 1308  
 Fariselli, G., 2572  
 Farkas-Himsley, H., 1359  
 Farmer, E. R., 5786  
 Farquhar, D., 6704  
 Farr-Jones, M. A., 2430  
 Faulkner, L., 4111, 5139  
 Fausto, N., 2611, 4656, 5440  
 Favaudon, V., 3204  
 Fay, J., 4052  
 Fazio, F., 5960  
 Fegiz, G., 5378  
 Feingold, K. R., 2803  
 Feitelson, M. A., 4971  
 Felder, B., 3802  
 Felder, T. B., 935  
 Feldman, D., 1823  
 Feldman, G. M., 3011  
 Feldman, L. E., 1065  
 Feldman, M., 6372  
 Felix, S. B., 43  
 Fellinger, E. J., 336  
 Ferber, A., 5997  
 Ferguson, R. J., 549  
 Fernandes, B., 718  
 Fernandes, D. J., 1829  
 Fernández, M. J., 2098  
 Fernsten, P. D., 926, 3657  
 Ferrari, S., 5491  
 Ferrario, A., 6574  
 Ferraro, T., 813  
 Ferrell, R. E., 6385  
 Ferrone, S., 1726, 4790, 6045  
 Fey, M., 2092  
 Fiala, E. S., 2826, 3143  
 Ficari, F., 5378  
 Fichtinger-Schepman, A. M., 4523  
 Ficsor-Jacobs, R., 3331  
 Fidler, I. J., 245, 2029, 2531, 3062, 3741, 4549, 6292  
 Field, F. G., 3807  
 Fields, S. Z., 4955  
 Fierro, M. T., 964  
 Fiers, W., 2229, 2366, 2469, 2803  
 Filpula, D. R., 6363  
 Finch, M., 181  
 Finke, J., 4199  
 Finkelman, M. A. J., 6363  
 Finklestein, J. Z., 4871  
 Finlay, T. H., 1092  
 Finn, O. J., 2908  
 Firestone, G. L., 6031  
 Fischer, S. M., 850, 907, 5642  
 Fisher, D. R., 4821, 5921  
 Fisher, M., 1738  
 Fisher, S. J., 3434  
 FitzGerald, D. J., 174, 2808, 2831, 3011  
 Fitzgerald, S. D., 105  
 Fix, D. V., 5774  
 Fleck, J. F., 4395  
 Flegel, W. A., 3862  
 Fleming, S., 422  
 Flotte, T., 4964  
 Floyd, J., 476  
 Floyd, R. A., 3882  
 Foa, R., 964  
 Fodstad, O., 2837  
 Fohn, M., 1406  
 Foidart, J., 405  
 Foidart, J.-M., 405, 3624  
 Fokas, A. S., 2084  
 Foley, J., 1391  
 Foley, J., 6338  
 Foley, J. W., 1109, 2710  
 Fong, A. T., 2362  
 Fong, K. J., 2636  
 Forastiere, A. A., 5781  
 Ford, C. P., 5929  
 Ford, H., Jr., 3733  
 Ford, J. M., 67  
 Forseth, B., 6273  
 Foster, B. D., 3405  
 Foster, C., 3497  
 Foster, T. H., 3261  
 Foulkes, W. D., 5329  
 Fournier, R. M., 556  
 Fournier, C., 5384  
 Fraioli, R., 652  
 Fraker, D. L., 2302  
 Franceschi, S., 629  
 Frankfurt, O. S., 1190  
 Franks, C. R., 2456  
 Frasca, V., 6125  
 Frasci, G., 4898  
 Frati, L., 1294, 2456, 5378  
 Fraumeni, J. F., Jr., 2885, 3044, 6094  
 Frazier, D. L., 1680  
 Fredman, P., 4643  
 Fredrix, E. W. H. M., 6138  
 Freed, J. J., 2973, 4415  
 Freedman, R. S., 4257  
 Freeman, J. W., 1973  
 Freeman, M. R., 1910  
 Frei, E., III, 780, 1086  
 Freireich, E. J., 753  
 French, D., 5378  
 French, R. R., 2353  
 Frenkel, K., 4443  
 Freyer, J. P., 3831, 4072  
 Friche, E., 4213, 5093  
 Fridman, M., 1426  
 Fridman, W. H., 612  
 Fried, S. K., 863  
 Friedman, E., 1154  
 Friedman, H. S., 3906, 4721  
 Friedman, N., 4287  
 Friend, S. H., 5435  
 Frincke, J. M., 6650  
 Fritzberg, A. R., 676  
 Frixen, U. H., 6328  
 Frolik, C. A., 4395  
 Frost, P., 1185  
 Frühauf, S., 2943  
 Fry, A. M., 6592  
 Fry, D. W., 4581  
 Fry, K. D., 3669  
 Fry, R. J. M., 6539  
 Fryburg, J. S., 1154  
 Fuchigami, M., 4631  
 Fuhrer, J. P., 2158  
 Fujie, K., 4038  
 Fujii, A., 2319  
 Fujii, H., 3471  
 Fujii, N., 2922  
 Fujii, S., 5888  
 Fujimori, K., 4776, 4821  
 Fujimori, M., 89  
 Fujita, T., 6180  
 Fujita, Y., 1448  
 Fujita, Y., 5322  
 Fujiwara, Y., 3237  
 Fukaura, Y., 5123  
 Fukazawa, N., 2420  
 Fuchs, Z., 2552, 6372  
 Fukuda, M., 2854  
 Fukui, S., 331  
 Fukushima, S., 824, 2548  
 Fulton, A. M., 2047  
 Funahashi, A., 5596  
 Funaki, K., 4059, 4415  
 Funakoshi, I., 331  
 Fung, P. Y. S., 1170  
 Funke, I., 4712  
 Fuqua, S. A. W., 105  
 Furmansk, P., 5454  
 Fürstenberger, G., 4328  
 Furukawa, K., 2223  
 Fuscoe, J. C., 6001  
 Fusenig, N. E., 4402  
 Fushida, S., 1034  
 Futami, H., 6596  
 Futscher, B. W., 1581
- G**
- Gabriele, T., 2636  
 Gaitan, E., 4785  
 Galan, T., 5405  
 Galanopoulos, T., 1345  
 Galanos, C., 2524  
 Galati, A. J., 365, 2063  
 Gali, H. U., 2820  
 Galivan, J., 3874  
 Gallagher, C. H., 2773  
 Gallagher, R. E., 2854  
 Gallagher, R. P., 2307  
 Gallick, G. E., 1452  
 Gallo, M. A., 3938  
 Gallo, M. G., 2808, 3781  
 Gallo, R. C., 2670  
 Gambone, J. C., 2124  
 Gamcsik, M. P., 3378  
 Ganapathi, R., 6133  
 Ganey, P. E., 2036  
 Ganis, B., 3715  
 Gansbacher, B., 150  
 Ganther, H. E., 595  
 Gao, C., 3753  
 Garber, J. E., 6094  
 Garbisa, S., 439  
 Garcia, I., 294  
 Garcia, M., 5679  
 Garcia, R., 1452  
 Garg, A., 5198  
 Garg, P. K., 4164  
 Garin-Chesa, P., 336  
 Garland, E. M., 1766, 1778, 3471  
 Garnett, M. C., 1990

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Garrido, F., 2463, 4948  
 Garrido, M. A., 5716  
 Garte, S. J., 4810  
 Gatenby, R. A., 2542  
 Gatter, K. C., 261, 5976  
 Gattioni-Celli, S., 3164  
 Gautam, S. C., 6133  
 Gavériaux, C., 4226  
 Gavin, J. B., 77  
 Gavosto, F., 964  
 Gazdar, A. F., 1708, 4999, 6142  
 Gazet, J.-C., 1817  
 Gazzaniga, G. M., 2273  
 Gazeri, S., 2566  
 Geacintov, N. E., 3482  
 Gelboin, H. V., 1059, 4636  
 Gelin, J., 415, 880  
 Geng, C.-S., 3131  
 Genua, G., 4898  
 Genz, T., 4712  
 Georgiadis, P., 5843  
 Gerlach, J. H., 3345  
 Geroni, C., 199  
 Gerson, S. L., 3391  
 Gervasoni, J. E., Jr., 4955  
 Gerwin, B. I., 4090  
 Getzenberg, R. H., 6514  
 Geurts-Moespot, A., 4544  
 Geyer, C., 6529  
 Ghatei, M. A., 5205  
 Ghetie, M.-A., 1482, 5876  
 Ghetie, V., 4052  
 Gheuens, E. E. O., 4523  
 Ghigo, D., 1741  
 Giaccia, A. J., 2636, 4463  
 Giacomini, P., 652  
 Giavazzi, R., 6358  
 Gibbons, G. R., 969  
 Gibson, N. W., 6586  
 Gibson, S. L., 1836  
 Gibson, V., 836, 857, 4199  
 Gibson, W., 5579  
 Gilbert, K., 4613  
 Gilbertson, J., 3497  
 Gilboa, E., 150  
 Gilchrist, K. W., 3323  
 Gill, G. N., 6170  
 Gill, R., 3497  
 Gillespie, A. J., 6079  
 Gilman, S. C., 5744  
 Giocanti, N., 3204  
 Giovannella, B. C., 3052, 6636  
 Giudici, G., 6358  
 Gladson, C. L., 4986  
 Glass, J., 3159  
 Glasser, S. R., 5943  
 Glatstein, E., 5065s  
 Glatt, H., 1659  
 Glatte, E., 1234  
 Gleason, M. C., 995  
 Gleave, M., 3753  
 Glennie, M. J., 2353  
 Glick, R. P., 3030  
 Glickson, J. D., 3378  
 Glode, L. M., 4299  
 Glogowski, J., 190  
 Godwin, K. S., 5467  
 Goeckeler, W., 2889  
 Goepel, J. R., 2490  
 Goff, B. A., 4762  
 Gogusev, J., 5712  
 Gold, A., 6163  
 Goldberg, I. D., 5315  
 Goldblatt, S. A., 5760  
 Goldenberg, D. M., 1619, 3102, 4192, 4594  
 Goldenberg, S., 1638  
 Goldfinger, N., 5232  
 Goldmacher, V. S., 6236  
 Goldsmith, M. E., 587  
 Goldstein, A. M., 1793, 6094  
 Goldstein, D., 4155  
 Goldstein, I. J., 657  
 Goldstein, J., 1391  
 Goldstein, L. J., 1478  
 Goldsworthy, T., 1391  
 Golightly, S., 476  
 Goltzman, D., 6521  
 Gomer, C. J., 4243, 6574  
 Gomi, K., 110, 4888  
 Gomm, J. J., 4685  
 Gong, Y., 5476  
 Gonzales, J., 1014  
 Gonzalez, A., 1922  
 Gonzalez, A., 4948  
 Gonzalez, F. J., 4636, 6622  
 Gonzalez, G. G., 2932  
 González, J. F., 2098  
 Good, R. A., 5123  
 Goodrow, T., 1148  
 Goodrow, T., 6615  
 Gope, M., 5626  
 Gordon, D. G., 3857  
 Gordon, G. B., 476, 1366  
 Gorelik, E., 227, 1521, 5153, 5212, 6210  
 Goss, M. W., 3281  
 Gottesman, M. M., 1478, 1638, 5417  
 Gould, M. N., 2642, 5298, 5649  
 Gout, P. W., 282  
 Gouw, A., 5915  
 Graeven, U., 4853  
 Graham, R. A., 841  
 Grahm, D., 4125  
 Grant, S. G. N., 4917  
 Grasso, P., 6415, 6452, 6470  
 Gratama, J. W., 2324  
 Grau, C., 707  
 Graver, M., 4131  
 Gray, G. S., 2077  
 Gray, R., 6415, 6452, 6470  
 Graziella Persico, M., 1051  
 Grdina, D. J., 4125  
 Green, H. A., 288  
 Greenberg, H. S., 870  
 Greenberg, J. P., 3482  
 Greenberg, R. S., 3044  
 Greene, D. R., 4084  
 Greene, G. L., 239  
 Greenoak, G. E., 2773  
 Greenspan, J. S., 1014  
 Greger, B., 3427  
 Gregory, W. M., 1210  
 Greiner, J. W., 926, 4155, 5694  
 Grem, J. L., 1651  
 Gridley, D. S., 1515  
 Griffin, T. W., 255, 4316  
 Griffiths, A., 1668  
 Griffiths, G. L., 4594  
 Grigioni, W. F., 439  
 Grimm, E. A., 3669  
 Grindey, G. B., 6110  
 Grisham, J. W., 5238  
 Griswold, D. P., Jr., 1979, 2837  
 Grochow, L. B., 5781  
 Grogan, T. M., 995, 2720  
 Groopman, J. D., 5501, 6185  
 Groot, K., 4757  
 Grooten, J., 2229  
 Groshen, S., 2015  
 Gross, M. E., 1452  
 Grossman, L., 5786  
 Grove, D. S., 82  
 Grueneberg, D. A., 2268  
 Grummer, M., 37  
 Grundel, R., 1003  
 Grunfeld, C., 2803  
 Grunicke, H. H., 807, 5821  
 Gruys, M. E., 6596  
 Gschmeissner, S., 4020  
 Guadagni, F., 4155  
 Guarini, A., 964  
 Gudas, L. J., 3972  
 Guénard, D., 4845  
 Guengerich, F. P., 5284  
 Guéritte-Voegelein, F., 4845  
 Guerquin-Kern, J.-L., 5770  
 Guerry, D., IV, 3334, 4853  
 Guillem, J. G., 1571  
 Gulati, S., 4828  
 Gullick, W. J., 3296  
 Gumerlock, P. H., 1632  
 Gunji, H., 741, 6636  
 Günther, U., 5292  
 Guo, J. Q., 3048  
 Guo, Z., 4798  
 Gupta, R. C., 5198  
 Gurnani, M., 7762  
 Gurrpide, E., 5476  
 Gurtoo, H. L., 886  
 Gurwith, M., 1499  
 Gusberg, S. B., 4114  
 Guthrie, J., 6031  
 Guthrie, P. D., 1910  
 Gutowski, M. C., 5471, 5774  
 Guy, J., 6199
- ## H
- Haagen, I. A., 3224  
 Haagensen, D. E., 4336  
 Habraken, Y., 499, 1217  
 Habres, J. M., 5539  
 Hackenberg, R., 5722  
 Hacker, H. J., 1952  
 Hadam, M., 6312  
 Hager, L. G., 5728  
 Haggitt, R. C., 5482, 5766  
 Haghighi, B., 1720  
 Hagiwara, A., 5655  
 Hahn, G. M., 2636, 5910, 6608  
 Hailey, J. A., 1339  
 Haimanot, R., 5430  
 Haimovitz-Friedman, A., 2552  
 Hait, W. N., 67  
 Hakomori, S., 2879  
 Hakomori, S.-i., 1406, 1613, 2199, 6019  
 Hakomori, S.-i., 4310  
 Halachmi, E., 612  
 Haldorsen, T., 1234  
 Haley, C. L., 1326  
 Haley, J. D., 4828  
 Hall, T. C., 4192  
 Hallahan, D. E., 4565, 6393  
 Halline, A. G., 5608  
 Halliwell, B., 5837  
 Hamada, N., 5123  
 Hamilton, S. R., 476  
 Hamilton, T. A., 6133  
 Hamilton, T. C., 5107  
 Hämmerling, G. J., 729  
 Hammond, G. D., 4871  
 Hampton, L. L., 5929  
 Han, F.-S., 1755  
 Hanahan, D., 4917  
 Hanawalt, P. C., 2867  
 Hancock, M. C., 4575  
 Hancock, S. L., 2280  
 Hand, P. H., 181, 3657  
 Handa, S., 1701  
 Handgretinger, R., 144  
 Haneda, H., 6346  
 Hann, H.-W. L., 6176  
 Hannigan, G. E., 3958  
 Hansen, H. H., 5093  
 Hansen, H. J., 4594  
 Hanski, C., 5342  
 Hanson, J., 556  
 Hansson, J., 94, 3384  
 Hanzawa, Y., 2599  
 Hao, Z., 3733  
 Hara, I., 4250  
 Hara, M., 434  
 Hara, T., 1701  
 Harada, H., 89  
 Harada, M., 6346  
 Haraguchi, M., 3503  
 Haramaki, N., 3555  
 Haran, M. S., 1855  
 Hardcastle, J. D., 5425  
 Hardman, W. E., 6388  
 Harlow, S. P., 2403  
 Harmon, J. M., 5224  
 Harning, R., 5003  
 Harrigan, P., 4111  
 Harris, A. L., 261, 2346, 5976, 6592  
 Harris, C. C., 365, 2490, 3793, 4090, 4102, 5023s, 5219, 5370  
 Harris, E. L., 1793  
 Harris, M. N., 3643  
 Harris, N., 2577  
 Harrison, C. L., 468  
 Harrison, S. D., Jr., 1979, 2837  
 Hart, I. R., 3281, 4768, 6660  
 Hartley, J. A., 6592  
 Hartman, S., 2268

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Hartmann, M., 1811  
Hartmann, O., 33  
Haruma, K., 2926  
Harvey, E. J., 5993  
Harvey, H., 4149  
Hasan, T., 4410, 4762  
Haschek, W. M., 4613  
Hasegawa, R., 2548  
Haskard, D. O., 4768  
Hass, G. M., 1876  
Hata, H., 195  
Hata, J-i., 5937  
Hatch, K. D., 568  
Hattori, H., 4182  
Hattori, T., 6084  
Hauck, W., 3526  
Haussler, M. R., 239  
Havlin, K. A., 6268  
Hawkins, P. A., 4581  
Hayashi, K., 3356, 5520, 5800  
Hayashi, M., 2582  
Hayashi, N., 4924  
Hayashi, S-i., 5177  
Hayashi, Y., 1286  
Hayden, J. H., 4942  
Hayes, C., 595  
Hayes, D. F., 3838  
Hayes, R. B., 3445  
Hayman, J. A., 3059  
Hayward, N. K., 4367  
He, J., 1684  
He, X., 3339  
Hearing, V. J., 5212  
Hebert, J. R., 6510  
Hecht, S. S., 1846, 5495, 5557  
Hecquet, B., 5384  
Hedayati, M. A., 5786  
Hedley-Whyte, E. T., 1345  
Heid, C., 4238  
Heiger-Bernays, W. J., 1866  
Heim, S., 954  
Hein, D. W., 549  
Heitjan, D. F., 1760  
Heitman, D. W., 6388  
Held, T. N., 3612  
Heldin, C-H., 5087  
Helman, L. J., 174, 4882  
Helzlsouer, K. J., 1366  
Hemstreet, G. P., III, 2762  
Henderson, B. E., 2307, 3617  
Henderson, J., 6521  
Henderson, M. A., 3059  
Hendricks, C. B., 5781  
Hendricks, J. D., 2362  
Hendriks, B. T., 2329  
Henn, M., 3643, 5003  
Hennings, H., 4206  
Henry, S., 6668  
Henslee, J. G., 1876  
Heo, D. S., 3891  
Heppner, G. H., 4378  
Herberman, R. B., 1521, 3891, 4355, 5153, 6153  
Herbst, H., 3243  
Herdt, J., 688  
Herfarth, C., 729  
Herlyn, M., 2205, 4853  
Herman, T. S., 780, 1086  
Hermans, J., 1694  
Hermonat, P. L., 3373  
Herold, M., 6250  
Herrero, R., 4785  
Herrington, P. N., 422  
Herrlich, P., 5292  
Herscovics, A., 3136  
Hershberg, R., 150  
Hertel, L. W., 6110  
Herter, M., 144  
Hess, A. D., 682  
Hester, S., 5361  
Heur, Y-H., 2063  
Heuvel, J. J. T. M., 4544  
Hicks, L., 3733  
Hickson, I. D., 6592  
Hida, T., 2416  
Hidaka, H., 4271  
Hidaka, T., 3555  
Higashi, H., 1242  
Higasiyama, M., 3544  
Higuchi, T., 3958  
Hiki, Y., 4631  
Hikiji, K., 820  
Hilf, R., 1836, 3261  
Hilken, J., 4028  
Hill, B. T., 4557  
Hill, H. Z., 3451  
Hill, L. L., 4937  
Hill, R. P., 1359  
Hill, S., 4978  
Hilton, J., 2410, 4360  
Hindenburg, A. A., 4955  
Hinds, M., 4729  
Hingerty, B. E., 3482  
Hino, O., 89, 1460  
Hinoda, Y., 2599  
Hinrichs, S. H., 6686  
Hinson, N. A., 2965  
Hinz, H. R., 3052, 6636  
Hirohashi, S., 2185, 2199, 3056, 4876, 5520, 5800  
Hirohata, T., 2842  
Hirose, M., 824, 2902, 5655  
Hirose, T., 4323  
Hirota, K., 5956  
Hirota, Y., 4187  
Hirsch, K. S., 4395  
Hiserodt, J. C., 4931  
Hixson, D. C., 1308  
Hiyama, E., 1946  
Hiyama, K., 1946  
Ho, J. J. L., 372, 1026  
Ho, S. B., 1026  
Hobbs, P. D., 4804  
Hochster, H., 3643  
Höckel, M., 3316, 6098  
Hoel, D. G., 6409  
Hofer, D. R., 2780  
Hoffman, R., 3886  
Hofmann, G. A., 5813  
Hofmann, J., 5722  
Hofmann, J., 5821  
Hofmann, M., 5292  
Hogan, M., 2041  
Hogan, V., 2173, 3507  
Holcenberg, J. S., 4871, 6079  
Holden, S. A., 780, 1086  
Holinka, C. F., 5476  
Hölker, I., 3702  
Holland, J. C., 5939  
Holland, J. F., 55  
Holland, L., 2205  
Hollas, W., 3690  
Hollema, H., 5915  
Hollis, L. S., 1866  
Hollstein, M. C., 4102  
Holly, E. A., 1014, 1370  
Holmes, L., 6073  
Holtermann, G., 1039  
Hölzel, F., 5722  
Hom, D. K., 5903  
Homan, S. M., 6558  
Homma, C., 5937  
Honda, S., 6656  
Hong, J-Y., 1509  
Hong, W. K., 3669  
Honma, Y., 2582, 4535, 4649  
Hooi, D. S. W., 1990  
Hook, K. E., 4581  
Hoon, D. S. B., 2002, 5687  
Hoover, E. A., 2740  
Hoover, R. N., 2885, 5219  
Hopman, A. H. N., 644, 1959  
Hori, A., 6180  
Hori, T-a., 4707  
Horie, T., 331  
Horii, A., 3544  
Hornik, V., 5602  
Horsman, D. E., 282  
Horwith, G., 1499, 5614  
Hoshiya, T., 318  
Hosking, L. K., 4557  
Hosono, M., 990  
Hotchkiss, J. H., 3925  
Houchens, D., 2889  
Houghton, P. J., 6286  
Houlihan, W. J., 43  
Howard, R. B., 3274  
Howell, B., 504  
Howell, S. B., 5903  
Howley, P. M., 5019s  
Hozumi, M., 2582, 4535, 4649  
Hsieh, J-T., 3753  
Hsieh, L-L., 1720  
Hsing, A. W., 3068  
Hsu, F. F., 514  
Hu, C-p., 1898  
Hu, L., 3972  
Hu, S-X., 2735, 4481, 5736  
Hu, X. F., 1750  
Huang, A. T., 3037  
Huang, D. H., 886  
Huang, D-Y., 4724  
Huang, E. Y. W., 6514  
Huang, J., 1026  
Huang, M-T., 813  
Huang, P., 6110  
Huang, Q., 1059  
Huang, Y., 1384  
Huang, Y., 5766  
Huber, H., 6250  
Huber, W., 666, 1789  
Huberman, E., 4565  
Hudes, G. R., 3080  
Hudson, M. A., 3726  
Huebner, K., 1553, 3818, 3821  
Huggett, A. C., 5929  
Huggins, R., 1750  
Hughes, L. R., 5579  
Hui, T. E., 5921  
Hülser, D., 5348  
Humphrey, P. A., 2979, 3339  
Hung, M-C., 3362  
Hunt, A. J., 2077  
Hunt, B., 1185  
Hunt, J. M., 1278  
Hunter, N., 3639  
Huot, J., 5245  
Hursey, M. L., 1247  
Hurst, R. E., 2762  
Husain, Z., 4964  
Husmann, M., 4804  
Hussain, N. S., 3143  
Hussein, A. M., 3329  
Hussein, S., 1738  
Hutchins, J. T., 1418  
Hutzell, P., 181  
Huybrechts, J. J., 4523  
Huynh, H. H., 3677  
Hwang, Y. C., 3108
- I
- Iacobelli, S., 1294  
Iaffaioli, R. V., 4898  
Ichihara, A., 6677  
Ichikawa, T., 3788  
Ichikawa, Y., 3788  
Ichinose, I., 5392  
Igarashi, Y., 1613, 6019  
Iglehart, J. D., 2605, 2979  
Ihde, D. C., 1708  
Iishi, H., 785, 2863, 3493, 6150  
Iizuka, Y., 5859  
Ikada, Y., 5532  
Ikawa, Y., 99  
Ikegami, Y., 4903  
Ikenaga, M., 2113  
Iliakis, G., 5113  
Imai, K., 2599  
Imai, K., 5177  
Imaida, K., 2902  
Imamura, M., 2113  
Imamura, S., 6219  
Imamura, T., 89  
Imanishi, K., 4631  
Imber, R., 632  
Inagake, M., 4310  
Ingamells, S., 2353  
Inoue, M., 5308, 5951  
Inoue, T., 3212  
Ioannides, C. G., 4257  
Ip, C., 595, 6118  
Ip, M. M., 2786  
Irie, R. F., 2002, 5687  
Irimura, T., 387, 5728  
Irino, S., 3886  
Irita, Y., 2842  
Irwin, J. C., 3982  
Isaacs, J. T., 162, 1591, 3788, 4693

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Isaacs, R. J., 528  
 Isaacs, W. B., 4716  
 Ishibashi, H., 2842  
 Ishida, R., 4903, 4909  
 Ishida, T., 1494, 3522, 4008  
 Ishida, T., 2599  
 Ishihara, H., 4182  
 Ishihara, H., 4450  
 Ishihara, T., 341  
 Ishii, N., 5667  
 Ishikawa, J., 820, 4707, 5736, 5817  
 Ishikawa, J., 3710  
 Ishikawa, T., 89  
 Ishizaki, K., 2113  
 Islas, A. L., 2867  
 Isobe, H., 6346  
 Isole, T., 157, 921  
 Isom, H. C., 5440  
 Isonishi, S., 5903  
 Isselbacher, K. J., 3164  
 Itaya, T., 1185  
 Itkonen, O., 2107  
 Ito, H., 2926  
 Ito, H., 3639  
 Ito, N., 318, 824, 1264, 5655  
 Ito, N., 4080  
 Ito, T., 255  
 Itoh, K., 2029  
 Iwahana, M., 903  
 Iwai, J., 3148  
 Iwama, T., 2874  
 Iwasaki, S., 1264  
 Iwashima, A., 1448  
 Iwashita, S., 5859  
 Iwata, J., 3327  
 Iwata, K. K., 4828  
 Iwatsuki, S., 6153  
 Iype, S. N., 1606, 4287  
 Izumi, S., 4038
- J**
- Jachez, B., 4226  
 Jackman, A. L., 5507, 5579  
 Jackson, J. E., 2593  
 Jacobson, J. O., 6103  
 Jacoby, R. F., 4305  
 Jacrot, M., 2566  
 Jahnke, K., 6328  
 Jain, R. K., 265, 1352, 1561, 2727, 3119, 3612, 6691, 6695  
 Jakate, S. M., 2720  
 Jakubowski, A., 3096  
 Jambrosic, J. A., 2205  
 James, C. D., 1684, 2164  
 James, S. M., 2373  
 Jamil, N., 556  
 Jani, J. P., 227  
 Jankun, J., 1221  
 Jansen, G., 5507  
 Jansen, R., 4729  
 Jardillier, J. C., 1996  
 Jarman, M., 5851  
 Jaroszewski, J. W., 1638  
 Jarrett, K. A., 3831, 4072  
 Järvinen, H., 4135  
 Jasti, R., 581  
 Jastorff, B., 1600, 6207
- Jaszewski, R., 3416  
 Jaworsky, C., 4937  
 Jay, G., 5212, 6686  
 Jehl, F., 2073  
 Jenkin, J., 6280  
 Jenkin, R. D. T., 2885  
 Jenkins, C., 1680  
 Jenkins, D. C., 6073  
 Jenkins, H., 556  
 Jensen, P. B., 5093  
 Jensen, P. S., 5093  
 Jerome, K. R., 2908  
 Jewett, P., 6142  
 Jhanwar, S. C., 1544, 5410  
 Ji, C., 1059  
 Jilg, W., 27  
 Jirtle, R. L., 130  
 Johannsson, S. L., 1766  
 Johansson, B., 954  
 Johansson, S. L., 4388  
 Johns, D. G., 3733  
 Johnson, B. E., 1708  
 Johnson, C., 123  
 Johnson, C. S., 5454  
 Johnson, D. A., 2965, 5471, 5774  
 Johnson, D. K., 255  
 Johnson, F. E., 6558  
 Johnson, H. M., 5304  
 Johnson, J. A., 1783  
 Johnson, J. T., 3891  
 Johnson, R. C., 394  
 Johnson, R. K., 5813  
 Johnston, M. R., 3274  
 Johnston, P. G., 6668  
 Jollow, D. J., 2536  
 Joncourt, F., 2092  
 Jones, D., 5876  
 Jones, P. A., 3617  
 Jones, P. H. M., 2885  
 Jones, P. L., 2762  
 Jones, R. T., 3793  
 Jones, S. A., 5454  
 Jones, T. A., 5329  
 Jonsson, N., 954  
 Jordan, K. G., 1846  
 Jordan, M. A., 2212  
 Joseph, C., 2826  
 Jücker, M., 3702  
 Judson, I. R., 5579  
 Juhasz, F., 2690  
 Julian, J. A., 5943  
 Juliano, R. L., 1738  
 Juliusson, G., 5570  
 Jung, D., 2307  
 Jung, E. G., 3456  
 Jung, J. K., 4146  
 Jungnelius, U., 94  
 Jurcisek, J. A., 1564
- K**
- Kabat, G. C., 6510  
 Kacinski, B. M., 5315  
 Kadlubar, F. F., 4371  
 Kaffka, K. L., 1823  
 Kagawa, S., 6677  
 Kageshita, T., 1726, 4790  
 Kahl, S. B., 4588
- Kahn, L. B., 4131  
 Kaighn, M. E., 365  
 Kajigaya, S., 4649  
 Kajikawa, F., 215  
 Kajiyama, G., 2926  
 Kakehi, Y., 949  
 Kakeji, Y., 3503  
 Kakinuma, H., 5487  
 Kalechman, Y., 1499, 5614  
 Kallman, R. F., 2280  
 Kalnicki, S., 6695  
 Kalvelage, H., 43  
 Kamada, N., 381  
 Kamen, B. A., 6125  
 Kamidono, S., 820, 5736  
 Kanayama, H.-o., 6677  
 Kanda, H., 3257  
 Kanda, Y., 110  
 Kane, R., 6323  
 Kaneko, S., 4008  
 Kaneko, Y., 2677  
 Kaneko, Y., 5937  
 Kanematsu, T., 2842  
 Kan-Mitchell, J., 1418  
 Kantor, A. F., 6094  
 Kantor, J. A., 3657  
 Kanzaki, T., 2133  
 Kaplan, D., 2889  
 Kaplan, D. R., 875  
 Kaplan, O., 1638  
 Kapuscinski, J., 3682  
 Karakousis, C. P., 422  
 Karp, J. E., 753, 3534, 4743  
 Karras, J. G., 3193  
 Kasahara, K., 3237  
 Kasai, M., 110  
 Kasayama, S., 4323  
 Kashimoto, S., 215  
 Kashmiri, S., 181  
 Kasper, H., 4238  
 Kasprzak, K. S., 5837  
 Kastan, M. B., 3534, 4279, 6304  
 Kasuga, T., 434  
 Kasukabe, T., 4535, 4649  
 Kasumi, F., 5794  
 Kaszkin, M., 4328  
 Katagiri, H., 4450  
 Katagiri, Y., 1286  
 Kataoka, K., 3229  
 Kataoka, K., 3919  
 Kath, R., 2205, 4853  
 Kathmann, I., 5507  
 Kato, A., 1242  
 Kato, S., 1242  
 Kato, T., 1264  
 Katsanis, E., 2127  
 Katsuda, S., 2015  
 Katz, B., 612  
 Katz, J., 1092  
 Katzav, S., 6712  
 Kauffman, F. C., 4511  
 Kaufmann, S. H., 581, 1129, 3534  
 Kaufmann, W. K., 2960  
 Kaveri, S.-V., 6045  
 Kawada, S.-z., 2922  
 Kawahata, R. T., 4219  
 Kawai, T., 1242
- Kawajiri, K., 5177  
 Kawakami, Y., 5888  
 Kawakami, Y., 6346  
 Kawakita, M., 1701  
 Kawasaki, T., 331  
 Kawase, Y., 2223  
 Kawata, M., 2655  
 Kawata, S., 4080  
 Kawato, Y., 4187  
 Kazakoff, K., 4757  
 Keane, P., 724  
 Keating, M., 935  
 Keenan, A. M., 688  
 Kehrer, J. P., 542  
 Keller, J. B., 2084  
 Kelley, J. A., 1803  
 Kelloff, G. J., 481, 3069, 4528  
 Kelly, S. A., 4020  
 Kende, A. S., 6568  
 Kennan, W. S., 2642, 5298, 5649  
 Kennel, S. J., 1529  
 Kensler, T. W., 5501  
 Kera, K., 2655  
 Kerbel, R. S., 985, 4486  
 Kerns, B.-J. M., 2605, 2979  
 Kerr, I. G., 6318  
 Kerrigan, D., 6280  
 Kerschmann, R., 3807  
 Kessel, D., 4665  
 Kessin, R. H., 1600, 6207  
 Keyomarsi, K., 3602  
 Keyse, S. M., 3384  
 Khachab, M., 1766  
 Khan, K. N., 5667  
 Kharbanda, S., 741, 6636  
 Khawli, L. A., 2694  
 Khazaeli, M. B., 5461  
 Khokhar, A. R., 2994  
 Kidd, L., 2395  
 Kiehnopf, M., 5342  
 Kienhuis, C. B. M., 4544  
 Kiebits, T., 1020  
 Kihana, T., 3056  
 Kikuchi, A., 2223  
 Kikuchi, K., 4250  
 Kikuchi, M., 4639  
 Kilbourn, R. G., 2531  
 Kilian, P. L., 1823  
 Killion, J. J., 3741  
 Kim, M., 5212  
 Kim, N., 1051  
 Kim, S.-G., 3108  
 Kim, S. J., 4146  
 Kim, Y. S., 372, 1026  
 Kimbell, R., 5579  
 Kimchi, N., 612  
 Kimes, B. W., 753  
 Kimura, G., 1494  
 Kimura, H., 1034  
 Kimura, H., 2655  
 Kimura, N., 2917, 4639  
 Kimura, S., 6019  
 Kinders, R. J., 1876  
 King, C. M., 2902  
 King, C. R., 445  
 King, D., 181, 5461  
 King, V., 6323

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Kinoshita, N., 5888  
 Kinouchi, T., 3919  
 Kinsella, A. R., 1855  
 Kinzel, V., 4328  
 Kirchner, H., 6312  
 Kirito, K., 1940  
 Kirk, G. A., 6650  
 Kirk, M. C., 499  
 Kirkwood, J. M., 6691  
 Kirley, S. D., 2710  
 Kirlin, W. G., 549  
 Kirsch, T., 1499  
 Kisiel, W., 349  
 Kiso, S., 4080  
 Kitagawa, H., 331  
 Kitagawa, H., 2599  
 Kitagawa, T., 89, 3257  
 Kitagawa, Y., 1504  
 Kitajima, S., 2133  
 Kitamura, K., 4310  
 Kitao, Y., 1448  
 Kitchingman, G., 5440  
 Kitson, J., 3910  
 Kiyokawa, H., 2842  
 Kjeldsen, T. B., 2879  
 Klann, R. C., 5642  
 Klaude, M., 3965  
 Kleihues, P., 6202  
 Klein, B., 3224  
 Klein, G., 4481  
 Klein, J., 857  
 Kleinman, H. K., 3624  
 Klein-Szanto, A. J. P., 3793, 4097, 6615  
 Kleynerman, L., 4131  
 Klier, F. G., 4986  
 Klingelutz, A. J., 3323  
 Klostergaard, J., 3362  
 Klug, T. L., 468  
 Klusens, L. F., 2720  
 Knabbe, C., 3590  
 Knapp, F. F., Jr., 4594  
 Kneba, M., 3243  
 Knoop, C., 3316, 6098  
 Knowles, B. B., 6176  
 Knowles, R. G., 6643  
 Knox, R. J., 123  
 Knudson, A. G., Jr., 2973, 4415, 5435  
 Knudson, W., 897  
 Kobari, S., 4639  
 Kobata, A., 1701  
 Kobayashi, E., 110  
 Kobayashi, T., 3544  
 Kochevar, I. E., 288  
 Kodaira, S., 2199  
 Kodama, S., 1934  
 Koeller, J. M., 6268  
 Koenders, P. G., 4544  
 Koerner, F. C., 624  
 Koga, S., 2842  
 Kohn, K. W., 6550  
 Kohno, K., 3951  
 Kohsaka, M., 4038  
 Koi, S., 5118  
 Koivunen, E., 2107  
 Koizumi, M., 990  
 Koji, T., 5667  
 Kojima, A., 1472  
 Komada, F., 4271  
 Komatsu, N., 341  
 Komeshima, N., 157  
 Komiya, K., 3237  
 Komschlies, K. L., 6596  
 Kondo, K., 764, 5398  
 Koniecki, J., 1465  
 Konishi, J., 990  
 Konn, S., 4250  
 Konno, A., 4250  
 Konno, Y., 3886  
 Kono, M., 110  
 Kopp, R., 205  
 Koprowski, H., 3334  
 Korbelik, M., 2251  
 Korc, M., 6243  
 Kordowska, J., 1465  
 Korenaga, D., 3503  
 Koretz, K., 729  
 Körfer, A., 6312  
 Kornfeld, S. B., 1689  
 Korngold, R., 4937  
 Koros, A. M. C., 6142  
 Korzekwa, K., 4636  
 Kosaka, T., 573  
 Koshiba, M., 949  
 Kotler, M., 2179  
 Koukoulis, G. K., 2720  
 Koyasaki, N., 2683  
 Kozai, Y., 6180  
 Kozarsky, K. F., 2395  
 Kozielski, A. J., 3052  
 Kozikowski, A. P., 2511  
 Kozlowski, J. M., 2780  
 Kraemer, K. H., 3177  
 Kragel, P., 2649  
 Krailo, M. D., 4871  
 Krainer, M., 6250  
 Kratz, D. A., 6025  
 Kraupp-Grasl, B., 666, 1789  
 Kraus-Berthier, L., 2312  
 Krause, B. E., 556  
 Krausz, T., 724, 3251  
 Kreitman, R. J., 2831  
 Kremer, M., 1537  
 Kremer, R., 6521  
 Krieger, G., 3243  
 Krigel, R. L., 3910  
 Krikorian, A., 2073, 5384  
 Kripke, M. L., 4176, 5893  
 Krishna, M. C., 6622  
 Krishna, S., 4955  
 Kristensen, P., 4067  
 Kristiansen, J. J., 1370  
 Kristjansen, P. E. G., 5160  
 Kritchevsky, S. B., 3198  
 Krohn, K. A., 5921  
 Krosi, G., 2251  
 Krushelnicky, B. W., 2430  
 Kruszewski, F. H., 4206  
 Ksander, B. R., 3153  
 Kubonishi, I., 1574, 3327  
 Kubota, T., 2199  
 Kudryk, B. J., 349, 354  
 Kuerbitz, S. J., 4279  
 Kufe, D. W., 741, 3838, 4476, 4565, 6636  
 Kuga, H., 4187  
 Kuhn, J. A., 2335, 3802  
 Kuhn, J. G., 6268  
 Kuhns, W., 1257  
 Kuipers-Dijkshoorn, N., 1020  
 Kukuruga, D., 4665  
 Kulesz-Martin, M. F., 4701  
 Kumaki, T., 2683  
 Kun, C., 2307  
 Kuniyoshi, J., 4994  
 Kunz, L. L., 676  
 Kunzmann, R., 5722  
 Kupfer, D., 6052  
 Kurachi, H., 5322, 5951, 5956  
 Kuranami, M., 4631  
 Kurata, Y., 2548  
 Kuriya, N., 1726  
 Kurnick, J. T., 3164  
 Kurokawa, K., 2677  
 Kusakabe, M., 3257  
 Kushner, B. H., 4865  
 Kushtai, G., 5602  
 Kusumoto, Y., 5667  
 Kuszak, J. R., 2720  
 Kutter, D., 4712  
 Kuwano, H., 5339  
 Kuwano, M., 3951  
 Kuzumaki, N., 6346  
 Kuzuoka, M., 2199  
 Kwast-Welfeld, J., 528  
 Kye, E. A., 1270  
 Kyprianou, N., 162, 4693  

L

 Labrie, F., 2797, 3131, 4336, 5165  
 LaCreta, F. P., 2041, 3080, 3171, 6059  
 Ladero, J. M., 2098  
 Laerum, O. D., 4643  
 LaForgia, S., 3821  
 Laguzza, B. C., 2965  
 Laiming, V. A., 4785  
 Lakshmi, V. M., 514  
 Lalitha, V. S., 3018  
 Lambek, C., 4828  
 Lambert, G. R., 5198  
 Lambert, H., 5245  
 Lambert, J. M., 6236  
 Lamers, C. H. J., 2324  
 Lampasona, V., 6358  
 Lampport, D. T. A., 1026  
 Lancaster, S., 1760  
 Lanciotti, M., 4342  
 Landberg, G., 4570  
 Lando, D., 6643  
 Landry, J., 5245  
 Lane, C., 4012  
 Lane, D. P., 5976  
 Lane, J. M., 336  
 Lange, B., 6712  
 Lange-Carter, C. A., 6699  
 Langley, K. E., 2151  
 Langstein, H. N., 2302  
 Langton, B. C., 2593, 4575  
 Lans, J. I., 3416  
 Lapiere, C. M., 405  
 Larocca, D., 4994  
 Larson, S. M., 688  
 Larsson, S.-E., 3585  
 Laskin, J. D., 813  
 Laskowitz, D. T., 3906  
 Lasley, J., 6163  
 Laster, B. H., 4588  
 Latham, K. M., 4455  
 Latham, M. D., 6543  
 Latif, F., 1071  
 Lau, D. H. M., 5181  
 Lauchner, L. J., 1922  
 Laude, M., 4516  
 Laulis, M. K., 682  
 Lauri, D., 2239  
 Lavagnini, P., 2636  
 Laval, F., 1217  
 La Vecchia, C., 629  
 Lavelle, F., 4845  
 Lavielle, G., 2312  
 Law, J. C., 6385  
 Law, K. L., 2965  
 Lawrence, T. S., 870, 3900  
 Lawrence, W. D., 2848  
 Layton, G. T., 5826  
 Lazar, C. S., 6170  
 Lazo, J. S., 227, 893, 2511, 5903  
 LeBerthon, B., 2694  
 Leblanc, J., 1078  
 Lebovitz, M. D., 2720  
 Ledley, F. D., 4729  
 LeDoux, S. P., 775  
 Lee, A. S., 6574  
 Lee, C., 2780  
 Lee, C.-S., 6586  
 Lee, D. C., 5238  
 Lee, G.-H., 3257  
 Lee, J., 3289  
 Lee, J. H., 5118  
 Lee, K.-H., 1755  
 Lee, L. W., 5238  
 Lee, M., 2307  
 Lee, M.-J., 1509  
 Lee, M. L., 850, 907  
 Lee, M.-S., 2902  
 Lee, S.-J., 3096  
 Lee, S. M., 619  
 Lee, S. W., 5587  
 Lee, W.-H., 6381  
 Lee, Y.-L., 601  
 Lees, A. W., 556  
 Lefebvre, J.-L., 5384  
 LeFever, A. V., 5596  
 Legendre, A., 1680  
 Lehman, J. M., 1334  
 Lehman, T. A., 4090  
 Lehmann, J. M., 4804  
 Lehotan, M., 4378  
 Leinonen, J., 222  
 Leith, J. T., 4111, 5139  
 Leitzel, K., 4149  
 Leland, P., 3011  
 Lemerle, J., 33  
 Lemire, J. M., 2611, 4656  
 Lemaerts, A., 2469  
 Leonard, A. S., 2127

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Leonard, J. E., 1689, 3183  
 Leone, A., 445, 2490  
 Leong, S. P. L., 422  
 Leopold, W. R., III, 4581  
 Lerman, M. I., 1071  
 Less, J. R., 265  
 Letessier, E. M., 3891  
 Leteurtre, F., 5770  
 Leveque, D., 2073  
 Lévesque, C., 3131  
 Levi, S., 3497  
 Levin, B., 4495  
 Levitz, M., 1092  
 Levitzki, A., 4430  
 Levo, Y., 5602  
 Levy, A. T., 439  
 Levy, B. K., 6558  
 Levy, F., 6580  
 Levy, M., 6230  
 Lewis, A. D., 4463, 5181  
 Ley, R. D., 6539  
 Leyland-Jones, B. R., 587, 1803  
 Leyton, J., 907  
 Lhoste, J.-M., 5770  
 Li, B.-Y., 4012  
 Li, C., 130  
 Li, F. P., 1544, 6094  
 Li, J., 3826  
 Li, J. J., 1922, 3626  
 Li, L., 245, 2531  
 Li, W., 1509  
 Liang, C.-M., 6668  
 Liao, D. C., 5539  
 Liaw, Y.-F., 5621  
 Libby, P. R., 3715  
 Licciardello, J., 3669  
 Licht, T., 5417  
 Lichtner, R. B., 5943  
 Lidereau, R., 2490  
 Liebert, M., 2395  
 Liehr, J. G., 3882  
 Lien, E. A., 4837  
 Liliemark, J., 5570  
 Lilley, E. R., 3906  
 Lim, S., 6185  
 Lin, C. C., 1460  
 Lin, C.-J., 4724  
 Lin, C.-W., 1109, 2710  
 Lin, J.-L., 4450  
 Lin, J. T., 789  
 Lin-Chao, S., 601  
 Lindahl, T., 3384  
 Lindstrom, M. J., 2642, 5298, 5649  
 Linehan, W. M., 1071, 2490  
 Ling, L.-q., 3353  
 Linker, C. A., 4141  
 Linnoila, R. I., 1708, 6142  
 Liotta, L. A., 439, 2490, 5054s  
 Lipford, G. B., 1326, 2296  
 Lipkin, M., 1917, 3069  
 Lipman, J. M., 1823  
 Lippard, S. J., 1866  
 Lippert, M. J., 6001  
 Lippman, M. E., 3590, 4978  
 Lipton, A., 4149  
 Liscia, D. S., 6194  
 Litwin, S., 3080, 3171, 3910, 6059  
 Liu, A. Y., 4107  
 Liu, C., 3826  
 Liu, D., 5315  
 Liu, J., 4613  
 Liu, L. F., 3534, 6039  
 Liu, R. H., 3925  
 Liu, S.-d., 780  
 Liu, S.-Y., 1755  
 Liu, T. P., 5461  
 Liu, Y., 3037  
 Liu, Y.-L., 5501  
 Llor, X., 4305  
 LoBuglio, A. F., 4155, 5461  
 Lock, R. B., 6543  
 Locniskar, M., 907  
 Loeb, L. A., 3075  
 Loechler, E. L., 2268  
 Loeffler, C. M., 2127  
 LoGerfo, P., 1571  
 Lointier, P., 1227  
 Lombardi, L., 400  
 Lombardo, F. A., 1803  
 London, T., 6176  
 London, W. T., 4971  
 Long, B. H., 5275  
 Longenecker, B. M., 1170  
 Longo, D. L., 2127  
 Lönnroth, C., 415  
 Loor, F., 4226  
 Lopalco, L., 5960  
 Lopes, A. D., 5744  
 Lopez Hänninen, E., 6312  
 Lorenson, M. Y., 6568  
 Lorico, A., 5275  
 Losa, G. A., 1443  
 Lotan, R., 387  
 Loullis, C. C., 181  
 Lovelace, E. T., 3781  
 Lowy, D. R., 712  
 Lu, B., 897  
 Lu, H., 4192  
 Lu, S.-N., 5621  
 Lu, X., 6230  
 Lubejko, B., 5781  
 Lubin, J. H., 2885  
 Lucas, R., 2469  
 Lucchini, V., 6358  
 Lucier, G. W., 1391  
 Luckert, P. H., 3610  
 Ludlum, D. B., 499, 1568  
 Ludwig, H., 6250  
 Luk, G. D., 657, 3416  
 Lun, Z., 2307  
 Luna, M. C., 4243  
 Lundholm, K., 415, 880  
 Lupu, R., 3590  
 Luqmani, Y., 5851  
 Luscher, P., 974  
 Lüttchens, S., 5722  
 Lyall, R. M., 4430  
 Lynch, H. T., 657  
 Lynch, J. H., 3304  
 Lyons, R. M., 5253  
 Lysz, T., 813  
 Ma, B.-L., 1509  
 Mabry, M., 581, 5514  
 Macatee, T. L., 3471  
 Maccubbin, A. E., 886  
 Machemer, T., 4378  
 Maciak, R. S., 2965  
 Mackensen, A., 2524  
 MacLeod, M. C., 4859  
 Madewell, B. R., 233  
 Madreperla, S. A., 6381  
 Maeda, S., 820, 5736  
 Maeda, Y., 2842  
 Maehara, Y., 3503  
 Maeura, Y., 6224  
 Magee, P. N., 6409  
 Magnani, J. L., 3781  
 Magnani, P., 5960  
 Magrath, I., 6550  
 Maguire, H. C., Jr., 2731  
 Maher, V. M., 1221, 2587  
 Mahmoud, S., 1798  
 Maida, B., 1499  
 Maier, L. A., 5361  
 Maimonis, P., 3838  
 Mainolfi, E., 5003  
 Maione, T. E., 2077  
 Mairhofer, H., 27  
 Majumdar, A. P. N., 3416  
 Makabe, T., 22  
 Maki, P. A., 4170  
 Makuch, R. W., 1708  
 Malcovati, M., 5960  
 Malik, R., 5626  
 Malik, S. T. A., 6643  
 Malins, D. C., 5430  
 Malkin, D., 3958  
 Malkinson, A. M., 450, 6699  
 Malone, J. M., 2848  
 Maloney, T., 1973  
 Malviya, V. K., 2848  
 Maly, K., 807, 5821  
 Mammarella, S., 5378  
 Mamone, J. Y., 6558  
 Man, M. S., 4486  
 Mancina, A., 3721  
 Mancini, W. R., 870  
 Mandahl, N., 954  
 Mandard, A. M., 4102  
 Mandecki, W., 1876  
 Mandelli, F., 964  
 Manderino, G., 4149  
 Manenti, G., 6299  
 Mangioni, C., 6358  
 Mani, C., 6052  
 Manly, K. F., 4701  
 Mann, A. M., 3471  
 Mann, D., 3793  
 Mann, K. L., 4859  
 Mann, S. C., 3677, 5903  
 Mannervik, B., 94  
 Mantovani, A., 2239  
 Marcell, T., 3274  
 Marder, V. J., 3261  
 Mareel, M., 2229  
 Margison, G. P., 619, 2092  
 Margolin, J. F., 5626  
 Margolis, B., 3818  
 Mariani-Costantini, R., 5378  
 Marinelli, A., 1694  
 Markert-Hahn, C., 27  
 Markovic, S. N., 1124  
 Marks, A., 1619  
 Marks, J. R., 2605, 2979  
 Maronpot, R. R., 1148, 1391  
 Marsh, J. P., 167  
 Marshall, C. J., 3497  
 Marshall, J. F., 4768  
 Marshall, M. V., 6268  
 Martelli, A., 2273  
 Marti, G. E., 6263  
 Martikainen, P., 4693  
 Martin, G. R., 2670  
 Martin, G. R., 3624  
 Martin, T. J., 3059  
 Martin, W., 5348  
 Martinez, A., 3088  
 Martinez, A., 3088  
 Martin-Padura, I., 2239  
 Maruyama, H., 6224  
 Marx, S. J., 1154  
 Masazza, G., 6358  
 Maseki, N., 5937  
 Mason, K. L., 6338  
 Mason, S. N., 1202  
 Masters, J. R. W., 6592  
 Mastrangelo, M. J., 2731  
 Mastro, A. M., 82  
 Masuda, Y.-i., 4639  
 Masui, H., 6170  
 Masui, S., 282  
 Masui, T., 1766, 1778, 3471  
 Matanoski, G. M., 5786  
 Matherly, L. H., 3420  
 Mathew, R., 5495  
 Matijasevic, Z., 1568  
 Maton, P. N., 1154  
 Matsubara, K., 89, 3544  
 Matsuda, A., 2319  
 Matsuda, H., 5339  
 Matsuda, T., 3237  
 Matsuda, Y., 4080  
 Matsui, Y., 2223  
 Matsuki, S., 3710  
 Matsukura, N., 365  
 Matsumoto, K., 3006, 4323, 5573  
 Matsunaga, T., 3148  
 Matsushita, Y., 387  
 Matsutani, E., 6180  
 Matsuzaki, G., 5261  
 Matta, K. L., 1257  
 Mattammal, M. B., 514  
 Mattern, M. R., 5813  
 Mattes, M. J., 1619, 3102  
 Matthews, D. C., 5921  
 Maxwell, F., 4299  
 Maxwell, I. H., 4229  
 Maxwell, M., 1345  
 May, R. D., 4052, 5045s  
 May, W. S., 682, 5514  
 Mayall, B. H., 3807  
 Maybaum, J., 3900  
 Mayes, J., 4729  
 Mayo, J. G., 2837

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Mazumder, A., 2015, 2694  
 Mazurkiewicz, J. E., 1334  
 Mazzei, M., 2273  
 McBlain, W. A., 556  
 McBride, M., 1117  
 McBride, O. W., 2490  
 McCabe, F. L., 5813  
 McCague, R., 5851  
 McCann, A. H., 3296  
 McCarthy, D., 1651  
 McClelland, R. A., 239  
 McCormick, J. J., 1221, 2587  
 McCoy, D. W., 181  
 McCoy, J. P., Jr., 5212  
 McCue, P., 4937  
 McCully, C. J., 4937  
 McDaniel, T., 5766  
 McDonnell, D. P., 105  
 McGee, D. L., 422  
 McGrath, P., 1973  
 McGuire, J. J., 3874  
 McGuire, W. L., 105, 944  
 McGuire, W. P., 5781  
 McKean, J. D., 2430  
 McKeever, P. E., 3900  
 McKenna, W. G., 5113  
 McKenzie, I. F. C., 310, 2908, 5826  
 McKenzie, S., 5361  
 McLaughlin, J. K., 3044, 3068  
 McLaughlin, K., 2242  
 McLaughlin, S. J., 3534  
 McLellan, E. A., 5270  
 McLemore, T. L., 3274, 4636  
 McMahon, N., 2242  
 McNally, N. J., 33  
 Meadows, A. J., 2885  
 Mechttersheimer, G., 1300  
 Mecklin, J.-P., 4135  
 Medendorp, S. V., 836  
 Medline, A., 5270  
 Medof, M. E., 2521  
 Meeker, D. P., 857  
 Meese, E., 5449  
 Meggough, F., 1227  
 Mehta, R. G., 481  
 Meisner, L. F., 3323  
 Meister, L., 6529  
 Melani, C., 2897  
 Melchiori, A., 2670  
 Melner, M. H., 3663  
 Meloni, G., 964  
 Meltzer, S. J., 5766  
 Memoli, V. A., 349, 354, 2451  
 Mendelsohn, J., 2780  
 Mendiguren-Rodriguez, A., 3669  
 Mendonca, M. S., 4455  
 Menzel, T., 6312  
 Menzies, S. W., 2773  
 Mérand, Y., 3131  
 Meredith, R. F., 5461  
 Merino, M. J., 1071  
 Merle, S., 5384  
 Merlino, G. T., 5417  
 Merlo, G. R., 6194  
 Merluzzi, V. J., 5003  
 Mertens, F., 954  
 Mertens, O., 954  
 Metcalf, D., 2494  
 Metcalf, R. A., 4090, 4102  
 Mewes, K., 3427  
 Meyer, C., 73  
 Meyer, R. A., 841  
 Meyer, S. A., 130  
 Meyers, F. J., 1632  
 Mezzananza, D., 5716  
 Miano, L., 2456  
 Michelson, S., 4111, 5139  
 Mickisch, G. H., 5417  
 Mielke, B., 2430  
 Mihich, E., 745  
 Miike, R., 5266  
 Miki, H., 5308  
 Miki, T., 4909  
 Mikkelsen, R. B., 359  
 Milas, L., 3639  
 Milenic, D. E., 2889, 6363  
 Millar, R., 2577  
 Miller, B. E., 4378  
 Miller, G., 6006  
 Miller, G. K., 2694  
 Miller, L. S., 2889  
 Miller, R. K., 3311  
 Miller, T., 2051  
 Milligan, A. J., 1680  
 Millikin, D., 5449  
 Milner, A. M., 3857  
 Milner, J. A., 4613  
 Milovanovic, S., 5980  
 Mimnaugh, E. G., 769  
 Min, K. W., 2762  
 Minke, J. M. H. M., 4028  
 Minna, J. D., 4999, 6194  
 Miozzo, M., 400  
 Miquel, R., 4436  
 Mirski, S. E. L., 3345  
 Mirvish, S. S., 1059  
 Mischak, R. P., 4575  
 Misdorp, W., 4028  
 Mistry, J. S., 227  
 Mitchell, D. L., 3965  
 Mitchell, G. B., 5487  
 Mitchell, J. B., 1606, 4287, 5065s, 6622  
 Mitchell, M. S., 1418  
 Mitchell, R. B., 3367  
 Mitchell, S., 6660  
 Mitichen, J., 6629  
 Mitelman, F., 954  
 Mitra, S., 3339  
 Mitsudomi, T., 4999, 6194  
 Mitsugi, K., 5392  
 Mitsunobu, M., 89  
 Miura, I., 3267  
 Miura, Y., 341, 4649  
 Mivechi, N. F., 6608  
 Miwa, A., 341  
 Miyaji, H., 6677  
 Miyake, A., 5322, 5951, 5956  
 Miyamoto, H., 6346  
 Miyauchi, M., 4038  
 Miyazaki, I., 1034  
 Miyazaki, I., 2683  
 Miyazaki, K., 5261  
 Miyoshi, I., 1574, 3327  
 Mizoguchi, A., 2223  
 Mizukami, Y., 2683  
 Modali, R. V., 4090  
 Moesker, O., 644, 1959  
 Mohamed, A., 2173  
 Mohler, J. L., 6580  
 Mohtai, H., 4639  
 Moir, D. T., 6712  
 Mokyr, M. B., 4516  
 Moldawer, L. L., 415  
 Moldenhauer, G., 729  
 Moley, J. F., 1596  
 Molina, C. A., 4624  
 Möller, P., 729, 1300  
 Momburg, F., 729  
 Momose, H., 5487  
 Monahan, J. J., 4575  
 Moncada, S., 6073  
 Moncharmont, B., 3843  
 Monfils, B. A., 1308  
 Monks, A., 2515  
 Monson, J. M., 6608  
 Montaldo, P. G., 4342  
 Monteil, H., 2073  
 Montes, G., 190  
 Montesano, R., 3825, 4102  
 Montgomery, B. T., 3748  
 Montgomery, J. A., 2386  
 Montz, F. J., 2124  
 Moody, T. W., 1798  
 Moon, R. C., 481  
 Moore, A. S., 233  
 Moore, G. E., 2735  
 Moore, M., 6318  
 Moradi, M., 4012  
 Morales, F. R., 5107  
 Moran, R. G., 4618  
 Moreau, J.-P., 1798  
 Morel, P. A., 4355  
 Moreno, C., 6372  
 Morgan, A. C., Jr., 676  
 Mori, M., 6656  
 Mori, T., 3544  
 Moriguchi, S., 5339  
 Morimoto, M., 110, 4888  
 Morishige, K.-i., 5322, 5951, 5956  
 Morita, K., 4271  
 Morita, M., 1472  
 Morita, M., 5339  
 Morita, R., 820, 4707, 5118, 5817  
 Moriwaki, S.-i., 2425, 6219  
 Moroi, M., 341  
 Moroson, B. A., 2291  
 Morotomi, M., 1571  
 Morris, D. L., 3198  
 Morris, J., 3595  
 Morrissey, D. T., 2063  
 Morrone, S., 2456  
 Morse, M. A., 1846  
 Mortarini, R., 2239  
 Morton, D. L., 2002, 5687  
 Moschel, R. C., 3367  
 Moser, A. H., 2803  
 Moses, H. L., 5253  
 Mossman, B. T., 167  
 Mottotse, M., 3001  
 Motz, J., 4810  
 Mpezo, M., 549  
 Mtiro, H., 1952  
 Mueller, B. M., 144, 2193  
 Mueller, G. C., 3626, 4114  
 Muindi, J. F., 3096  
 Mujoo, K., 2768  
 Mukhopadhyay, T., 1744, 4495  
 Mulcahy, R. T., 1099, 1783  
 Mulder, K. M., 2256  
 Mulder, N. H., 116  
 Mulé, J. J., 2649  
 Mullen, M. D., 1689  
 Mulshine, J. L., 688, 1798, 4999  
 Mulvin, D. W., 3274  
 Mummert, C., 3367  
 Mundy, G. R., 2438, 4430  
 Munemitsu, S., 1811  
 Munn, D. H., 1117  
 Münz, I., 27  
 Murad, T., 2403  
 Murakami, Y., 3356, 5520  
 Muramatsu, S., 5532  
 Muraro, R., 5378  
 Murasko, D. M., 1124  
 Murata, J., 22  
 Murata, M., 1494  
 Murnane, M. J., 1137  
 Murphy, G., 2731, 4937  
 Murphy, L. C., 2051, 5476  
 Murphy, L. J., 2051, 5476  
 Murphy, M. J., Jr., 2158  
 Murphy, R. F., 6079  
 Murray, J. L., 521  
 Murray, J. L., 2768  
 Murthy, S., 836, 4199  
 Muscat, J. E., 2263, 3067  
 Muschel, R. J., 5113  
 Mutai, M., 318, 824  
 Muzio, G., 4603

## N

- Naaktgeboren, J. M., 1177  
 Naber, S. P., 1345  
 Nabi, I. R., 2699, 3507  
 Nackerdien, Z., 5837  
 Nadler, L. M., 6236  
 Nagahara, A., 2940  
 Nagai, M., 3886  
 Nagarajan, L., 2486  
 Nagasaki, K., 6656  
 Nagashunmugam, T., 5626  
 Nagataki, S., 5667  
 Naiki, M., 1242  
 Nair, U. J., 3018  
 Naito, K., 6180  
 Naito, M., 157  
 Naito, M., 1398  
 Naito, Z., 365  
 Nakachi, K., 5177  
 Nakada, H., 331  
 Nakagama, H., 89  
 Nakai, T., 990  
 Nakaizumi, A., 3493  
 Nakamura, M., 1940  
 Nakamura, S., 215  
 Nakamura, S., 2670

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Nakamura, T., 434  
 Nakamura, T., 1726  
 Nakamura, Y., 89, 820, 2926,  
 4707, 5118, 5794, 5817  
 Nakano, H., 2922  
 Nakano, H., 5800  
 Nakano, S., 5392  
 Nakata, K., 215  
 Nakata, K., 5667  
 Nakatani, K., 5800  
 Nakauchi, H., 99, 341  
 Nakayama, E., 2223  
 Nakayama, H., 2926  
 Nakayama, T., 3639  
 Nakazawa, S., 1574, 2917, 6708  
 Namiki, M., 3550  
 Nanus, D. M., 4815, 5881  
 Napolitano, L. A., 6686  
 Napolitano, T., 2456  
 Narang, P. K., 6079  
 Narasimhan, J., 6199  
 Narita, T., 4909  
 Nash, S., 6059  
 Natale, A., 3102  
 Natale, R. B., 1065  
 Natali, P. G., 652, 3001  
 Nathan, C. F., 794  
 Natsumeda, Y., 3886  
 Nau, M. M., 6194  
 Nawata, H., 2842  
 Nawaz, Z., 105  
 Neal, D., 422  
 Neblock, D. S., 5716  
 Neefe, J. R., 3159  
 Neeman, M., 3831, 4072  
 Negri, E., 629  
 Nelkin, B. D., 5514  
 Nelson, G., 6163  
 Nelson, J. M., 4581  
 Neri, A., 1318  
 Nesnow, S., 5198, 6163  
 Neumann, C., 3243  
 Neuringer, L. J., 3289  
 Neville-Golden, J., 1345  
 Newcomb, E. W., 5129, 6202  
 Newell, A. D., 233  
 Newkirk, C., 5766  
 Newman, E. M., 4871  
 Newman, J., 4052  
 Newman, R. A., 3559, 3568  
 Newmark, H., 3069  
 Newton, C., 5851  
 Nezelof, C., 5712  
 Ng, S.-f., 2340  
 Ng, T. C., 1384  
 Ngo, L., 6686  
 Nhamburo, P. T., 4636  
 Nicklas, J. A., 6001  
 Nicolson, G. L., 245, 387, 5943  
 Nie, G., 3143  
 Niedzwiecki, D., 789  
 Nielsen, L. L., 3762  
 Niethammer, D., 6066  
 Niho, Y., 5392  
 Nii, A., 5526  
 Niloff, J., 4476  
 Nimec, Z., 3874  
 Ning, S., 5910  
 Ning, S. M., 1509  
 Ninomiya, I., 1034  
 Nisar, M., 1613, 6019  
 Nishigori, C., 2425, 6219  
 Nishii, K., 5573  
 Nishikawa, A., 5888  
 Nishikawa, K., 6084  
 Nishikawa, M., 4271  
 Nishino, H., 1448  
 Nishino, N., 2842  
 Nishino, T., 3522  
 Nishio, K., 3237  
 Nishioka, M., 4080  
 Nishioka, Y., 5526  
 Nishiura, T., 5888  
 Nishiya, S., 5859  
 Nishizawa, Y., 3006, 5573  
 Nishizawa, Y., 5573  
 Nistér, M., 1553  
 Nitta, T., 5565  
 Niwa, K., 5987  
 Nobori, T., 3193  
 Noël, A. C., 405, 3624  
 Noelke, B., 205  
 Noguchi, A., 4310  
 Noguchi, A., 4310  
 Noguchi, M., 2683  
 Noguchi, P. D., 6263  
 Noguchi, Y., 863  
 Nojiri, H., 1940  
 Nolan, C., 1817  
 Nomoto, K., 1494, 5261  
 Nomura, K., 3056  
 Nomura, K., 3257  
 Nonomura, N., 3006  
 Nordenskjöld, M., 1684  
 Normanno, N., 1294, 4898  
 Normolle, D. P., 3900  
 North, S. M., 5943  
 Northoff, H., 3862  
 Norton, J. A., 1154, 2302  
 Norton, K., 3391  
 Norton, K. A., 372  
 Norton, T. R., 504  
 Nourigat, C., 5921  
 Novick, S., 5410  
 Nowell, P. C., 2494, 6712  
 Nudelman, E. D., 2199  
 Nugent, P., 1465  
 Numata, M., 195  
 Numata, Y., 331  
 Nusgens, B. V., 405  
 Nuzzo, F., 3965  
 Nyce, J. W., 6563  
  
**O**  
 Obara, T., 3550  
 Obata, Y., 2416  
 Oberberg, D., 43, 3862  
 Oberhammer, F., 2478  
 Oberhuber, H., 807  
 Oberley, L. W., 1922  
 Oberley, T. D., 1922, 6629  
 O'Brien, S., 935  
 O'Brien, W. J., 6199  
 Ochoa, A. C., 2127  
 Ochoa, J. B., 2127  
 O'Connor, B. M., 3874  
 O'Connor, P. M., 6550  
 O'Connor, T., 1708  
 Odom-Maryon, T., 5704  
 Odoroff, C. L., 3311  
 O'Dwyer, J. L., 2041  
 O'Dwyer, P. J., 2041, 3080, 3171,  
 6059  
 Oesch, F., 1659  
 Ogata, M., 3011  
 Ogawa, K., 318, 5655  
 Ogawa, K., 949  
 Ogawa, M., 3544, 5694  
 Ogawa, O., 949, 5817  
 Ogawa, T., 4038  
 Ogolla, F., 549  
 Ogura, K., 1701  
 Ogura, R., 3555  
 Ogura, T., 5526  
 Ohannesian, D. W., 387  
 O'Hara, C., 4476  
 Ohe, Y., 1472  
 Ohgaki, H., 6202  
 Oh-hara, T., 921  
 Ohishi, T., 2199  
 Ohkubo, C., 1561  
 Ohmori, T., 3237  
 Ohnishi, Y., 3919  
 Ohno, H., 110  
 Ohno, M., 5888  
 Ohno, S., 2994, 3559, 3568  
 Ohnuma, N., 3148  
 Ohnuma, T., 55  
 Ohoyama, S., 1034  
 Ohryohji, F., 2842  
 Ohshima, K., 4639, 5392  
 Ohtsuki, Y., 3327  
 Ohyashiki, J. H., 2917  
 Ohyashiki, K., 2917  
 Oie, H. K., 4999  
 Oikawa, A., 195  
 Oishi, K., 3445  
 Oishi, M., 764, 5398  
 Ojwang, J. O., 2268  
 Oka, T., 3522  
 Oka, Y., 4450  
 Okabe, M., 110, 4888  
 Okabe-Kado, J., 2582, 4535, 4649  
 Okada, F., 6677  
 Okada, M., 341  
 Okamoto, A., 5171, 5632  
 Okamoto, E., 89  
 Okamura, K., 3550  
 Okamura, T., 1766, 1778, 3471  
 Okano, T., 3229  
 Okarma, T., 3891  
 Okoshi, H., 6019  
 Okubo, T., 6084  
 Okuda, S., 785, 6150  
 Okuhara, M., 4038  
 Okumoto, T., 2319  
 Okumura, K., 5565  
 Okun, E., 2002, 5687  
 Okunieff, P., 3289  
 Okuzumi, J., 1448  
 Old, L. J., 2706  
 Oldfield, E. H., 1154  
 Oldiviera, R., 4948  
 O'Leary, D. F., 1412  
 Oleinick, N. L., 5993  
 Oliva, M. R., 2463  
 Olive, M., 1452  
 Olive, P. L., 4671  
 Olsnes, S., 916  
 Olsson, J. M., 3774  
 O'Malley, B. W., 105  
 O'Neill, J. P., 6001, 6603  
 Ong, G. L., 1619  
 Ono, M., 3951  
 Onoda, M., 3304  
 Onozuka, Y., 4535  
 Onyekwere, O., 4279, 6304  
 Opacic, D., 6691  
 Oppenheim, J. J., 1158  
 Oratz, R., 3643  
 Ordentlich, P., 1996  
 O'Regan, M., 3296  
 Orino, E., 5526  
 O'Riordan, M. A., 1564  
 Orloff, M., 2009  
 Oron, M., 1499  
 Orosz, C. G., 2373  
 Ortaldo, J. R., 6596  
 Osada, Y., 903  
 Osann, K. E., 4893  
 Osborne, M. P., 2706  
 Osborne, R. J., 6194  
 Oshimura, M., 4415  
 Osman, S., 2107  
 Ossowski, L., 274  
 Österdahl, B.-G., 4388  
 Ostrowski, L. E., 3339  
 Ota, D. M., 387, 5728  
 Otake, N., 157  
 Otto, A. M., 3217  
 Otto, H. F., 729  
 Oval, J., 150  
 Overgaard, J., 707  
 Owen, R. D., 6010  
 Owen-Schaub, L. B., 3669  
 Ownby, H., 1973  
 Oyama, F., 4876  
 Oyasu, R., 3323, 5487  
 Ozdemirli, M., 1137  
 Ozols, R. F., 6059  
 Ozturk, M., 6185  
  
**P**  
 Paans, A. M. J., 1930  
 Pacelli, R., 4898  
 Pacula-Cox, C. M., 1247  
 Padarathsingh, M., 5440  
 Padavic-Shaller, K., 3910  
 Padfield, G., 4111, 5139  
 Padma, R., 2486  
 Paffenbarger, R. S., Jr., 2307  
 Paganelli, G., 5960  
 Paganin, C., 301  
 Pai, L. H., 2808  
 Paik, S., 3590  
 Palacin, A., 4436  
 Palefsky, J. M., 1014  
 Palmer, L. A., 5224

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Palmer, P., 2456  
 Palmieri, G., 1294  
 Palomba, M. L., 4931  
 Pan, C.-J., 2058  
 Pan, S.-s., 4360  
 Pandolfi, F., 3164  
 Panella, T. J., 3037  
 Pantazis, P., 6636  
 Pantel, K., 4712  
 Panting, L., 6059  
 Paolini, M., 301  
 Papageorge, A. G., 712  
 Pardee, A. B., 3602  
 Pariza, M. W., 2940, 6118  
 Park, S. S., 1059  
 Parker, H. M., 4613  
 Parker, W. B., 2386  
 Parkin, J. L., 3990  
 Parkinson, D. R., 3669  
 Parl, F. F., 3405  
 Parmiani, G., 2239, 2897  
 Parpia, B., 3826  
 Parry, R. L., 2101  
 Partridge, E. E., 568  
 Parysek, L. M., 6338  
 Parzefall, W., 1143, 2478  
 Pasero, L., 1270  
 Pass, H. I., 4287, 4999  
 Pastan, I., 174, 2808, 2831, 3011, 3781, 5417  
 Pastorino, U., 400  
 Pate, D. W., 4588  
 Patel, R., 4871  
 Paterson, A. H. G., 556  
 Paterson, M. C., 556  
 Pathak, M. A., 4964  
 Pathak, S., 6292  
 Patrick, K. E., 850, 5642  
 Patterson, D., 3821  
 Paugh, D., 2395  
 Pauley, R., 3331  
 Pauli, B. U., 394  
 Pauli, G., 2073  
 Pauly, K., 1659  
 Paumgartner, G., 205  
 Pauwels, R. P. E., 644  
 Pawluczky, I. Z. A., 1990  
 Payan, M. J., 5679  
 Pearson, P. L., 1020  
 Peccatori, F., 6358  
 Pegg, A. E., 3367  
 Pegoraro, L., 1741  
 Pegram, C. N., 3339  
 Pelhate, S., 1537  
 Pellicer, A., 1627, 5129, 5410  
 Pelling, J. C., 1851, 3471  
 Peltomäki, P., 4135  
 Pence, J. C., 2979  
 Pepe, S., 4898, 6263  
 Perantoni, A. O., 5308  
 Perchellet, E. M., 2820  
 Perchellet, J.-P., 2820  
 Perentesis, P., 688  
 Perez, A., 4828  
 Pérez-Ayala, M., 2463  
 Peri, L., 4102  
 Perrett, E. A., 5253  
 Perrotti, D., 5491  
 Persons, P. E., 4430  
 Persson, B., 954  
 Perucho, M., 5129  
 Peter, R., 3171  
 Peter, S., 1811  
 Peters, R. H., 2536  
 Petersen, B. H., 2286  
 Peterson, J. A., 4994  
 Peterson, L. A., 5495, 5557  
 Peto, R., 6415, 6452, 6470  
 Petrakis, N. L., 5266  
 Petruk, K. C., 2430  
 Pettersson, R. F., 2164  
 Pettinato, A., 2456  
 Pettit, G. R., 682  
 Pfahl, M., 4804  
 Pfeffer, L. M., 5881  
 Pfeifer, A. M. A., 3793  
 Pfeiffer, A., 205  
 Pflug, B., 3304  
 Phan, S.-C., 1571  
 Phelps, R. M., 1708, 4999  
 Phillips, P. D., 5997  
 Philpot, R. M., 4636  
 Piccoli, M., 2456  
 Pié, A., 1659  
 Pienta, K. J., 6514  
 Pieper, R. O., 1581  
 Pierotti, M. A., 400  
 Pierré, A., 2312  
 Pietersz, G. A., 310  
 Pike, J. W., 239  
 Pike, M. C., 3617  
 Pilotti, S., 400  
 Pinsky, C., 688  
 Pisani, P., 2572  
 Pittman, A., 2515  
 Pizzorno, G., 2291  
 Plasse, T. F., 2021  
 Platsoucas, C. D., 4257  
 Platt, J. L., 2127  
 Pleasure, D., 6529  
 Plowman, J., 1979, 2837  
 Plunkett, M. L., 1339  
 Plunkett, W., 4141, 6110  
 Podczaski, E., 4149  
 Poddighe, P. J., 1959  
 Podhasky, P., 969  
 Poggensee, L., 2403  
 Poliwooda, H., 6312  
 Pollard, M., 3610  
 Pomfret, E. A., 16  
 Pommier, Y., 6280  
 Pon, R. T., 3996  
 Ponchio, L., 536  
 Ponchon, T., 3024  
 Ponta, H., 5292  
 Pontes, E., 4199  
 Pontes, J. E., 2521  
 Ponti, M., 199  
 Ponton, A., 2138  
 Pontzer, C. H., 5304  
 Ponzoni, M., 4342  
 Poole, S., 4768  
 Poonamallee, U. R., 1632  
 Popanda, O., 3456  
 Popenoe, E. A., 4588  
 Poplack, D. G., 3171, 5467, 6079  
 Popper, T. L., 1339  
 Porcu, P., 1741, 5997  
 Porter, C. W., 3715  
 Porter, L., 445  
 Potischman, N., 4785  
 Potmesil, M., 3052, 6039  
 Pott, C., 3243  
 Poupon, M.-F., 2312  
 Pour, P. M., 4757  
 Pourreau, C. N., 2456  
 Pourtier-Manzanedo, A., 4226  
 Powell, G. J., 3059  
 Pradel, P., 3633  
 Prakash, N. J., 62  
 Prat, F., 3024  
 Prat, M., 3001  
 Prehn, R. T., 2  
 Prendergast, R. A., 6381  
 Presti, J. C., Jr., 1544, 5405  
 Preston-Martin, S., 3044  
 Pretlow, T. G., 1564, 3814  
 Pretlow, T. P., 1564, 3814  
 Price, J. E., 2029  
 Price, M. R., 1990  
 Priest, D. G., 789  
 Primavera, M. C., 3261  
 Primus, F. J., 181, 926  
 Prince, C. W., 2144  
 Prior, T. I., 174  
 Prochownik, E. V., 2118  
 Proctor, R. A., 1651  
 Proksch, B., 3427  
 Prusoff, W. H., 1586  
 Puett, D., 3663  
 Puisieux, A., 6185  
 Pulciani, S., 744  
 Puri, R. K., 3011, 6209  
 Pyke, C., 4067  
 Pylkkänen, L., 4135
- Q**
- Qi, W., 4250  
 Qiu, H., 255  
 Qiu, S., 3748  
 Queen, C., 465  
 Quistorff, B., 5160  
 Quoix, E., 2073
- R**
- Raatgever, J. W., 3445  
 Rabbits, P. H., 5205  
 Rabinovitch, P. S., 5482  
 Radacic, M. M., 707  
 Rademaker, A., 5487  
 Radin, A. I., 4279  
 Radomski, M. W., 6073  
 Radulovic, S., 5980, 6006  
 Radzikowsky, C., 916  
 Raffel, C., 639  
 Ragaz, J., 1904  
 Rago, R., 6629  
 Ralfkiaer, E., 4067, 5976  
 Ramackers, F. C. S., 644, 1959  
 Ramakrishnan, S., 4012  
 Ramel, S., 5482  
 Ramp, G., 3843  
 Ran, M., 612  
 Rannikko, S., 222  
 Rao, C. V., 4528  
 Rao, G., 5837  
 Rao, J. Y., 2762  
 Rao, P. H., 1544  
 Rappaport, W. D., 422  
 Rashed, S., 4257  
 Raskind, W. H., 5482, 5766  
 Raso, V., 4316  
 Rastetter, J., 43  
 Ratain, M. J., 1749  
 Ratko, T. A., 481  
 Ratliff, T. L., 3726  
 Ratner, L., 4295  
 Ravdin, P. M., 6268  
 Ravikumar, T. S., 6323  
 Ravindranath, Y., 4279  
 Rawson, N. S. B., 1817  
 Raychaudhuri, S., 3183, 6045  
 Rayman, P., 4199  
 Raymond, V. W., 5238  
 Raz, A., 2173, 2699, 3507  
 Raz, T., 2173  
 Reaman, G. H., 4871  
 Reardan, D. T., 4219  
 Recchione, C., 2572  
 Reddel, R. R., 365  
 Reddy, B. S., 487, 2826, 4528  
 Reddy, K. B., 3451  
 Redmond, S. M. S., 2092  
 Redondo, M., 2463, 4948  
 Redpath, J. L., 4455  
 Reed, J. C., 6529  
 Rees, R. C., 2490  
 Reeve, J. G., 5205  
 Reeve, V. E., 2773  
 Reeves, W. C., 4785  
 Refsum, H., 828  
 Reggio, H., 5679  
 Reibnegger, G., 6250  
 Reid, B. J., 5482, 5766  
 Reiners, J. J., Jr., 4859  
 Reinlib, L., 359  
 Reisfeld, R. A., 144, 2193, 4986  
 Reiss, K., 5997  
 Reiss, M., 5315, 6254  
 Remick, S. C., 1651  
 Resau, J. H., 365, 657, 3267, 5219, 5766  
 Rettig, W. J., 336  
 Reuter, V. E., 1544, 5405  
 Revoltella, R. P., 301  
 Reynier, M., 1270  
 Reynolds, J. C., 688  
 Reynolds, S. H., 1148  
 Reznikoff, C. A., 3323  
 Rheinwald, J. G., 3972  
 Rhim, J. S., 5967, 6521  
 Rhinehardt-Clark, A., 468  
 Riboni, R., 3965  
 Ricciardi, R. P., 3334  
 Rice, J. M., 5308  
 Richards, J., 4328  
 Richards, M. A., 1210

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Richardson, J., 5876  
 Richie, E. R., 737  
 Richter, K. H., 6010  
 Ricketts, D., 1817  
 Riecken, E.-O., 5342  
 Rieder, C. L., 4942  
 Riethmüller, G., 4712  
 Rigotty, J., 487, 4528  
 Rijksen, G., 5507  
 Riley, C. M., 3096  
 Rimoldi, D., 324, 5929  
 Rinderle, S. J., 657  
 Ringborg, U., 94  
 Ringer, D. P., 504  
 Rio, M.-C., 624  
 Riordan, J. M., 886  
 Riou, G., 33  
 Risio, M., 1917  
 Ristimäki, A., 2107  
 Ritchey, J. K., 3726  
 Ritter, M. A., 261  
 Ritts, R. E., Jr., 4155  
 Rivoltini, L., 2897  
 Rizkalla, L. R., 5760  
 Rizkalla, W. M., 5760  
 Rizzino, A., 5898  
 Ro, J. Y., 4495  
 Robb, D., 2690  
 Robbiano, L., 2273  
 Robbins, P. F., 3657  
 Roberts, D. W., 4371  
 Roberts, J., 2577  
 Roberts, J. J., 123  
 Robertson, N., 3183  
 Robertson, N. E., 1339  
 Robins, R. A., 1990, 5425  
 Robinson, W. R., 4045  
 Robison, L. L., 2885  
 Roche, J. K., 4423  
 Rodeck, U., 2205  
 Rodriguez, G., 6268  
 Roebuck, B. D., 5501  
 Roelofs, M. E. M., 2628  
 Roffler, S. R., 4001  
 Rofstad, E. K., 4609  
 Rogers, A. E., 5501  
 Rogers, K., 5461  
 Roh, H. D., 6695  
 Rokukawa, C., 1701  
 Romanini, A., 789  
 Romano, J. W., 4090  
 Romerdahl, C. A., 2193  
 Romero, M., 4436  
 Romero, P. A., 3136  
 Rommel, M. E., 3733  
 Ronan, S. G., 2025  
 Roninson, I. B., 2720  
 Roop, D. R., 4402  
 Roos, G., 4570  
 Rorke, E. A., 3982  
 Rosado, M., 4955  
 Rosati, R., 4234  
 Rose, L. M., 2386  
 Roselli, M., 181  
 Rosen, E. M., 5315  
 Rosen, N., 4978  
 Rosen, P. P., 2706  
 Rosenberg, J., 3183  
 Rosenberg, S. A., 2649, 5074s  
 Rosenblum, M. G., 2768  
 Rosenblum, N. G., 2041  
 Rosenfeld, M. G., 6170  
 Rosengard, A. M., 445  
 Rosenstrauss, M. J., 5744  
 Roses, D. F., 3643  
 Ross, D. D., 4360  
 Ross, J., 6163  
 Ross, R. K., 3617  
 Rossetti, C., 5960  
 Rossignol, G., 2009, 3946  
 Rossini, F. P., 1917  
 Rosti, V., 536  
 Roth, B. J., 4395  
 Roth, J. A., 1744, 3669, 4495  
 Roth, J. S., 1803  
 Rothlein, R., 5003  
 Rotter, V., 5232  
 Rotundo, R. F., 3874  
 Rousseau, S. M., 349, 354  
 Rowinsky, E. K., 5781  
 Rowley, J. D., 2494  
 Rowlinson-Busza, G., 3251  
 Roy, D., 3882  
 Roy, G., 5245  
 Roy-Burman, P., 5440  
 Rozengurt, E., 1674, 3621  
 Rozental, J. M., 1099  
 Rubin, E., 6636  
 Rubin, H., 1003, 2751  
 Rubinstein, L. R., 1247  
 Rucker, N., 6574  
 Ruco, L., 2456  
 Rudolf, A. R., 233  
 Rudy, W., 5292  
 Ruggeri, B., 4097, 6615  
 Ruiz-Cabello, F., 2463, 4948  
 Rummel, S. A., 737  
 Runkle, R. L., Jr., 1339  
 Ruscetti, F. W., 1158  
 Roelofs, M. E. M., 1708  
 Russo, A., 4287, 6622  
 Russo-Payne, H., 274  
 Rustum, Y. M., 3476  
 Rutherford, A. V., 3781  
 Ryall, G. K., 1817, 4685  
 Ryle, C. M., 4402
- S
- Sacchi, A., 5491  
 Sachs, L., 2494  
 Saclarides, T. J., 2720  
 Saez, S., 1227  
 Safa, A. R., 521  
 Saga, T., 990  
 Sagman, U., 718  
 Saidi, J., 4388  
 Saijo, N., 1472, 3237  
 Saiki, I., 22  
 Sai-Maurel, C., 1537  
 Saito, H., 5118  
 Saito, M., 1940  
 Saito, M., 2917, 6708  
 Saito, S., 5817  
 Saitoh, O., 2854  
 Saitoh, Y., 110  
 Sakahara, H., 990  
 Sakakura, T., 3257  
 Sakamoto, G., 5794  
 Sakamoto, N., 903  
 Sakurai, K., 4476  
 Sakata, S., 2319  
 Sakata, T., 1778  
 Sakoyama, Y., 5951  
 Sakura, Y., 6180  
 Sakurai, M., 4355  
 Sakurai, M., 5937  
 Sakurai, Y., 3229  
 Salahuddin, S. Z., 2670  
 Saleh, M. N., 4155, 5461  
 Salemark, L., 954  
 Salgaller, M., 3657  
 Salomon, D. S., 1051  
 Salwen, H. R., 6338  
 Sameshima, Y., 5171, 5632  
 Samid, D., 324  
 Samuels, B. L., 521, 1749  
 Samuni, A., 6622  
 Sanchez, A. B., 6539  
 Sanchez, C. A., 5482  
 Sanchez-Madrid, F., 2239  
 Sandberg, A. A., 422  
 Sandgren, M., 2021  
 Sandoval, L., 3602  
 Sandvig, K., 916  
 Sangaiah, R., 6163  
 Sano, T., 2926  
 Santella, R. M., 1720, 6230  
 Santen, R. J., 1760  
 Santoni, A., 2456  
 Sarang, M., 6280, 6550  
 Sari, H., 1270  
 Sarid, J., 3595  
 Saris, W. H. M., 6138  
 Sarre, O., 1339  
 Sartorius, S., 5781  
 Sartwell, A. D., 2058  
 Sasada, R., 6180  
 Sasaki, T., 1034, 2319  
 Sasaki, Y., 1472  
 Sasazuki, T., 2874  
 Satake-Ishikawa, R., 3710  
 Sato, A., 110  
 Sato, B., 3006, 4323, 5573  
 Sato, J. K., 4871  
 Sato, K., 2511  
 Sato, K., 4187  
 Sato, K., 5565  
 Sato, M., 3177  
 Sato, M., 4909  
 Sato, N., 4250  
 Sato, S., 921  
 Sato, S., 6677  
 Sato, T., 5118, 5794  
 Sato, W., 2420  
 Sato, Y., 341  
 Satoh, M., 6677  
 Satyaswaroop, P. G., 5661  
 Saunders, D. E., 2848  
 Sausville, E., 688  
 Sauter, G., 205  
 Savina, P. M., 3906  
 Savoldelli, R., 629  
 Sawicka, J. M., 624  
 Saylor, R. L., III, 4721  
 Scala, S., 4898  
 Scalliet, P. G., 4523  
 Scanlon, K. L., 4618  
 Scardino, P. T., 4084  
 Scarpelli, D. G., 2403  
 Schachter, H., 1257  
 Schackert, G., 2029  
 Schaffel, S., 3838  
 Schalken, J. A., 606, 2329  
 Schaller, G., 4712  
 Schally, A. V., 4757, 5980, 6006  
 Schanbacher, C. F., 1109  
 Schecter, R. L., 1434  
 Schellhammer, P. F., 1326  
 Schepbach, W., 4238  
 Scher, C. D., 5626  
 Scher, H. I., 3096  
 Schildberg, F. W., 205  
 Schilder, R., 6059  
 Schiller, J. H., 1651  
 Schimke, R. T., 2949  
 Schinkel, A. H., 2628  
 Schipper, J. H., 6328  
 Schlag, P., 729  
 Schlenger, K., 3316, 6098  
 Schlesinger, J., 3818  
 Schlessinger, J., 150, 2438  
 Schlimok, G., 4712  
 Schlom, J., 181, 926, 2889, 3657, 4155, 5461, 5694, 6363  
 Schlossman, D. M., 468  
 Schmidberger, H., 1883, 1891  
 Schmidt, C. A., 4213  
 Schmidt, H., 2690  
 Schmittgen, T. D., 3849  
 Schmitz, B., 3702  
 Schneck, D. W., 2286  
 Schneekloth, C., 6312  
 Schneider, S., 4131  
 Schneider, W. P., 465  
 Schnipper, L. E., 510  
 Schoenberg, J. B., 3044  
 Schoenhaus, M., 4131  
 Schoenig, G. P., 1766  
 Schoenlein, P., 1638  
 Schold, S. C., Jr., 3906  
 Scholz, M., 4410  
 Schönenberger, H., 3217  
 Schor, P. L., 3831  
 Schornagel, J. H., 5507  
 Schrappe, M., 4986  
 Schraufstätter, I. U., 6066  
 Schreiner, C., 1738  
 Schrode, R., 1659  
 Schroeder, F. H., 3445  
 Schroit, A. J., 3062  
 Schuchter, L. M., 682  
 Schuller, H. M., 2009  
 Schulte-Hermann, R., 666, 1143, 1789, 2478  
 Schulz, K.-D., 5722  
 Schulz, S., 6563  
 Schulz, V., 4665  
 Schuster, J. M., 4164

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Schut, H. A. J., 5636  
 Schuur, E., 4028  
 Schwartz, G. K., 55  
 Schwartz, J. L., 3857  
 Schwartz, L. H., 624  
 Schwartz, M. S., 3595  
 Schweighardt, S. A., 6650  
 Scimeca, J. A., 6118  
 Scott, J., 6273  
 Scott, O. C. A., 757, 5434  
 Scott, W. L., 5774  
 Scrable, H., 5100  
 Scudiero, D., 2515  
 Sebag, M., 6521  
 Sebt, S. M., 227  
 Seccamani, E., 5960  
 Secher, D., 5461  
 Seckinger, D., 1190  
 Secreto, G., 2572  
 Secrist, J. A., III, 2386  
 Sedivy, R., 1143  
 Sedwick, W. D., 3930  
 See, W. A., 1373, 1378  
 Segal, D. M., 5716  
 Sehagl, S. N., 5614  
 Sehested, M., 5093  
 Sehgal, S. N., 1499  
 Seidel, A., 1659  
 Seidler, L., 4328  
 Seidman, I., 4917  
 Seigner, C., 5679  
 Sekely, L. L., 3626  
 Sekido, Y., 2416  
 Sekiguchi, K., 4876  
 Sekiya, S., 2655  
 Sekiya, T., 3356, 5520, 5800  
 Sela, B.-A., 4853  
 Selhub, J., 16  
 Seliger, B., 2164  
 Selkirk, S., 4768  
 Sell, S., 1278  
 Selliah, N., 1973  
 Sem, D. S., 6199  
 Sendo, F., 3212  
 Seon, B. K., 2985  
 Sergi, J. S., 836, 4199  
 Serre, C.-M., 2621  
 Serve, H., 3862  
 Sethi, T., 1674, 3621  
 Seto, M., 1574, 6708  
 Setter, E., 5315  
 Seveck, E. M., 265, 1352, 2727  
 Seyama, T., 381  
 Seyedsadr, M., 3108  
 Seyoum, E., 16  
 Sgagias, M. K., 1488  
 Shabon, U., 3334  
 Shaddix, S. C., 2386  
 Shah, G. N., 6243  
 Shaper, J. H., 581  
 Sharfman, W. J., 836, 4199  
 Sharief, Y., 6580  
 Shariff, S. Y., 5487  
 Sharkey, R. M., 1619, 3102, 4192  
 Sharma, R. C., 2949  
 Sharpe, R. J., 2077  
 Shaulsky, G., 5232  
 Shawver, L. K., 4575  
 Shea, C. R., 4410  
 Shea, W. K., 2786  
 Sheahan, K., 1137  
 Sheehan, C., 4486  
 Sheehan, J., 5342  
 Sheibani, N., 5967  
 Shellard, S. A., 4557  
 Sherman, M. L., 4565  
 Sherry, B., 415  
 Sherwood, E. R., 2780  
 Sherwood, M., 288  
 Shi, Y., 2690  
 Shibamoto, Y., 5134  
 Shibasaki, Y., 4450  
 Shibata, M.-A., 2548  
 Shibata, Y., 3550  
 Shibazaki, C., 3229  
 Shibuya, M. L., 573  
 Shida, T., 5392  
 Shih, A. G., 288  
 Shih, L. B., 4192  
 Shiku, H., 2223  
 Shima, M., 5667  
 Shima, T. B., 2670  
 Shimada, H., 2151, 5100  
 Shimada, S., 5694  
 Shimada, T., 5284  
 Shimada, Y., 2113  
 Shimbara, N., 6677  
 Shimizu, N., 1504  
 Shimizu, Y., 6153  
 Shimokata, K., 2416  
 Shimosato, Y., 2199, 4876  
 Shimoyama, Y., 2185  
 Shin, K. C., 1065  
 Shingleton, H. M., 568  
 Shinkai, T., 1472  
 Shinozawa, Y., 1504  
 Shiojiri, N., 2611  
 Shiota, S., 3339  
 Shirai, T., 1264, 5655  
 Shirai, Y., 4080  
 Shirakawa, S., 4271  
 Shirasawa, H., 3148  
 Shirasawa, S., 2874  
 Shiu, R. P. C., 3996  
 Shively, J. E., 1876, 3802  
 Shochat, D., 5461  
 Shoemaker, R. H., 2837  
 Shoff, S. M., 37  
 Shortnacy, A. T., 2386  
 Shoyab, M., 2813  
 Shu, Z., 2307  
 Shuja, S., 1137  
 Shulman, H., 5921  
 Shulok, J. R., 1109, 2710  
 Siccardi, A. G., 5960  
 Siddik, Z. H., 2994, 3559, 3568  
 Siddiki, B., 1026  
 Sidransky, D., 4721, 6304  
 Siegall, C. B., 2831  
 Siegel, F. L., 1783  
 Siegel, S. E., 2885  
 Siegfried, J. M., 3267  
 Siessmann, K. L., 4516  
 Sigdestad, C. P., 4125  
 Sijens, P. E., 1384  
 Sikic, B. I., 5181  
 Sikorska, M., 528, 1078  
 Silber, J. H., 1426  
 Silber, R., 3052  
 Siler, K., 2889  
 Sillerud, L. O., 3831, 4072  
 Silletti, S., 3507  
 Silver, H. K. B., 1904  
 Simar, L., 405  
 Simard, J., 2797, 4336, 5165  
 Simizu, B., 3148  
 Simmons, A. M., 1708  
 Simon, D., 6176  
 Simons, J. W., 4135  
 Simons, J. W. I. M., 1177  
 Simpkins, H., 1334  
 Simpson, J. F., 926  
 Simpson, S., 3590  
 Simpson, W., 2451  
 Sinclair, W. K., 2740  
 Singer, S., 3289  
 Singh, S. B., 3482  
 Singh, U. C., 3482  
 Singhal, A., 1406  
 Sinha, B. K., 521, 769  
 Siracký, J., 4701  
 Sirica, A. E., 5752  
 Sirotak, F. M., 1412  
 Sistonen, P., 4135  
 Sitrin, M. D., 4305, 5608  
 Siu, H., 5045s  
 Sjoerdsma, A., 62  
 Skalak, T. C., 265  
 Skehan, P., 2515  
 Skierski, J., 4828  
 Skipper, P. L., 5219  
 Skipper, P. W., 4371  
 Sklar, M. D., 2118  
 Skolnik, E. Y., 3818  
 Skopek, T. R., 5188  
 Skornick, Y., 5602  
 Skup, D., 2138  
 Sladek, N. E., 4170  
 Slaga, T. J., 907  
 Slagle, B. L., 49  
 Slamon, D. J., 556, 1811  
 Slater, J. B., 6650  
 Slebos, R., 958  
 Sledge, G. W., Jr., 4395  
 Sleemi, A., 5370  
 Slevin, M. L., 1210  
 Sloan, S. R., 1627  
 Sluys, M., 1930, 3843  
 Smeds, S., 3585  
 Smeets, A. W. G. B., 644  
 Smeets, D., 1959  
 Smidt, M., 4295  
 Smith, C., 1078  
 Smith, C. A., 5843  
 Smith, H. S., 4978  
 Smith, J., 4685  
 Smith, K. L., 6089  
 Smith, R. A., 1766, 4388  
 Smith, R. D., 542  
 Smith, T. J., 1509, 4798  
 Smyth, M. J., 310  
 Sneed, D., 3183  
 Snover, D. C., 1891  
 Snow, G. B., 211  
 Snoy, P., 6363  
 Snyder, K. A., 4423  
 Snyder, S. W., 4360  
 Sobel, M. E., 439, 5672  
 Sobelman, D., 1499  
 Sodum, R. S., 137  
 Soeters, P. B., 6138  
 Sohn, O. S., 2826  
 Soi, A., 5760  
 Solheim, E., 4837  
 Sone, S., 5526  
 Song, Y., 1910  
 Sonobe, H., 3327  
 Soper, J. T., 468  
 Sørensen, B. S., 5093  
 Soued, M., 2803  
 Souhami, R. L., 1210  
 Southby, J., 3059  
 Sozzi, G., 400  
 Spada, A. P., 4430  
 Spadafora, C. G., 3814  
 Spagnesi, M. T., 3721  
 Spang-Thomsen, M., 5160  
 Spector, A. A., 6025  
 Speicher, D., 4853  
 Spengler, B. A., 1596  
 Speyer, J. L., 3643  
 Spiegel, A. M., 1154  
 Spillare, E., 3793  
 Spindel, E. R., 5205  
 Spiro, R. C., 4986  
 Sporn, L. A., 3261  
 Sporn, M. B., 3610, 6215  
 Sprancmanis, L. A., 3096  
 Spreafico, F., 199  
 Sprengel, J., 3702  
 Spriggs, D., 4476  
 Sredni, B., 1499, 5614  
 Sreekantaiah, C., 422  
 Srikantan, V., 324  
 Stackpole, C. W., 2444  
 Stadler, M., 2478  
 Stähelin, H. F., 5  
 Stahl, J. A., 445  
 Staley, J., 1798  
 Stamato, T. D., 2636, 4463  
 Stamp, G., 6643  
 Stanbridge, E. J., 4455  
 Stanescu, G., 2521  
 Stanley, J., 4199  
 Stanners, C. P., 3526  
 Stark, H.-J., 4402  
 Starkey, J., 3183, 6045  
 Starling, J. J., 2965  
 Staroselsky, A. H., 6292  
 Stash, E. B., 6254  
 Stastny, J. J., 3768  
 Staudter, M., 1300  
 St. Clair, D. K., 939, 4539  
 St. Clair, W. H., 4539  
 Stearns, M. E., 5866  
 Steeg, P. S., 445, 2490  
 Steele, G., Jr., 6323  
 Stefanik, D. F., 5760

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Stefanini, M., 3965  
 Stehlin, J. S., Jr., 3052  
 Stein, H., 3243, 5342  
 Stein, L. S., 696  
 Steinberg, S. M., 4999  
 Steinbrecher, T., 1659  
 Steinhäuser, G., 43, 3862  
 Steinman, L., 5565  
 Stellato, T. A., 1564  
 Stenman, G., 1553  
 Stenman, U.-H., 222, 2107  
 Stensky, V., 2690  
 Stephens, I., 2242  
 Stephens, L. C., 2994, 3559, 3568  
 Stern, A. C., 116  
 Stern, E. W., 1866  
 Stetler-Stevenson, W. G., 439, 5054s, 6190  
 Stetson, P. L., 870, 3900  
 Stettner, S. L., 737  
 Stevenson, G. T., 2353  
 Stickney, D. R., 1515, 6650  
 Stillwell, R. G., 3059  
 Stillwell, W. G., 190  
 St. John, M., 1778  
 Stobie, K. M., 1196  
 Stoica, G., 696  
 Stolwijk, J. A. M., 4028  
 Stolze, B., 5342  
 Stone, A., 4114  
 Stone, B. J., 2885  
 Stone, K. D., 4279  
 Stone, M., 4052  
 Stoner, G. D., 365, 2063  
 Stoppacciaro, A., 2456  
 Stoppelli, M. P., 1294  
 Storer, B. E., 1651, 3323  
 Storkson, J., 2940  
 Stoter, G., 2324  
 Stoudemire, J. B., 4219  
 Stovall, M., 2885  
 Strebel, F. R., 2994, 3559, 3568  
 Streeten, E., 1154  
 Streffer, C., 5134  
 Streilein, J. W., 3153  
 Stretch, J. R., 5976  
 Strife, A., 4828  
 Strohmeyer, T., 1811  
 Strong, L. C., 6385  
 Stroud, M. R., 2199  
 Stuart, R. K., 2536  
 Stuart, S. G., 2593  
 Studzinski, G. P., 3451  
 Stump, D. C., 354  
 Su, S. L., 336  
 Suciu, D., 573  
 Suda, T., 341, 4649  
 Sudati, F., 5960  
 Suffys, P., 2469  
 Sugarbaker, E. V., 1190  
 Sugimachi, K., 1494, 2842, 3503, 3522, 4008, 5261, 5339  
 Sugimoto, Y., 99  
 Sugimoto, Y., 921  
 Sugimoto, Y., 3237  
 Sugimura, T., 3056, 5171, 5800  
 Sugio, K., 4008  
 Sugiyama, M., 3555  
 Sugiyama, T., 949  
 Sullivan, D. M., 6543  
 Sullivan, L. M., 6603  
 Sumegi, J., 4481  
 Sumitani, S., 4323  
 Sumiyoshi, H., 2069  
 Sumiyoshi, Y., 4639  
 Sundquist, W. I., 1866  
 Sutherland, B. M., 288  
 Sutherland, D. R., 1257  
 Sutton, R. C., 387  
 Suyama, M., 2416  
 Suzuki, H., 1286  
 Suzuki, T., 2420  
 Suzumori, K., 2133  
 Suzushima, H., 6084  
 Svennerholm, L., 4643  
 Swann, P. F., 5843  
 Sweeney, B., 2879  
 Swenberg, J. A., 3512, 5188, 6409  
 Swinnen, L. J., 1984  
 Sykes, D., 2786  
 Symbula, M., 4423  
 Szallasi, Z., 5355  
 Szatrowski, T. P., 794  
 Szepeshazi, K., 5980  
 Szoke, B., 5980  
 Szolgay-Daniel, E., 1039
- T
- Tabata, Y., 5532  
 Tabibzadeh, S. S., 5661  
 Taetle, R., 150, 1689  
 Taggart, R. T., 1154  
 Taghizadeh, K., 5219  
 Tagliabue, E., 400  
 Tagliaferri, P., 1294, 4898  
 Tahara, E., 2926  
 Tainsky, M., 1744  
 Taioli, E., 3067  
 Takahashi, E.-i., 4707  
 Takahashi, H., 3148  
 Takahashi, M., 1934  
 Takahashi, N., 2366  
 Takahashi, N., 4250  
 Takahashi, R., 5736  
 Takahashi, S., 824, 1264, 5655  
 Takahashi, T., 1448, 4310  
 Takahashi, T., 1574, 2416, 6708  
 Takahashi, T., 1934  
 Takahashi, T., 6194  
 Takai, S., 3544  
 Takai, Y., 2223  
 Takaishi, K., 4080  
 Takakuwa, K., 1934  
 Takamizawa, H., 2655  
 Takano, H., 3951  
 Takashima, T., 4250  
 Takashina, K.-i., 4310  
 Takatori, T., 5859  
 Takatsuki, K., 6084  
 Takayama, K., 2223  
 Takayama, Y., 5859  
 Takebe, H., 2425, 3177, 6219  
 Takehara, N., 3327  
 Takeshita, M., 4639  
 Takeshita, S., 2842  
 Takeuchi, T., 2985  
 Takeyama, H., 4476  
 Taki, T., 1701  
 Tamano, S., 1264, 2548  
 Tamaoki, T., 1460  
 Tamaoki, T., 4888  
 Tamargo, R. J., 672  
 Tamaya, T., 5987  
 Tamura, G., 3056  
 Tamura, S., 4080  
 Tamura, S., 6622  
 Tamura, T., 1472  
 Tanabe, K., 4903, 4909  
 Tanabe, M., 3148  
 Tanaka, A., 3006  
 Tanaka, H., 3710  
 Tanaka, J., 1086  
 Tanaka, K., 1934  
 Tanaka, K., 2842  
 Tanaka, K., 6677  
 Tanaka, M., 1034  
 Tanaka, N. G., 903  
 Tanaka, S., 6529  
 Tanaka, T., 6224  
 Tandon, A. K., 105  
 Taniguchi, H., 785, 2863, 3493, 6150  
 Taniguchi, N., 5888  
 Taniya, T., 2683  
 Tanizawa, O., 5308, 5322, 5951, 5956  
 Tannenbaum, S. R., 190, 4371, 5219  
 Tanoue, K., 1286  
 Taper, H., 666  
 Taraboletti, G., 5672  
 Tartaglia, L., 3171  
 Tarui, S., 4080  
 Tashiro, K., 6019  
 Tatematsu, M., 318  
 Tatsumi-Miyajima, J., 3177  
 Tatsuta, M., 785, 2863, 3493, 6150  
 Taub, R. N., 4955  
 Tauchi, T., 2917  
 Tay, L., 2902  
 Taylor, G. A., 5579  
 Taylor, J., 1798  
 Taylor, P. T., 4423  
 Taylor, S. R., 4084  
 Taylor-Papadimitriou, J., 2908  
 Teh, C.-Z., 2307  
 Teicher, B. A., 510, 780, 1086  
 Teillaud, J.-L., 612  
 Teitel, C. H., 4371  
 Templeton, N. S., 6190  
 ten Dijke, P., 4828  
 Teng, B.-B., 4305  
 Teng, C. T., 3037  
 Tennant, B. C., 3925  
 Tenorio, F., 4785  
 Terachi, T., 2521  
 Terada, M., 3056, 5171, 5632, 5800  
 Terada, N., 3006  
 Teranishi, Y., 2223  
 Terashima, Y., 5171, 5632  
 Terrier-Lacombe, M. J., 33  
 Tesch, H., 3702  
 Teshima, S.-i., 5632  
 Testa, J. R., 3267, 4090  
 Tew, K. D., 6059  
 Thai, G., 4859  
 Thakar, J. H., 6286  
 Thangada, M., 775  
 Thatcher, N., 619  
 Thedrez, P., 1537  
 Theilen, G. H., 233  
 Theodorescu, D., 4486  
 Theologides, A., 3990  
 Thiebaut, F. B., 5903  
 Thielmann, H. W., 3456  
 Thomas, D. M., 3497  
 Thomas, G. A., 639  
 Thomas, G. E., 6558  
 Thomas, P. E., 1509, 4798  
 Thomas, T., 3938  
 Thomas, T. J., 3938  
 Thomason, A., 4149  
 Thomassen, M. J., 857  
 Thompson, E. A., 5544, 5551  
 Thompson, E. W., 2670  
 Thompson, H. J., 3411  
 Thompson, S. M., 4492  
 Thomsen, L. L., 77  
 Thor, A. D., 624  
 Thoresen, S. O., 1234  
 Thorgerisson, S. S., 5929  
 Thorpe, P. E., 4052, 4768  
 Thrower, D., 2212  
 Thuraissamy, K., 4955  
 Thurman, R. G., 2036, 4511  
 Tilby, M. J., 123  
 Till, M., 4052  
 Tilley, R., 696  
 Tindall, D. J., 3748  
 Tinsley, P. W., 3080, 6059  
 Tisdale, M. J., 6089  
 Titani, K., 4876  
 Tjaden, U. R., 1694  
 Tobe, T., 2113  
 Tobin, B. M. J., 3296  
 Todd, R. F., III, 1065  
 Tohda, H., 195  
 Tokes, Z. A., 1318  
 Tokino, T., 89  
 Tokiwa, K., 1448  
 Tokuchi, S., 2599  
 Tokumo, K., 4528  
 Tokunaga, A., 1934  
 Tokunaga, K., 2842  
 Tokura, S., 22  
 Tölg, C., 5292  
 Tomasoni, A., 6358  
 Tomassetti, A., 6125  
 Tomaszewski, J. E., 3733  
 Tombes, M. B., 1099, 1105, 1651  
 Tomita, J., 4149  
 Tomita, N., 3544  
 Tonin, P. N., 5100  
 Tonini, G. P., 1733  
 Toniolo, P., 2572  
 Torrigio, T., 4250  
 Torrisi, M. R., 1294

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Tortora, G., 6263  
 Tory, K., 1071  
 Tos, A. G., 964  
 Tositani, K., 2874  
 Tosti, S., 964  
 Totis, A., 2572  
 Totpal, K., 4266  
 Townsend, A. J., 521, 587  
 Townsend, C. M., Jr., 5253  
 Toy, P., 4575  
 Toyama, K., 2917  
 Toyokuni, T., 4310  
 Toyoshima, K., 990  
 Traganos, F., 3682  
 Travali, S., 5997  
 Trent, J. M., 995, 2193, 5449  
 Trentin, L., 3164  
 Tribby, I., 4149  
 Trinidad, A., 549  
 Tritscher, A., 1391  
 Troll, W., 4810  
 Trono, D., 6615  
 Trown, P. W., 4219  
 Trowsdale, J., 5329  
 Trump, B. F., 3793, 5219  
 Trump, D. L., 1099, 1651  
 Truong, K. N., 3198  
 Trzeciak, M.-C., 2621  
 Tsai, S. J., 3331  
 Tsao, M.-S., 5238  
 Tso, J. Y., 465  
 Tsujimoto, Y., 1574  
 Tsujino, T., 2926  
 Tsujisaki, M., 2599  
 Tsujitani, S., 3503  
 Tsukada, Y., 820  
 Tsukamoto, A., 2677  
 Tsukuda, K., 4450  
 Tsumuraya, M., 381  
 Tsuneizumi, K., 5398  
 Tsurumi, H., 4310  
 Tsuruo, T., 110, 157, 921, 2420, 2582, 4898, 5859  
 Tsuta, Y., 22  
 Tsutsumi, M., 820  
 Tu, C.-P. D., 587  
 Tubaro, A., 2456  
 Tubbs, R., 4199  
 Tucker, M. A., 2885  
 Tucker, R. W., 4206, 4693  
 Tucker, S. L., 6292  
 Tucker, T., 5045s, 5876  
 Tuhkanen, K., 222  
 Tung, E., 4001  
 Tungekar, M., 261  
 Tureaud, J., 3416  
 Turley, H., 261  
 Turnbull, L., 1817, 4685  
 Tutsch, K. D., 1099, 1105  
 Tuttle, S. W., 5539  
 Twardy, D. J., 4355  
 Tyler, G., 5514  
 Tyler, R. D., 3762  
 Tyroler, H. A., 3198  
 Tyrrell, R. M., 974  
 Tzeng, J.-J., 2373
- U
- Überall, F., 807, 5821  
 Ublacker, G. A., 1783  
 Uchida, Y., 3951  
 Uchiyama, C., 1418  
 Ueda, M., 1504, 6656  
 Ueda, R., 1574, 2416, 6708  
 Ueda, T., 2319  
 Uehara, H., 3493  
 Ueland, P. M., 828, 4837  
 Uemura, Y., 4271  
 Uhr, J. W., 1482, 4052, 5045s, 5876  
 Ullrich, A., 1811  
 Ullrich, S., 4090  
 Unger, A., 6328  
 Uno, K., 5532  
 Unterman, T. G., 3030  
 Uozumi, N., 5888  
 Ura, H., 3550  
 Urabe, K., 2874  
 Urano, Y., 1460  
 Urba, W. J., 2127  
 Urbano-Ispizua, A., 3497  
 Urrea, R., 4994  
 Usui, N., 769  
 Utsugi, T., 3062, 3741  
 Utsumi, H., 573  
 Utsumi, K. R., 4909, 6708  
 Utsumi, T., 3362  
 Uzvolgyi, E., 4481
- V
- Vaalburg, W., 1930  
 Valenzuela, R., 836  
 Valle, E. F., 2444  
 Valleria, D. A., 1883, 1891  
 Valli, C., 5378  
 Van Bladel, S., 2469  
 van den Berghe, R., 4028  
 van den Brink, M. R. M., 4931  
 Vanderheyden, J.-L., 676  
 van der Leun, J. C., 979  
 van der Maas, P. J., 3445  
 VanDerMeid, K. R., 1836  
 van der Meide, P. H., 2329  
 Vanderploeg, L. C., 3399  
 Vander Velde, D., 3096  
 van der Zee, A. G. J., 5915  
 van de Velde, C. J. H., 1694  
 van de Ven, W. J. M., 606  
 Vande Woude, G. F., 5435  
 van Dongen, G. A. M. S., 211  
 van Emmerik, N., 5507  
 Vangsted, A. J., 2879  
 Vanhaesebroeck, B., 2229, 2469  
 Van Lookeren Campagne, M. M., 1600, 6207  
 van Moorselaar, R. J. A., 2329  
 Van Oosterom, A. T., 4523  
 van Osdol, W., 4776  
 van Putten, W. L. J., 2324  
 Van Roy, F., 2229, 2469  
 Vanseymortier, L., 5384  
 van Stratum, P., 2329  
 van Vliet, M., 1020
- Van Waes, C., 2395  
 Vargas, E., 2098  
 Vass, W. C., 712  
 Vater, S. T., 492  
 Vaughan, A. T. M., 3857  
 Vaupel, P., 3289, 3316, 6098  
 Vaysse, N., 3633  
 Vecchio, G., 4234  
 Veigl, M. L., 3930  
 Veilleux, R., 4336, 5165  
 Vellenga, E., 73, 116  
 Vellucci, V. F., 6254  
 Velotti, F., 2456  
 Venesio, T., 6194  
 Venkatesan, P., 676  
 Verbeek, S., 958  
 Verhagen, A., 1930  
 Vermorken, J. B., 211  
 Vert, M., 5384  
 Vesselinovich, S. D., 1952  
 Viallet, J., 4999  
 Viinikka, L. U., 4146  
 Vilain, M.-O., 5384  
 Villa, E., 5960  
 Villacorte, D. G., 4871  
 Villalba Díaz, F., 1600, 6207  
 Villar, H. V., 422  
 Vindeløv, L., 5093  
 Virudachalam, S., 4565  
 Vistica, D. T., 2515  
 Vitetta, E. S., 1482, 4052, 5045s, 5876  
 Vives, J., 4436  
 Vlodavsky, I., 2552  
 Vocaturo, A., 3001  
 Vocaturo, G., 3001  
 Vogel, J., 6686  
 Vogelstein, B., 4135, 4721, 5449, 6304  
 Voltz, R., 27  
 von Eschenbach, A. C., 3741, 3753  
 Von Hoff, D. D., 5107, 6268, 6273  
 von Meyenfeldt, M. F., 6138  
 von Wartburg, A., 5  
 von Wronski, M. A., 3339  
 Vooijs, G. P., 644  
 Vos, J.-M. H., 2867  
 Voss, S. D., 1651  
 Vredenburg, J. J., 2451  
 Vrionis, F. D., 4643  
 Vuento, M., 2107  
 Vydelingum, N. A., 863
- W
- Wachter, H., 6250  
 Wada, H., 341  
 Waddelow, T., 6273  
 Wagata, T., 2113  
 Wagner, J. G., 870, 3434  
 Wagner, S. A., 2063  
 Wagner, T., 3391  
 Wagteveld, L., 73  
 Wahl, G., 6273  
 Wahl, R. L., 3434  
 Waidelich, D., 3427  
 Wainai, T., 1940  
 Waites, G. T., 3030
- Wakamiya, N., 4476  
 Wakeling, A. E., 3867  
 Walczak, J., 3080  
 Waldman, F. M., 3807  
 Waldren, C. A., 2636, 4463  
 Walker, C., 2973, 4059, 4415  
 Walker, G. J., 4367  
 Walker, M. C., 6592  
 Walker, P. R., 528, 1078  
 Walker, S. B., 1045  
 Walker, S. C., 1398  
 Wall, F., 2335  
 Wall, M. E., 6039  
 Wallace, S. S., 2740  
 Wallach, D., 5602  
 Walsh, A. A., 288  
 Waltz, T. A., 3193, 4986  
 Walz, T. M., 3585  
 Walzel, H., 916  
 Wanek, P. M., 2335, 3802  
 Wang, B., 2642, 5298, 5649  
 Wang, C., 1196  
 Wang, C. Y., 2902  
 Wang, J., 3578  
 Wang, J.-L., 1553  
 Wang, J.-x., 6084  
 Wang, J. Y. J., 3048  
 Wang, L., 5275  
 Wang, L.-W., 1720  
 Wang, M., 5587  
 Wang, M., 5866  
 Wang, M. G., 2490  
 Wang, Q.-c., 3353  
 Wang, R. C. C., 5275  
 Wang, S., 1059  
 Wang, W., 4971  
 Wang, Z., 3088  
 Wang, Z.-Q., 1755  
 Wani, M. C., 6039  
 Wankel, A., 422  
 Ward, B. G., 5826  
 Ward, F. T., 1803  
 Ward, K. A., 3612  
 Wargovich, M. J., 2069  
 Warren, A. B., 2395  
 Warren, L., 1996  
 Warshawsky, D., 492  
 Washington, G. C., 6263  
 Wassermann, K., 5093, 6550  
 Wasteson, A., 3585  
 Watanabe, H., 2699, 3507  
 Watanabe, J., 5177  
 Watanabe, K., 1460  
 Watanabe, M., 157, 921, 2199  
 Watanabe, T., 764, 5398  
 Watanabe, T., 4631  
 Watanabe, Y., 990  
 Watatani, K., 2438  
 Watson, J. V., 799  
 Watson, P. H., 3996  
 Watts, P., 3910  
 Waud, W. R., 1979  
 Waxman, D. J., 2340  
 Webb, C. D., 6543  
 Weber, G., 3886  
 Webster, M. K., 6031  
 Wehner, J. M., 1766

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

- Wei, H., 4443  
 Wei, W.-Z., 3331  
 Weichselbaum, R. R., 521, 4565, 6393  
 Weidmann, E., 6153  
 Weinberg, J. B., 1202  
 Weiner, L. M., 3910  
 Weinstein, I. B., 1571, 5080s, 6230  
 Weinstein, J. N., 688, 4776, 4821  
 Weinstein, R. S., 897, 2720  
 Weintraub, J., 294  
 Weir, B. K., 2430  
 Weisburger, J. H., 6224  
 Weiss, G. H., 1071  
 Weiss, R. B., 1803  
 Weissman, J., 3643  
 Wells, A., 6170  
 Wells, S. A., 1596  
 Welsch, C. W., 3399  
 Welsh, J. A., 4090, 4102  
 Wennerberg, J., 954  
 Wesenberg, F., 828  
 Wesley, J. W., 1529  
 Westergaard, O., 5093  
 Westerhof, G. R., 5507  
 Westermarck, B., 1553, 5087  
 Weston, A., 2490, 5219  
 Westphal, H., 6506  
 Wharton, J. T., 4257  
 Wheaton, L., 1668  
 Wheeler, C. A., 510  
 Wheeler, R. H., 5461  
 Wheeler, T. M., 4084  
 White, A., 4131  
 White, E. L., 2386  
 White, J. C., 2559  
 White, L. T., 1851  
 White, R. W. V., 1632  
 White, T., 2879  
 Whiteley, L. O., 2973  
 Whiteside, T. L., 3891, 6153  
 Whitfield, J. F., 528, 1078  
 Whitfield, L. R., 6318  
 Whitin, J. C., 6568  
 Whitlow, M., 6363  
 Whitmore, G. F., 1860  
 Whittemore, A. S., 2307  
 Whitten, D. G., 1836  
 Whittle, N., 181  
 Whittum-Hudson, J. A., 6381  
 Wick, M. M., 4964  
 Wiebecke, B., 4712  
 Wiedemann, H. P., 857  
 Wiedlocha, A., 916  
 Wiencke, J. K., 5266  
 Wientjes, E., 958  
 Wientjes, M. G., 3849, 4347, 5144  
 Wiestler, O. D., 6202  
 Wiethorn, B. E., 4360  
 Wikstrand, C. J., 4643  
 Wilcosky, T. C., 3198  
 Wild, C. P., 3825  
 Wilder, P. J., 5898  
 Wilding, G., 1099, 1105, 3590, 6629  
 Wilke, A. V., 1680  
 Wilkes, B. M., 6103  
 Willecke, K., 5348  
 Willemsse, P. H. B., 116, 5915  
 Willey, J. C., 5370  
 Williams, B. R. G., 3958  
 Williams, D. E., 2362  
 Williams, G., 724  
 Williams, G. M., 6224  
 Williams, K., 6712  
 Williams, L. E., 2335, 5704  
 Williams, R. D., 1373, 1378  
 Willigeroth, S., 3243  
 Willingham, M. C., 3781  
 Willumsen, B. M., 712  
 Wilson, E. L., 274  
 Wilson, G. D., 33  
 Wilson, G. L., 775  
 Wilson, L., 2212  
 Wilson, P., 239  
 Wilson, R. E., 3281  
 Wilson, V. L., 324  
 Wilttrout, R. H., 6596  
 Wingren, S., 3585  
 Winn, D. M., 3044  
 Wishnok, J. S., 190  
 Witkowski, C., 5449  
 Witt, P. L., 1651, 4155  
 Witte, L., 2552  
 Witz, I. P., 612  
 Wlodek, D., 4671  
 Wolf, H., 27  
 Wolf, W., 5806  
 Wolfe, H. J., 1345  
 Wolff, A. J., 2124  
 Wolfrom, D. M., 3399  
 Wolkow, C. A., 4279  
 Wolman, S. R., 2173  
 Womer, R. B., 5626  
 Wondergem, J., 2994, 3559  
 Wong, B., 6318  
 Wong, E. L., 1154  
 Wong, F.-H., 1898  
 Wong, G. Y., 2706  
 Wong, J. Y. C., 2335, 3802  
 Wong, M. S. J., 2051  
 Wong, S., 6574  
 Wong, Y.-K., 1109  
 Woo, A., 1434  
 Woo, T., 4279  
 Wood, J. F., 6363  
 Wood, R. D., 3384  
 Workman, P., 799  
 Worton, K. S., 985  
 Wouters, E. F. M., 6138  
 Wrathall, J., 3304  
 Wrensch, M. R., 5266  
 Wright, G. L., Jr., 1326, 2296  
 Wu, S.-Q., 3323  
 Wu, Z. M., 5921  
 Wunderlich, J. R., 5716  
 Wu-Williams, A. H., 2307  
 Wynder, E. L., 2263  
 Wynn, D. M., 5728  
 Wyrick, S. D., 969  
 Xu, F.-J., 4012  
 Xu, F. J., 5361  
 Xu, H.-J., 2735, 4481, 5736  
 Xu, H.-X., 190  
 Xuan, H., 4192  
 Y  
 Yabkowitz, R., 1645, 3648  
 Yabuuchi, I., 4080  
 Yachi, A., 2599  
 Yagi, T., 2425, 3177, 6219  
 Yagihashi, A., 4250  
 Yaginuma, Y., 6506  
 Yague, J., 4436  
 Yagura, M., 89  
 Yamada, M., 824  
 Yamada, M., 1726  
 Yamada, Y., 5632, 5800  
 Yamagami, K., 2319  
 Yamaguchi, A., 1034  
 Yamaguchi, E., 6346  
 Yamaguchi, K., 4631, 6656  
 Yamaguchi, T., 1448, 4310  
 Yamakawa, K., 4707, 5817  
 Yamamoto, T., 990  
 Yamamoto, T., 5322  
 Yamane, T., 1448  
 Yamanishi, H., 3006  
 Yamanoi, J., 1940  
 Yamaoka, T., 5532  
 Yamashina, I., 331  
 Yamashita, Y., 2922  
 Yamauchi, D. M., 5704  
 Yamazaki, A., 5859  
 Yamazaki, H., 1286  
 Yamori, T., 5859  
 Yan, P.-s., 372, 1026  
 Yanagawa, Y., 2874  
 Yanagihara, K., 381  
 Yandell, D. W., 5736, 6393  
 Yang, C. S., 1509, 4798  
 Yang, G.-Y., 1720  
 Yang, H., 4790  
 Yang, J.-m., 67  
 Yang, S. C., 3669  
 Yang, S. S., 753  
 Yang, Z.-h., 3353  
 Yano, T., 1494, 5261  
 Yao, X. J., 2307  
 Yao, Z., 2158  
 Yarosh, D., 4131  
 Yarranton, G., 181  
 Yasargil, M. G., 6202  
 Yasminew, W. G., 3990  
 Yasuda, T., 3544  
 Yasui, A., 195  
 Yasukawa-Barnes, J., 2642, 5298, 5649  
 Yasumoto, K., 5261  
 Yatvin, M. B., 37  
 Yawata, Y., 341  
 Yazaki, Y., 4450  
 Ye, J. N., 2158  
 Yean, T.-D., 2151  
 Yee, D., 5107  
 Yefenof, E., 2179  
 Yeger, H., 3958  
 Yeh, M.-Y., 4001  
 Yen-Lieberman, B., 836  
 Yeoman, L. C., 1452  
 Yerokun, T., 504, 549  
 Yerram, N. R., 6025  
 Yin, J., 5766  
 Ying, W.-b., 3353  
 Ylikorkala, R. O., 4146  
 Yokoro, K., 381  
 Yokota, J., 5171, 5632, 5800  
 Yokota, K., 3550  
 Yokota, T., 6363  
 Yokouchi, H., 3544  
 Yokoyama, H., 4008  
 Yokoyama, M., 3229  
 Yokoyama, S., 5171  
 Yokoyama, T., 1946  
 Yokoyama, Y., 5987  
 Yoneda, T., 2438, 4430  
 Yonemura, Y., 1034  
 Yoshida, H., 3148  
 Yoshida, K., 2926  
 Yoshida, O., 949, 3445, 5817  
 Yoshida, T., 4639  
 Yoshida, T., 5800  
 Yoshiki, A., 3257  
 Yoshino, I., 1494  
 You, M., 365, 1148  
 You, S.-L., 5621  
 Youdale, T., 1078  
 Younes, R. N., 863  
 Young, C. W., 3096  
 Young, C. Y.-F., 3748  
 Young, D. A., 2786  
 Young, H. A., 6596  
 Young, J. F., 4371  
 Yu, A. L., 144  
 Yu, C., 6039  
 Yu, M. C., 4045  
 Yu, M.-H., 4001  
 Yu, M.-W., 5621  
 Yu, Y. H., 468  
 Yu, Y.-H., 4012  
 Yuan, F., 3119  
 Yuan, M., 372  
 Yui, R., 4909  
 Yum, S., 6529  
 Yun, J., 3391  
 Yusa, K., 2420  
 Yuspa, S. H., 4206, 4677  
 Z  
 Zacharski, L. R., 349, 354  
 Zack, M., 3696  
 Zafferani, M., 43  
 Zahniser, D., 359  
 Zaknun, J., 807  
 Zalcborg, J. R., 1750  
 Zalutsky, M. R., 4164  
 Zang, E., 4528, 6224  
 Zava, D., 4470  
 Zavala, D., 190  
 Zbar, B., 1071  
 Zee, B., 6318  
 Zeisel, S. H., 16  
 Zeligman, B. E., 3274  
 Zeller, K.-P., 3427

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 51\*

- |                     |                      |                        |  |
|---------------------|----------------------|------------------------|--|
| Zeller, W. J., 2943 | Zhang, Z-c., 3353    | Zhuang, L., 77         | Zöller, M., 5292                         |
| Zempel, G., 5348    | Zhang, Z-G., 3476    | Ziemiacki, A., 2092    | Zorbas, M. A., 1452                      |
| Zenser, T. V., 514  | Zheng, J., 4045      | Zierold, K., 1039      | Zou, M., 2690                            |
| Zeuthen, J., 2879   | Zhong, Z., 4511      | Zijlstra, J. G., 5915  | Zu, H-X., 5636                           |
| Zhang, H. B., 5113  | Zhou, Q., 1613, 6019 | Zilberstein, A., 4430  | Zugmaier, G., 3590                       |
| Zhang, R. D., 2029  | Zhou, W., 294        | Zimbrick, J. D., 2740  | Zurawski, V. R., Jr., 468, 5716,<br>6125 |
| Zhang, S-z., 2047   | Zhou, Y-Z., 49       | Zimmerman, L. J., 6001 | Zwelling, L. A., 4729, 6704              |
| Zhang, X-G., 3224   | Zhou, Z-l., 6254     | Zimniski, S. J., 3663  |  |
| Zhang, Y-J., 1720   | Zhu, D., 394         | Zito, F., 5960         |  |

\* For title of article and coauthors, see listing in Contents of Volume 51 beginning on page i at the end of this index issue.

L

1

I

# SUBJECT INDEX

## Volume 51

### A

- A9 antigen**  
aggressive human squamous carcinoma integrin  $\alpha^6\beta_4$ , 2395
- Acetylaminofluorene**  
-induced hepatocarcinogenesis  
hepatic mRNA translation, arylsulfotransferase IV, 504
- 2-Acetylaminofluorene**  
chronic low-level exposure  
liver and bladder carcinogenesis, modulation by butylated hydroxytoluene, 6224
- Acetylator**  
polymorphism  
human colorectal carcinoma, 2098
- $\alpha$ -N-Acetylgalactosamine-O-serine**  
-threonine antigen-mediated cellular response  
active immunotherapy, mice, 1406
- N-Acetylglucosaminidase**  
secretion of lysosomal enzymes  
drug-sensitive and multiple drug-resistant cells, 1996
- Acivicin**  
-induced monocytoid differentiation  
myeloid leukemia cells, mRNA expression, 1202
- Aclarubicin**  
antagonistic effect on daunorubicin-induced cytotoxicity  
DNA integrity, small cell lung cancer cells, 5093
- Acoustic cavitation**  
cytotoxic effects  
HT-29 cells, rat peritoneal carcinomatosis, 3024
- Acquired immunodeficiency syndrome**  
non-Hodgkin's lymphoma and, 4743  
-related Kaposi's sarcoma  
supernatants, endothelial cell chemotaxis and invasiveness, 2670
- 4'-(9-Acridinylamino)-3-methanesulfon-m-aniside**  
camptothecin or teniposide  
degradation of nuclear DNA, S phase of HL-60 cells, 1165
- Activin A**  
inhibition of P-glycoprotein expression  
multidrug-resistant K562 cells, 2582
- AD198**  
modulation of effects by caffeine, 3682
- Adeno-associated virus**  
Rep78  
inhibition of H-ras expression, 3373
- Adenocarcinoma**  
Barrett's  
17p allelic deletions, p53 protein overexpression, 5482  
breast  
protein core of mucin molecule, cytotoxic T-lymphocytes, 2908  
carcinogenicity of diethylstilbestrol, 3311  
c-erbB-2 proto-oncogene products  
immunoscintigraphy, 990  
colonic  
Astler-Collier Dukes stage C, DNA aneuploidy, 2403  
glycosyltransferase changes, differentiation, 3136  
inhibition of platelet aggregation, metastasis, 921  
inhibition of proliferation, c-myc antisense oligodeoxynucleotides, 2897  
inhibition of protein isoprenylation, dehydroepiandrosterone, 6563  
M, 72,000 type IV collagenase, 439  
colorectal  
differential nitric oxide synthesis, platelet aggregation, 6073  
sex steroid and 1,25-dihydroxyvitamin D<sub>3</sub> receptors, 1227  
endometrial  
patterns of differentiation, extracellular matrix, 5661  
premalignant and malignant epithelial lesions, K-ras activation, 5308  
regulation by progestins, transforming growth factor gene expression, 5476  
esophageal  
frequent loss of heterozygosity, retinoblastoma locus, 5766  
lung  
interleukin 4 receptor expression, 261  
mammary  
coexpression of cytokeratins, myoepithelial and luminal cell lines, 5943  
epiglycanin, immunosuppressive activity, 1170  
glucocorticoid growth suppression response, dominant transacting factors, 6031  
proteinase inhibitors, metastatic potential, 1318  
mucinous  
monoclonal antibodies B1 and B3, 3781  
prostatic  
hormonal regulation, prostate-specific antigen messenger RNA, 3748  
mesenchyme-induced changes, neoplastic characteristics, 4924  
metastatic potential and substrate dependence, cell motility, 6580  
monoclonal antibody PD41, 1326  
pulmonary  
primary and metastatic tumors, urokinase-type plasminogen activator, 3522  
renal  
spontaneous lung metastasis, CGP 31362, 3741
- Adenoma**  
colonic  
altered protein kinase C activity, biopsies, 205  
hepatocellular  
histochemical profile, diethylnitrosamine, 1952
- Adenosine monophosphate, cyclic**  
8-Cl-cAMP and, 6206, 6207  
8-Cl-cAMP and N<sup>6</sup>-benzyl-cAMP kinetics, HL-60 leukemia cells, 6263  
-dependent protein kinase messenger RNA  
normal vs. neoplastic mouse lung epithelial cells, 6699  
-responsive element binding proteins  
rat hepatoma, 528
- Adenosine triphosphatase**  
angiogenesis  
tumors growing in irradiated bed, 3289
- Adenosine triphosphate**  
transport multiplicity and energetics  
methotrexate efflux, L1210 cells, 1412
- Adhesion**  
tumor H-59 cells to hepatocytes  
M, 64,000 plasma membrane glycoprotein, 3578
- Adipose**  
tissue lipoprotein lipase activity  
tumor-induced alterations, messenger RNA levels, 863
- $\beta$ -Adrenergic-blocking agents**  
N-nitroso derivatives  
genotoxic effects, rat and human hepatocytes, 2273
- Adriamycin**  
combined with whole body hyperthermia  
tumor and normal tissues, 3559  
-induced heart mitochondrial damage  
mechanism, electron spin resonance, 3555  
interleukin 2 and  
augmentation of immunity, renal cell carcinoma, 6133  
pharmacokinetics  
hyperthermia, normal tissue toxicity, 1680  
protective effect of ICRF-187  
normal tissue injury, whole body hyperthermia, 3568  
reversal of resistance  
 $\alpha$ -interferon, colon carcinoma, 4898  
toxicity and antitumor activity  
micelle-forming polymeric anticancer drug, 3229
- Aflatoxin**  
association between hepatitis C virus antibodies  
hepatocellular carcinoma, Taiwan, 5621  
nonassociation with primary liver cancer, 3825
- Aflatoxin B<sub>1</sub>**  
-DNA adducts  
immunofluorescence, woodchuck hepatocytes and rat liver, 1720  
promotion of carcinogenesis  
indole-3-carbinol, 2362
- Agar**  
culture  
drug sensitivity, human tumor cell line growth, 1247
- Agglutinin**  
antibody-lectin enzyme immunoassay  
sugar chains, myeloma IgG, 5888
- Aging**  
hepatocarcinogenesis  
nafenopin, 666  
role of oxidative stress, nafenopin, 1789  
therapeutic radiation  
secondary thyroid neoplasms, 2885
- Alcohol**  
association between hepatitis C virus antibodies  
hepatocellular carcinoma, Taiwan, 5621
- Aldehydes**  
podophyllotoxin glucoside to etoposide

- chemical and biological route, 5
- Alkaline phosphatase**  
 germ cell  
   transcriptional regulation, sodium butyrate and glycosylation, 2058
- intestinal  
   tumorigenic potential, irradiated hybrids, 4455
- progesterone regulation  
   breast cancer cell line, 4470
- Alkylating agents**  
 carmethizole  
   *in vivo* and *in vitro* evaluation, 4581
- cytotoxic effects  
   *O*<sup>6</sup>-benzylguanine analogues, 3367
- modulation by etanidazole and fluosol-DA/carbogen  
   fibrosarcoma, mammary carcinoma, 1086
- modulator of activity  
   lonidamine, 780
- ThioTEPA**  
   Phase I/pharmacokinetic reevaluation, 3171
- O*<sup>6</sup>-Alkylguanine-DNA alkyltransferase**  
   activity in cell strains  
     mouse skin tumors, UV irradiation, 2425
- constitutive drug resistance  
   P-glycoprotein, human colorectal tumors, 2092
- depletion and regeneration  
   dacarbazine and fotemustine, peripheral lymphocytes, 619
- 7-Alkylguanines**  
   release from modified DNA  
     3-methyladenine DNA glycosylase II, 499
- Alkyl-lysophospholipid**  
   glioblastoma cell invasion  
     fetal rat brain tissue, 1713
- ALL-1* locus**  
   cloning of, 6712
- Allele**  
   acetylator genotype-dependent expression  
     arylamine *N*-acetyltransferase, colon cytosol, 549
- activated *ras*  
   human prostatic carcinoma, 1632
- allele study  
   primary hepatocellular carcinoma, 89
- frequent losses and mutations  
   *p53* gene, human ovarian cancer, 5171
- hepatitis B virus integration event  
   chromosome 17p near *p53* gene, hepatocellular carcinoma, 49
- loss on chromosome 17p and *p53* mutations  
   human endometrial carcinoma, 5632
- marker  
   chromosome 1, primary breast carcinoma, 1020
- normal and mutated *K-ras*  
   differential expression, induced thymic lymphomas, 5129
- 17p deletions and *p53* protein overexpression  
   Barrett's adenocarcinoma, 5482
- somatic deletion  
   *nm23*, human cancer, 2490
- Allelotype**  
   human ovarian cancer, 5118
- Alopecia**  
   1- $\beta$ -D-arabinofuranosylcytosine-induced interleukin 1 protection, 3329
- Amaranthus caudatus***  
   lectin  
     histochemical probe, proliferating colonic epithelial cells, 657
- American Association for Cancer Research**  
   50th anniversary  
     symposium, discoveries and opportunities in cancer research, 5013s
- Amiloride**  
   glioma and colon carcinoma treatment, 1039
- Amino acids**  
   *p53* gene analysis  
     human uterine carcinoma cell lines, 6506
- 4-Aminobiphenyl**  
   adduct formation  
     frequency of urination, 4371
- hemoglobin adducts in lung cancer  
   measurement of, cases and controls, 5219
- Amino- $\alpha$ -carboline**  
   cytochrome P-450 activation of cigarette smoke, 5284
- 2-Amino-3-methylimidazo[4,5-*f*]quinoline**  
   formation and persistence of DNA adducts, 5636
- 2-Amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine**  
   cytochrome P-450 activation of cigarette smoke, 5284
- 2-Amino-4-(5-nitro-2-furyl)thiazole**  
   mechanisms of resistance  
     bladder cancer, 514
- S-2-(3-Aminopropylamino)**  
   ethylphosphorothioic acid  
   protection against late effects of radiation, 4125
- 9-Amino-20(S)-camptothecin**  
   *c-jun* expression  
     human myeloid leukemia cells, 6636
- Ammonium**  
   <sup>14</sup>N nuclear magnetic resonance spectroscopy  
     tumors, 3378
- Amonafide**  
   Phase I clinical investigation  
     refractory or relapsed acute leukemia, 935
- Amsacrine**  
   -induced lesions in DNA  
     modulation, novobiocin and 2,4-dinitrophenol, 573
- resistant form of topoisomerase II  
   point mutation, topoisomerase II gene, 4729
- topoisomerase II levels and chemosensitivity  
   testis and bladder tumor cell lines, 6592
- $\alpha$ -Amylase**  
   isozymes  
     expression, human thyroid tissues, 3544
- Anal neoplasms**  
   anal intraepithelial neoplasia and human papillomavirus DNA, 1014
- Anchorage independence**  
   role of postreplication repair transformation, human fibroblasts, 2960
- Androgen**  
   antiestrogen EM-170 and estradiol-stimulated growth, breast tumors in athymic mice, 3131
- biphasic action  
   antiproliferative effects, EM-139, 5165
- dependent and -independent prostatic tumors  
    $\gamma$ -interferon, tumor necrosis factor- $\alpha$ , 2329
- independent prostatic cancer  
   autonomous growth, transforming growth factor- $\alpha$ , 2780
- programmed death, 4693
- induced proliferation  
   thyroid hormone, Shionogi carcinoma 115 mammary carcinoma cells, 4323
- primed chemotherapy  
   Dunning R3327 G model, prostatic cancer, 1760
- sensitivity  
   new human breast cancer cell line, 5722
- serum and urinary  
   risk of breast cancer, postmenopausal women, 2572
- Androstenedione**  
   serum and urinary androgens  
   risk of breast cancer, postmenopausal women, 2572
- Anesthesia**  
   maternal and perinatal risk factors  
     childhood leukemia, 3696
- Angiogenesis**  
   blood flow and metabolism  
     growth and ATPase kinetics, tumors growing in irradiated bed, 3289
- growth factor genes  
   primary human astrocytomas, 1345
- inhibition by minocycline, 672
- suppression of solid tumor growth  
   immunoneutralizing monoclonal antibody, basic fibroblast growth factor, 6180
- tumor growth and  
   inhibition by CDPGYIGSR-NH<sub>2</sub>, 903
- tumor-induced  
   inhibitors, *in vivo* mouse assay, 1339
- sulfated chitin derivatives, 22
- Anthracyclines**  
   *N*-(5,5-diacetoxypentyl)doxorubicin  
     DNA interstrand cross-linking, human leukemia cells, 6704
- immunoconjugates  
   site-specific linkage, amino-dextrin intermediate carrier, 4192
- Anthracycline**  
   Phase I pharmacokinetic and pharmacodynamic study  
     CI-937, 6317
- Antibodies**  
   antipeptide  
     production and characterization, *O*<sup>6</sup>-methylguanine-DNA methyltransferase, 3339
- bifunctional and enzyme-conjugated  
   pharmacokinetic analysis, two-step approaches, 3119

- galactose-conjugated cancer therapy, 1619
- $\alpha_1$ -Antichymotrypsin prostate-specific antigen and sera of patients, prostatic cancer, 222
- Antiestrogens**  
clinical potential, 3867  
5 $\alpha$ -dihydrotestosterone and inhibition of cell cycle kinetics, breast cancer, 2797  
EM-170 and androgen estradiol-stimulated growth, breast tumors in athymic mice, 3131  
pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen treatment of breast cancer, 5851  
tamoxifen  
P-450-mediated activation, proteins in rat and human liver, 6052
- Antifolates**  
compounds and natural folates membrane transport, L1210 leukemia cells, 5507  
lipophilic phenotype conferring selective resistance, Chinese hamster ovary cells, 2949
- Antineoplastic agents**  
survival after treatments  
Chinese hamster cells, M, 27,000 heat shock protein, 5245
- Antipain**  
-induced suppression of oncogene expression  
H-ras-transformed NIH3T3 cells, 4810
- Antitumor activity**  
interleukin 1 $\alpha$  and combination effect, syngeneic tumors in mice, 215  
taxotere, 4865  
UCN-01  
murine and human tumor models, 4888
- Aphidicolin**  
fludarabine triphosphate inhibition of primer RNA formation, CCRF-CEM cells, 1829
- Apolipoprotein D**  
stimulation of secretion by steroids inhibition of cell proliferation, prostate cancer cells, 4336
- Apomucin**  
pancreatic relationship, mammary and intestinal apomucins, 1026
- Apoptosis**  
DNA cross-links and cell cycle nitrogen mustard sensitivity, Burkitt's lymphoma, 6550  
rapid cell death induction by photodynamic therapy, mouse lymphoma cells, 5993  
topoisomerase II-reactive chemotherapeutic drugs thymocytes, 1078
- 1- $\beta$ -D-Arabinofuranosylcytosine**  
1- $\beta$ -D-arabinofuranosyluracil and plasma and cerebrospinal pharmacokinetics, 4141  
cis-diammine-1,1-cyclobutane dicarboxylatoplatinum(II) inhibition of DNA interstrand cross-link removal, 1984  
-induced alopecia interleukin 1 protection, 3329  
internucleosomal DNA fragmentation myeloid leukemia, 741  
phosphorylation in human leukemia cells regulation of deoxycytidine kinase, uridine nucleotides, 2559  
potentiation of cytotoxicity to HL-60 cells  
1,25-dihydroxyvitamin D $_3$ , maturation of DNA replication intermediates, 3451
- 1- $\beta$ -D-Arabinofuranosylcytosine 5'-triphosphate**  
fludarabine triphosphate inhibition of primer RNA formation, CCRF-CEM cells, 1829
- Arachidonate**  
release from epidermal cells  
4 $\beta$ - and 4 $\alpha$ -12-O-tetradecanoylphorbol-13-acetate, 850
- Arachidonic acid**  
inhibitory effects of curcumin lipoxygenase and cyclooxygenase, mouse epidermis, 813  
lipid peroxidation rat AH-130 hepatoma cells, 4603
- Arginine**  
dietary restriction ornithine and polyamine metabolism, two-stage epidermal carcinogenesis, 2932
- Arylalkyl isothiocyanates**  
inhibition  
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone lung tumorigenesis, 1846
- Arylamine N-acetyltransferase**  
acetylator genotype-dependent expression colon cytosol, non-cancer and colorectal cancer, 549
- Arylsulfotransferase IV**  
modulation of hepatic messenger RNA translation activity acetylaminofluorene-induced hepatocarcinogenesis, 504
- AS101**  
protection of bone marrow colony forming units-granulocyte-macrophage purging with ASTA-Z 7557, 5614  
protective and restorative role combined with chemotherapy, 1499
- Asbestos**  
activation of ornithine decarboxylase tracheal epithelial cells, 167  
exposure cigarette smoking, malignant mesothelioma, 2263  
size-dependent microtubule-mediated transport endocytosis, vertebrate lung epithelial cells, 4942
- Ascites**  
Ehrlich daunorubicin resistance, decreased DNA topoisomerase II, 4213  
ovarian malignant infiltrating lymphocytes, tumor cytotoxicity, 4257
- Ascorbic acid**  
bladder carcinogenesis  
L-ascorbic acid amplification, 2548  
enhanced effects of 6-hydroxydopamine hydrogen peroxide, iron-dependent DNA strand-breaks, 6060
- L-Asparagine**  
measurement of serum levels  
L-asparaginase inhibitor, 6568
- Asparagine synthetase**  
hypomethylation and reactivation of gene  
L-asparagine, ethyl methanesulfonate, 985
- Assays**  
DNA repair field-test validation, circulating human lymphocytes, 5786  
drug sensitivity human tumor cell line growth, soft agar culture, 1247  
flow cytometry glutathione S-transferases, cellular glutathione determination, 1783  
gp185 antigen shed from mouse tumors c-erbB2 oncogene overexpression, 2593  
inhibitors of tumor-induced angiogenesis, 1339  
lung cancer-associated protein, 3838  
temporal mapping of differentiation pathway murine erythroleukemia cells, 1668  
tetrazolium-based cellular viability, formazan production parameters, 2515
- ASTA-Z 7557**  
purging protection of bone marrow colony forming units-granulocyte-macrophage, AS101, 5614
- Astrocytoma**  
primary human angiogenic growth factor genes, 1345
- Astroglial cells**  
chondroitin sulfate proteoglycan expression proliferating brain capillary endothelial cells, 4986
- Autocrine motility factor**  
B16-F1 melanoma receptor and, purification, 3507
- Autocrine-paracrine factors**  
consequences of "binding site barrier", 4776
- Avidin**  
three-step monoclonal antibodies tumor targeting, carcinoembryonic antigen-positive patients, 5960
- 2-Aza-2'-deoxycytidine**  
ras or myc oncogenes nontumorigenic fibroblasts, 324
- Azoxymethane**  
enhancement of colon carcinogenesis methionine enkephalin, 785  
-induced colon carcinogenesis inhibition by haloperidol, 6150  
mechanism, benzylselenocyanate inhibition, 2826

B

B859-35

- inhibition of cell proliferation, 5821
- Bacillus Calmette-Guérin**  
fibronectin-mediated attachment to bladder mucosa  
drugs influencing coagulation pathways, 3726
- Bacteriocin**  
partially purified  
studies of action, murine fibrosarcoma, 1359
- Basal cells**  
regression of forestomach lesions, 318
- Basement membrane**  
invasion of matrix  
lack of correlation, malignant metastatic cell phenotype, 3624  
reconstituted matrix  
malignant metastatic cell phenotype, 405
- B-cells**  
AIDS and non-Hodgkin's lymphoma, 4743  
diffuse large cell lymphoma  
cell line establishment, 8;22 chromosomal translocation, 5392  
genetic approaches to study  
molecular basis of human cancer, 5015s  
no expansion of pre-B and B-cell compartments  
bone marrow patient, multiple myeloma, 3224
- BCR-ABL proteins**  
detection in blood cells  
benign phase chronic myelogenous leukemia, 3048
- Benzisquinolinedione: see Amonafide**
- Benzljaceanthrylene**  
morphological transformation and DNA adduct formation  
C3H10T½ cells, 6163
- Benzo(a)pyrene**  
*trans*-7,8-dihydroxy-*anti*-9,10-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene  
guanine N<sup>2</sup>, duplex dodecamer, 3482  
-induced mouse forestomach neoplasia  
inhibition, dietary soy sauce, 2940
- Benzo(a)pyrene diol epoxide**  
inhibition of 2,6-dithiopurine and thio-purine binding  
two-stage tumorigenesis, mouse epidermis, 4859
- Benzo(a)pyrene phenols**  
inhibition of glucuronidation  
long-chain fatty acids, 4511
- N<sup>6</sup>-Benzyl-cAMP**  
8-Cl-cAMP and  
cell cycle effects, HL-60 leukemia cells, 6263
- O<sup>6</sup>-Benzylguanine analogues**  
sensitivity of human tumor cells  
cytotoxic effects, alkylating agents, 3367
- Benzylselenocyanate**  
inhibition  
azoxymethane-induced colon carcinogenesis, 2826
- Bifunctional antibody**  
binary radiopharmaceutical delivery system  
colorectal carcinoma, 6650  
enzyme-conjugated antibodies and  
pharmacokinetic analysis, two-step approaches, 3119
- Bile acids**  
fecal  
starch malabsorption, colonic carcinogenesis, 4238
- Bile ducts**  
liver development  
cell lineages, oval cell progenitors, 2611
- Biologic response modifiers**  
tumor transplantation and tumor immunity, 5433
- Biotin**  
three-step monoclonal antibodies  
tumor targeting, carcinoembryonic antigen-positive patients, 5960
- Bis(2,6-dioxopiperazine) derivatives**  
inhibition of intracellular topoisomerase II, 4909  
inhibition of topoisomerase II  
antitumor agents, 4903
- 1,3-Bis(2-chloroethyl)-1-nitrosourea**  
inhibition of poly(adenosine diphosphate-ribose) polymerase  
thymidine and its analogues, L1210 cells, 1586  
resistance by  $\gamma$ -irradiation or drug pretreatment  
rat hepatoma cells  
streptozotocin combination therapy  
O<sup>6</sup>-methylguanine DNA methyltransferase, messenger RNA levels in HT-29 cells, 1581
- N,N'-Bis[3-(ethylamino)propyl]-1,7-heptanediamine**  
participation of T-cells in curative effect  
L1210 leukemia, 62
- Blacks**  
familial breast cancer, 1793
- Bladder**  
carcinogenesis  
L-ascorbic acid amplification, K<sub>2</sub>CO<sub>3</sub>, 2548  
modulation by butylated hydroxytoluene, 2-acetylaminofluorene exposure, 6224  
tumor-promoting effect, urinary epidermal growth factor, 5487  
carcinogens  
mechanism of resistance, bladder cancer, 514  
tumor promoting activity  
lack of, sodium saccharin in AIN-76A diet, 1778  
sodium saccharin, sodium ascorbate and calcium salts, 1766  
wall penetration  
intravesical Mitomycin C, 4347
- Bladder neoplasms**  
effect of urine on clonal growth, 4631  
fibronectin-mediated *Bacillus Calmette-Guérin* attachment  
mucosa, drugs influencing coagulation pathways, 3726  
genital and urinary tract diseases, 629  
H-*ras* mutations, 3471  
human  
molecular genetic alterations, 5405  
inhibition of H-*ras* expression  
adeno-associated virus Rep78, 3383  
intravesical administration  
radiolabeled antitumor monoclonal antibody, 724  
local activation of immune response  
intraarterial infusion, interleukin 2, 2456  
numerical chromosome 1, 7, 9, and 11 aberrations  
*in situ* hybridization, 644  
pharmacodynamics of Mitomycin C, 3849  
pharmacokinetics of intravesical mitomycin C, 5144  
photosensitization  
phenoxazine Nile blue derivatives, 1109  
prevention of implantation  
single-dose preoperative systemic cyclophosphamide, 1373, 1378  
risk of development  
cellular F-actin levels as marker, 2762  
serum levels, dehydroepiandrosterone and its sulfate, 1366  
topoisomerase II levels and chemosensitivity, 6592  
tumor grade and labeling index  
centromeric copy number, chromosome 7, 3807
- Bleomycin**  
human tumor resistance  
metabolic inactivation, 227  
killing  
hypersensitivity of CHO variants, glutathione S-transferase- $\alpha$  activity, 4463
- Blood**  
capture and growth of CD8<sup>+</sup> and CD4<sup>+</sup> T-cells, 3891  
detection of BCR-ABL proteins  
benign phase chronic myelogenous leukemia, 3048  
micelle-forming polymeric anticancer drug  
toxicity and antitumor activity, 3229  
peripheral  
immunological changes, interleukin 2-treated acute leukemia, 964  
rapid clearance  
immunoglobulin G2a and G2b, nude mice, 3102
- Blood flow**  
angiogenesis  
growth and ATPase kinetics, tumors growing in irradiated bed, 3289  
radiation-induced fibrosarcoma-1 tumor metabolism  
glucose and mannitol effects, nuclear magnetic resonance, 3108  
rate  
intravenous vs. intraperitoneal glucose injection, normal and tumor tissues, 3612  
tumor  
red blood cell rigidity, hyperglycemia, 2727
- Blood vessels**  
inhibition of tumor growth  
platelet factor 4 analogue, angiostatic activity, 2077
- B-lymphoid cells**  
diphtheria toxin A-chain coding sequence  
immunoglobulin genes, 4299

- Body weight**  
changes in  
prior to cancer diagnosis, 3198
- Bombesin**  
analogues  
inhibition of growth, small cell lung cancer, 1798  
gastrin releasing peptide antagonist  
inhibition of growth, human colon cancer xenografts, 6006  
RC-3095 and RC-160  
inhibitory effect, nitrosamine-induced pancreatic cancer, 5980
- Bone**  
breast cancer metastases  
localization, parathyroid hormone-related protein, 3059  
fibroblasts  
prostate cancer growth acceleration, 3753
- Bone marrow**  
biodistribution and dosimetry  
infusion, antibodies labeled with  $^{131}\text{I}$ , 5921  
colony forming units-granulocyte-macrophage  
protection with AS101, purging with ASTA-Z 7557, 5614  
elimination of breast cancer cells  
reactivity, anti-CD15 monoclonal antibody PM-81, 2451  
human hematopoietic progenitors  
transforming growth factor- $\beta$ , 4828  
human multidrug resistance gene  
chemotherapy and chemosensitization, transgenic mice, 5417  
immunological changes  
interleukin 2-treated acute leukemia, 964  
leukemic human hematopoietic progenitors  
cytotoxic activity, antitransferrin receptor immunotoxin, 536  
no expansion of pre-B and B-cell compartments  
multiple myeloma, 3224  
sensitivity of immunocytochemical detection  
breast cancer cells, 2706  
topoisomerase II levels  
granulocytic maturation, 3534  
transplantation  
induction of graft vs. leukemia effect, interleukin 2, 2015
- Boron neutron capture theory**  
biological efficacy  
boronated low-density lipoprotein, 4588
- Bowman-Birk protease inhibitor**  
expression of oncogenes  
irradiated rat colon, 4539  
inhibition of proteolytic activity  
human fibroblasts, 5539
- Bradykinin**  
stimulation of clonal growth  
small cell lung cancer, 3621
- Brain**  
fetal rat  
glioblastoma cell invasion, alkyl-lysophospholipid, 1713  
human normal and tumor tissue  
O<sup>6</sup>-methylguanine-DNA methyltransferase, 4131  
lack of parenchymal infiltration  
overexpression of oncogene products, tumor progression, 3595  
metastases  
malignant potential of cells, melanoma, 2029  
proliferating capillary endothelial cells  
chondroitin sulfate proteoglycan expression, malignant phenotype of astroglial cells, 4986  
tumor xenografts  
preclinical antitumor activity, penclo-medicine, 1979
- Brain neoplasms**  
immunogenic and nonimmunogenic phenotype and functional activity, tumor-infiltrating lymphocytes, 2373  
large-animal tumor xenograft model  
immunosuppressed cats, 2430  
nonastrocytic  
p53 mutations, 6202
- Breast**  
cyst fluid  
esterase, purification and properties, 1092  
fibroblasts  
growth factor messenger RNA expression, benign and malignant lesions, 4978  
neoplasia  
 $\beta$ 1-6 branched oligosaccharides, tumor progression, 718  
neoplastic and nonneoplastic tissue  
fibrinolysis pathways, 354  
partial characterization, proteoglycans, 1443  
normal female  
estrogen and progesterone receptors, 1817
- Breast neoplasms**  
advanced  
pS2 expression and response, hormonal therapy, 624  
antiestrogen with clinical potential, 3867  
-associated epitope  
monoclonal antibody 3E1.2, N-glycolylneuraminic acid, 5826  
binding analysis of estrogen receptor  
DNA target site, 3405  
c-erbB2 oncogene overexpression  
gp185, antigen shed from mouse tumors, 2593  
combined effects  
1,25-dihydroxyvitamin D<sub>3</sub>, platinum drugs, 2848  
dissociation of estrogenic and cytotoxic properties  
estrogen receptor-binding platinum complex, 3217  
estradiol receptor-positive  
epidermal growth factor receptor-negative tumors, 4544  
estradiol-stimulated growth  
androgen and EM-170, athymic mice, 3131  
estrogen receptor  
constitutive transcriptional activity, 105  
evolution of progesterin resistance, 2051  
factors influencing mutation  
hprt locus, T-cells, 6603
- familial  
blacks, 1793
- female**  
major alterations in nucleotide structure, DNA, 5430  
follow-up study of twenty-four families  
Li-Fraumeni syndrome, 6094  
gonadotropin-releasing hormone gene expression, 2577
- growth**  
inhibition of c-myc expression, phosphorothioate antisense oligonucleotide, 3996  
induction of cachexia and systemic fibrosis  
transforming growth factor- $\beta$ 1, nude mice, 3590  
inhibition of cell cycle kinetics and proliferation  
5 $\alpha$ -dihydrotestosterone, antiestrogen, 2797  
internalization of murine monoclonal antibody  
HER-2/neu gene product c-erbB-2, 5361  
lactoferrin and polymorphism, 3037  
M, 46,000 human milk fat globule protein, 4994  
milk epithelial cells  
loss of heterozygosity, short arm of chromosome 11, 294  
monoclonal antibody against c-erbB-2 protein  
enhanced cisplatin cytotoxicity, 4575  
node-negative  
c-erbB-2 amplification, risk of recurrent disease, 556  
new cell line  
androgen sensitivity, 5722  
oxygenation, 3316  
parathyroid hormone-related protein in metastases  
localization, incidence in bone, 3059
- primary**  
accumulation, genetic alterations, 5794  
fibrinogen deposition, no thrombin generation, 349  
HER-2/neu amplification, 944  
p53 gene mutations, 6194  
somatic imbalance, marker alleles for chromosome 1, 1020
- progesterin regulation**  
alkaline phosphatase, 4470
- prognosis**  
c-erbB-2 and estrogen receptor status, 3296  
estrogen and progesterone receptors, 1,25-dihydroxyvitamin D<sub>3</sub> receptor, 239
- progression**  
maintenance, p53 alterations, 2605  
pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen  
new analogues of tamoxifen, 5851  
reactivity of anti-CD15 monoclonal antibody PM-81  
elimination of cells, bone marrow, 2451
- risk of**  
serum and urinary androgens, postmenopausal women, 2572

- sensitivity of immunocytochemical detection
  - human bone marrow, 2706
- tumor-associated antigen
  - monoclonal antibody BCA 227, 1537
- vinorelbine-loaded polymeric bioresorbable implants, 5384
- Breeding stock**
  - tumor transplantation and tumor immunity, 5433
- Bromocriptine**
  - azoxymethane-induced colon carcinogenesis
    - inhibition by haloperidol, 6150
- 5-Bromo-2'-deoxyuridine**
  - incorporation into DNA of glioma cell lines
    - modulation, fluoropyrimidines, 870
- Bryostatins**
  - successful treatment of murine melanoma, 682
- Busulfan**
  - hepatohepatic
    - Phase I and pharmacokinetic study, 5781
    - Phase I clinical and pharmaceutical trial, 6268
- Buthionine sulfoximine**
  - toxicity of verapamil and doxorubicin multidrug resistant cells, 67
- Butylated hydroxytoluene**
  - modulation of liver and bladder carcinogenesis
    - chronic low-level exposure, 2-acetylaminofluorene, 6224

C

- CA 15.3**
  - relative operating characteristic analysis group modeling, tumor markers in breast carcinoma, 1904
- CA 125**
  - determinants
    - coexpression, different antigenic markers, 468
- Cachectin**
  - tumor necrosis factor
    - decrease in catalase activity, rat liver, 3990
- Cachexia**
  - anticachectic and antitumor effect
    - protein turnover, eicosapentaenoic acid, 6089
  - changes in plasma cholesterol and cancer, 3198
  - development
    - tumor growth, indomethacin, cytokines and cyclosporin A, 880
  - experimental model
    - $\gamma$ -interferon, tumor necrosis factor- $\alpha$ , 2303
  - leukemia-inhibitory factor
    - mice bearing melanoma cells, 6656
  - tissue lipoprotein lipase activity
    - mRNA levels, tumor-induced alterations, 863
  - tumor growth and development
    - tumor necrosis factor- $\alpha$ , interleukin 1, 415
- E-Cadherin**
  - P-cadherin and

- expression in gastric carcinoma, 2185
- squamous cell carcinomas
  - head and neck, lymph node metastasis, 6328
- Caffeic acid**
  - forestomach and kidney carcinogenicity
    - rats and mice, 5655
- Caffeine**
  - modulation of effects
    - DNA-intercalating drugs, 3682
- Cain Memorial Award Lecture**, 5
- Calbindin**
  - hybrid human endogenous retrovirus and prostate cell line PC3, 4107
- Calcitriol**
  - induction of nonphosphorylated osteopontin
    - mouse JB6 epidermal cells, 2144
- Calcium**
  - altered intracellular regulation
    - colorectal cancer, "normal" adjacent mucosa, 4492
  - cytosolic
    - hyperthermia, digitized imaging microscopy, 359
  - dietary
    - vitamin D and, colonic carcinogenesis, 5608
  - intracellular
    - epidermal neoplasia, 4206
  - programmed death
    - nonproliferating androgen-independent cancer cells, 4693
  - stimulation of mobilization by galanin
    - inositol phosphate accumulation, small cell lung cancer, 1674
  - supplemental
    - K-ras mutations, 1,2-dimethylhydrazine-induced colonic tumors, 4305
    - suppression of colonic ornithine decarboxylase, adenomatous polyps, 3416
  - vitamin D and colon cancer, 3069
- Calcium salts**
  - sodium saccharin and sodium ascorbate
    - bladder tumor promoting activity, 1766
- Calcein**
  - inducible expression
    - neuroblastoma cell differentiation, Schwann-like cell lines, 1733
- Camptothecin**
  - antitumor effect of CPT-11
    - intracellular roles, SN-38, 4187
  - derivatives and
    - c-jun expression, human myeloid leukemia cells, 6636
  - ionizing radiation and topotecan synergistic cell killing, 5813
  - MDR1-mediated resistance
    - human KB carcinoma cells, 6039
  - teniposide or 4'-(9-acridinylamino)-3-methanesulfon-m-aniside
    - degradation of nuclear DNA, S phase of HL-60 cells, 1165
  - topoisomerase II-directed chemotherapeutic agents and
    - antagonism, human leukemia cell line, 1129
- 20-(S)-Camptothecin**
  - complete growth inhibition
    - human cancer xenografts, nude mice, 3052

- Capillary**
  - filtration coefficient
    - measurement, solid tumors, 1352
- Carbohydrate**
  - breast tumor-associated antigen
    - monoclonal antibody 3E1.2, N-glycolylneuraminic acid, 5826
  - dietary
    - growth of dysplastic crypt foci, colon, 3721
- Carboplatin**
  - combined with whole body hyperthermia
    - normal tissue and tumor, rats, 2994
  - detection of DNA modifications
    - monoclonal antibody, 123
- Carcinoembryonic antigen**
  - anti-CEA antibodies
    - induction of antigen-specific immune response, anti-idiotypic monoclonal antibodies, 2599
  - binary radiopharmaceutical delivery system
    - bifunctional antibody, colorectal carcinoma, 6650
  - control of gene family expression
    - differentiating colon carcinoma, 3526
  - different molecular weight in normal colon and cancer cells
    - N-glycosylation differences, 5679
  - endogenous lactose-binding lectin
    - metastatic stages, colorectal carcinoma, 387
  - expression of resurgent human colon carcinoma
    - $^{90}\text{Y}$ - $\alpha$ -carcinoembryonic antigen monoclonal antibody, 3802
  - positive patients
    - three-step monoclonal antibodies, 5960
  - preparation of synthetic polypeptide domains
    - epitope mapping, 1876
  - related human gastric gene product, 5694
  - relative operating characteristic analysis group modeling, breast carcinoma, 1904
  - serum
    - tumor-associated glycoprotein-72 levels, interferons, 4155
  - transduction and expression of antigen gene
    - murine colon carcinoma cell line, 3657
  - $^{90}\text{Y}$ -labeled C110 anti-CEA antigen immunotoxin
    - preclinical assessment, colon cancer, 255
- Carcinogenesis**
  - aflatoxin B<sub>1</sub>
    - promotion by indole-3-carbinol, 2362
  - allotype of renal cell carcinoma, 820
  - bioassays
    - mechanistic and statistical insight, N-nitrosodiethylamine and N-nitrosodimethylamine, 6409
  - bladder
    - L-ascorbic acid amplification, K<sub>2</sub>CO<sub>3</sub>, 2548
    - tumor-promoting effect, urinary epidermal growth factor, 5487
  - cancer and, 6215
  - c-erbB-2 proto-oncogene products

immunoscintigraphy, 990  
cervical  
  role of human papillomaviruses, 5019s  
chemical and physical  
  advances and perspectives for the  
  1990s, 5023s  
colonic  
  chemoprevention, 4528  
  enhancement of methionine enkephalin, azoxymethane, 785  
  induction by azoxymethane, benzylsenecyanate inhibition, 2826  
  initiation and promotion,  $\omega$ -3 and  $\omega$ -6 fatty acids, 487  
  modulation, dietary calcium and vitamin D, 5608  
  starch malabsorption, fecal bile acids and neutral sterols, 4238  
diethylnitrosamine-induced  
  strain-specific sensitivity, hepatocytes, 3257  
drug-metabolizing enzymes  
  liver epithelial cells, procarcinogens, 301  
experimental  
  inhibition by haloperidol, rat colon, 6150  
forestomach  
  phenolic antioxidants, *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine, 824  
  frequent induction of mammary carcinoma  
  *neu* oncogene transfer, 5649  
gastric  
  *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine, low-protein diet, 3493  
  *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine, deoxycorticosterone acetate-NaCl hypertensive rats, 2863  
genetic errors and cell proliferation, 6493  
hepatocellular  
  chromosome abnormalities, peripheral blood cells, 6176  
  hormonal, 3626  
  inhibition in mammary gland  
  dietary dehydroepiandrosterone, 481  
  liver and bladder  
  modulation by butylated hydroxytoluene, 2-acetylaminofluorene exposure, 6224  
  liver and lung  
  genetic susceptibility, mice, 6299  
lung  
  bronchial epithelial cells, *c-ras*-1 and *c-myc*, 3793  
  mouse colon  
  heterogeneity of ornithine decarboxylase, human colon tumors, 2069  
multistage  
  mutator phenotype, 3075  
multistep transformation  
  cell-cell communication, ovarian granulosa cell culture, 696  
*N*-nitrosobenzylmethylamine  
  inhibitory effects of phenethyl isothiocyanate, rat esophagus, 2063  
nonfamilial neoplasia of large intestine  
  rectal mucosa cell proliferation, 1917  
  origin and development of cancer  
  cellular adaptation, 2751  
  17p allelic deletions

p53 protein overexpression, Barrett's adenocarcinoma, 5482  
pulmonary  
  mouse, memorial to Dr. Michael B. Shimkin, 450  
  resistance to growth inhibitory effects  
  transforming growth factor- $\beta$ 1, liver epithelial cells, 5929  
skin  
  diet and calorie restriction, Sencar mouse model, 1851  
  two-stage epidermal  
  dietary arginine restriction, ornithine and polyamine metabolism, 2932  
  ultraviolet radiation-induced murine tumors  
  absence, UV-induced systemic tumor immunosuppression, 2773  
**Carcinogenicity**  
  1-, 2- and 4-nitropyrene  
  structurally related compounds, female rats, 2902  
  forestomach and kidney  
  caffeic acid, rats and mice, 5655  
  studies of tobacco extract  
  vitamin A-deficient Sprague-Dawley rats, 3018  
**Carcinogens**  
  bladder  
  mechanisms of resistance, bladder cancer, 514  
  -induced lymphomagenesis  
  *pim*-1 transgenic mice, 958  
  p53 mutations, 6185  
  rapid evolution  
  field of molecular epidemiology, 3617  
  spontaneously occurring non-liver tumors  
  activation, protooncogenes, 1148  
**Carcinoid cells**  
  production of paracrine growth factors  
  fibroblast and endothelial cell growth, 5253  
**Carcinoid neoplasms**  
  metastatic  
  early invasiveness, transgenic mice, 4917  
**Carcinoma**  
  altered protein kinase C activity  
  biopsies, 205  
  cell lineage studies  
  "resistant hepatocyte" model system, 1308  
  1,25-dihydroxyvitamin D<sub>3</sub> receptors, 2021  
  *in situ* transfer of v-Ha-ras  
  replication-defective retrovirus vectors, mammary epithelial cells, 2642  
  invasive  
  accessory sex organs, 3,2'-dimethyl-4-aminobiphenyl and testosterone propionate, 1264  
  multidifferentiated  
  *c-ras*-1 and *c-myc*, 3793  
  primary and metastatic tumor cell populations  
  expression, HLA-A, -B, -C antigens, 6372  
  stimulation of epithelial tumor cell motility  
  tumor necrosis factor, 5315  
**Carcinoma, basal cell**

cytogenetic analysis, 954  
**Carcinoma, bladder**  
  inactivation of retinoblastoma gene, 5736  
  mechanism of photosensitization  
  microsphere-bound chlorin e<sub>6</sub>, 4410  
**Carcinoma, breast**  
  major alterations  
  nucleotide structure of DNA, 5430  
  monoclonal antibody  
  immunohistochemistry, 15A8-glycyl-tyrosyl-(*N*- $\epsilon$ -diethylenetriamine pentaacetic acid)-lysine, 5744  
  prognostic significance of P120, 1973  
  relative operating characteristic analysis  
  group modeling, tumor markers, 1904  
**Carcinoma, bronchogenic**  
  HLA class I and II antigens, 4948  
  immortalization of normal bronchial epithelial cells  
  human papillomaviruses 16 or 18, 5370  
  phenotype and function  
  natural killer cells, 5596  
**Carcinoma, cervical**  
  interstitial hypertension  
  tumor oxygenation, radiation response, 6695  
  oxygenation of, 6098  
  therapy  
  monoclonal antibody-*Pseudomonas* exotoxin conjugates, 4001  
**Carcinoma, colonic**  
  amiloride treatment, 1039  
  cellular growth response  
  epidermal growth factor, 1452  
  differentiating  
  control, carcinoembryonic antigen gene family, 3526  
  establishment of quiescent state  
  differential regulation, *c-myc* and TGF- $\alpha$  messenger RNA, 2256  
  interferon enhancement of radioimmunotherapy, 2335  
  mechanisms of resistance  
  etoposide and teniposide, 5275  
  metastatic  
  insulin-like growth factor I, tyrosine phosphorylation, 5859  
  reversal of Adriamycin resistance  
   $\alpha$ -interferon, 4898  
  transduction and expression  
  human carcinoembryonic antigen gene, mouse, 3657  
**Carcinoma, colorectal**  
  acetylator polymorphism, 2098  
  -associated antigen  
  monoclonal antibody, 926  
  binary radiopharmaceutical delivery system  
  bifunctional antibody, 6650  
  cytotoxic effects of acoustic cavitation  
  HT-29 cells, peritoneal carcinomatosis, 3024  
  loss of heterozygosity  
  p53 protein expression, 4436  
**Carcinoma, embryonal**  
  binding to insulin-like growth factors  
  differentiation, 4395  
  induction of *in vitro* differentiation  
  inhibitors of topoisomerases, 5398  
**Carcinoma, endometrial**

- allelic loss on chromosome 17p and *p53* mutations, 5632  
 patterns of differentiation  
 extracellular matrix, 5661
- Carcinoma, esophageal**  
 autocrine stimulation  
 overexpression, epidermal growth factor and insulin-like growth factor-I receptors, 1898  
 deletion of 17p  
 amplification of *int-2* gene, 2113
- Carcinoma, gastric**  
 E- and P-cadherin expression, 2185  
 gene loss, 2926  
 liver metastasis  
 autotumor-reactive T cell clones, tumor-infiltrating lymphocytes, 6153
- Signet ring cell**  
 cell line establishment, *c-myc* oncogene, 381  
 transforming growth factor- $\beta$  release  
 contraction, collagen-matrix gels containing fibroblasts, 3550  
 tumor-associated *M*, 110,000 gene product  
 relation to carcinoembryonic antigen, 5694
- Carcinoma, hepatocellular**  
 aberrations of tumor suppressor *p53*  
 retinoblastoma genes, 5520  
 association with hepatitis C virus antibodies  
 Taiwan, 5621  
 chromosome abnormalities  
 peripheral blood cells, hepatitis B virus chronic carriers, 6176  
 elevated levels of transforming growth factor- $\beta$  messenger RNA  
 polypeptide and, 4080  
 hepatitis B virus integration event  
 chromosome 17p near *p53* gene, 49  
 hepatitis C and hepatitis B  
 Japanese population, 2842  
 histochemical profile  
 diethylnitrosamine, 1952  
 interleukin 6-*Pseudomonas* exotoxin chimeric molecules  
 antitumor activity, 2831  
 loss of somatic heterozygosity, 4367  
 membrane-associated glycoprotein gp43  
 monoclonal antibody, 2158  
 primary  
 allelotype study, 89  
 transcatheter arterial embolization  
 evaluation, nontumorous tissue damage, 5667
- Carcinoma, Lewis lung**  
 3LL metastatic variants  
 differential expression, transforming growth factor- $\beta$ 1 gene, 5491
- Carcinoma, lung**  
 activation of *myc* gene family  
 heterotransplantation, nude mice, 2566  
 gene mutations  
*p53*, *ras* and *p53*-heat shock 70 protein complexes, 4090  
 mechanisms of resistance  
 etoposide and teniposide, 5275
- Carcinoma, mammary**  
 dose-responsive  
 intraperitoneal injection, 1-methyl-1-nitrosourea, 3411  
 effects of thyroid hormone  
 androgen- or basic fibroblast growth factor, proliferation, 4323  
 frequent induction following *neu* oncogene transfer, 5649  
 isolation of two distinct epithelial cell lines  
 single feline mammary carcinoma, heterogeneity, 4028  
 microvascular architecture, 265  
 rat model  
 mechanisms, drug resistance, 1434  
 suppressor gene  
*v-H-ras* oncogene transfer, mammary epithelial cells, 5298  
 tumorigenesis  
 indomethacin, high- or low-fat diet, 2683
- Carcinoma, non-small cell lung**  
 absence of expression  
 retinoblastoma protein, 2735  
 correlation of modal chromosome number  
 DNA index, solid tumor tissue, 3267
- Carcinoma, ovarian**  
 anomalous relationship between cisplatin sensitivity  
 formation and removal of platinum-DNA adducts, 4557  
 antiproliferative effect of interleukin 1, 1823  
 broad cross-resistance  
 multifactorial mechanisms, cyanomorpholino doxorubicin, 5181  
 cloning of tumor-associated antigen  
 monoclonal antibodies, folate binding protein, 6125  
 distinction of low grade from high grade  
 loss of heterozygosity, genetic abnormalities, 4045  
 granulocyte-macrophage colony-stimulating factor  
 chemotherapy, 116  
*Na<sup>+</sup>, K<sup>+</sup>-adenosine triphosphatase*  
 accumulation of *cis*-diaminedichloroplatinum(II), 3677  
 photoimmunotherapy, 4762  
 single step selection  
*cis*-diaminedichloroplatinum(II) resistant mutants, 2242  
 tumor necrosis factor expression, 4476  
 xenografts  
 malignant behavior, resistance to cisplatin, 6358
- Carcinoma, prostatic**  
 activated *ras* alleles, 1632  
 androgen-independent  
 autonomous growth, transforming growth factor- $\alpha$ , 2780  
 disruption of cellular energy balance  
 suramin, 6629
- Carcinoma, renal cell**  
 allelotype, 820  
 augmentation of immunity  
 Adriamycin and interleukin 2, 6133  
 clear cell phenotype  
 allelic loss, chromosome 3p, 949  
 common regions of deletion  
 chromosomes 5q, 6q and 10q, 5817  
 down-regulation of epidermal growth factor receptors  
 $\alpha$ -interferon, 5881  
 genetic changes in origin and development  
 molecular analysis, 1071  
 hereditary  
 altered expression, transforming growth factor- $\alpha$ , 2973  
 nonrandom loss, chromosomes 5 and 6, 4415  
 inactivation of retinoblastoma gene, 5736  
 inhibition of cell growth  
 interleukin 4,  $\gamma$ -interferon or  $\alpha$ -tumor necrosis factor, 5687  
 sporadic  
 detailed deletion mapping, short arm of chromosome 3, 4707  
 tumor-infiltrating lymphocytes  
 with and without interleukin 2, 4199
- Carcinoma, Shionogi**  
 proliferation  
 glucocorticoid-induced autocrine heparin-binding growth factors, 3006
- Carcinoma, small cell lung**  
 hematopoietic growth factors, 73
- Carcinoma, spindle**  
 progression of squamous carcinoma  
*H-ras* alleles on chromosome 7, 4097
- Carcinoma, squamous cell**  
 A9 antigen  
 integrin  $\alpha^6\beta_4$ , 2395  
 antiproliferative effects  
 tyrphostins, 4430  
 associated paraneoplastic syndrome  
 epidermal growth factor receptor pathway, 2438
- esophageal**  
 frequent loss of heterozygosity, retinoblastoma locus, 5766  
 prognostic significance, argyrophilic nucleolar organizer regions, 5339  
 significance, *int-2/hst-1* coamplification, 1504  
 genetic susceptibility of the lung  
 relation to cigarette smoking dose, 5177
- head and neck**  
 E-cadherin expression, lymph node metastasis, 6328  
 preclinical activity, gemcitabine, 211  
 oral and epidermal  
 abnormal expression, retinoic acid receptors and keratin 19, 3972  
 progression to spindle carcinoma  
 mouse skin, *H-ras* alleles on chromosome 7, 4097  
 transforming growth factor- $\alpha$  pathway, 6254
- Carcinoma, thymic**  
 novel t(15;19)(q15;p13) chromosome abnormality, 3327
- Carcinoma, transitional cell**  
 bladder wall penetration  
 intravesical Mitomycin C, 4347  
 papillary  
*H-ras* induction of invasive phenotype, epidermal growth factor receptors, 4486
- Carcinoma, uterine**  
*p53* gene analysis, 6506
- Carcinoma cells**  
 binding of thrombospondin

- M*, 80,000/105,000 receptor, 3648  
 damage and differential cytotoxicity in DNA-produced, 6586  
 individual micrometastatic frequent down-regulation, major histocompatibility class I antigen expression, 4712  
 MDR1-mediated resistance camptothecin, 6039  
 receptor expression distinct domains, thrombospondin, 1645  
 schedule-dependent enhancement of cytotoxicity fluoropyrimidines, folinic acid, 4618
- CAR-3 macromolecules**  
 normal and transformed endometrium diagnosis, postmenopausal patients, 3001
- Carmethizole**  
*in vivo* and *in vitro* evaluation, 4581
- Catalase**  
 decrease in activity tumor necrosis factor, liver, 3990
- Cathepsin B**  
 messenger RNA stage-specific increases, colorectal carcinoma, 1137
- Cathepsin L**  
 expression in human tumors, 1478
- CCRF-CEM cells**  
 inhibition of primer RNA formation fludarabine triphosphate, 1829  
 normal and mutant glucocorticoid receptor gene, 5224  
 nucleotide metabolism (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid, 2291
- CD3**  
 anti-CD3-stimulated T cells interleukin 2 liposomes, hepatic metastasis, 2127  
 T-cell receptor discordant gene and surface expression, adult T-cell leukemia, 6084
- CD4<sup>+</sup> cells**  
 immature *N*-methyl-*N*-nitrosourea, lymphoma development, 737
- CD15**  
 anti-CD15 monoclonal antibody elimination of breast cancer cells, bone marrow, 2451
- CD19**  
 immunotoxin prepared with blocked ricin therapeutic use, 6235
- CD44**  
 high and low levels melanoma cell variants, 6660  
 splice variants metastatic behavior, tumor cell lines, 5292
- CD56**  
 CD57 and human neural and striated muscle cells, 1300
- CDPGYIGSR-NH<sub>2</sub>**  
 inhibition of angiogenesis and tumor growth, 903
- Cell culture**  
 soft agar morphometric and colorimetric analyses, human tumor cell line growth and drug sensitivity, 1247
- Cell cycle**  
 activation of late G<sub>1</sub> genes interleukin 3-dependent proliferation, human MO-7e cell line, 1741  
 cellular response to DNA damage participation of p53 protein, 6304  
 developmental genetics and childhood cancer, 5435  
 7 $\beta$ ,8 $\alpha$ -dihydroxy-9 $\alpha$ ,10 $\alpha$ -epoxy-7,8,9,10-tetrahydro benzo(a)pyrene mutations  
*HPRT* gene, XP12BE cells, 2587  
 DNA cross-links and apoptosis nitrogen mustard sensitivity, Burkitt's lymphoma, 6550  
 DNA repair characteristics xeroderma pigmentosum, patients from Germany, 3456  
 effects of 8-Cl-cAMP and N<sup>6</sup>-benzyl-cAMP kinetics, HL-60 leukemia cells, 6263  
 estimation of proliferative activity cytochalasin B, 5134  
 G<sub>1</sub> phase growth arrest cell resistance, IL-1/IL-6/TNF/TGF- $\beta$ , 2379  
 G<sub>2</sub> block induced by ionizing radiation cyclin B expression, HeLa cells, 5113  
 inhibition of kinetics and proliferation 5 $\alpha$ -dihydrotestosterone and antiestrogen, breast cancer, 2797  
 S-phase probes flow cytometry, antibodies to proliferating cell nuclear antigen, 4570  
 synchronization tumor and normal cells from G<sub>1</sub>, lovastatin, 3602
- Cell death**  
 programmed androgen-independent prostatic cancer, 4693  
 secondary DNA fragmentation topoisomerase II inhibitors, human tumor cell lines, 6280  
 thymidylate synthase inhibition 2'-deoxyuridine-5'-triphosphate accumulation, 2346  
 transforming growth factor- $\beta$  cultured rat hepatocytes, 2478  
 truncated glucocorticoid receptor P1798 mouse lymphosarcoma, 2786
- Cell membrane**  
 signaling target in cancer therapy, 1613
- Cell wall**  
*Nocardia rubra* interleukin 2 and, LAK cell induction, 5261  
*Nocardia rubra* skeleton antitumor effect, syngeneically transplanted P388 tumors, 4038
- Central nervous system**  
 neoplasms insulin-like growth factor binding proteins, 3030  
 primitive neuroectodermal tumors loss of heterozygosity, 6q/16q/17p, 639
- c-erbB-2***  
 estrogen receptor status and prognostic significance, breast cancer, 3296  
 internalization of murine monoclonal antibody, 5361
- Cerebrospinal fluid**  
 pharmacokinetics 1- $\beta$ -D-arabinofuranosylcytosine, 1- $\beta$ -D-arabinofuranosyluracil, 4141
- Cervical neoplasms**  
 serum folate levels, 4785
- Cervix**  
 secretions HPV-related cervical disease, HPV-16-specific antibody, 4423  
 uterine oxygenation of carcinomas, 6098
- c-fos***  
 phorbol ester-induced expression inhibition of cell proliferation, B859-35, 5821
- CGP 31362**  
 therapy of spontaneous lung metastasis murine renal adenocarcinoma, 3741
- Chemoinmunotherapy**  
 adoptive polyethylene glycol-cultured spleen cells, plasmacytoma, 4516
- Chemoprevention**  
 cancer, 5080s  
 chemical form of selenium critical metabolites, cancer prevention, 595  
 colon carcinogenesis piroxicam and  $\alpha$ -difluoromethylornithine, 16 $\alpha$ -fluoro-5-androsten-17-one and ellagic acid, 4528  
 dietary dehydroepiandrosterone tumorigenesis, premalignant colonic epithelium, 476  
*N*-(4-hydroxyphenyl)retinamide primary prostate cancer, 3610  
 inhibition of protein isoprenylation dehydroepiandrosterone, colonic adenocarcinoma cells, 6563  
 need for end point validation putative biomarkers, colon cancer, 6388  
 suppression of colonic ornithine decarboxylase supplemental calcium, adenomatous polyps, 3416
- Chemoresistance**  
 survival after treatments with anticancer agents Chinese hamster cells, *M*, 27,000 heat shock protein, 5245
- Chemosensitivity**  
 topoisomerase II level human tumor cell lines, 6592
- Chemotaxis**  
 endothelial cell supernatants, AIDS-related Kaposi's sarcoma, 2670
- Chemotherapy**  
 androgen-primed Dunning R3327 G model, prostatic cancer, 1760  
 antitumor drugs and interleukin 1 $\alpha$  combination effect, syngeneic tumors in mice, 215  
 1,3-bis(2-chloroethyl)-1-nitrosourea re-

- sistance  
 $\gamma$ -irradiation or drug pretreatment, hepatoma cells, 1217  
 chemosensitization and human multidrug resistance gene in bone marrow, transgenic mice, 5417  
 cisplatin-containing tumor-infiltrating lymphocytes, epithelial ovarian cancer, 1934  
 combination regimens  
   *myc* family DNA amplification, 1708  
 factors influencing mutation  
   *hprt* locus in T-cells, breast cancer treatment, 6603  
 granulocyte-macrophage colony-stimulating factor  
   ovarian carcinoma, 116  
 intercellular transfer of drug resistance, 1190  
 lonidamine and hyperthermia  
   combination therapy, RIF-1 tumor, 5910  
 new developments in clinical oncology, 5060s  
 platinum/cyclophosphamide  
   P-glycoprotein expression, ovary, 5915  
 protective and restorative role of AS101, 1499  
 targeting  
   chemical engineering, monoclonal antibody A7, 4310  
 topoisomerase II-directed camptothecin, human leukemia cell line, 1129  
 type II inosine 5'-monophosphate dehydrogenase  
   messenger RNA expression, up-regulation, 3886  
**Chinese hamster ovary cells**  
   attenuated topoisomerase II content  
   correlation, low level of drug resistance, 6543  
   ethanol potentiation  
   doxorubicin-induced inhibition, cell survival, 2036  
   glucose transporter expression  
   thymidine uptake, 4450  
   hypersensitivity of variant BL-10  
   bleomycin killing, lack of glutathione *S*-transferase- $\alpha$  activity, 4463  
   inhibition of growth  
   adenosine metabolite, 8-chloroadenosine 3',5'-monophosphate, 1600  
   phenotype conferring selective resistance  
   lipophilic antifolates, 2949  
   resistance to Mitomycin C  
   aerobic conditions, DT-diaphorase deficiency, 1860  
   variants  
   increased tumorigenicity, fibronectin receptor deficiency, 1738  
**Chitin derivatives**  
   sulfated  
   tumor-induced angiogenesis, 22  
**Chloramphenicol acetyltransferase**  
   enhanced promoter activity  
   human *M*, 72,000 type IV collagenase gene, metastatic cell line, 6190  
**Chlorin *e*<sub>6</sub>**  
   microsphere-bound  
   mechanism of photosensitization, bladder carcinoma cells, 4410  
**8-Chloroadenosine 3',5'-monophosphate**  
   cAMP analogue distinctions, 6206, 6207  
   inhibition of growth  
   Chinese hamster ovary and Molt-4 cells, 1600  
   N<sup>6</sup>-benzyl-cAMP and cell cycle effects, HL-60 leukemia cells, 6263  
**2-Chloro-2'-deoxyadenosine**  
   pharmacokinetics in humans, 5570  
**2-Chloro-9-(2-deoxy-2-fluoro- $\beta$ -D-arabinofuranosyl)adenine**  
   K562 cellular metabolism  
   inhibition of human ribonucleotide reductase, DNA polymerases, 2386  
**Chloroethylnitrosourea**  
   -sensitive Chinese hamster cell lines, 195  
**3'-[3-(2-Chloroethyl)-3-nitrosoureido]-3'-deoxythymidine**  
   inhibition of poly(adenosine diphosphate-ribose) polymerase  
   thymidine and its analogues, L1210 cells, 1586  
**Cholangiocarcinoma**  
   multiple *K-ras* codon 12 mutations  
   polymerase chain reaction technique, 3497  
**Cholangiofibrosis**  
   furan-induced  
   rats, 5752  
**Cholecystokinin**  
   stimulation of clonal growth  
   small cell lung cancer, 3621  
**Cholesterol**  
   changes in  
   prior to cancer diagnosis, 3198  
**Choline**  
   deficiency  
   liver folate content and distribution, methotrexate treatment, 16  
**Chondroitin sulfate**  
   partial characterization of proteoglycans  
   neoplastic and nonneoplastic breast tissue, 1443  
   proteoglycan expression  
   proliferating brain capillary endothelial cells, malignant phenotype of astroglial cells, 4986  
**Choriocarcinoma**  
   gestational  
   prostacyclin, thromboxane, 4146  
**Chromatin**  
   differential introduction and repair  
   psoralen photoadducts, specific human genes, 2867  
   nickel(II)- and cobalt(II)-dependent damage  
   hydrogen peroxide, DNA bases, 5837  
**Chromatography**  
   high performance liquid  
   preliminary metabolic fate, navelbine, 2073  
**Chromosome**  
   1, 7, 9, and 11  
   aberrations, bladder cancer, 644  
   5 and 6  
   nonrandom loss, hereditary renal cell carcinoma, 4415  
   1q, 5q, and 17p  
   loss of heterozygosity, gastric carcinoma, 2926  
   5q, 6q, and 10q  
   common regions of deletion, renal cell carcinoma, 5817  
   18q and *DCC* gene  
   susceptibility, hereditary nonpolyposis colorectal carcinoma, 4135  
**abnormalities**  
   histologic and clinical features, Wilms' tumor, 5937  
   peripheral blood cells, 6176  
**AIDS and non-Hodgkin's lymphoma**, 4743  
   allelotype of renal cell carcinoma, 820  
   breakpoint t(11;14)(q23;q32)  
   molecular cloning, B-cell lymphoma, 1574  
   deletion of 17p  
   amplification of *int-2* gene, esophageal carcinoma, 2113  
   genetic abnormalities  
   ovarian tumor development, 4045  
   genetic approaches to study  
   molecular basis of human cancer, 5015s  
   growth factor abnormalities  
   leukemia, 2494  
   induced damage  
   individual susceptibility, genotoxic exposures, 5266  
   interphase cytogenetics  
   classical karyotyping, *in situ* hybridization, 1959  
   interstitial deletion  
   4q11-q13, human hepatoma cell line, 1460  
   locations of *MYB* related genes  
   *AMYB* and *BMXB*, 3821  
   mapping of galactoside-binding protein, 2173  
   modal number  
   DNA index of solid tumor tissue, non-small cell lung carcinoma, 3267  
   molecular analysis of genetic changes  
   origin and development, renal cell carcinoma, 1071  
   nonrandom losses  
   stepwise neoplasia, uroepithelial cells, 3323  
   novel t(15;19)(q15;13) abnormality  
   thymic carcinoma, 3327  
   oncogenic mechanisms  
   radiation-induced cancer, 2740  
   rearrangements  
   deletions, point mutations, 5440  
   region 5q12-13  
   human gene, phosphatidylinositol-3 kinase associated p85 $\alpha$ , 3818  
   renal cortical tumors  
   characterization, 1544  
   8:22 translocation  
   diffuse large cell lymphoma, cell line establishment, 5392  
   t(4;11), t(9;11), t(11;19) translocations  
   cloning of *ALL-1* locus, 6712  
**Chromosome 1**  
   somatic imbalance of marker alleles  
   primary breast carcinoma, 1020  
   trisomy  
   association, mesothelial cell transformation, 4059  
**Chromosome 3**  
   detailed deletion mapping of short arm  
   sporadic renal cell carcinoma, 4707

- Chromosome 3p**  
allelic loss  
clear cell phenotype, renal cell carcinoma, 949
- Chromosome 6**  
loss of heterozygosity for loci on long arm  
human malignant melanoma, 5449
- Chromosome 7**  
centromeric copy number  
tumor grade and labeling index, bladder carcinoma, 3807  
imbalance of alleles  
progression of squamous cell carcinoma, H-ras, 4097
- Chromosome 9**  
deletion mapping  
interferon  $\alpha$  and interferon  $\beta$ -1 gene deletions, glial tumors, 1684
- Chromosome 11**  
allelic loss in hereditary and sporadic tumors  
familial multiple endocrine neoplasia type 1, 1154  
short arm  
loss of heterozygosity, milk epithelial cells, 294
- Chromosome 11q23**  
rearrangements  
hematopoietic tumor-associated t(11;14) and t(11;19) translocations, 6708
- Chromosome 13**  
inactivation of retinoblastoma gene  
human bladder and renal cell carcinoma, 5736
- Chromosome 17**  
infrequent p53 gene mutations  
medulloblastoma, 4721
- Chromosome 17p**  
allelic loss  
p53 mutations, endometrial carcinoma, 5632  
hepatitis B virus integration event  
nearness to p53 gene, hepatocellular carcinoma, 49
- C3H10T $\frac{1}{2}$  cells**  
morphological transformation and DNA adduct formation  
benz[a]aceanthrylene, 6163
- CI-937**  
Phase I pharmacokinetic and pharmacodynamic study, 6317
- Cigarette smoking**  
asbestos exposure and malignant mesothelioma, 2263  
association between hepatitis C virus antibodies  
hepatocellular carcinoma, Taiwan, 5621  
cytochrome P-450 activation, 5284  
genetic susceptibility  
squamous cell carcinoma, lung, 5177  
genital and urinary tract diseases  
bladder cancer, 629  
lung cancer in women, 4893  
use of mentholated cigarettes  
lung cancer risk, 6510
- Cisplatin: see cis-Diamminedichloroplatinum(II)**
- 8-Cl-cAMP: see 8-Chloroadenosine 3',5'-monophosphate**
- Clerocidin**  
heat-stable topoisomerase II-DNA cleavable complex, 2922
- Clostridium perfringens**  
recombinant, membrane-acting immunotoxin, 465
- c-myb**  
antisense oligodeoxynucleotides  
inhibition of proliferation, colon adenocarcinoma, 2897  
insulin-like growth factor receptor messenger RNA  
transcriptional mechanism, 5997
- c-myc**  
AIDS and non-Hodgkin's lymphoma, 4743  
carcinogen-induced lymphomagenesis  
pim-1 transgenic mice, 958  
cell line establishment  
Signet ring cell gastric carcinoma, 381  
c-fos and  
Bowman-Birk protease inhibitor, irradiated rat colon, 4539  
gene-induced alterations  
protein kinase C expression, myc-ras gene complementation, 5514  
independence of activation  
altered HLA class I expression, non-small cell lung cancer, 2463  
inhibition by phosphorothioate antisense oligonucleotide  
growth of breast cancer, 3996  
modulation of cis-diamminedichloroplatinum(II) resistance  
Friend erythroleukemia cells, 2118  
multidifferentiated carcinoma, 3793  
secondary DNA fragmentation  
topoisomerase II inhibitors, human tumor cell lines, 6280  
transforming growth factor- $\alpha$  and clonal cosegregation of tumorigenicity, liver epithelial cells, 5238  
establishment of quiescent state, colon carcinoma cells, 2256
- Coagulation**  
components of fibrinolysis pathways  
neoplastic and nonneoplastic breast tissue, 354  
drugs influencing these pathways  
fibronectin-mediated *Bacillus Calmette-Guérin* attachment, bladder mucosa, 3726  
fibrinogen deposition  
no thrombin generation, primary breast cancer, 349
- Cobalt(II)**  
-dependent damage by hydrogen peroxide  
DNA bases, human chromatin, 5837
- Collagen**  
-matrix gels containing fibroblasts  
transforming growth factor- $\beta$  release, gastric carcinoma, 3550
- Collagenase**  
decreased expression of tissue inhibitor metalloproteinases, metastatic tumor cells, 2138  
M, 72,000 type IV  
colonic adenocarcinoma, 439  
type IV  
human M, 72,000 gene, basal promoter in metastatic cell line, 6190  
regulation of kinesin expression, prostate tumor cells, 5866
- Colon**  
azoxymethane-induced carcinogenesis  
inhibition by haloperidol, 6150  
cytosol  
acetylator genotype-dependent expression, arylamine N-acetyltransferase, 549  
growth of dysplastic crypt foci  
dietary carbohydrates, 1,2-dimethylhydrazine, 3721  
mucosa  
preneoplastic foci, aberrant crypts, 1564  
neoplasia  
 $\beta$ 1-6 branched oligosaccharides, tumor progression, 718  
pre-malignant epithelium  
chemoprevention, dietary dehydroepiandrosterone, 476  
proliferating epithelial cells  
histochemical probe, *Amaranthus caudatus* lectin, 657
- Colonic neoplasms**  
calcium and vitamin D, 3069  
1,2-dimethylhydrazine-induced K-ras mutations, supplemental calcium and vitamin D deficiency, 4305  
facilitation of extracellular matrix invasion  
role of urokinase receptor, 3690  
fluorodeoxyuridine-mediated modulation  
iododeoxyuridine incorporation, 3900  
hereditary nonpolyposis  
exclusion of DCC gene, chromosome 18q, 4135  
heterogeneity of ornithine decarboxylase  
mouse colon carcinogenesis, 2069  
immunologic quantitation of TIMP-1, 6231  
increased levels of 1,2-sn-diacylglycerol, 1571  
mucin antigens recognized by monoclonal antibodies, 331  
mucins  
accessible sugar epitopes, monoclonal antibody AM-3, 5342  
need for end point validation  
putative biomarkers, 6388  
normal colon and  
molecular weight of carcinoembryonic antigen, N-glycosylation differences, 5679  
plasminogen activation system, 4067  
preclinical assessment  
<sup>90</sup>Y-labeled C110 anticarcinomaembryonic antigen immunotoxin, 255  
purification of cell growth inhibitor  
insulin-like growth factor binding protein, 2813  
superoxide dismutase  
gene expression, complementary DNA, 939  
xenografts  
hyperthermia, <sup>111</sup>In-labeled hapten to bifunctional antibody, 1515  
hypoxic fractions, 5139  
inhibition of growth, bombesin/gastrin releasing peptide antagonist, 6006
- Colony forming units**

granulocyte-macrophage  
protection of bone marrow by AS101,  
purging with ASTA-Z, 5614

**Colony-stimulating factor**  
granulocyte  
conjugation to polyethylene glycol,  
pharmacokinetics, 3710

granulocyte-macrophage  
chemotherapy, ovarian carcinoma, 116  
induction of cytokine messenger RNA,  
lung cancer, 857  
megakaryotypic features, leukemic cell  
line establishment, 341

macrophage  
biological and antitumor effects, 2649

**Colorectal neoplasms**  
acetylator genotype-dependent expres-  
sion  
arylamine *N*-acetyltransferase, 549  
altered intracellular calcium regulation  
"normal" adjacent mucosa, 4492  
antitumor immune response and inter-  
leukin 2 production  
immunization, human monoclonal  
anti-idiotypic antibody, 5425

comparison  
immunoscintigraphy, computerized to-  
mography, 5704

constitutive drug resistance  
P-glycoprotein, glutathione-based de-  
toxifying enzymes, 2092

*p53* gene mutations  
familial polyposis coli, 2874

reproductive factors  
Chinese females, 2307

stage-specific increases  
cathepsin B messenger RNA, 1137

survival  
influence, MHC class I and II anti-  
gens, 729

TAG-72 epitopes, 5370

**Colorimetry**  
human tumor cell line growth  
drug sensitivity, soft agar culture, 1247

**Complementation groups**  
formation of groups 9 and 10  
ultraviolet-sensitive mutants, excision  
repair, 3965

**Computerized tomography**  
immunoscintigraphy and  
comparison, identification of colorec-  
tal cancer, 5704

**Confocal microscopy**  
laser-assisted  
subcellular distribution, daunorubicin,  
4955

**Conjugase: see  $\gamma$ -Glutamyl hydrolase**

**Copper phthalocyanine cellulose**  
cytochrome P-450 activation of cigarette  
smoke, 5284

**CPT-11**  
antitumor effect  
intracellular roles, SN-38, 4187

**Cryosurgery**  
hepatic  
colorectal metastases, 6323

**Crypts**  
aberrant  
growth, morphological characteristics,  
5270  
preneoplastic foci, colonic mucosa,  
1564

**Curcumin**  
inhibitory effects  
lipoxygenase and cyclooxygenase,  
mouse epidermis, 813

**Cyanomorpholino doxorubicin**  
broad cross-resistance of ovarian carci-  
noma cells  
multifactorial mechanisms, 5181

**Cyclin B**  
expression in HeLa cells  
G<sub>2</sub> block, ionizing radiation, 5113

**Cycloheximide**  
cyclic AMP-dependent protein kinase  
messenger RNA  
normal vs. neoplastic mouse lung epi-  
thelial cells, 6699

**Cyclooxygenase**  
inhibitory effects of curcumin  
mouse epidermis, 813

**Cyclopentanone oxime**  
oxidative damage to liver  
nitroalkanes, 3143

**Cyclopentyl cytosine**  
cellular pharmacology  
Molt-4 lymphoblasts, 3733

**Cyclophosphamide**  
cooxidation as alternative pathway  
lung toxicity, 542  
DNA phosphoester adduct formation,  
886  
lack of effect on immunogenicity  
melanoma antigen vaccine, 3643  
-platinum chemotherapy  
P-glycoprotein expression, ovary, 5915  
single-dose preoperative systemic  
prevention, bladder tumor implanta-  
tion, 1373, 1378  
SR-2508 and  
Phase I study, 1099  
-treated rats  
gonadal protection, fecundity rates,  
2124

**Cyclosporin A**  
podophyllotoxin glucoside to etoposide  
chemical and biological route, 5  
tumor growth  
development of cancer cachexia, 880  
verapamil and  
modulation of multidrug resistance,  
human leukemia cell lines, 1749

**Cytidine deaminase**  
sensitivity of erythroleukemia cells  
hemin, 1- $\beta$ -D-arabinofuranosylcyto-  
sine, 4535

**Cytochalasin B**  
estimation of proliferative activity, 5134  
temporal mapping of differentiation  
pathway  
murine erythroleukemia cells, 1668

**Cytochrome P-450**  
activation of cigarette smoke, 5284  
complementary DNA-expressed  
metabolic activation, 4-ipomeanol,  
4636  
hepatic enzymes  
thio-TEPA oxygenation, drug metabo-  
lism and clearance, 2340  
isozymes  
positional specificity, methyl-*n*-amyl-  
nitrosamine hydroxylation, 1059  
-mediated activation and irreversible  
binding

tamoxifen, proteins in rat and human  
liver, 6052  
quantitation of microsomal  $\alpha$ -hydroxyl-  
ation  
4-(methylnitrosamino)-1-(3-pyridyl)-1-  
butanone, 5495

**Cytokeratin**  
coexpression for myoepithelial and lu-  
minal cell lines  
spontaneous metastases, rat mammary  
adenocarcinoma, 5943  
rearrangement and vacuole formation  
teleocidin, hepatoma cells, 2677

**Cytokines**  
acivicin-induced monocytoid differentia-  
tion  
myeloid leukemia cells, 1202  
-activated endothelial cells  
melanoma cell adhesion, VLA-4  
expression, 2239  
nitric oxide, lysis of tumor cells, 2531  
-activated murine vascular endothelial  
cells  
lysis, metastatic cells, 245  
biological monitoring  
low-dose interleukin 2, 6312  
consequences of "binding site barrier",  
4776  
-induced lipogenesis  
inhibition of, interleukin 4, 2803  
induction of gene expression  
flavone acetic acid, mouse splenic leu-  
kocytes, 6596  
messenger RNA and secretion  
alveolar macrophages and blood  
monocytes, lung cancer, 857  
tumor growth  
development of cancer cachexia, 880

**Cytomegalovirus**  
single 3.7-kilobase messenger RNA  
hybridization to immediate-early pro-  
moter-enhancer, HL-60 and acute  
myeloid leukemia, 4724

**Cytoplasm**  
human cells and tissue  
human thymidylate synthase, mono-  
clonal antibodies, 6668

**Cytosol**  
colon  
acetylator genotype-dependent expres-  
sion, arylamine *N*-acetyltransferase,  
549

**Cytotoxic T-lymphocytes**  
breast adenocarcinoma  
recognition, protein core of mucin  
molecule, 2908  
expression of class I MHC  
Epstein-Barr virus-carrying lympho-  
blastoid cell lines, Burkitt's lym-  
phoma cells, 27  
precursor  
infiltration and accumulation, progres-  
sively growing ocular tumors, 3153  
tumor cytotoxicity by lymphocytes  
infiltrating ovarian malignant ascites,  
4257

**D**

**Dacarbazine**  
O<sup>6</sup>-alkylguanine-DNA alkyltransferase  
depletion and regeneration, peripheral

- lymphocytes, 619
- Danorubicin**  
 -induced cytotoxicity  
   antagonistic effect of aclarubicin, small cell lung cancer cells, 5093  
 -resistant Ehrlich ascites tumor cells  
   decreased DNA topoisomerase II, 4213  
   subcellular distribution  
     P-glycoprotein-positive and -negative drug-resistant cell lines, 4955
- Decay-accelerating factor**  
 coexistence of autologous antibodies  
   human renal tumor cells, 2521
- Dehydroepiandrosterone**  
 dietary  
   chemoprevention, tumorigenesis in premalignant colonic epithelium, 476  
   inhibition, mammary gland chemical carcinogenesis, 481  
   inhibition of protein isoprenylation  
     p21<sup>ras</sup> membrane association, colonic adenocarcinoma cells, 6563  
   serum levels  
     risk, development of bladder cancer, 1366
- Dehydroepiandrosterone sulfate**  
 serum and urinary androgens  
   risk of breast cancer, postmenopausal women, 2572
- 4'-O-Demethylepipodophyllotoxin**  
 4 $\beta$ -arylamino derivatives  
   DNA topoisomerase II, tubulin polymerization and KB cells, 1755
- Deoxycorticosterone acetate**  
 -NaCl hypertensive rats  
   gastric carcinogenesis, *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine, 2863
- 2'-Deoxycytidine**  
 derivative  
   antitumor activity, 2'-deoxy-2'-methylidenecytidine, 2319
- Deoxycytidine kinase**  
 regulation by uridine nucleotides  
   human leukemia cells, 2559  
 sensitivity of erythroleukemia cells  
   hemin, 1- $\beta$ -D-arabinofuranosylcytosine, 4535
- 2-Deoxyglucose**  
 toxicity  
   multidrug resistance phenotype, 1638
- 2'-Deoxy-2'-methylidenecytidine**  
 antitumor activity, 2319
- Deoxyspergualin**  
 clinical pharmacology  
   advanced cancer, 3096
- 2'-Deoxyuridine-5'-triphosphate**  
 accumulation  
   cell death, thymidylate synthase inhibition, 2346
- Desulfatohirudin**  
 recombinant  
   inhibition, murine melanoma experimental metastasis, 4549
- Dexamethasone**  
 -induced metallothionein expression  
   suppression, *cis*-diamminedichloroplatinum(II) resistance, 893  
   induction of cisplatin resistance  
     c-Ha-ras oncogene, mouse NIH 3T3 cells, 5903
- Dextran sulfate**  
 interleukin 2-induced leukocyte adhesion  
   normal and tumor microvascular endothelium, 1561
- N*-(5,5-Diacetoxypentyl)doxorubicin**  
 DNA interstrand cross-linking  
   rapid endonucleolytic cleavage, human leukemia cells, 6704
- 1,2-sn-Diacylglycerol**  
 increased levels in human colon tumors, 1571
- Diallyl sulfide**  
 metabolism of carcinogenic nitrosamines  
   nasal mucosa, 1509
- cis*-Diammine-1,1-cyclobutane dicarboxylatoplatinum(II)**  
 -induced DNA interstrand cross-link removal  
   hydroxyurea, 1- $\beta$ -D-arabinofuranosylcytosine, 1984
- cis*-Diamminedichloroplatinum(II)**  
 accumulation of  
   Na<sup>+</sup>, K<sup>+</sup>-adenosine triphosphatase, ovarian carcinoma, 3677  
 cellular sensitization  
   lyngbyatoxin A analogues, 2511  
   combined with trimetrexate  
     pharmacokinetic study, 3080  
 -containing chemotherapy  
   tumor-infiltrating lymphocytes, epithelial ovarian cancer, 1934  
 detection of DNA modifications  
   monoclonal antibody, 123  
 DNA excision repair in cell extracts  
   hypersensitivity, 3384  
 enhanced cytotoxicity  
   monoclonal antibody against c-erbB-2 protein, breast and ovarian tumor cell lines, 4575  
 estrogen receptor-binding platinum complex  
   breast cancer, 3217  
 host cell reactivation  
   damaged plasmid DNA, 601  
 4-hydroperoxycyclophosphamide and role of glutathione in synergism, leukemia cell lines, 2536  
 hyperthermia and  
   radiation, mammary carcinoma, 707  
 induction of resistance  
   c-Ha-ras, mouse NIH 3T3 cells, 5903  
 ionizing radiation and  
   resistance patterns, 4523  
 malignant behavior and resistance  
   ovarian carcinoma xenografts, different disease stages, 6358  
 modulation of resistance by c-myc  
   Friend erythroleukemia cells, 2118  
 morphological and phenotypic analysis  
   Walker 256 cells, 1334  
 sensitivity  
   formation and removal of platinum-DNA adducts, ovarian carcinoma, 4557  
   single step selection of resistant mutants  
     human ovarian carcinoma cell line, 2242  
   suppression of dexamethasone-induced metallothionein, 893
- cis*-Diammine(glycolato)platinum**  
 Phase I study and pharmacological analysis, 1472
- Diarylsulfonylurea**  
 mitochondrial structure and functions, 6286
- Diaziquone**  
 DNA adducts, 5198
- Dibutyl cyclic adenosine 3':5'-monophosphate**  
 retinoic acid and  
   differentiation of neuroblastoma, interferon, 3958
- 5,6-Dichloro-1- $\beta$ -ribofuranosyl-benzimidazole**  
 cyclic AMP-dependent protein kinase messenger RNA  
   normal vs. neoplastic mouse lung epithelial cells, 6699
- (6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid**  
 nucleotide metabolism  
   CCRF-CEM cells, 2291
- Diepoxybutane**  
 induced chromosome damage  
   individual susceptibility, genotoxic exposures, 5266
- Diet**  
 $\omega$ -3 and  $\omega$ -6 fatty acids  
   initiation and promotion, stages of colon carcinogenesis, 487  
   calorie restriction and  
     skin carcinogenesis, Sencar mouse model, 1851  
   cancer prevention, 5080s  
   carbohydrates  
     growth of dysplastic crypt foci, colon, 3721  
   concentration-dependent increase  
     P388 and B16 doubling time, acyclic monoterpene geraniol, 37  
   dehydroepiandrosterone  
     chemoprevention, tumorigenesis in premalignant colonic epithelium, 476  
     inhibition, mammary gland chemical carcinogenesis, 481  
   high- or low-fat  
     indomethacin and tumorigenesis, mammary carcinoma, 2683  
   low-protein  
     gastric carcinogenesis, *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine, 3493  
   modulation  
     proviral expression, 5123  
   need for end point validation  
     putative biomarkers, colon cancer, 6388
- Dietary fat**  
 patterns of prostatic cancer  
   *N*-nitrosobis(2-oxopropyl)amine, testosterone, 4757  
   phorbol ester-elicited tumor promotion  
     mouse skin, 907
- Diethylnitrosamine**  
 histochemical profile  
   hepatocellular adenoma, carcinoma, 1952  
 -induced carcinogenesis  
   strain-specific sensitivity, hepatocytes, 3257
- Diethylstilbestrol**  
 carcinogenicity  
   postnatal oral contraceptive steroids, Wistar rat, 3311

# SUBJECT INDEX TO VOLUME 51

- treated Syrian hamsters
  - elevated 8-hydroxydeoxyguanosine levels, 3882
- 2',2'-Difluorodeoxycytidine: *see* Gemcitabine
- $\alpha$ -Difluoromethylornithine
  - chemoprevention of colon carcinogenesis, 4528
- Dihydropyridine
  - derivative B859-35
    - inhibition of cell proliferation, 5821
- Dihydrotestosterone
  - androgen and EM-170
    - estradiol-stimulated growth, breast tumors in athymic mice, 3131
  - serum and urinary androgens
    - risk of breast cancer, postmenopausal women, 2572
- 5 $\alpha$ -Dihydrotestosterone
  - antiestrogen and
    - inhibition of cell cycle kinetics, breast cancer, 2797
- 7 $\beta$ ,8 $\alpha$ -Dihydroxy-9 $\alpha$ ,10 $\alpha$ -epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene
  - mutations in XP12BE cells
    - HPRT gene, 2587
- trans*-7,8-Dihydroxy-*anti*-9,10-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene
  - adducts to guanine-N<sup>2</sup>
    - duplex dodecamer, 3482
- 1,25-Dihydroxyvitamin D<sub>3</sub>
  - platinum drugs and
    - growth of MCF-7 cells, 2848
  - potentiation of 1- $\beta$ -D-arabinofuranosylcytosine cytotoxicity
    - HL-60 cells, 3451
  - receptor in breast cancer
    - prognosis, 239
  - receptors and sex steroids
    - human colorectal adenocarcinoma, normal mucosa, 1227
  - receptors in human carcinomas, 2021
- 1 $\alpha$ ,25-Dihydroxyvitamin D<sub>3</sub>
  - synthesis and secretion of nonphosphorylated osteopontin
    - mouse JB6 epidermal cells, 2144
- 3,2'-Dimethyl-4-aminobiphenyl
  - testosterone propionate and
    - invasive carcinoma, accessory sex organs, 1264
- Dimethylbenz(a)anthracene
  - conjugated dienoic derivative of linoleic acid
    - mammary cancer prevention, 6118
- 7,12-Dimethylbenz(a)anthracene
  - hepatic metabolism, 492
    - induced mammary tumors
      - DNA adducts, inhibition by dietary selenium, 4613
      - indomethacin and tumorigenesis, high- or low-fat diet, 2683
      - promoting effect of snuff, 4388
      - role of ultraviolet radiation
        - melanocytic tumors, hairless mice, 4964
- 1,2-Dimethylhydrazine
  - growth of dysplastic crypt foci in colon
    - effect of dietary carbohydrates, 3721
  - induced colonic carcinogenesis
    - modulation, dietary calcium and vitamin D, 5608
  - induced colonic tumors
    - K-ras mutations, dietary calcium and vitamin D deficiency, 4305
- N,N-Dimethyl sphingosine derivatives
  - cell membrane signaling
    - target in cancer therapy, 1613
- 2,4-Dinitrophenol
  - novobiocin and
    - modulation, amsacrine-induced DNA lesions, 573
- sn*-1,2-Dioctanoylglycerol
  - 12-O-tetradecanoylphorbol-13-acetate and
    - phosphorylation, protein kinase C, 4624
- Diol-epoxides
  - fjord- and bay-region
    - stability, SOS induction in *Escherichia coli*, 1659
- Diphtheria
  - toxin A-chain coding sequence
    - immunoglobulin genes, toxicity to B-lymphoid cells, 4299
- Distamycin
  - derivative FCE 24517
    - selective DNA interaction, 199
- 2,6-Dithiopurine
  - thiopurinol and
    - inhibition of binding, benzo(a)pyrene diol epoxide to DNA in epidermis, 4859
- DNA
  - alkylation
    - metabolic activation, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 4798
  - amplification and rearrangement
    - neuroblastoma, N-myc gene region, 1946
  - amplification in tumors and cell lines by myc family
    - combination chemotherapy regimens, small cell lung cancer, 1708
  - amsacrine-induced lesions
    - modulation, novobiocin and 2,4-dinitrophenol, 573
  - aneuploidy
    - Astler-Coller Dukes stage C colonic adenocarcinoma, 2403
  - binding of progesterone receptor
    - R5020 and RU486, 3938
  - carmethizole
    - in vivo* and *in vitro* evaluation, 4581
  - cellular
    - interaction, thioTEPA and TEPA, 4360
  - N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea-modified
    - release of 7-alkylguanines, 3-methyladenine DNA glycosylase II, 499
  - chloroethylnitrosourea-sensitive Chinese hamster cell lines, 195
  - cross-links
    - sensitivity to nitrogen mustard, Burkitt's lymphoma, 6550
  - cis*-diammine-1,1-cyclobutane dicarboxylatoplatinum(II)
    - inhibition of cross-link removal, hydroxyurea and 1- $\beta$ -D-arabinofuranosylcytosine, 1984
  - damage and differential cytotoxicity
    - human carcinoma cells, 6586
  - DNA cross-link at unique plasmid location
    - human shuttle vector, single nitrogen mustard interstrand, 2268
  - down-regulation of cdc2
    - senescent human and hamster cells, 6010
  - elevated 8-hydroxydeoxyguanosine levels
    - diethylstilbestrol-treated Syrian hamsters, 3882
  - excision repair
    - formation of complementation groups 9 and 10, ultraviolet-sensitive mutants, 3965
  - excision repair in cell extracts
    - hypersensitivity, DNA-damaging agents, 3384
  - extrachromosomally amplified genes
    - from tumor cells
      - acceleration of loss, hydroxyurea, 6273
  - fragmentation
    - 1- $\beta$ -D-arabinofuranosylcytosine, myeloid leukemia, 741
  - heterogeneous repair
    - methylnitrosourea-induced alkali-labile sites, 775
  - HLA class I and II antigens
    - bronchogenic carcinoma, 4948
  - identification of nuclear matrix proteins
    - cancer and normal rat prostate, 6514
  - index of solid tumor tissue
    - modal chromosome number, non-small cell lung carcinoma, 3267
  - induction of synthesis
    - rat liver tumor promoters, human hepatocyte primary cultures, 1143
  - intercalating drugs
    - modulation of effects, caffeine, 3682
  - interstrand cross-linking
    - N-(5,5-diacetoxypentyl)doxorubicin, human leukemia cells, 6704
  - Kiel classification
    - t(14;18) major breakpoint regions, non-Hodgkin's lymphoma, 3243
  - major alterations in nucleotide structure
    - cancer of female breast, 5430
  - mechanistic studies
    - trisubstituted platinum(II) antitumor agents, 1866
  - nickel(II)- and cobalt(II)-dependent damage
    - hydrogen peroxide, human chromatin, 5837
  - nuclear
    - degradation, S phase of HL-60 cells, 1165
  - origin and development of cancer
    - cellular adaptation, 2751
  - oxidative damage by nitroalkanes
    - liver, 3143
  - oxidized bases
    - formation of, tumor promoter-treated mouse skin, 4443
  - papillomavirus
    - anal intraepithelial neoplasia, anal cancer, 1014
  - patterns of methylation
    - human lymphoma and leukemia cell lines, 3702
  - phosphoester adduct formation
    - cyclophosphamide, 886
  - plasmid

- host cell reactivation, HeLa cells, 601
- ploidy
- image analysis, individual foci of prostate cancer, 4084
- ras* p21 expression, lung cancer, 6346
- ploidy index and *N-myc* genomic content neuroblastoma, 33
- quantitation of microsomal  $\alpha$ -hydroxylation
- 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 5495
- replication intermediates
- vitamin D, HL-60 cells, 3451
- secondary fragmentation
- topoisomerase II inhibitors, human tumor cell lines, 6280
- selective interaction
- distamycin derivative FCE 24517, 199
- sequence specificity
- doxorubicin-induced mutational damage, *uvrB<sup>-</sup> Escherichia coli*, 3930
- silver-stained nucleolar organizer regions
- norethindrone, Ishikawa cells, 5987
- single-strand breaks
- 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, vitamin A, 3846
- spontaneously occurring non-liver tumors
- activation, protooncogenes, 1148
- strand-breaks and related processes
- ascorbic acid, 6-hydroxydopamine and hydrogen peroxide effects, 6060
- supercoiled
- ionizing radiation, interaction within human cells, 3857
- synthesis
- action of 2',2'-difluorodeoxycytidine, 6110
- target site
- binding analysis of estrogen receptor, breast cancer, 3405
- variability of 5-bromo-2'-deoxyuridine incorporation
- fluoropyrimidine modulation, glioma, 870
- DNA, complementary**
- colon cancer manganese superoxide dismutase
- gene expression, human cells, 939
- expressed human cytochromes P-450
- metabolic activation, 4-ipomeanol, 4636
- folate-binding protein
- marker for ovarian cancer, 5329
- glial fibrillary acidic protein
- glioma cell lines, 1553
- laminin receptor
- synthetic peptide, inhibition of cancer cell attachment, 5672
- nm23-H2* gene, 445
- DNA adducts**
- aflatoxin B<sub>1</sub>
- immunofluorescence, woodchuck hepatocytes and rat liver, 1720
- 4-aminobiphenyl-hemoglobin
- measurement of, lung cancer, 5219
- 2-amino-3-methylimidazo[4,5-f]quinoline
- formation and persistence, 5636
- antitumor agent diaziquone, 5198
- benz[j]aceanthrylene and metabolites
- C3H10T $\frac{1}{2}$  cells, 6163
- detection with monoclonal antibody
- cisplatin and carboplatin, 123
- trans*-7,8-dihydroxy-*anti*-9,10-epoxy-7,8,9,10-tetrahydrobenz o(a)pyrene
- guanine N<sup>2</sup>, duplex dodecamer, 3482
- 7,12-dimethylbenz(a)anthracene-induced
- mammary tumors
- inhibition by dietary selenite, 4613
- formation after 4-aminobiphenyl
- frequency of urination, 4371
- O<sup>6</sup>-methylguanine
- enhanced repair in liver, *ada* gene, 3391
- nucleic acid
- stereoselective formation, 2,3-epoxy-4-hydroxynonanal, 137
- platinum
- cisplatin sensitivity, ovarian carcinoma, 4557
- psoralen photoadducts
- differential introduction and repair, specific human genes, 2867
- DNA damage**
- AIDS and non-Hodgkin's lymphoma, 4743
- cell death following thymidylate synthase inhibition
- 2'-deoxyuridine-5'-triphosphate, 2346
- cellular response
- participation of p53 protein, 6304
- 7 $\beta$ ,8 $\alpha$ -dihydroxy-9 $\alpha$ ,10 $\alpha$ -epoxy-7,8,9,10-tetrahydro benzo(a)pyrene mutations
- HPRT* gene, XP12BE cells, 2587
- double-strand breaks
- measurement in individual cells, gel electrophoresis, 4671
- from gene to carcinogen
- rapid evolution, field of molecular epidemiology, 3617
- modulation of *cis*-diamminedichloroplatinum(II) resistance
- c-myc*, Friend erythroleukemia cells, 2118
- 193-nm radiation in mammalian cells, 288
- non-P-glycoprotein-mediated multidrug resistance
- small cell lung cancer, 3345
- platinum/titanium/ruthenium complexes
- ovarian tumor cells, 2943
- DNA polymerase**
- inhibition of human ribonucleotide reductase
- 2-chloro-9-(2-deoxy-2-fluoro- $\beta$ -D-abinofuranosyl)adenine, 2386
- DNA polymerase- $\alpha$**
- SV40 T antigen
- posttranscriptional regulation, proliferating cell nuclear antigen, 1465
- DNA polymerase chain reaction**
- multiple *K-ras* codon 12 mutations
- cholangiocarcinoma, 3497
- DNA repair**
- different phenotypes
- N*-ethyl-*N*-nitrosourea-induced toxicity and mutation, human cells, 5188
- field-test validation of assay
- circulating human lymphocytes, 5786
- ionizing radiation and topotecan
- synergistic cell killing, 5813
- N*-methyl-*N*-nitrosourea-induced mutations
- shuttle vector plasmid, O<sup>6</sup>-methylguanine-DNA methyltransferase-deficient cells, 6219
- postreplication
- anchorage independence, transformed fibroblasts, 2960
- xeroderma pigmentosum
- patients from Germany, 3456
- DNA topoisomerase II**
- antagonistic effect of aclarubicin
- daunorubicin-induced cytotoxicity, small cell lung cancer cells, 5093
- 4 $\beta$ -arylamine derivatives
- 4'-O-demethylepipodophyllotoxin, tubulin polymerization and KB cells, 1755
- attenuated content correlation to low drug resistance
- Chinese hamster ovary cells, 6543
- daunorubicin-resistant Ehrlich ascites tumor cells, 4213
- directed chemotherapeutic agents
- camptothecin, human leukemia cell line, 1129
- heat-stable cleavable complex
- nonintercalative terpenoids, 2922
- increased phosphorylation
- etoposide-resistant mutants, human cancer KB cells, 3951
- inhibition by bis(2,6-dioxopiperazine) derivatives, 4903, 4909
- inhibitors
- secondary DNA fragmentation, human tumor cell lines, 6280
- levels and chemosensitivity
- human tumor cell lines, 6592
- levels during granulocytic maturation, 3534
- non-P-glycoprotein-mediated multidrug resistance
- small cell lung cancer, 3345
- point mutation in gene
- amsacrine resistance, leukemia cell line, 4729
- reactive chemotherapeutic drugs
- induction of apoptosis, thymocytes, 1078
- DNA topoisomerases**
- inhibitors
- in vitro* differentiation, embryonal carcinoma, 5398
- ionizing radiation and pazelliptine
- additive and supraadditive interaction, 3204
- ionizing radiation and topotecan
- synergistic cell killing, 5813
- P-glycoprotein expression
- platinum/cyclophosphamide chemotherapy, benign and malignant ovarian tumors, 5915
- Dopamine**
- azoxymethane-induced colon carcinogenesis
- inhibition by haloperidol, 6150
- Dormancy**
- cancer
- murine BCL<sub>1</sub> lymphoma, 5045s
- Dosimetry**
- antibodies labeled with <sup>131</sup>I
- infusion, biodistribution, 5921
- protection by Oltipaz
- aflatoxin B<sub>1</sub>-induced hepatocarcinoge-

# SUBJECT INDEX TO VOLUME 51

- nesis, 5501
- Doxorubicin**
  - analogue and modulation of effects by caffeine, 3682
  - induced inhibition of cell survival
  - ethanol potentiation, Chinese hamster ovary cells, 2036
  - induced mutational damage in *uvrB*<sup>-</sup> *Escherichia coli*
  - DNA sequence specificity, 3930
  - inherent resistance
  - increased glutathione peroxidase, sarcoma, 521
  - verapamil and
  - buthionine sulfoximine effect, multidrug resistant cells, 67
- Drug resistance: see also Multidrug resistance**
  - broad cross-resistance of ovarian carcinoma cells
  - multifactorial mechanisms, cyanomorpholino doxorubicin, 5181
  - constitutive
  - P-glycoprotein, human colorectal tumors, 2092
  - hypomethylation and reactivation
  - asparagine synthetase gene, L-asparaginase and ethyl methanesulfonate, 985
  - intercellular transfer, 1190
  - low level
  - attenuated topoisomerase II content, Chinese hamster ovary cells, 6543
  - metabolic inactivation
  - bleomycin, 227
  - P-glycoprotein expression and DNA topoisomerases
  - platinum/cyclophosphamide chemotherapy, ovary, 5915
  - rat mammary carcinoma model, 1434
  - resistance patterns
  - cis*-diamminedichloroplatinum(II), ionizing radiation, 4523
  - response durations and resistant disease mathematical model, 1210
- DT-diaphorase**
  - deficiency
  - Mitomycin C-resistant CHO cells, aerobic conditions, 1860
- Dyes**
  - fluorescent
  - characterization, multidrug resistance, 4665

## E

- Eicosapentaenoic acid**
  - anticachetic and antitumor effect
  - protein turnover, 6089
- Electron spin resonance**
  - mechanism
  - Adriamycin-induced heart mitochondrial damages, 3555
- Electrophoresis**
  - gel
  - measurement in individual cells, DNA double-strand breaks, 4671
- Ellagic acid**
  - chemoprevention of colon carcinogenesis, 4528
- Ellipticine**
  - modulation of effects by caffeine, 3682

- EM-139**
  - biphasic action of androgens
  - human prostatic cancer cells, 5165
  - inhibition of cell cycle kinetics and proliferation
  - breast cancer, 2797
- EM-170**
  - androgen and
  - estradiol-stimulated growth, breast tumors in athymic mice, 3131
- Embryo cells**
  - Syrian hamster
  - immortalization, multistep event, 1177
- EMT6 cells**
  - modulation of tumor cell membrane permeability
  - multiparametric flow cytometry, 799
- Endocytosis**
  - immunotoxin-791T/36-RTA
  - tumor cells, relation to cytotoxic action, 1990
- Endometrial neoplasms**
  - expression of CAR-3 and TAG-72 macromolecules
  - diagnosis, postmenopausal patients, 3001
- Obesity and body fat distribution, 568**
- Endothelial cells**
  - autocrine effects of fibroblast growth factor
  - repair, radiation damage, 2552
- brain**
  - chondroitin sulfate proteoglycan
  - expression, malignant phenotype of astroglial cells, 4986
  - chemotaxis and invasiveness
  - supernatants, AIDS-related Kaposi's sarcoma, 2670
  - cytokine-activated
  - melanoma cell adhesion, VLA-4
  - expression, 2239
  - nitric oxide, lysis of tumor cells, 2531
- growth**
  - carcinoid cell production, paracrine growth factors, 5253
  - inhibition of tumor invasion
  - smooth muscle cell layers, metalloproteinase inhibitor, 2151
  - melanoma interactions
  - tumor-derived interleukin 1, 4768
- membrane vesicles**
  - study of organ preference, metastasis, 394
- photosensitized release**
  - von Willebrand factor, 3261
- plasminogen activation system**
  - human colon cancer, 4067
- suppression of solid tumor growth**
  - immunoneutralizing monoclonal antibody, basic fibroblast growth factor, 6180
- vascular**
  - cytokine activation, lysis of metastatic tumor cells, 245
- Endothelium**
  - inhibition of cancer cell attachment
  - peptide G, 5672
  - normal and tumor microvascular
  - interleukin 2-induced leukocyte adhesion, dextran sulfate, 1561
- Endotoxins**
  - Phase I trial of *Salmonella abortus equi*
- cancer patients, 2524**
- Energy expenditure**
  - metabolism in small cell lung cancer, 5160
  - resting
  - effect, different tumor types, 6027
- Epidermal cells**
  - arachidonate release
  - 4 $\beta$ - and 4- $\alpha$ -12-O-tetradecanoylphorbol-13-acetate, 850
  - calcitriol induction
  - nonphosphorylated osteopontin, 2144
  - tumor progression
  - 12-O-tetradecanoylphorbol-13-acetate or retinoic acid, 4701
- Epidermal growth factor**
  - cellular growth response
  - colon carcinoma, familial adenomatous polyposis, 1452
- cripto gene**
  - transformation, mammary epithelial cells, 1051
- effect of urine**
  - clonal growth, bladder cancer cell lines, 4631
- expression in human gliomas, 2164**
- insulin-like growth factor-I receptors and autocrine stimulation, esophageal carcinoma, 1898**
- modification of growth rates**
  - hypoxic fractions, xenografted A431 tumors, 4111
- phorbol esters and**
  - progression of G<sub>2</sub> phase, mitosis of HeLa cells, 4328
- receptor pathway**
  - squamous carcinoma, associated paraneoplastic syndromes, 2438
- transforming growth factor- $\alpha$  and differential binding, human pancreatic cancer cell line, 6243**
- urinary**
  - tumor-promoting effect, rat bladder carcinogenesis, 5487
- Epidermal neoplasia**
  - regulation of intracellular calcium
  - normal and neoplastic keratinocytes, 4206
- Epidermis**
  - inhibition by 2,6-dithiopurine and thio-purinol
  - benzo(a)pyrene diol epoxide binding to DNA, 4859
  - inhibitory effects of curcumin
  - lipoxigenase and cyclooxygenase activities, 813
  - tumor promoter-induced ornithine decarboxylase activity
  - tannic acid, other polyphenols, 2820
- Epidermoid neoplasms**
  - upregulation of epidermal growth factor receptor
  - $\alpha$ -interferon, 1294
- Epiglycanin**
  - specific immunosuppressive activity, 1170
- Epithelial cells**
  - bronchial
  - immortalization, human papillomaviruses 16 or 18, 5370
  - transformation by *c-raf*-1 and *c-myc*, lung carcinogenesis, 3793

- coexpression of cytokeratins  
myoepithelial and luminal cell lines,  
rat mammary adenocarcinoma, 5943
- ectocervical  
retinoid regulation, papillomavirus  
type 16, 3982
- frequent induction of mammary carcinoma  
*neu* oncogene transfer, 5649  
growth factor messenger RNA expression  
human breast fibroblasts, benign and  
malignant lesions, 4978
- isolation of two cell lines  
single feline mammary carcinoma, heterogeneity, 4028
- liver  
clonal cosegregation of tumorigenicity,  
*c-myc* and transforming growth factor- $\alpha$ , 5238  
resistance to growth inhibitory effects,  
transforming growth factor- $\beta$ 1, 5929
- lung  
behavior of asbestos fibers, 4942  
cyclic AMP-dependent protein kinase  
messenger RNA, 6699
- mammary  
carcinoma induction, *in situ* transfer of  
*v-H-ras*, 2642  
*v-H-ras* oncogene transfer, mammary  
carcinoma suppressor gene, 5298
- murine  
anchorage-independent growth, transforming growth factor- $\beta$ , 5898
- ovarian  
development of monoclonal antibodies, reactivity to surface antigen, 4012
- regulation of growth  
nerve growth factor-like protein, human prostate, 3304
- tumor cell motility  
stimulation, tumor necrosis factor, 5315
- Epithelium**  
Barrett's  
p53 gene mutations, esophageal cancer, 4495  
normal bronchial  
lung cancer and, cytogenetics and growth factors, 400
- Epitopes**  
mapping  
synthetic polypeptide domains, carcinoembryonic antigen, 1876
- 2,3-Epoxy-4-hydroxynonanal**  
stereoselective formation  
nucleic acid adducts, 137
- Epstein-Barr virus**  
AIDS and non-Hodgkin's lymphoma, 4743  
-carrying lymphoblastoid cell lines  
expression of class I MHC, 27  
-negative diffuse large cell lymphoma  
cell line establishment, 8;22 chromosomal translocation, 5392
- Erythroid differentiation factor**  
inhibition of P-glycoprotein expression  
K562 cells, 2582
- Erythroleukemia cells**  
induction of differentiation  
genistein, 764
- sensitivity to 1- $\beta$ -D-arabinofuranosylcytosine  
hemin, deoxycytidine kinase, 4535
- Erythropoietin**  
megakaryocytic features  
leukemic cell line establishment, 341
- Escherichia coli***  
doxorubicin-induced mutational damage  
DNA sequence specificity, 3930  
recombinant membrane-acting immunotoxin, 465  
SOS induction  
stability, fjord- and bay-region diol-epoxides, 1659
- Esophageal neoplasms**  
chronic ingestion of NDEA or NDMA  
detailed dose-response study, 6415  
frequent loss of heterozygosity  
retinoblastoma locus, 5766  
genetic analysis  
high incidence geographic areas, 4102  
p53 gene mutations  
Barrett's epithelium, 4495  
squamous carcinoma  
significance, *int-2/hst-1* coamplification, 1504
- Esophagus**  
epithelial cells  
immortalization, SV40 T-antigen, 365  
inhibitory effects of phenethyl isothiocyanate  
*N*-nitrosobenzylmethylamine carcinogenesis, 2063  
liver and  
tumor induction, dose and time relationships, 6452
- Esterase**  
breast cyst fluid  
purification and properties, 1092
- Estradiol**  
receptor-positive primary breast cancers  
epidermal growth factor receptor-negative tumors, 4544  
-stimulated growth  
androgen and EM-170, breast tumors  
in athymic mice, 3131  
interleukin 1 $\alpha$ , MCF-7 cells, 1488
- Estrogen**  
ablation  
MCF-7 cells, programmed cell death, 162  
-induced tumors  
early kidney lesions, 1922  
inhibition by leukotrienes  
murine transformed Leydig cell proliferation, 5573  
natural history  
Sinclair swine cutaneous melanoma, 2025  
2,3,7,8-tetrachlorodibenzo-*p*-dioxin-mediated increases  
cell proliferation, rat hepatocarcinogenesis, 1391
- Etanidazole**  
modulation of alkylating agents  
fibrosarcoma, mammary carcinoma, 1086
- Ethacrynic acid**  
combined with thiotepa  
Phase I study, 6059  
sensitization of melanoma cells  
cytotoxic effect, melphalan, 94
- Ethanol**  
potentiation of doxorubicin-induced inhibition  
cell survival, Chinese hamster ovary cells, 2036
- Ether lipid**  
modulation of tumor cell membrane permeability  
multiparametric flow cytometry, EMT6 cells and HL-60 cells, 799
- Ethyl methanesulfonate**  
hypomethylation and reactivation  
asparagine synthetase gene, 985
- N*-Ethyl-*N*-nitrosourea**  
-induced toxicity and mutation  
human cells, 5188
- Ethyl phenylpropionate**  
tumor-promoting activity, 5642
- Etoposide**  
from podophyllotoxin glucoside  
chemical and biological route, 5  
interleukin 1 receptor and interleukin 1 $\alpha$   
melanoma cells, 769  
intraperitoneal  
Phase I pharmacokinetic study, 2041  
-resistant mutants of human cancer KB cells  
increased phosphorylation, DNA topoisomerase II, 3951
- teniposide and  
mechanisms of resistance, colon and lung carcinoma, 5275
- Extracellular matrix**  
androgen receptor expression and transformation, prostate fibroblasts, 1910  
cancer cell-mediated degradation  
tumor-associated trypsin, 2107  
invasion by colon cancer  
role of urokinase receptor, 3690  
neural rosette formation  
within *in vitro* spheroids, teratocarcinoma cell line, 2655  
papillomavirus type 16-transformed keratinocytes, 5967  
patterns of differentiation  
human endometrial carcinoma, 5661  
tumor invasion and metastasis  
positive and negative regulation, 5054s
- Eye**  
intraocular tumor formation  
RB reconstituted retinoblastoma cells, 4481  
intraocular tumor suppression  
RB-reconstituted retinoblastoma cells, 6381  
progressively growing ocular tumors  
infiltration and accumulation, precursor CTL, 3153  
ultraviolet radiation-induced tumors, in *Monodelphis domestica*, photoreactivation, 6539
- F**
- Fab**  
portion of myeloma IgG  
sugar chains, antibody-lectin enzyme immunoassay, 5888
- F(ab')**, fragments  
targeted T-cell antitumor responses  
human ovarian carcinoma, 5716

# SUBJECT INDEX TO VOLUME 51

- F-actin**  
cellular levels  
marker for cellular transformation,  
bladder cancer risk, 2762
- Factor VIII**  
-like domains  
M, 46,000 human milk fat globule  
protein, breast tumors, 4994
- Familial adenomatous polyposis**  
cellular growth response  
epidermal growth factor, 1452
- Familial multiple endocrine neoplasia**  
type 1  
allelic loss, chromosome 11, 1154
- Familial polyposis coli**  
p53 gene mutations  
colorectal tumors, 2874
- Fatty acids**  
 $\omega$ -3 and  $\omega$ -6  
dietary effects, stages of colon carcino-  
genesis, 487  
conjugated dienoic derivative of linoleic  
acid  
mammary cancer prevention, 6118  
cytotoxic effect of *cis*-parinaric acid  
cultured malignant cells, 6144  
lipid peroxidation  
enrichment *in vitro* with arachidonic  
acid, hepatoma cells, 4603  
long-chain  
inhibition of glucuronidation,  
benzo(a)pyrene phenols, 4511
- Fazarabine**  
Phase I clinical trial, 1105
- FCE 24517**  
selective DNA interaction, 199
- F9 cells**  
induction of *in vitro* differentiation  
inhibitors of topoisomerases, 5398
- Ferritin**  
DNA strand-breaks and related proc-  
esses  
6-hydroxydopamine and hydrogen per-  
oxide, neuroblastoma cell line, 6060  
models to predict outcome  
childhood neuroblastoma, 1426
- $\alpha$ -Fetoprotein**  
multiple RNAs  
adult rat liver, 4656
- Fetus**  
localization  
parathyroid hormone-like peptide,  
6351
- Fibrinogen**  
deposition without thrombin generation  
primary breast cancer tissue, 349
- Fibrinolysis**  
pathways  
neoplastic and nonneoplastic breast  
tissue, 354
- Fibroblast growth factor**  
acidic and basic  
presence in glioblastoma multiforme,  
5760  
autocrine effects  
repair of radiation damage, endothelial  
cells, 2552  
basic  
suppression of solid tumor growth, im-  
munoneutralizing monoclonal anti-  
body, 6180  
transforming growth factor- $\beta_1$  and, lo-
- calization in human mammary  
gland, 4685  
growth factors in hormone-related tu-  
mors, 4114  
-induced proliferation  
thyroid hormone, Shionogi carcinoma  
115 mammary carcinoma cells,  
4323
- Fibroblasts**  
bone  
prostate cancer growth acceleration,  
3753  
breast  
growth factor mRNA expression, be-  
nign and malignant lesions, 4978  
cell growth  
carcinoid cell production, paracrine  
growth factors, 5253  
contraction of collagen-matrix gels  
transforming growth factor- $\beta$  release,  
gastric carcinoma, 3550  
ionizing radiation and pazelliptine  
additive and supraadditive interaction,  
3204  
malignant transformation  
increased activity, receptor-bound  
plasminogen activator, 1221  
oncogene-transformed  
growth inhibition, cocultured normal  
cells, 5348  
transformation, natural killer target  
molecules, 4250  
prostate  
transformation, extracellular matrix  
and androgen receptor expression,  
1910  
proteolytic activity  
inhibition by Bowman-Birk protease  
inhibitor, 5539  
*ras*-transformed  
Thy-1 as negative growth regulator, 99  
sensitivity to cytotoxic agents  
increases in tumorigenicity, 1855  
transformation  
role of postreplication repair, anchor-  
age independence, 2960  
tumor progression  
hypomethylating drug, 324
- Fibronectin**  
-mediated *Bacillus Calmette-Guérin* at-  
tachment  
bladder mucosa, drugs influencing co-  
agulation pathway, 3726  
modulation of tenascin expression  
lung tumors, 4876
- Fibrosarcoma**  
action of partially purified bacteriocin,  
1359  
*dbl* protooncogene  
preferential expression, 4234  
modulation of alkylating agents  
etanidazole, fluosol-DA/carcinogen,  
1086  
 $^{14}\text{N}$  nuclear magnetic resonance spectrosc-  
opy, 3378
- Fibrosarcoma-1**  
radiation-induced tumor metabolism and  
blood flow  
glucose and mannitol effects, nuclear  
magnetic resonance, 3108
- Fibrosis**  
systemic
- transforming growth factor- $\beta_1$ , nude  
mice, 3590
- Fine-needle aspiration**  
estrogen and progesterone receptors  
normal female breast, 1817
- Flavin**  
-containing monooxygenase  
P-450-catalyzed binding of tamoxifen  
to proteins, 6052
- Flavone acetic acid**  
cytokine gene expression  
mouse splenic leukocytes, 6596
- Flavone-8-acetic acid**  
analogues and  
antitumor effect, plasma nitrate con-  
centrations, 77
- Flow cytometry**  
DNA ploidy and *ras* p21 expression  
lung cancer, 6346  
influence of glutathione S-transferases  
cellular glutathione determination,  
monochlorobimane, 1783  
modulation of tumor cell membrane  
permeability  
ether lipid, EMT6 cells and HL-60  
cells, 799
- Fludarabine triphosphate**  
inhibition of primer RNA formation  
CCRF-CEM leukemia cells, 1829
- Fluorine-18**  
progesterone receptor positive tumors  
positron emission tomography, 1930
- 16 $\alpha$ -Fluoro-5-androsten-17-one**  
chemoprevention of colon carcinogene-  
sis, 4528
- Fluorodeoxyuridine**  
-mediated modulation of iododeoxyuri-  
dine incorporation  
radiosensitization, colon cancer cells,  
3900
- 5-Fluoro-2'-deoxyuridine**  
diastereoisomers of 5-formyltetrahydro-  
folate  
cellular growth, sensitivity, 3476
- Fluoropyrimidines**  
biochemical modulation  
folylpolyglutamates, leucovorin, 789  
5-bromo-2'-deoxyuridine incorporation  
into DNA  
glioma cell lines, 870  
schedule-dependent enhancement of cy-  
totoxicity  
folinic acid, carcinoma cells, 4618
- 5-Fluorouracil**  
high-dose oral leucovorin and  
children with refractory cancer, 4871  
interferon-blocked cell-mediated cytotox-  
icity  
melanoma, 3159  
intratumoral metabolism  
 $^{19}\text{F}$  nuclear magnetic resonance spec-  
troscopy, 5821  
pharmacokinetics,  $^{19}\text{F}$  nuclear mag-  
netic resonance spectroscopy, 5806  
liver perfusion and hepatic artery infu-  
sion, 1694  
metabolism in RIF-1 tumors and liver  
 $^{19}\text{F}$  magnetic resonance spectroscopy,  
1384  
uptake  
pH dependence,  $^{31}\text{P}$  and  $^{19}\text{F}$  nuclear  
magnetic resonance spectroscopy,

- 5770  
**Fluosol-DA/carbogen**  
 modulation of alkylating agents  
 fibrosarcoma, mammary carcinoma,  
 1086  
**Folate**  
 -binding protein  
 cloning of tumor-associated antigen,  
 monoclonal antibodies, 6125  
 marker for ovarian cancer, 5329  
 content and distribution in liver  
 choline deficiency, methotrexate treat-  
 ment, 16  
 mutation at *hprt* locus in T-cells  
 breast cancer treatment, 6603  
 natural  
 antifolate compounds and, membrane  
 transport in leukemia cells, 5507  
 secretion of  $\gamma$ -glutamyl hydrolase, 3874  
 serum levels  
 invasive cervical cancer, 4785  
**Folinic acid**  
 schedule-dependent enhancement of cy-  
 totoxicity  
 fluoropyrimidines, carcinoma cells,  
 4618  
**Folypolyglutamates**  
 biochemical modulation of fluoropyrimi-  
 dines  
 leucovorin, 789  
**Forestomach**  
 benzo(a)pyrene-induced neoplasia  
 inhibition, dietary soy sauce, 2940  
 kidney carcinogenicity and  
 caffeic acid, rats and mice, 5655  
**Formazan**  
 production parameters  
 tetrazolium-based assays, cellular via-  
 bility, 2515  
**5-Formyltetrahydrofolate**  
 diastereoisomers  
 cellular growth, HCT-8 cells, 3476  
**Fotemustine**  
*O*<sup>6</sup>-alkylguanine-DNA alkyltransferase  
 depletion and regeneration, peripheral  
 lymphocytes, 619  
**Free radicals**  
 elevated 8-hydroxydeoxyguanosine levels  
 diethylstilbestrol-treated Syrian ham-  
 sters, 3882  
**Friend erythroleukemia cells**  
 modulation of *cis*-diamminedichloropla-  
 tinum(II) resistance  
*c-myc*, 2118  
 temporal mapping of differentiation  
 pathway, 1668  
**Furan**  
 -induced cholangiofibrosis in rats, 5752

G

- Galactose**  
 -conjugated antibodies  
 cancer therapy, 1619  
 **$\beta$ -Galactosidase**  
 secretion of lysosomal enzymes  
 drug-sensitive and multiple drug-resist-  
 ant cells, 1996  
**Galactoside**  
 -binding protein  
 molecular cloning, chromosomal map-  
 ping, 2173

- Galanin**  
 stimulation of  $Ca^{2+}$  mobilization  
 inositol phosphate accumulation,  
 small cell lung cancer, 1674  
 stimulation of clonal growth  
 small cell lung cancer, 3621  
**Gallium**  
 inhibition of ribonucleotide reductase  
 murine leukemic L1210 cells, 6199  
**Gangliosides**  
 chimeric anti-G<sub>D2</sub> antibody-mediated  
 lysis  
 neuroblastoma cells, 144  
 detection of antigen in serum  
 immunochemistry, small cell lung can-  
 cer, 2879  
 G<sub>M2</sub>-rich cultures of a human glioma cell  
 line  
 induction of necrosis, anti-G<sub>M12</sub> mono-  
 clonal antibodies, 4643  
 G<sub>M3</sub>  
 megakaryocytoid differentiation, K562  
 cells, 1940  
**Gap junctions**  
 growth inhibition of oncogene-trans-  
 formed fibroblasts  
 cocultured normal cells, 5348  
**Gas chromatography-mass spectrometry**  
*N*-glycolylneuraminic acid expression  
 human cancerous tissues, avian lym-  
 phoma cell lines, 1242  
**Gastric neoplasms**  
 detection of frequent *p53* gene mutations  
 cell sorting and polymerase chain reac-  
 tion, 3056  
 lymph node metastasis  
 protective value of Ki-67, 3503  
 metastases  
*p53* gene mutations, 5800  
 mucosal ornithine decarboxylase activity,  
 1448  
 poor short term prognosis  
 immunoreactivity, *erbB-2* protein,  
 1034  
*smg* p21A and *ras* p21 in human tissues,  
 2223  
**Gastrin releasing peptide**  
 antagonist  
 inhibition of growth, human colon  
 cancer xenografts, 6006  
 RC-3095 and RC-160  
 inhibitory effect, nitrosamine-induced  
 pancreatic cancer, 5980  
**Gel electrophoresis**  
 measurement in individual cells  
 DNA double-strand breaks, 4671  
**Gemcitabine**  
 action on DNA synthesis, 6110  
 preclinical activity  
 human head and neck cancer, 211  
**Gene**  
 abnormalities  
 distinction of low grade from high  
 grade, ovarian carcinoma, 4045  
 acetylator polymorphism  
 human colorectal carcinoma, 2098  
*ada*  
 enhanced repair of *O*<sup>6</sup>-methylguanine  
 DNA adducts, 3391  
 alterations  
 progression, primary breast cancer,  
 5794

- alterations of *p53*  
 malignant mesothelioma, 5410  
**AMYB and BMYB**  
 chromosome locations, 3821  
 angiogenic growth factor  
 primary human astrocytomas, 1345  
 approaches to study  
 molecular basis of human cancer,  
 5015s  
 carcinoembryonic antigen-related  
 gastric carcinoma, 5694  
 carcinogen  
 rapid evolution, field of molecular epi-  
 demiology, 3617  
 $\alpha$  class glutathione *S*-transferase  
 antineoplastic drug sensitivity, MCF-7  
 cells, 587  
 colon cancer manganese superoxide dis-  
 mutase  
 complementary DNA, human cells,  
 939  
 common pathway  
 skin tumor promotion, promoting  
 agents, 1398  
*cripto*  
 transformation, mammary epithelial  
 cell line, 1051  
*c-sis*  
 structure and expression, sporadic me-  
 ningiomas, 4295  
 cyclic adenosine monophosphate-respon-  
 sive element binding proteins  
 rat hepatoma, 528  
 cytokine  
 induction by flavone acetic acid,  
 mouse splenic leukocytes, 6596  
**DCC**  
 susceptibility, nonpolyposis colorectal  
 carcinoma, 4135  
 differential introduction and repair  
 psoralen photoadducts, 2867  
 discordant expression  
 T-cell receptor/CD3 complex, adult T-  
 cell leukemia, 6084  
 errors  
 cell proliferation, carcinogenesis, 6493  
 extrachromosomally amplified  
 acceleration of loss by hydroxyurea, tu-  
 mor cells, 6273  
 glucocorticoid receptor  
 CCRF-CEM cells, 5224  
**GLUT1** glucose transporter  
 thymidine uptake, Chinese hamster  
 ovary cells, 4450  
**HER-2/*neu***  
*c-erbB-2*, internalization of monoclo-  
 nal antibody, 5361  
 distinction of low grade from high  
 grade, ovarian carcinoma, 4045  
**H-2K<sup>b</sup>**  
 melanoma-associated antigen and lec-  
 tin-binding cells, BL6 melanoma  
 cells, 5212  
**HPRT**  
 7 $\beta$ ,8 $\alpha$ -dihydroxy-9 $\alpha$ ,10 $\alpha$ -epoxy-7,8,9,  
 10-tetrahydrobenzo(a)pyrene muta-  
 tions, XP12BE cells, 2587  
*hprt* deletion  
 VDJ recombinase-like activity, fetal T-  
 cells, 6001  
**H-ras**  
 imbalance of alleles on chromosome 7,

progression of squamous carcinoma cells, 4097

human

- phosphatidylinositol-3 kinase associated p85 $\alpha$ , chromosome region 5q12-13, 3818
- immunologic quantitation of TIMP-1 colon cancer, 6231
- int-2* amplification
  - deletion of 17p, esophageal carcinoma, 2113
- interstitial chromosomal deletion
  - 4q11-q13, human hepatoma cell line, 1460
- lactoferrin
  - polymorphism, leukemic cells and breast cancer, 3037
- L-myc*
  - galactoside-binding protein, chromosomal mapping, 2173
- loss in human gastric carcinoma, 2926
- mammary cancer suppressor, 1591
- mcs*
  - v-H-ras oncogene transfer, mammary epithelial cells, 5298
- muscle-specific expression
  - rhabdomyosarcoma, human fetal skeletal muscle development, 5100
- mutations
  - p53/ras/p53-hsp 70, lung carcinoma, 4090
- mutator phenotype
  - multistage carcinogenesis, 3075
- myc* activation
  - heterotransplantation, lung carcinoma, 2566
- myc-ras* complementation
  - c-myc gene-induced alterations, protein kinase C expression, 5514
- nm23*
  - somatic allelic deletion, human cancer, 2490
- nm23-H2*
  - identification, second *nm23* gene, 445
- N-myc*
  - DNA amplification, neuroblastoma, 1946
  - human neuroblastoma, 6338
  - nonrandom chromosome losses
    - stepwise neoplastic transformation, uroepithelial cells, 3323
  - normal and mutated K-ras alleles
    - differential expression, induced thymic lymphomas, 5129
  - oncogenic mechanisms
    - radiation-induced cancer, 2740
- p53*
  - frequent allelic losses and mutations, ovarian cancer, 5171
  - mutations in colorectal tumors, familial polyposis coli, 2874
- p53* alleles
  - detection of aberrations, single-strand conformation polymorphism analysis, 3356
- p53* mutations
  - gastric cancer metastases, 5800
  - nonastrocytic human brain tumors, 6202
  - primary human breast cancer, 6194
- p53* tumor suppressor
  - mouse skin tumor progression, 6615

*PIM-1*

- protein serine kinase, 2486

$\beta$ -platelet-derived growth factor receptor

- structure and expression, human tumor cell lines, 5626

platelet-derived growth factor

- autocrine transformation, 5087

proteasome and ubiquitin

- renal cancer cells, 6677

*ras*

- regulation of intracellular calcium, epidermal neoplasia, 4206

*ras* mutations

- low frequency, neuroectodermal tumors, 1596

*ras* mutations in non-small cell lung cancer

- shortened survival irrespective of treatment, 4999

*RB*

- intraocular tumor suppression, 6381

renal cortical tumors

- characterization, 1544

retinoblastoma

- inactivation, human bladder and renal cell carcinoma, 5736

susceptibility of squamous cell carcinoma

- lung, relation to cigarette smoking dose, 5177

susceptibility to liver and lung carcinogenesis

- quantitative analysis, mice, 6299

*tat*

- HIV, liver cancer in transgenic mice, 6686

T-cell receptor

- T-cell neoplasms, acute lymphoblastic leukemia, 6103

therapy

- immunotherapy and, cancer treatment, 5074s

transforming

- neoplasia, reticulum cell sarcoma, 744

transforming growth factor

- regulation by progestins, endometrial adenocarcinoma cells, 5476

tumor necrosis factor

- reduced tumorigenicity and invasiveness, 2229

tumor suppressor

- molecular genetic alterations, human bladder cancer, 5405

Genetics

- familial breast cancer in blacks, 1793

Genistein

- induction of differentiation
  - erythroleukemia cells, 764

Genital tract

- disease
  - bladder cancer, 629

Genotoxicity

- N-nitroso derivatives of  $\beta$ -adrenergic-blocking agents
  - rat and human hepatocytes, 2273

Genotoxins

- induced chromosome damage
  - individual susceptibility, 5266

Geraniol

- concentration-dependent increase
  - murine P388 and B16 population doubling time, 37

Germ cell neoplasms

- testicular
  - expression, *hst-1* and *c-kit* protooncogenes, 1811

Germ cells

- alkaline phosphatase
  - transcriptional regulation, sodium butyrate and glycosylation, 2058

Gestation

- normal parturition and lactation
  - dietary restriction, suppression of MMTV, 5123

Glial cells

- 3-methyladenine DNA glycosylase activity
  - haloethylnitrosoureas, 1568

Glial fibrillary acidic protein

- complementary DNA cloning
  - messenger RNA expression, glioma cell lines, 1553

Glial neoplasms

- chromosome 9 deletion mapping
  - interferon  $\alpha$  and interferon  $\beta$ -1 gene deletions, 1684

Glioblastoma

- cell invasion into fetal rat brain tissue
  - alkyl-lysophospholipid, 1713
- chondroitin sulfate proteoglycan expression
  - proliferating brain capillary endothelial cells, 4986

Glioblastoma multiforme

- presence of acidic and basic fibroblast growth factors, 5760

Glioma

- absence of methylthioadenosine phosphorylase, 3193
- amiloride treatment, 1039
- 5-bromo-2'-deoxyuridine incorporation into DNA
  - modulation, fluoropyrimidines, 870
- epidermal growth factor receptor system, 2164
- G<sub>M2</sub>-rich cultures
  - induction of necrosis, anti-G<sub>M2</sub> monoclonal antibodies, 4643

Gliosarcoma

- sensitization to low dose rate irradiation
  - long duration 41° hyperthermia, 3088

$\alpha_2$ -Globulin

- necessity for D-limonene promotion
  - male rat kidney tumors, 3512

Glucagon

- gene expression in rat and hamster islet cell tumors
  - differential glucocorticoid regulation, 1196

Glucocorticoids

- differential regulation
  - glucagon gene expression, rat and hamster islet cell tumors, 1196
- growth suppression response
  - dominant transacting factors, adenocarcinoma-derived rat mammary tumor cells, 6031
- induced autocrine heparin-binding
  - growth factors
    - proliferation, Shionogi carcinoma, 3006
- insensitivity of P1798 lymphoma cells
  - production of factor, attenuation of lytic response, 5551

- insensitivity to cytolytic effects  
novel "slow death" phenotype, 5544  
resistance to lysis  
truncated glucocorticoid receptor, lymphosarcoma, 2786
- Glucose**  
intravenous vs. intraperitoneal injection  
systemic hemodynamics and blood flow rate, normal and tumor tissues, 3612  
radiation-induced fibrosarcoma-1 tumor metabolism  
blood flow, nuclear magnetic resonance, 3108  
stress protein induction  
porphyrin photosensitization and, 6574  
transporter expression  
thymidine uptake, Chinese hamster ovary cells, 4450
- Glucosides**  
podophyllotoxin glucoside to etoposide chemical and biological route, 5  
7-*N*-[2-{2-( $\gamma$ -L-Glutamylamino)ethyl}thio]ethyl]-mitomycin C  
antitumor activity, 110  
 $\gamma$ -Glutamyl hydrolase  
secretion, 3874
- Glutathione**  
-based detoxifying enzymes  
P-glycoprotein, human colorectal tumors, 2092  
role in synergism  
4-hydroperoxycyclophosphamide and cisplatin, leukemia cell lines, 2536  
selenium and mammary tumors, 4617  
thiol measurements and surgically resected lung tumor, normal lung tissue, 4287
- Glutathione peroxidase**  
increased activity in sarcoma cell line doxorubicin resistance, 521
- Glutathione S-transferase  $\alpha$**   
antineoplastic drug sensitivity  
MCF-7 cells, 587  
hypersensitivity of CHO variants  
bleomycin killing, 4463
- Glutathione S-transferases**  
cellular glutathione determination  
flow cytometry, monochlorobimane, 1783  
human and rodent  
differential specificity of monochlorobimane, isozymes, 1606  
specificity of isozymes  
conjugation, glutathione with L-phenylalanine mustard, 2410
- Glutathione transferase**  
inhibitor ethacrynic acid  
combined with thiopeta, Phase I study, 6059  
sensitization of melanoma cells, melphalan, 94
- O-Glycans**  
aberrant  
attachment to leukosialin, differentiation-deficient HL-60 cells, 2854  
biosynthesis in leukocytes  
normal donors, patients with leukemia, 1257
- Glycolipids**  
composition  
Had-1, cell growth inhibition by lactosylceramide, 1701  
mouse monoclonal anti-fucosylceramide antibody  
establishment and characterization, 4182
- N-Glycolylneuraminic acid**  
breast tumor-associated antigen  
monoclonal antibody 3E1.2, 5826  
expression in human cancerous tissues  
avian lymphoma cell lines, gas chromatography-mass spectrometry, 1242
- Glycoproteins**  
gp43  
monoclonal antibody, hepatocellular carcinoma, 2158  
gp185  
antigen shed from mouse tumors, c-*erbB-2* oncogene, 2593  
M, 64,000 plasma membrane  
adhesion of tumor H-59 cells to hepatocytes, 3578  
mucin-like  
epiglycanin, immunosuppressive activity, 1170
- Glycosyltransferase**  
changes upon differentiation  
human colonic adenocarcinoma cells, 3136
- 15A8-Glycyl-tyrosyl-(*N*- $\epsilon$ -diethylenetriamine pentaacetic acid)-lysine**  
immunohistochemistry and pharmacokinetics  
anti-breast carcinoma monoclonal antibody, 5744
- Gonadotropin-releasing hormone**  
gene expression in breast carcinoma cell lines, 2577
- Gonads**  
protection and fecundity rates  
cyclophosphamide-treated rats, 2124
- G proteins**  
low molecular weight  
similarity of *smg* p21A and *ras* p21, normal and malignant tissues, 2223
- Graft-vs-host disease**  
yttrium-90-labeled anti-Ly1 monoclonal antibody  
radiotherapy, major histocompatibility barrier, 1891
- Granulocytes**  
maturation  
topoisomerase II levels, 3534
- Granulocytopoiesis**  
chronic myelogenous leukemia and mathematical model, 2084
- Granulosa cells**  
ovarian  
cell-cell communication, multistep transformation, 696
- Growth factors**  
abnormalities  
chromosomes, leukemia, 2494  
acivicin-induced monocytoid differentiation  
myeloid leukemia cells, 1202  
angiogenic  
primary human astrocytomas, 1345  
cytogenetics  
normal bronchial epithelium, lung cancer, 400
- hormone-related tumors, 4114  
-independent cell variants  
primary human melanomas, 2205  
messenger RNA expression by human breast fibroblasts  
benign and malignant lesions, 4978
- paracrine**  
carcinoid cell production, fibroblast and endothelial cell growth, 5253  
 $\beta$ -platelet-derived receptor gene structure and expression, human tumor cell lines, 5626  
RNA expression  
human malignant melanoma, markers of transformation, 4815
- Guanosine triphosphate**  
nucleotide metabolism in CCRF-CEM cells  
(6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid, 2291
- Gynecological neoplasms**  
inhibition of tumor growth  
Müllerian inhibiting substance, 2101

H

- Had-1**  
composition of glycolipids  
cell growth inhibition, lactosylceramide, 1701
- 2-Haloethylnitrosourea**  
release of 7-alkylguanines  
modified DNA, 3-methyladenine DNA glycosylase II, 499
- Haloethylnitrosoureas**  
3-methyladenine DNA glycosylase activity  
glial cell line, 1568
- Haloperidol**  
inhibition of experimental carcinogenesis  
azoxymethane, rat colon, 6150
- H-59 cells**  
M, 64,000 plasma membrane glycoprotein  
adhesion to hepatocytes, 3578
- HCT-8 cells**  
diastereoisomers of 5-formyltetrahydrofolate  
cellular growth :3476
- Head and neck cancer**  
capture and growth of CD8<sup>+</sup> and CD4<sup>+</sup> T-cells, 3891
- Heart**  
mitochondrial damage  
Adriamycin, electron spin resonance, 3555
- Heat shock protein**  
expression in human x hamster hybrids  
loss, intrinsic heat resistance, 2636  
HSP-28 and HSP-70 genes  
thermotolerance, leukemic and non-leukemic human tumors, 6608  
M, 27,000  
Chinese hamster cells, anticancer agent treatments and survival, 5245
- HeLa cells**  
cyclin B expression  
G<sub>2</sub> block, ionizing radiation, 5113  
host cell reactivation  
damaged plasmid DNA, 601  
mechanism of G<sub>2</sub> inhibition  
epidermal growth factor, phorbol es-

- ters, 4328
- Hematological neoplasms**  
interphase cytogenetics  
classical karyotyping, *in situ* hybridization, 1959
- Hematopoietic cells**  
functional epidermal growth factor receptors, 150  
maturation  
increased p53 protein levels, 4279
- Hematopoietic growth factors**  
new developments in clinical oncology, 5060s  
small cell lung carcinoma, 73
- Hematopoietic progenitors**  
bone marrow  
transforming growth factor- $\beta$ , 4828  
leukemic  
cytotoxic activity, antitransferrin receptor immunotoxin, 536
- Heme oxygenase**  
induction in mammalian cells, 974
- Hemin**  
sensitivity of erythroleukemia cells  
1- $\beta$ -D-arabinofuranosylcytosine, 4535
- Hemodynamics**  
systemic  
intravenous vs. intraperitoneal glucose injection, normal and tumor tissues, 3612
- Hemoglobin**  
adduct formation  
frequency of urination, 4-aminobiphenyl, 4371  
4-aminobiphenyl adducts  
measurement of, lung cancer, 5219
- Heparin**  
-binding growth factors  
glucocorticoid induction, proliferation of Shionogi carcinoma, 3006  
lack of affinity  
platelet factor 4 analogue, inhibition of tumor growth, 2077  
platelet aggregation  
human melanoma cell line, 1286
- Hepatitis B virus**  
antigen and  
hepatitis B virus carrier patients, liver cancer, 4971  
chemical hepatocarcinogens and synergy, transgenic mice, 1278  
chromosome abnormalities  
peripheral blood cells, 6176  
integration event in chromosome 17p  
nearness to p53 gene, hepatocellular carcinoma, 49
- Hepatitis C virus**  
antibodies  
association with hepatocellular carcinoma, Taiwan, 5621  
hepatitis B and  
etiology of hepatocellular carcinoma, Japanese population, 2842
- Hepatitis virus**  
woodchuck  
elevated formation, nitrate and N-nitrosodimethylamine, 3925
- Hepatocarcinogenesis**  
aflatoxin B<sub>1</sub>-induced  
protection by Oltipaz, 5501  
age-dependent  
oxidative stress, nafenopin, 1789
- cell lineage studies  
"resistant hepatocyte" model system, 1308  
cell proliferation and preneoplastic foci  
ovarian hormones, 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated increases, 1391  
modulation of hepatic mRNA translation activity  
arylsulfotransferase IV, 504  
nafenopin in aged rats, 666
- Hepatocarcinogens**  
hepatitis B virus and  
synergy, transgenic mice, 1278
- Hepatocytes**  
adhesion of tumor H-59 cells  
M, 64,000 plasma membrane glycoprotein, 3578  
origin and development of cancer  
cellular adaptation, 2751  
primary culture  
induction of DNA synthesis, rat liver tumor promoters, 1143
- rat  
cell death, transforming growth factor- $\beta$ , 2478
- rat and human  
genotoxic effect, N-nitroso derivatives of  $\beta$ -adrenergic-blocking agents, 2273
- rat liver tissue and  
aflatoxin B<sub>1</sub>-DNA adducts, immunofluorescence, 1720  
reversible and phorbol ester-specific defect  
protein kinase C translocation, 130  
strain-specific sensitivity  
diethylnitrosamine-induced carcinogenesis, 3257
- Hepatoma**  
1,3-bis(2-chloroethyl)-1-nitrosourea resistance  
 $\gamma$ -irradiation or drug pretreatment, 1217  
cyclic adenosine monophosphate-responsive element binding proteins, 528  
cytotoxicity  
trichosanthin-monochemical antibody conjugate, 3353  
human cell line  
interstitial chromosomal deletion, 4q11-q13, 1460  
tumor metabolism  
*ex vivo* model, tumor metabolism, 841
- Hepatoma cells**  
lipid peroxidation  
enrichment *in vitro* with arachidonic acid, 4603  
vacuole formation and cytochrome arrangement  
teleocidin, 2677
- Hepsulfam**  
Phase I and pharmacokinetic study, 5781  
Phase I clinical and pharmacokinetic trial, 6268
- Herpes simplex virus**  
anal intraepithelial neoplasia and anal cancer  
human papillomavirus DNA, 1014
- Herpesviruses**  
AIDS and non-Hodgkin's lymphoma, 4743
- Hexadecylphosphocholine**  
inhibition of inositol phosphate formation  
protein kinase C activity, 807
- Hexamethylene bisacetamide**  
administration via nasogastric tube  
Phase I bioavailability, pharmacokinetics, 1803
- Hippel-Lindau disease**  
detailed deletion mapping  
short arm of chromosome 3, sporadic renal cell carcinoma, 4707
- Histiocytoma**  
human malignant fibrous  
biological behavior, cloned cells, 2133
- Histiocytosis**  
malignant  
differentiation into macrophage-like cells, phorbol diester, 5712
- HLA complex**  
-A, -B, -C antigens  
primary and metastatic tumor cell populations, human carcinoma, 6372  
A2 antigen in human melanoma cell lines  
T-cell recognition, 3164  
class I and II antigens  
bronchogenic carcinoma, 4948  
class I expression  
independence of c-myc activation, non-small cell lung cancer, 2463
- HL-60 cells**  
cell cycle effects  
8-Cl-cAMP, N<sup>6</sup>-benzyl-cAMP, 6263  
degradation of nuclear DNA in S phase  
camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidine, 1165  
differentiation-deficient  
aberrant O-glycans attached to leukosialin, 2854  
modulation of tumor cell membrane permeability  
multiparametric flow cytometry, 799  
potentiation of 1- $\beta$ -D-arabinofuranosylcytosine cytotoxicity  
1,25-dihydroxyvitamin D<sub>3</sub>, 3451  
single 3.7-kilobase messenger RNA  
cytomegalovirus enhancer, acute myeloid leukemia, 4724
- Homocysteine**  
plasma  
methotrexate, acute lymphoblastic leukemia, 828
- Hormones**  
carcinogenesis, 3626  
-related tumors  
growth factors, 4114  
reproductive factors and  
uvea melanoma, women, 1370
- HT-29 cells**  
cytotoxic effects  
acoustic cavitation, 3024  
streptozotocin/bis-chloroethylnitrosourea therapy  
O<sup>6</sup>-methylguanine DNA methyltransferase activity, 1581  
undifferentiated and enterocytic-differentiated  
lipid characteristics, 1270

- HTLV-I**  
defective provirus form  
adult T-cell leukemia/lymphoma, 4639
- Human anti-murine antibody**  
single and multiple dose clinical studies  
human immune response, LY256787 and LY203728, 2286
- Human immunodeficiency virus**  
*tat* gene  
liver cancer in transgenic mice, 6686
- Hyaluronate**  
high and low levels of CD44  
melanoma cell variants, 6660
- Hybridomas**  
anti-ricin  
ligand effect, intracellular trafficking of ricin A chain, 1689
- Hydrogen peroxide**  
6-hydroxydopamine and ascorbic acid, DNA strand-breaks in neuroblastoma, 6060  
neutrophil-mediated tumor cytotoxicity modulation by Na<sup>+</sup>/H<sup>+</sup> exchange, 3212  
nickel(II)- and cobalt(II)-dependent damage  
DNA bases, human chromatin, 5837  
production of large amounts  
human tumor cells, 794
- 4-Hydroperoxycyclophosphamide**  
cisplatin and  
role of glutathione in synergism, leukemia cell lines, 2536
- 4-Hydroxyandrostenedione**  
murine Leydig tumor cell steroidogenesis, 3663
- 8-Hydroxydeoxyguanosine**  
elevated levels in DNA  
diethylstilbestrol-treated Syrian hamsters, 3882
- 6-Hydroxydopamine**  
hydrogen peroxide and ascorbic acid, DNA strand-breaks in neuroblastoma, 6060
- Hydroxyl radical**  
major alterations in nucleotide structure  
DNA, cancer of female breast, 5430  
*N*-(4-Hydroxyphenyl)retinamide  
prevention of primary prostate cancer, 3610
- 12-Hydroxystearic acid**  
nontoxic polyethylene esters  
Solutol HS 15, reversal of multidrug resistance, 897
- Hydroxyurea**  
acceleration of loss  
extrachromosomally amplified genes, tumor cells, 6273  
*cis*-diammine-1,1-cyclobutane dicarboxylatoplatinum(II)  
inhibition of DNA interstrand cross-link removal, 1984
- Hypercalcemia**  
malignancy-associated  
dysregulation, parathyroid hormone-like peptide expression, 6521
- Hyperglycemia**  
glucose and mannitol effects  
radiation-induced fibrosarcoma-1 tumor metabolism, 3108  
red blood cell rigidity  
tumor blood flow, 2727
- Hyperplasia**  
inhibition of tumor growth by tumor mass, 2  
squamous cell  
regression, forestomach lesions, 318
- Hypertension**  
interstitial  
carcinoma of uterine cervix, tumor oxygenation and radiation response, 6695  
superficial metastatic melanoma, 6691
- Hyperthermia**  
cytosolic Ca<sup>2+</sup>  
digitized imaging microscopy, cell survival, 359  
*cis*-diamminedichloroplatinum(II) and radiation, mammary carcinoma, 707  
localization of <sup>111</sup>In-labeled hapten bifunctional antibody, human colon tumor xenografts, 1515  
long duration 41°  
sensitization of gliosarcoma cells, low dose rate irradiation, 3088  
lonidamine and chemotherapy  
combination therapy, RIF-1 tumor, 5910  
normal tissue toxicity  
Adriamycin pharmacokinetics, 1680  
whole body  
Adriamycin, tumor and normal tissues, 3559  
carboplatin and, normal tissue and tumor in rats, 2994  
protective effect of ICRF-187, Adriamycin, 3568
- Hypertriglyceridemia**  
tissue lipoprotein lipase activity  
messenger RNA levels, tumor-induced alterations, 863
- Hypomethylating agents**  
increased sensitivity of nontumorigenic fibroblasts  
*ras* or *myc* oncogenes, 2-aza-2'-deoxycytidine, 324
- Hypoxanthine-guanine phosphoribosyl transferase**  
factors affecting mutation  
T-cells, breast cancer treatment, 6603
- Hypoxia**  
fractions  
xenografted human colon tumors, 5139  
oxygenation of human tumors, 3316
- I**
- ICAM-1**  
serum levels  
human malignant melanoma, 5003
- ICI 182,780**  
clinical potential, 3867
- ICI D1694**  
potent inhibitor of L1210 tumor cell growth, 5579
- ICRF-187**  
protective effect against normal tissue injury  
Adriamycin, whole body hyperthermia, 3568
- Idarubicin**  
-monoclonal antibody conjugates  
disseminated thymic lymphoma model, 310
- Imidazoisoquinolines**  
cytotoxicity  
human malignant cell lines, 43
- Imidazopiperidines**  
cytotoxicity  
human malignant cell lines, 43
- Immortalization**  
Syrian hamster embryo cells  
multistep event, 1177
- Immune response**  
antigen-specific  
anti-idiotypic monoclonal antibodies, anti-CEA antibodies, 2599  
<sup>131</sup>I-chimeric mouse/human B72.3 monoclonal antibody  
pharmacokinetics, humans, 5461  
local activation  
interleukin 2 intraarterial infusion, bladder neoplasms, 2456
- Immunity**  
tumor  
transplantation, 757
- Immunoassay**  
quantitation of TIMP-1  
colon cancer, 6231
- Immunochemistry**  
small cell lung cancer-associated ganglioside antigen  
detection in serum, 2879
- Immunoconjugates**  
epidermal growth factor receptor-reactive monoclonal antibodies  
xenograft antitumor activity, 5471  
interleukin 2  
enhanced tumor uptake, macromolecules, 2694  
<sup>177</sup>lutetium-labeled  
monoclonal antibody-based therapy, human tumor xenograft, 2889  
monoclonal antibody-*Vinca* alkaloid  
solid tumor membrane antigen, antigen-antibody complexes, 2965
- Immunocytochemistry**  
estrogen and progesterone receptors  
normal female breast, 1817  
sensitivity  
detection of breast cancer cells, human bone marrow, 2706
- Immunofluorescence**  
aflatoxin B<sub>1</sub>-DNA adducts  
woodchuck hepatocytes, rat liver tissue, 1720
- Immunogenicity**  
lack of effect of cyclophosphamide melanoma antigen vaccine, 3643  
monoclonal antibodies  
conjugation of drugs, 5774  
natural cell-mediated cytotoxicity  
ultraviolet radiation, MCA105 tumor cells, 5153
- Immunoglobulin G**  
-anti-CD22 and Fab'  
antitumor activity, human B lymphoma in SCID mice, 5876  
G2a and G2b  
rapid blood clearance, nude mice, 3102  
myeloma  
glycosylation at Fab portion, antibody-lectin enzyme immunoassay, 5888

- Immunoglobulins**  
 binding to HPV-16-derived proteins L1 and E4  
 cervical secretions, HPV-related cervical disease, 4423  
 diphtheria toxin A-chain coding sequence  
 toxicity to B-lymphoid cells, 4299
- Immunoscintigraphy**  
*c-erbB-2* proto-oncogene products, 990  
 computerized tomography and identification, colorectal cancer, 5704
- Immunosuppression**  
 epiglycanin  
 mucin-like glycoprotein, mammary adenocarcinoma, 1170  
 large-animal human brain tumor xenograft model  
 cats, 2430  
 ultraviolet radiation-induced systemic absence of, UV-induced murine tumors, 2773
- Immunotherapy**  
 adoptive  
 peripheral blood T-cells, LAK cells and interleukin 2, 1494  
 cloning of tumor-associated antigen monoclonal antibodies, folate binding protein, 6125  
 gene therapy and cancer treatment, 5074s  
 interleukin 2 liposomes  
 anti-CD3-stimulated T cells, hepatic metastasis, 2127  
 interleukin 2 production  
 colorectal cancer patients, human monoclonal anti-idiotypic antibody, 5425  
 low-dose interleukin 2 and tumor necrosis factor- $\alpha$   
 advanced non-small cell lung cancer, 3669  
 Tn antigen, 1406  
 transduction and expression of human CEA gene  
 murine colon carcinoma cell line, 3657
- Immunotoxins**  
 anti-transferrin receptor  
 cytotoxic activity, leukemic human hematopoietic progenitors, 536  
 covalent binding of  $\alpha_2$ -macroglobulin deglycosylated ricin A chain, 1482  
 Fab' and immunoglobulin G-anti-CD22 antitumor activity, B lymphoma, 5876  
 mistletoe lectin A-chain, 916  
 pharmacokinetics and tumor localization  
*M*, 30,000 form, ricin A chain, 4219  
 Phase I trial  
 B-cell lymphoma, 4052  
 preparation with blocked ricin therapeutic use, 6235  
 recombinant membrane-acting, 465  
 ricin A chain  
 potentiation, monensin in lipid emulsion, 4316  
<sup>90</sup>Y-labeled C110 anti-carcinoembryonic antigen  
 preclinical assessment, colon cancer, 255
- Immunotoxin-791T/36-RTA**  
 endocytosis by tumor cells  
 relation to cytotoxic action, 1990
- Implants**  
 "artificial organ"  
 B16 melanoma metastasis, 2444
- Indium-111**  
 localization of hapten to bifunctional antibody  
 human colon tumor xenografts, 1515
- Indole-3-carbinol**  
 promotion of aflatoxin B<sub>1</sub> carcinogenesis, 2362
- Indomethacin**  
 misonidazole and therapeutic ratio of radiotherapy, murine sarcoma, 3639  
 tumor growth  
 development of cancer cachexia, 880  
 tumorigenesis  
 mammary carcinoma, high- or low-fat diet, 2683
- Inflammation**  
 immunization with haptenized tumor cells  
 induction, melanoma metastases, 2731
- Inosine 5'-monophosphate dehydrogenase type II**  
 messenger RNA expression, human leukemias, 3886
- Inositol phosphate**  
 accumulation  
 stimulation by galanin, small cell lung cancer, 1674  
 differential binding and biological activities  
 epidermal growth factor, transforming growth factor- $\alpha$ , 6243  
 inhibition of formation  
 hexadecylphosphocholine, protein kinase C activity, 807
- Insulin-like growth factor**  
 binding proteins  
 human central nervous system tumors, 3030  
 purification, colon cancer cell growth inhibitor, 2813  
 binding to Tera-2 human embryonic carcinoma cells  
 differentiation, 4395  
 receptor messenger RNA  
 transcriptional mechanism, *c-myc*, 5997
- Insulin-like growth factor-I**  
 epidermal growth factor receptors and autocrine stimulation, esophageal carcinoma, 1898  
 expression and binding proteins  
 receptors, ovarian cancer, 5107  
*Pseudomonas* exotoxin and recombinant fusion protein, cytotoxic activity, 174  
 tyrosine phosphorylation of *M*, 150,000 kDa protein  
 metastatic colon carcinoma cells, 5859
- Insulin-like growth factor-II**  
 growth factor mRNA expression  
 breast fibroblasts, benign and malignant lesions, 4978
- Integrin  $\alpha^6\beta_4$**   
 A9 antigen  
 aggressive human squamous carcinoma, 2395
- $\beta_1$  Integrin**  
 human small cell lung cancer cells, 1065
- Intercellular adhesion molecule 1: see ICAM-1**
- Interferon**  
 differentiation of neuroblastoma  
 retinoic acid, dibutyryl cyclic adenosine 3':5'-monophosphate, 3958  
 elevation of serum carcinoembryonic antigen  
 TAG-72, 4155  
 -induced inhibition of spontaneous metastases  
 natural killer and T-cells, melanoma, 1124  
 -induced resistance  
 abrogation of, cell-mediated cytotoxicity and 5-fluorouracil in melanoma, 3159
- $\alpha$ -Interferon**  
 class I major histocompatibility complex peripheral blood mononuclear cells, plasma of melanoma patients, 652  
 down-regulation of epidermal growth factor receptors  
 renal carcinoma cells, 5881  
 inhibition of cytokine-induced lipogenesis  
 interleukin 4, 2803  
 interferon  $\beta$ -1 gene deletions and chromosome 9 deletion mapping, glial tumors, 1684  
 -gelatin conjugate  
*in vivo* murine tumor cell growth, 5532  
 reversal of Adriamycin resistance  
 colon carcinoma, 4898  
 upregulation of epidermal growth factor receptor  
 human epidermoid cancer cells, 1294
- $\beta$ -Interferon**  
 natural  
 Phase I trial, metastatic malignancy, 836
- $\gamma$ -Interferon**  
 antitumor activity  
 ascitic and solid tumor models, ovarian cancer, 6643  
 enhancement of metastatic potential, 4020  
 enhancement of radioimmunotherapy  
 colon carcinoma, 2335  
 interleukin 2 and  
 Phase I evaluation, 3910  
 interleukin 4 and  $\alpha$ -tumor necrosis factor modulation, melanoma cells, 2002  
 reduced tumorigenicity of murine tumor cells  
 nonspecific host responses, 1185  
 tumor necrosis factor- $\alpha$  and androgen-dependent and -independent prostatic tumors, 2329  
 experimental model, cancer cachexia, 2302  
 $\alpha$ -tumor necrosis factor or interleukin 4, inhibition of cell growth in renal cell carcinoma, 5687
- Interleukin 1**  
 antiproliferative effect  
 human ovarian carcinoma cell line, 1823  
 cell resistance to tumor necrosis factor cytotoxicity  
 growth arrest, G<sub>1</sub> phase of cell cycle, 2379

- inhibition of cytokine-induced lipogenesis  
interleukin 4, 2803  
protection  
1- $\beta$ -D-arabinofuranosylcytosine-induced alopecia, 3329  
transcription by human melanoma cells  
monocytes, 3334  
tumor-derived  
melanoma-endothelial cell interactions, 4768  
tumor necrosis factor- $\alpha$  and tumor growth and development, cancer cachexia, 415
- Interleukin 1 $\alpha$**   
antitumor drugs and combination effect, syngeneic tumors in mice, 215  
block of estradiol-stimulated growth down-regulation of estrogen receptor, MCF-7 cells, 1488  
interleukin 1 receptor and etoposide melanoma cells, 769  
potentiation of antitumor activity mitomycin C and porfiromycin, solid tumor models, 5454
- Interleukin 1 $\beta$**   
initial sensitization and subsequent protection  
photon radiation, stem cells, 2280
- Interleukin 2**  
Adriamycin and augmentation of immunity, renal cell carcinoma, 6133  
cytolytic potential of peripheral blood T-cells  
adoptive immunotherapy, 1494  
exogenous  
in *vitro* LAK activity, in *vivo* activated lymphocytes, 2324  
-induced leukocyte adhesion  
normal and tumor microvascular endothelium, dextran sulfate, 1561  
induction of graft vs. leukemia effect bone marrow transplantation, 2015  
 $\gamma$ -interferon and Phase I evaluation, 3910  
intraarterial infusion  
local activation of immune response, bladder neoplasms, 2456  
liposomes  
anti-CD3-stimulated T cells, hepatic metastasis, 2127  
low-dose  
biological monitoring, cytokines and cell surface phenotypes, 6312  
*Nocardia rubra* cell wall skeleton and LAK cell induction, 5261  
novel vasoactive immunoconjugate enhanced tumor uptake, macromolecules, 2694  
production induced in colorectal cancer patients  
immunization, human monoclonal anti-idiotypic antibody, 5425  
protein kinase C modulation  
lymphocyte proliferation, 82  
solid phase, 875  
tumor-infiltrating lymphocytes  
renal cell carcinoma, 4199  
tumor necrosis factor- $\alpha$  and Phase I, advanced non-small cell lung cancer, 3669  
preclinical study, canine neoplasms, 233
- Interleukin 3**  
-dependent proliferation  
human MO-7e cell line, activation of late G<sub>1</sub> genes, 1741  
hematopoietic growth factors  
small cell lung carcinoma, 73  
megakaryocytic features  
leukemic cell line establishment, 341  
phorbol ester and activated H-ras mast cells, 632  
receptor-associated protein  
inhibition of growth by monoclonal antibody, mouse leukemic cell lines, 4355
- Interleukin 4**  
alone and with  $\gamma$ -interferon or  $\alpha$ -tumor necrosis factor  
inhibition of cell growth, renal cell carcinoma, 5687  
down-regulation  
tumoricidal state, human alveolar macrophages, 5526  
high-affinity receptors  
chimeric protein, murine sarcoma cells, 3011  
inhibition of stimulation  
hepatic lipogenesis, various cytokines, 2803  
 $\gamma$ -interferon and  $\alpha$ -tumor necrosis factor modulation, melanoma cells, 2002  
potentiation of antiproliferative effect tumor necrosis factor, various tumor cell lines, 4266
- Interleukin 6**  
cell resistance to tumor necrosis factor cytotoxicity  
growth arrest, G<sub>1</sub> phase of cell cycle, 2379  
human malignant nonhematopoietic cell lines and interactions, 3862  
inhibition of cytokine-induced lipogenesis  
interleukin 4, 2803  
neopterin and predictive value, multiple myeloma, 6250  
-*Pseudomonas* exotoxin chimeric molecules  
human hepatocellular carcinoma in mice, 2831
- Interleukins**  
AIDS and non-Hodgkin's lymphoma, 4743
- Intermediate filaments**  
expression of N-myc  
human neuroblastoma, 6338
- Intestinal mucosa**  
altered protein kinase C activity  
biopsies, colonic adenoma and carcinoma, 205
- Intestine**  
alkaline phosphatase  
tumorigenic potential, irradiated hybrids, 4455  
apomucins  
relationship, pancreatic apomucin, 1026  
furan-induced cholangiofibrosis in rats, 5752
- large  
nonfamilial neoplasia, rectal mucosal cell proliferation, 1917
- Iodide**  
-deficient area  
ras codon 61 mutation, thyroid tumors, 2690
- Iodine-131**  
labeled monoclonal antibodies  
infusion, biodistribution and dosimetry, 5921
- m-Iodobenzylguanidine**  
accumulation by neuroblastoma cells  
independent uptake and storage mechanisms, 4342
- Iododeoxyuridine**  
incorporation  
fluorodeoxyuridine-mediated modulation, colon cancer cells, 3900
- 4-Iodotamoxifen**  
pyrrolidino-4-iodotamoxifen and treatment of breast cancer, 5851
- 4-Isoprenalol**  
metabolic activation  
complementary DNA-expressed human cytochromes P-450, 4636
- Iron**  
-dependent DNA strand-breaks  
6-hydroxydopamine and hydrogen peroxide, neuroblastoma cell line, 6060
- Irradiation**  
low dose rate  
sensitization of gliosarcoma cells, long duration 41° hyperthermia, 3088  
nude rat model  
orthotopic human lung cancers, 3274
- $\gamma$ -Irradiation**  
1,3-bis(2-chloroethyl)-1-nitrosourea resistance  
rat hepatoma cells, 1217  
intestinal alkaline phosphatase expression  
tumorigenic potential, hybrids, 4455
- Ishikawa cells**  
silver-stained nucleolar organizer regions  
norethindrone, 5987
- Isoprenoids**  
concentration-dependent increase  
P388 and B16 doubling time, acyclic monoterpene geraniol, 37
- N-Isopropyl-p-formylbenzamide**  
potentiation of cytotoxic action  
mafosfamide, 4170
- Isothiocyanate**  
inhibition of metabolic activation  
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 4798
- J**
- Japan**  
hepatitis C and hepatitis B  
etiology, hepatocellular carcinoma, 2842
- JB6 cells**  
phorbol ester-induced transformation  
synergistic inhibition, transforming growth factor- $\beta$  and retinoic acid, 1158
- K**
- Karyotyping**

- classical  
  *in situ* hybridization, interphase cytogenetics of hematological cancer, 1959
- KB cells**  
  4 $\beta$ -arylamine derivatives of 4'-O-demethylpodophyllotoxin  
  DNA topoisomerase II, tubulin polymerization, 1755  
  etoposide-resistant mutants  
  increased phosphorylation, DNA topoisomerase II, 3951
- K562 cells**  
  highly glycosylated methotrexate membrane carrier, 3420  
  inhibition of human ribonucleotide reductase  
  2-chloro-9-(2-deoxy-2-fluoro- $\beta$ -D-arabinofuranosyl)adenine, 2386  
  megakaryocytoid differentiation  
  induction, ganglioside GM<sub>3</sub>, 1940  
  multidrug-resistant  
  inhibition of P-glycoprotein expression, Actin A, 2582
- Keratin**  
  expression  
  c-Ha-ras-transfected tumorigenic clones, 4402
- Keratin 19**  
  abnormal expression of retinoic acid receptors  
  oral and epidermal squamous cell carcinoma, 3972
- Keratinocytes**  
  activation of autocrine transforming growth factor- $\alpha$  pathway  
  human squamous carcinoma cells, 6254  
  malignant human papillomavirus type 16-transformed  
  altered expression, extracellular matrix glycoproteins, 5967  
  normal and neoplastic  
  induction of protein kinase C agonist effects, staurosporine, 4677  
  regulation of intracellular calcium, ras gene mutations, 4206  
  parathyroid hormone-like peptide expression and secretion  
  dysregulation, tumor progression, 6521
- Ki-67**  
  protective value  
  argyrophilic nucleolar organizer region, lymph node metastasis in gastric cancer, 3503
- Kidney**  
  early lesions  
  estrogen-induced tumors, 1922  
  forestomach carcinogenicity and caffeic acid, rats and mice, 5655
- Kidney neoplasms**  
  coexistence  
  autologous antibodies, decay-accelerating factor, 2521  
  cortical tumors  
  characterization, 1544  
  genetic approaches to study  
  molecular basis of human cancer, 5015s  
  presence of  $\alpha_{2u}$ -globulin  
  D-limonene promotion, 3512
- proteasome and ubiquitin genes  
  changes in expression, 6677
- Kiel classification**  
  frequency and structure  
  t(14;18) major breakpoint regions, non-Hodgkin's lymphoma, 3243
- Kinesin**  
  expression and type IV collagenase secretion  
  invasive prostate PC-3 tumor sublines, 5866
- K-ras**  
  mutations  
  1,2-dimethylhydrazine-induced colonic tumors, dietary calcium and vitamin D deficiency, 4305
- KW-2149**  
  antitumor activity, 110
- L
- Lactation**  
  normal parturition and  
  dietary restriction, suppression of  
  mouse mammary tumor virus, 5123
- Lactoferrin**  
  polymorphism and altered methylation of gene  
  normal leukocytes, leukemic cells and breast cancer, 3037
- Lactose**  
  -binding lectin  
  metastatic stages, colorectal carcinoma, 387
- Lactosylceramide**  
  cell growth inhibition  
  Had-1, composition of glycolipids, 1701
- LAK cells**  
  cytolytic potential of peripheral blood T-cells  
  adoptive immunotherapy, 1494  
  *in vitro* activity  
  *in vivo* activated lymphocytes, exogenous interleukin 2, 2324  
  synergistic effect  
  *Nocardia rubra* cell wall skeleton, interleukin 2, 5261
- Laminins**  
  A and C  
  differential expression, lung cancer cell lines, 581  
  synthetic peptide CDPGYIGSR-NH<sub>2</sub>  
  inhibition, angiogenesis and tumor growth, 903
- L1210 cells**  
  inhibition of poly(adenosine diphosphate-ribose) polymerase  
  thymidine and its analogues, 1,3-bis(2-chloroethyl)-1-nitrosourea, 1586  
  inhibitor of tumor cell growth  
  ICI D1694, 5579  
  transport multiplicity and energetics  
  methotrexate efflux, 1412  
  unexpected biotransformation pathway  
  tetrachloro-(*d,l-trans*)-1,2-diaminocyclohexaneplatinum(IV), 969
- Le<sup>a</sup> antigen**  
  dimeric epitope  
  antitumor effects, monoclonal antibody, 2199
- Lectin**
- A-chain  
  mistletoe, immunotoxin, 916
- Amaranthus caudatus*  
  histochemical probe, proliferating colonic epithelial cells, 657
- binding cells  
  H-2K<sup>b</sup> gene expression, BL6 melanoma cells, 5212  
  endogenous lactose-binding  
  metastatic stages, colorectal carcinoma, 387
- Leiomyosarcoma**  
  *dbf* protooncogene  
  preferential expression, 4234
- Lens culinaris**  
  agglutinin for antibody-lectin enzyme immunoassay  
  sugar chains, myeloma IgG, 5888
- Leucovorin**  
  biochemical modulation of fluoropyrimidines  
  folylpolyglutamates, 789  
  high-dose oral  
  plus 5-fluorouracil, children with refractory cancer, 4871
- Leukemia**  
  acute  
  interleukin 2, immunological changes, 964  
  ALL-1 involved in  
  cloning of, 6712  
  antagonism  
  camptothecin and topoisomerase II-directed chemotherapeutic agents, 1129  
  biosynthesis of O-glucans in leukocytes, 1257  
  breakpoint of t(11;14) and t(11;19), 6708  
  childhood  
  maternal and perinatal risk factors, 3696  
  chromosomal and growth factor abnormalities, 2494  
  DNA interstrand cross-linking  
  rapid endonucleolytic cleavage, N-(5,5-diacetoxypentyl)doxorubicin, 6704  
  effects of 8-Cl-cAMP and N<sup>6</sup>-benzylcAMP  
  kinetics, HL-60 cells, 6263  
  expression of HSP-28 and HSP-70 genes  
  thermotolerance, 6608  
  graft vs. leukemia effect  
  interleukin 2, bone marrow transplantation, 2015  
  interphase cytogenetics  
  classical karyotyping, *in situ* hybridization, 1959  
  meningeal  
  preclinical pharmacology, intrathecal 6-mercaptopurine, 6079  
  modulation of multidrug resistance  
  cyclosporin A, verapamil, 1749  
  patterns of DNA methylation, 3702  
  point mutation in topoisomerase II gene  
  amsacrine-resistant form, topoisomerase II, 4729  
  refractory or relapsed acute  
  Phase I clinical investigation, amonafide, 935  
  regulation of deoxycytidine kinase  
  uridine nucleotides, 1- $\beta$ -D-arabinofuranosylcytosine phosphorylation, 2559

- role of glutathione
  - synergism, 4-hydroperoxycyclophosphamide and *cis*-diamminedichloroplatinum(II), 2536
- type II inosine 5'-monophosphate dehydrogenase
  - messenger RNA expression, up-regulation, 3886
- Leukemia, B-cell**
  - lymphoma
    - monoclonal antibody SN10, internalization into cells, 2985
- Leukemia, L1210**
  - inhibition of ribonucleotide reductase
    - gallium, 6199
  - membrane transport
    - natural folates, antifolate compounds, 5507
  - participation of T-cells in curative effect
    - N,N'*-bis[3-(ethylamino)propyl]-1,7-heptanediamine, 62
- Leukemia, lymphoblastic**
  - acute
    - measurement of serum L-asparagine, 6568
    - plasma homocysteine, children, 828
    - T-cell receptor gene configurations, 6103
  - B precursor acute
    - methylation status, T-cell receptor  $\beta$ -chain, 2917
  - trimetrexate resistance
    - protein kinase C activity, multidrug resistance, 55
- Leukemia, myelogenous**
  - benign phase chronic
    - detection of BCR-ABL proteins, blood cells, 3048
  - chronic
    - granulocytopoiesis and, mathematical model, 2084
- Leukemia, myeloid**
  - acivicin-induced monocytoid differentiation
    - messenger RNA expression, 1202
  - acute
    - cytomegalovirus enhancer, single 3.7-kilobase messenger RNA, 4724
  - c-jun* expression
    - camptothecin and its derivatives, 6636
  - internucleosomal DNA fragmentation
    - 1- $\beta$ -D-arabinofuranosylcytosine, 741
- Leukemia, P388**
  - concentration-dependent increase in doubling time
    - acyclic monoterpene geraniol, 37
  - pleiotropic drug-resistant cells
    - cellular pharmacology, MX2, 157
- Leukemia, T-cell**
  - adult
    - defective provirus form, HTLV-I, 4639
    - discordant gene and surface expression, T-cell receptor/CD3 complex, 6084
- Leukemia-inhibitory factor**
  - cancer cachexia syndrome
    - mice bearing melanoma cells, 6656
- Leukemia virus**
  - Abelson murine
    - SV40 retrovirus and, induction of differentiation by protein kinase inhibitors, 4649
- radiation
  - induction, preleukemic cells, 2179
- Leukemic cells**
  - CCRF-CEM cells
    - normal and mutant glucocorticoid receptor gene, 5224
  - cell line establishment
    - megakaryocytic features, 341
  - expression of three major protein kinase C isozymes, 4271
  - inhibition of growth by monoclonal antibody
    - interleukin 3 receptor-associated protein, 4355
  - inhibition of protooncogene expression
    - antisense oligodeoxynucleotides, 4505
  - lactoferrin and polymorphism, 3037
- Leukocytes**
  - biosynthesis of *O*-glycans
    - normal donors, patients with leukemia, 1257
  - interleukin 2-induced adhesion
    - normal and tumor microvascular endothelium, dextran sulfate, 1561
  - normal
    - lactoferrin and polymorphism, 3037
  - polymorphonuclear
    - nonoxidative lysis, neuroectodermal tumor cells, 4865
  - splenic
    - cytokine gene expression, flavone acetic acid, 6596
- Leukosialin**
  - aberrant *O*-glycans
    - differentiation-deficient HL-60 cells, 2854
- Leukotrienes**
  - inhibition
    - murine transformed Leydig cell proliferation, 5573
- Leydig cells**
  - proliferation
    - inhibition by leukotrienes, 5573
  - steroidogenesis
    - effect of 4-hydroxyandrostenedione, 3663
- Li-Fraumeni syndrome**
  - follow-up study of twenty-four families, 6094
  - germ line mutation in exon 5
    - p53* gene, 6385
- Ligands**
  - intracellular trafficking of ricin A chain
    - anti-ricin hybridomas, 1689
- D-Limonene**
  - promotion
    - presence of  $\alpha_{2u}$ -globulin, 3512
- Linoleic acid**
  - conjugated dienoic derivative
    - mammary cancer prevention, 6118
  - phorbol ester-elicited tumor promotion
    - dietary fat, mouse skin, 907
- Lipid peroxidation**
  - conjugated dienoic derivative of linoleic acid
    - mammary cancer prevention, 6118
  - cytotoxic effect of *cis*-parinaric acid
    - cultured malignant cells, 6144
  - enrichment *in vitro* with arachidonic acid
    - rat AH-130 hepatoma cells, 4603
- Lipids**
  - characteristics
    - undifferentiated and enterocytic-differentiated HT29 colonic cells, 1270
  - compositions of intracellular membranes
    - rat liver nodules, 3774
  - dependent proliferation
    - pancreatic cancer cell line, 3633
  - emulsion
    - monensin, potentiation of ricin A chain immunotoxins, 4316
  - lipophilic antifolates
    - phenotype conferring selective resistance, Chinese hamster ovary cells, 2949
  - lipoprotein cholesterol changes
    - weight changes, prior to cancer diagnosis, 3198
- Lipogenesis**
  - cytokine-induced
    - inhibition of, interleukin 4, 2803
- Lipoma**
  - cytogenetic profile, 422
- Lipoprotein**
  - boronated low-density
    - boron neutron capture theory, biological efficacy, 4588
  - lipase activity
    - messenger RNA levels, tumor-induced alterations, 863
- Lipoprotein lipase**
  - cancer cachexia syndrome
    - leukemia-inhibitory factor, mice bearing melanoma cells, 6656
- Liposomes**
  - interleukin 2
    - anti-CD3-stimulated T cells, hepatic metastasis, 2127
  - lipophilic tumor necrosis factor
    - preparation and characterization, 3362
  - macrophage activator CGP 31362
    - therapy of spontaneous lung metastasis, renal adenocarcinoma, 3741
- Lipoxygenase**
  - inhibitory effects of curcumin
    - mouse epidermis, 813
- Liver**
  - adduct formation after 4-aminobiphenyl
    - frequency of urination, 4371
  - adult rat
    - multiple  $\alpha$ -fetoprotein RNAs, 4656
  - carcinogenesis
    - modulation by butylated hydroxytoluene, 2-acetylaminofluorene exposure, 6224
  - cell lineage studies
    - hepatocarcinogenesis, 1308
  - cryosurgery
    - colorectal metastases, 6323
  - decrease in catalase activity
    - tumor necrosis factor/cachectin, 3990
  - development
    - cell lineages, oval cell progenitors, 2611
  - DNA and RNA
    - oxidative damage, nitroalkanes, 3143
  - epithelial cells
    - clonal cosegregation of tumorigenicity, *c-myc* and TGF- $\alpha$ , 5238
    - drug-metabolizing enzymes, procarcinogens, 301
    - resistance to growth inhibitory effects, transforming growth factor- $\beta$ 1, 5929

- esophagus and  
tumor induction, dose and time relationships, 6452
- 5-fluorouracil metabolism  
<sup>19</sup>F magnetic resonance spectroscopy, 1384
- folate content and distribution  
choline deficiency, methotrexate treatment, 16
- glutathione *S*-transferase  
specificity of isozymes, L-phenylalanine mustard, 2410
- hepatic metastasis  
interleukin 2 liposomes, anti-CD3-stimulated T cells, 2127
- hepatitis B virus and chemical hepatocarcinogens  
synergy, transgenic mice, 1278
- inhibition of cytokine-induced lipogenesis  
interleukin 4, 2803
- lung carcinogenesis and  
quantitative analysis, genetic susceptibility, 6299
- metabolic activation and inactivation  
1-nitropyrene, species differences, 3919
- metabolism of 7,12-dimethylbenz(a)anthracene, 492
- metastasis of gastric carcinoma  
autotumor-reactive T cell clones, tumor-infiltrating lymphocytes, 6153
- microsomes  
cytochrome P-450 activation, cigarette smoke, 5284
- nodules  
lipid compositions, intracellular membranes, 3774
- P450 enzymes  
thio-TEPA oxygenation, drug metabolism and clearance, 2340
- perfusion and hepatic artery infusion  
5-fluorouracil, 1694
- rat and human  
P-450-mediated activation, tamoxifen, 6052
- rat fetus  
localization, parathyroid hormone-like peptide, 6351
- tumor promotion  
induction of DNA synthesis, human hepatocyte primary cultures, 1143
- protein kinase C translocation, 130
- woodchuck hepatocytes and  
aflatoxin B<sub>1</sub>-DNA adducts, immunofluorescence, 1720
- Liver neoplasms**  
aberrations of tumor suppressor p53  
retinoblastoma genes, hepatocellular carcinoma, 5520
- aflatoxin B<sub>1</sub>-induced hepatocarcinogenesis  
protection by Oltipaz, 5501
- chronic ingestion of NDEA or NDMA  
detailed dose-response study, 6415
- hepatitis B virus carrier patients  
hepatitis B x antigen, 4971
- nonassociation of aflatoxin, 3825
- p53 mutations and carcinogens, 6185
- transgenic mice carrying HIV *tar* gene, 6686
- Locus**
- hprt*  
factors influencing mutation in T-cells, breast cancer, 6603
- Lonidamine**  
hyperthermia and chemotherapy  
combination therapy, RIF-1 tumor, 5910
- modulator of alkylating agent activity, 780
- Lovastatin**  
inhibition of cell growth  
independence of *ras* function, 712
- inhibition of protein isoprenylation  
dehydroepiandrosterone, colonic adenocarcinoma, 6563
- synchronization of tumor and normal cells  
G<sub>1</sub> to multiple cell cycles, 3602
- Lung**  
carcinogenesis  
bronchial epithelial cells, *c-raf-1* and *c-myc*, 3793
- colonization capacity  
motility factor receptor internalization, melanoma cells, 2699
- epithelial cells  
behavior of asbestos fibers, 4942
- cyclic AMP-dependent protein kinase messenger RNA, 6699
- human alveolar macrophages  
down-regulation by interleukin 4, tumor-inhibitory state, 5526
- human normal and tumor tissue  
*O*<sup>6</sup>-methylguanine-DNA methyltransferase, 4131
- inhibition of murine melanoma experimental metastasis  
recombinant desulfatohirudin, 4549
- liver carcinogenesis and  
quantitative analysis, genetic susceptibility, 6299
- 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone tumorigenesis  
critical determinant, *O*<sup>6</sup>-methylguanine, 5557
- inhibition by arylalkyl isothiocyanates, structure-activity relationships, 1846
- modulation of uptake and metabolism by nicotine  
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 2009
- spontaneous metastasis  
renal adenocarcinoma, CGP 31362, 3741
- squamous cell carcinoma  
genetic susceptibility, relation to cigarette smoking dose, 5177
- toxicity  
cooxidation of cyclophosphamide, alternative pathway, 532
- Lung neoplasms**  
4-aminobiphenyl-hemoglobin adducts  
measurement of, cases and controls, 5219
- associated protein  
development of new assay, cancer marker, 3838
- differential expression  
laminins A and C, 581
- DNA ploidy and *ras* p21 expression, 6346
- effect of different tumor types
- resting energy expenditure, 6027
- genetic approaches to study  
molecular basis of human cancer, 5015s
- induction of cytokine messenger RNA and secretion  
alveolar macrophages, blood monocytes, 857
- modulation of tenascin expression  
fibronectin, 4876
- mouse pulmonary carcinogenesis, 450
- neural cell adhesion molecule  
messenger RNA splicing patterns, 6019
- non-small cell  
altered HLA class I expression, *c-myc*, 2463
- interleukin 2 and tumor necrosis factor- $\alpha$ , 3669
- ras* gene mutations, shortened survival, 4999
- stage I prognostic indicator, nucleolar organizer regions, 4008
- vinorelbine-loaded polymeric biore-sorbable implants, 5384
- normal bronchial epithelium and  
cytogenetics, growth factors, 400
- normal lung and  
interleukin 4 receptor expression, 261
- orthotopic human  
irradiated nude rat model, 3274
- p53 mutations and carcinogens, 6185
- production of neuromedin B and its gene expression, 5205
- small cell  
antagonistic effect of aclarubicin, daunorubicin-induced cytotoxicity, 5093
- c-kit* protooncogene transcripts, 2416
- different energy metabolism, magnetic resonance spectroscopy, 5160
- galanin, Ca<sup>2+</sup> mobilization, 1674
- immunochemical detection, ganglioside in serum, 2879
- inhibition of growth, bombesin analogues, 1798
- $\beta$ <sub>1</sub> integrin, 1065
- myc* family DNA amplification, combination chemotherapy regimens, 1708
- non-P-glycoprotein-mediated multi-drug resistance, 3345
- <sup>186</sup>Re radioimmunotherapy, nude mice, 676
- sensitivity to cisplatin, metallothionein, 3237
- stimulation of clonal growth, neuropeptides, 3621
- specific inhibition of *K-ras*  
tumorigenicity, antisense RNA, 1744
- surgically resected  
cellular glutathione, thiol measurements, 4287
- use of mentholated cigarettes, 6510
- women, 4893
- <sup>177</sup>Lutetium  
-labeled immunoconjugate  
monoclonal antibody-based therapy, human tumor xenograft, 2889
- LY256787**  
LY203728 and  
human immune response, single and multiple dose clinical studies, 2286

- Lymph node**  
capture and growth of CD8<sup>+</sup> and CD4<sup>+</sup> T-cells, 3891  
direct intralymphatic injection  
<sup>111</sup>In-T101, cutaneous T-cell lymphoma, 688  
metastasis  
E-cadherin expression, squamous cell carcinoma, 6328  
malignant potential of cells, melanoma, 2029  
multidrug resistance gene product, colon carcinoma, 2720  
protective value of Ki-67, gastric cancer, 3503
- Lymphoblastoid cell lines**  
Epstein-Barr virus-carrying  
expression of class I MHC, 27
- Lymphoblasts**  
Molt-4  
cellular pharmacology, cyclopentyl cytosine, 3733
- Lymphocytes**  
circulating  
field-test validation of assay, DNA repair, 5786  
infiltration of ovarian malignant ascites tumor cytotoxicity, 4257  
*in vivo*  
*in vitro* LAK activity, exogenous interleukin 2, 2324  
pattern of DNA methylation, 3702  
peripheral  
O<sup>6</sup>-alkylguanine-DNA alkyltransferase, dacarbazine and fotemustine, 619  
proliferation  
protein kinase C modulation, 82  
tumor-infiltrating  
autotumor-reactive T cell clones, liver metastasis of gastric carcinoma, 6153  
cisplatin-containing chemotherapy and, epithelial ovarian cancer, 1934  
interleukin 2, renal cell carcinoma, 4199  
intraocular tumors, precursor CTL, 3153  
phenotype and functional activity, immunogenic and nonimmunogenic brain tumors, 2373  
T-cell receptor V $\beta$  gene expression, primary and metastatic melanoma, 5565
- Lymphoid cells**  
chromosomal and growth factor abnormalities  
leukemia, 2494
- Lymphokines**  
consequences of "binding site barrier", 4776
- Lymphoma**  
avian cell lines  
N-glycylneuraminic acid, gas chromatography-mass spectrometry, 1242  
B-cell  
Phase I immunotoxin trial, 4052  
-B leukemia  
monoclonal antibody SN10, internalization into cells, 2985  
Burkitt's  
epidermal growth factor receptors, 150  
expression of class I MHC, 27  
nitrogen mustard sensitivity, DNA cross-links, 6550  
defective provirus form of HTLV-I, 4639  
deliverance of saporin  
comparative mixtures, bispecific F(ab')<sub>2</sub> antibodies, 2353  
development  
immature CD4<sup>+</sup>8<sup>+</sup> cells, N-methyl-N-nitrosourea, 737  
diffuse large cell  
cell line establishment, 8;22 chromosomal translocation, 5392  
disseminated thymic  
idarubicin-monoclonal antibody conjugates, antitumor activity, 310  
glucocorticoid insensitivity  
production of factor, attenuation of lytic response, 5551  
Hodgkin's  
patterns of DNA methylation, 3702  
immunotoxin prepared with blocked ricin  
therapeutic use, 6235  
insensitivity to cytolytic effects  
glucocorticoids, novel "slow death" phenotype, 5544  
karyotypic changes  
loss of prolactin dependency, 282  
murine BCL<sub>1</sub>  
cancer dormancy, 5045s  
non-Hodgkin's  
acquired immunodeficiency syndrome, 4743  
frequency and structure, t(14;18) major breakpoint regions, 3243  
rapid cell death by apoptosis  
induction by photodynamic therapy, 5993  
thymic  
differential expression, normal and mutated K-ras alleles, 5129  
staging, T-cell receptor  $\beta$  chain gene rearrangements, 1627
- Lymphoma, B-cell**  
Fab' and IgG-anti-CD22 immunotoxins  
antitumor activity, SCID mice, 5876  
molecular cloning of chromosomal breakpoint, 1574
- Lymphoma, T-cell**  
cutaneous  
direct intralymphatic injection, radio-labeled <sup>111</sup>In-T101, 688  
yttrium-90-labeled anti-Ly1 monoclonal antibody  
radiotherapy, 1883
- Lymphomagenesis**  
carcinogen-induced  
pim-1 transgenic mice, 958
- Lymphosarcoma**  
P1798 mouse  
truncated glucocorticoid receptor, 2786
- Lyngbyatoxin A**  
novel analogues  
cellular sensitization, cis-diamminedichloroplatinum(II), 2511
- Lysis resistance factor**  
glucocorticoid insensitivity, 5544, 5551
- Lysosomes**  
enzyme secretion  
drug-sensitive and multiple drug-resistant cells, 1996  
lipid compositions of intracellular membranes  
rat liver nodules, 3774  
localization and mechanism of uptake  
Nile blue photosensitizers, tumor cells, 2710

M

- $\alpha_2$ -Macroglobulin**  
covalent binding to deglycosylated ricin A chain  
immunotoxins, 1482
- Macromolecules**  
consequences of "binding site barrier", 4776  
enhanced tumor uptake  
novel vasoactive interleukin 2 immunconjugate, 2694
- Macrophages**  
activator CGP 31362  
therapy of spontaneous lung metastasis, renal adenocarcinoma, 3741  
alveolar  
cytokine messenger RNA, lung cancer, 857  
colony-stimulating factor  
biological and antitumor effects, mice, 2649  
human alveolar  
tumoricidal state, down-regulation by interleukin 4, 5526  
*in vivo* murine tumor cell growth  
 $\alpha$ -interferon-gelatin conjugate, 5532  
-like cells  
phorbol diester, human malignant histiocytosis, 5712  
monocyte-derived  
low-affinity Fc receptors, antibody-dependent tumor cell phagocytosis, 1117  
murine  
Photofrin uptake, 2251
- Mafosfamide**  
potentiation of cytotoxic action  
N-isopropyl-p-formylbenzamide, 4170
- Magnetic resonance imaging**  
self-diffusion of water  
multicellular spheroids, 4072
- Magnetic resonance spectroscopy**  
different energy metabolism  
small cell lung cancer, 5160  
<sup>19</sup>F  
5-fluorouracil metabolism, RIF-1 tumors and liver, 1384
- Major histocompatibility complex class I**  
Epstein-Barr virus-carrying lymphoblastoid cell lines, Burkitt lymphoma cells, 27  
interferon- $\alpha$ , peripheral blood mononuclear cells and plasma, 652  
class I and II  
survival, colorectal carcinoma, 729  
frequent down-regulation of class I antigen expression  
individual micrometastatic carcinoma cells, 4712  
H-2K<sup>b</sup> gene expression  
lectin-binding cells, BL6 melanoma cells, 5212

- interferon-blocked cell-mediated cytotoxicity
  - melanoma, 3159
- reduced tumorigenicity of murine tumor cells
  - $\gamma$ -interferon secretion, nonspecific host responses, 1185
- yttrium-90-labeled anti-Ly1 monoclonal antibody
  - radiotherapy, graft-vs-host disease, 1891
- Malignancy**
  - accessible sugar epitopes
    - colon cancer-associated mucins, monoclonal antibody AM-3, 5342
  - associated hypercalcemia
    - dysregulation, parathyroid hormone-like peptide expression, 6521
  - behavior and resistance to cisplatin ovarian carcinoma xenografts, different disease stages, 6358
  - characterization of multidrug resistance fluorescent dyes, 4665
  - components of fibrinolysis pathways
    - neoplastic and nonneoplastic breast tissue, 354
  - cytotoxic effect of *cis*-parinaric acid, 6144
  - cytotoxicity
    - antagonists of platelet activating factor, 43
  - developmental genetics and childhood cancer, 5435
  - DNA ploidy and *ras* p21 expression lung cancer, 6346
  - effect of different tumor types
    - resting energy expenditure, 6027
  - elimination of V $\beta$ 2 bearing T-cells preneoplastic and neoplastic mammary lesions, 3331
  - expression of cathepsin L in human tumors, 1478
  - fibrinogen deposition
    - no thrombin generation, primary breast cancer, 349
  - frequent induction of mammary carcinoma
    - neu* oncogene transfer, 5649
  - growth factor messenger RNA expression
    - human breast fibroblasts, benign and malignant lesions, 4978
  - individual foci of prostate cancer
    - DNA ploidy, image analysis, 4084
  - interleukin 6 and nonhematopoietic cell lines
    - interactions, 3862
  - metastatic
    - Phase I trial, natural human interferon  $\beta$ , 836
  - metastatic cell phenotype
    - invasion, reconstituted basement membrane matrix, 3624
  - monoclonal antibody-*Vinca* alkaloid immunconjugate
    - solid tumor membrane antigen, antigen-antibody complexes, 2965
  - mutant p53 expression in melanoma, 5976
  - new developments in clinical oncology, 5060s
  - nonrandom chromosome losses
    - stepwise neoplastic transformation, uroepithelial cells, 3323
  - origin and development of cancer
    - cellular adaptation, 2751
  - potential of cells
    - lymph node or brain metastases, melanoma, 2029
  - prognostic significance
    - argyrophilic nucleolar organizer regions, 5339
  - protein core of mucin molecule
    - cytotoxic T-lymphocytes, breast adenocarcinoma, 2908
  - response durations and resistant disease
    - mathematical model, 1210
  - transformation of human fibroblasts
    - increased activity, receptor-bound plasminogen activator, 1221
  - wild type or mutant p53 proteins
    - alterations, tumor development, 5232
- Mammalian cells**
  - DNA damage
    - 193-nm radiation, 288
  - fjord- and bay-region diol epoxides
    - SOS induction, *Escherichia coli*, 1659
  - induction of heme oxygenase, 974
- Mammary gland**
  - apomucins
    - relationship, pancreatic apomucin, 1026
  - epithelial cell transformation
    - cripto* gene, 1051
  - inhibition of chemical carcinogenesis
    - dietary dehydroepiandrosterone, 481
  - localization
    - basic fibroblast growth factor, transforming growth factor- $\beta$ , 4685
- Mammary neoplasms**
  - adenocarcinoma-derived
    - glucocorticoid growth suppression response, dominant transacting factors, 6031
  - composition of glycolipids
    - Had-1, cell growth inhibition by lactosylceramide, 1701
  - dietary modulation of proviral expression, 5123
  - 7,12-dimethylbenz(a)anthracene-induced DNA adducts, inhibition by dietary selenium, 4613
  - hepatic metabolism, 492
  - histopathology
    - H-*ras* oncogene, 3762
  - hormone-dependent and hormone-independent Grunder strain mouse
    - comparison, estrogen receptors, 3843
  - hyperthermia and *cis*-diamminedichloroplatinum(II)
    - radiation, 707
  - metastasis
    - prostaglandin E<sub>2</sub> receptors, 2047
  - modulation of alkylating agents
    - etanidazole, fluosol-DA/carbogen, 1086
  - preneoplastic and neoplastic lesions
    - elimination, V $\beta$ 2 bearing T-cells, 3331
  - prevention
    - conjugated dienoic derivative of linoleic acid, 6118
  - suppressor gene and its site of action, 1591
  - tumor subpopulation interactions
    - melphalan sensitivity, 4378
- Mannitol**
  - radiation-induced fibrosarcoma-I tumor metabolism
    - blood flow, nuclear magnetic resonance, 3108
- Mast cells**
  - synergistic reduction of interleukin 3 phorbol ester, activated H-*ras*, 632
- Mathematical models**
  - population ecology issues in tumor growth, 2542
  - response durations
    - amount of subclinical resistant disease, 1210
- Matrigel**
  - transplantation of human prostatic carcinoma
    - nude mice, 3814
- MCF-7 cells**
  - antineoplastic drug sensitivity
    - $\alpha$  class glutathione S-transferase gene, 587
  - estradiol-stimulated growth
    - block by interleukin 1 $\alpha$ , 1488
  - estrogen ablation
    - programmed cell death during regression, 162
  - growth
    - 1,25-dihydroxyvitamin D<sub>3</sub>, platinum drugs, 2848
- Medroxyprogesterone**
  - androgen and EM-170
    - estradiol-stimulated growth, breast tumors in athymic mice, 3131
- Medulloblastoma**
  - infrequent p53 gene mutations, 4721
- Megakaryoblastic cells**
  - induction of differentiation by protein kinase inhibitors
    - Abelson murine leukemia virus, recombinant SV40 retrovirus, 4649
- Melanocyte**
  - growth
    - protein kinase C down-regulation, 3281
- Melanocytic neoplasms**
  - role of ultraviolet radiation
    - hairless mice, 4964
- Melanoma**
  - antigen vaccine
    - lack of effect of cyclophosphamide, immunogenicity, 3643
  - associated antigens
    - differential expression, acral lentiginous melanoma and nodular melanoma lesions, 1726
  - associated proteoglycan antigen
    - monoclonal anti-idiotypic antibodies, 3183
  - augmented binding
    - radiolabeled monoclonal antibodies, 2768
  - cancer cachexia syndrome
    - leukemia-inhibitory factor, 6656
  - cell adhesion to cytokine-activated endothelial cells
    - correlation, VLA-4 expression, 2239
  - cell variants
    - high and low levels of CD44, 6660
  - class I MHC enhancement
    - interferon- $\alpha$ , peripheral blood mono-

- nuclear cells, 652
- endothelial cell interactions
- tumor-derived interleukin 1, 4768
- fresh human tissue in mice
- growth and metastasis, SCID, 4937
- growth
  - local effect, ultraviolet radiation, 4176
  - psoralen plus ultraviolet A radiation, 5893
- HLA-A2 antigen
  - T-cell recognition, 3164
- human malignant
  - loss of heterozygosity for loci, long arm of chromosome 6, 5449
- interferon-blocked cell-mediated cytotoxicity
  - 5-fluorouracil, 3159
- interleukin 1 receptor
  - interleukin 1 $\alpha$  and etoposide, 769
- malignant
  - induction, growth factor RNA expression, 4815
  - ionizing radiation, tissue-type plasminogen activator, 5587
  - serum levels, circulating intercellular adhesion molecule 1, 5003
- malignant potential of cells
  - lymph node or brain metastases, 2029
- metastases
  - inflammation, immunization with haptenized tumor cells, 2731
  - modulation of cells by interleukin 4
    - $\gamma$ -interferon and  $\alpha$ -tumor necrosis factor, 2002
  - motility factor receptor internalization
    - lung colonization capacity, 2699
- murine
  - experimental metastasis, recombinant desulfatohirudin, 4549
  - successful treatment, bryostatin 1, 682
  - mutant p53 expression, 5976
- novel gene sequences
  - molecular subtraction, 1418
- platelet aggregation, 1286
- practical spontaneous metastasis model
  - therapeutic studies, 2837
- predominance of metastatic phenotype
  - somatic cell hybrids, 6292
- primary and metastatic
  - tumor-infiltrating lymphocytes, T-cell receptor V $\beta$  gene expression, 5565
- primary human
  - invasive and growth factor-independent cell variants, 2205
- sensitization to cytotoxic effect of melphalan
  - ethacrynic acid, 94
- Sinclair swine cutaneous
  - natural history of, influence of estrogens, 2025
- spermidine/spermine N<sup>1</sup>-acetyltransferase activity, 3715
- spontaneous metastasis
  - interferon-induced inhibition, natural killer and T-cells, 1124
  - suppression in SCID mice, antibody to epidermal growth factor receptor, 2193
- superficial metastatic
  - interstitial hypertension, 6691
- tenascin secretion, 4853
- transcription of interleukin 1 gene
  - monocytes, 3334
- uveal
  - hormonal and reproductive factors, women, 1370
- xenografts
  - cellular radiation sensitivity, local tumor control, 4609
- Melanoma, B16**
  - B16-F1
    - autocrine motility factor, receptor, 3507
  - metastasis to "artificial organ" implant, 2444
  - metastatic potential
    - inhibitory effect, N,N,N-trimethylsphingosine, 6138
- Melanoma-associated antigen**
  - H-2K<sup>b</sup> gene expression
    - lectin-binding cells, BL6 melanoma cells, 5212
  - mimicry
    - anti-idiotypic antibody, 6045
    - mouse anti-idiotypic monoclonal antibody TK7-371, 4790
- Melphalan**
  - carmethizole
    - in vivo* and *in vitro* evaluation, 4581
  - resistant human rhabdomyosarcoma
    - xenograft
      - therapeutic analysis, 3906
  - resistant multiple myeloma
    - development of cell line, 995
- sensitivity
  - tumor subpopulation, palpable mouse mammary tumors, 4378
- sensitization of melanoma cells to cytotoxic effect
  - ethacrynic acid, 94
- Membrane proteins**
  - platelet aggregation
    - human melanoma cell line, 1286
- Membrane vesicles**
  - endothelial cell
    - study of organ preference, metastasis, 394
- Meningioma**
  - sporadic
    - structure and expression, c-sis gene, 4295
- Menthol**
  - cigarettes
    - lung cancer risk, 6510
- 6-Mercaptopurine**
  - intrathecal
    - preclinical pharmacology, Phase I/II trial, 6079
- Mesenchyme**
  - induced changes
    - neoplastic characteristics, Dunning prostatic adenocarcinoma, 4924
- Mesothelial cells**
  - transformation
    - trisomy, rat chromosome 1, 4059
- Mesothelioma**
  - malignant
    - cigarette smoking, asbestos exposure, 2263
    - genetic alterations, p53 gene, 5410
- Metalloproteinases**
  - inhibitor
    - inhibition of tumor invasion, smooth muscle cell layers, 2151
- tissue inhibitor
  - collagenase activity, metastatic tumor cells, 2138
- Metallothionein**
  - dexamethasone-induced
    - suppression, cis-diamminedichloroplatinum(II) resistance, 893
  - sensitivity to cisplatin
    - small cell lung cancer cell lines, 3237
- Metaplasia**
  - uran-induced cholangiofibrosis
    - rats, 5752
- Metastasis**
  - accumulation of genetic alterations
    - progression, primary breast cancer, 5794
  - B16 melanoma
    - "artificial organ" implant, 2444
  - breast cancer
    - bone, localization of parathyroid hormone-related protein, 3059
  - breast cancer progression
    - maintenance, p53 alterations, 2605
  - carcinoid tumors
    - transgenic mice, 4917
  - CD44 splice variants
    - tumor cell lines, 5292
  - colon carcinoma cells
    - insulin-like growth factor I, tyrosine phosphorylation, 5859
  - colorectal
    - hepatic cryosurgery, 6323
  - colorectal carcinoma
    - endogenous lactose-binding lectin, 387
  - decreased expression of tissue inhibitor metalloproteinases, collagenase activity, 2138
  - enhanced promoter activity
    - human M, 72,000 type IV collagenase gene, 6190
  - frequent down-regulation of MHC class I antigen expression
    - individual micrometastatic carcinoma cells, 4712
  - growth and
    - fresh human melanoma tissue, SCID mice, 4937
  - hepatic
    - interleukin 2 liposomes, anti-CD3-stimulated T cells, 2127
  - human carcinoma
    - HLA-A, -B, -C antigen expression, 6372
  - inhibition of cancer cell attachment to endothelium
    - peptide G, 5672
  - inhibition of platelet aggregation
    - monoclonal antibody, colon adenocarcinoma, 921
  - inhibition of tumor growth by tumor mass, 2
  - liver
    - autotumor-reactive T cell clones, tumor-infiltrating lymphocytes, 6153
  - 3LL variants
    - differential expression, transforming growth factor- $\beta$ 1 gene, 5491
  - lung
    - murine renal adenocarcinoma, CGP 31362, 3741
  - lymph node
    - E-cadherin expression, squamous cell

# SUBJECT INDEX TO VOLUME 51

- carcinoma, 6328  
gastric cancer, protective value of Ki-67, 3503  
local tumor aggressiveness and P-glycoprotein, colon carcinoma, 2720  
lymph node or brain  
malignant potential of cells, melanoma, 2029  
lysis  
cytokine-activated vascular endothelial cells, 245  
macrophage colony-stimulating factor biological and antitumor effects, mice, 2649  
malignancy  
Phase I trial, natural human interferon  $\beta$ , 836  
malignant behavior and resistance to cisplatin  
ovarian carcinoma xenografts, 6358  
malignant cell phenotype  
invasion, reconstituted basement membrane matrix, 3624  
malignant metastatic cell phenotype  
invasion, reconstituted basement membrane matrix, 405  
mammary tumor  
prostaglandin  $E_2$  receptors, 2047  
melanoma  
suppression with antibody to EGF receptor, 2193  
tumor-infiltrating lymphocytes, T-cell receptor V $\beta$  gene expression, 5565  
murine melanoma  
recombinant desulfatohirudin, 4549  
*nm23-H2* gene, 445  
phenotype predominance  
somatic cell hybrids, murine melanoma, 6292  
poor short term prognosis in gastric cancer  
*erbB-2* protein, 1034  
potential of murine B16 melanoma cell line  
inhibitory effect, *N,N,N*-trimethylsphingosine, 6138  
potential progression marker  
high mobility protein I(Y), prostate cancer, 606  
practical spontaneous model  
therapeutic studies, human melanoma, 2837  
production of large amounts of hydrogen peroxide  
human tumor cells, 794  
prognosis in breast cancer  
estrogen receptor, progesterone receptor and 1,25-dihydroxyvitamin  $D_3$  receptor, 239  
pulmonary adenocarcinoma  
urokinase-type plasminogen activator, 3522  
rat mammary adenocarcinoma  
coexpression of cytokeratins, myoepithelial and luminal cell lines, 5943  
renal cell carcinoma  
common regions of deletion, chromosomes 5q,6q,10q, 5817  
significance of *int-2/hst-1* coamplification  
esophageal squamous carcinoma, 1504  
spontaneous  
interferon-induced inhibition, natural killer and T-cells, 1124  
study of organ preference  
endothelial cell membrane vesicles, 394  
suppression of metastatic ability  
genetic factors, prostatic cancer, 3788  
tumor-induced angiogenesis  
inhibition, sulfated chitin derivatives, 22  
tumor invasion and  
positive and negative regulation, 5054s  
urokinase-type plasminogen activator  
inhibition by antibodies, tumor dissemination, 274  
Metastatic potential  
differential release of proteinase inhibitors  
mammary adenocarcinoma variants, 1318  
enhancement by  $\gamma$ -interferon, 4020  
substrate dependence of cell motility and attachment  
Dunning R-3327 rat prostatic adenocarcinoma model, 6580  
Methionine enkephalin  
enhancement of colon carcinogenesis  
azoxymethane, 785  
Methotrexate  
efflux  
transport multiplicity, L1210 cells, 1412  
glycoprotein carrier  
K562 cells, 3420  
liver folate content and distribution  
choline deficiency, 16  
plasma homocysteine in children  
acute lymphoblastic leukemia, 828  
sensitivity  
increases in tumorigenicity, human fibroblasts, 1855  
3-Methyladenine  
DNA glycosylase activity  
haloethylnitrosourea, glial cell line, 1568  
urinary excretion in high-risk population  
stomach cancer, 190  
3-Methyladenine DNA glycosylase II  
release of 7-alkylguanines  
modified DNA, 499  
Methylenetetrahydrofolate polyglutamate  
diastereoisomers of 5-formyltetrahydrofolate  
cellular growth, HCT-8 cells, 3476  
7-Methylguanine  
urinary excretion in high-risk population  
stomach cancer, 190  
O<sup>6</sup>-Methylguanine  
critical determinant  
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone tumorigenesis, mouse lung, 5557  
enhanced repair of DNA adducts  
liver, *ada* gene, 3391  
sequence selective repair and conformation, 5843  
O<sup>6</sup>-Methylguanine-DNA methyltransferase-deficient cells  
*N*-methyl-*N*-nitrosourea-induced mutations, shuttle vector plasmid, 6219  
human normal and tumor tissue  
brain, lung and ovary, 4131  
messenger RNA levels in HT-29 cells  
streptozotocin/bis-chloroethylnitrosourea combination therapy, 1581  
production and characterization  
antipeptide antibodies, 3339  
Methyl-*N*-amylnitrosamine  
hydroxylation  
positional specificity, cytochrome P-450 isozymes, 1059  
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone  
lung tumorigenesis  
inhibition by arylalkyl isothiocyanates, structure-activity relationships, 1846  
metabolic activation measured by DNA alkylation  
inhibition by isothiocyanate, 4798  
metabolism and sister chromatid exchange  
modulation by vitamin A, 3946  
modulation of uptake and metabolism  
nicotine, hamster lung, 2009  
quantitation of microsomal  $\alpha$ -hydroxylation, 5495  
tumorigenesis in mouse lung  
critical determinant, O<sup>6</sup>-methylguanine, 5557  
1-Methyl-1-nitrosourea  
intraperitoneal injection  
dose-responsive induction, mammary gland carcinoma, 3411  
*N*-Methyl-*N'*-nitro-*N*-nitrosoguanidine  
butylated hydroxyanisole and/or  
regression, forestomach lesions, 318  
deoxycorticosterone acetate-NaCl hypertensive rats  
enhanced induction, gastric carcinogenesis, 2863  
enhanced induction of gastric carcinogenesis  
low-protein diet, Wistar rats, 3493  
phenolic antioxidants  
forestomach carcinogenesis, 824  
*N*-Methyl-*N*-nitrosourea  
-induced alkali-labile sites  
DNA sequences, heterogeneous repair, 775  
-induced mutations  
shuttle vector plasmid, O<sup>6</sup>-methylguanine-DNA methyltransferase-deficient cells, 6219  
thymocyte subset distribution and targets  
immature CD4<sup>+</sup>8<sup>+</sup> cells, lymphoma development, 737  
Methylthioadenosine phosphorylase  
absence of  
human gliomas, 3193  
Mevalonate  
lipid compositions of intracellular membranes  
rat liver nodules, 3774  
Mezerein  
differential activation and inhibition  
lymphocyte proliferation, 82  
Micelle  
-forming polymeric anticancer drug  
toxicity and antitumor activity, solid tumors, 3229  
Microscopy  
digitized imaging  
hyperthermia effects, cytosolic Ca<sup>2+</sup>, 359

- Microsomes**  
 $\alpha$ -hydroxylation  
 quantitation, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 5495
- Microspheres**  
 -bound chlorin  $e_6$   
 mechanism of photosensitization, bladder carcinoma cells, 4410
- Milk epithelial cells**  
 loss of heterozygosity  
 short arm of chromosome 11, 294
- Milk fat globule protein**  
*M*, 46,000  
 human breast tumors, factor VIII-like domains, 4994
- Minocycline**  
 angiogenesis inhibition, 672
- Misonidazole**  
 indomethacin and  
 radiotherapy, improvement in therapeutic ratio, 3639
- Mistletoe**  
 lectin A-chain  
 immunotoxin, 916
- Mitochondria**  
 Adriamycin-induced damage in heart  
 electron spin resonance, 3555  
 disruption of cellular energy balance  
 suramin, prostatic carcinoma, 6629  
 lipid compositions of intracellular membranes  
 rat liver nodules, 3774  
 photosensitizing activities  
 picket fence porphyrins, 1836  
 structure and functions  
 effect, antitumor diarylsulfonylureas, 6286
- Mitomycin C**  
 hypoxic and aerobic cytotoxicity  
 Chinese hamster V79 cells, 6622  
 intravesical  
 bladder wall penetration, 4347  
 pharmacokinetics, bladder cancer, 5144  
 KW-2149 antitumor activity, 110  
 pharmacodynamics  
 bladder tumors, 3849  
 porfirimycin and  
 potentiation of antitumor activity, interleukin 1 $\alpha$ , 5454  
 -resistant CHO cells  
 aerobic conditions, DT-diaphorase deficiency, 1860
- Mitosis**  
 HeLa cells  
 progression of G<sub>2</sub> phase, phorbol esters and epidermal growth factor, 4328
- Mitoxantrone**  
 urinary metabolites  
 isolation and structure, 3427
- MO-7e cells**  
 interleukin 3-dependent proliferation  
 activation, late G<sub>1</sub> genes, 1741
- Molt-4 cells**  
 inhibition of growth  
 adenosine metabolite, 8-chloroadenosine 3',5'-monophosphate, 1600
- Monensin**  
 lipid emulsion  
 potentiation, ricin A chain immunotoxins, 4316
- Monochlorobimane**  
 differential specificity for isozymes  
 human and rodent glutathione S-transferases, 1606  
 influence of glutathione S-transferases  
 cellular glutathione determination, flow cytometry, 1783
- Monoclonal antibodies**  
 3.2.3  
 natural killer cells and, tissues from normal and tumor-bearing rats, 4931  
 accessible sugar epitopes  
 colon cancer-associated mucins, 5342  
 anti-CD15  
 elimination of breast cancer cells, bone marrow, 2451  
 anti-fucosylceramide  
 establishment and characterization, 4182  
 anti-G<sub>M12</sub>  
 induction of necrosis, G<sub>M2</sub>-rich cultures of glioma, 4643  
 anti-idiotypic  
 human high-molecular-weight melanoma-associated antigen mimicry, 4790  
 induction of antigen-specific immune response, anti-carcinoembryonic antigen antibodies, 2599  
 interleukin 2 production, colorectal cancer patients, 5425  
 melanoma-associated proteoglycan antigen, 3183
- B1 and B3**  
 reaction with mucinous adenocarcinoma, 3781  
 -based therapy of human tumor xenografts  
<sup>177</sup>lutetium-labeled immunoconjugate, 2889
- BCA 227**  
 tumor-associated antigen, breast carcinoma, 1537
- bifunctional and enzyme-conjugated antibodies**  
 pharmacokinetic analysis, two-step approaches, 3119
- bifunctional antibody**  
 hyperthermia, human colon tumor xenografts, 1515
- binary radiopharmaceutical delivery system**  
 bifunctional antibody, colorectal carcinoma, 6650
- bispecific F(ab')<sub>2</sub> antibodies**  
 delivering of saporin to lymphoma, comparative mixtures, 2353
- carcinoembryonic antigen-related human gastric gene product, 5694**
- c-erbB-2 protein**  
 cytotoxicity of *cis*-diamminedichloroplatinum, breast and ovarian tumor cell lines, 4575
- chemical engineering of A7**  
 polyethylene glycol, targeting of cancer chemotherapy, 4310
- cloning of tumor-associated antigen**  
 folate binding protein, 6125
- colorectal carcinoma-associated antigen, 926**  
 conjugation with drugs
- induction of immunogenicity, 5774
- detection of DNA modifications**  
 cisplatin and carboplatin, 123
- direct radiolabeling**  
 generator-produced rhenium-188, radioimmunotherapy, 4594
- distribution in microscopic tumor nodules**  
 "binding site barrier", 4776
- 3E1.2**  
 breast tumor-associated epitope, *N*-glycolylneuraminic acid, 5826
- epidermal growth factor receptor**  
 suppression, spontaneous melanoma metastasis, 2193  
 xenograft antitumor activity, drug immunoconjugates, 5471
- 3F8** mediation of nonoxidative lysis  
 polymorphonuclear leukocytes, neuroectodermal tumor cells, 4865
- folate-binding protein**  
 marker for ovarian cancer, 5329
- high molecular weight melanoma-associated antigen mimicry, 6045**
- human thymidylate synthase**  
 cytoplasm, human cells and tissue, 6668
- <sup>131</sup>I-chimeric mouse/human B72.3**  
 pharmacokinetics, immune response, 5461
- idarubicin conjugates**  
 disseminated thymic lymphoma model, 310
- identification of human colonic sulfomucin, 5728**
- immunoglobulin G2a**  
 intraperitoneal injection volume, antibody protein dose, 3434
- immunohistochemistry and pharmacokinetics**  
 15A8-glycyl-tyrosyl-(*N*- $\epsilon$ -diethylenetriamine pentaacetic acid)-lysine, 5744
- immunoneutralizing**  
 suppression of solid tumor growth, basic fibroblast growth factor, 6180
- inhibition of growth of mouse leukemic cell lines**  
 interleukin 3 receptor-associated protein, 4355
- inhibition of platelet aggregation and metastasis**  
 colon adenocarcinoma, 921
- <sup>111</sup>In-T101**  
 direct intralymphatic injection, cutaneous T-cell lymphoma, 688
- internalization**  
 HER-2/*neu* gene product *c-erbB-2*, 5361
- labeling with large amounts of <sup>131</sup>I**  
 infusion, biodistribution and dosimetry, 5921
- LY256787 and LY20378**  
 human immune response, single and multiple dose clinical studies, 2286
- macrophage colony-stimulating factor**  
 biological and antitumor effects, mice, 2649
- membrane-associated glycoprotein gp43**  
 human hepatocellular carcinoma, 2158
- mouse tissues**  
 microdistribution, human tumor xenografts, 1529

# SUBJECT INDEX TO VOLUME 51

- mucin antigens
  - human colon cancer cells, 331
- NCC-ST-421
  - antitumor effects, dimeric Le<sup>a</sup> epitope, 2199
- pan carcinoma CC49
  - construction, binding properties, 6363
- pancreatic cancer-reactive
  - purified mucin, 372
- PD41
  - antigen restricted to prostate adenocarcinoma, 1326
- P-glycoprotein-specific
  - characterization, *MDR3* P-glycoprotein, 2628
- PM-81
  - breast cancer, elimination from bone marrow, 2451
- positional specificity
  - methyl-*n*-amyl nitrosamine hydroxylation, 1059
- proliferating cell nuclear antigen
  - S-phase probes, flow cytometry, 4570
- Pseudomonas* exotoxin conjugates
  - therapy, cervical carcinoma, 4001
- radioconjugates
  - integrated microscopic-macroscopic pharmacology, 4821
- radioiodination
  - improved efficacy, *N*-succinimidyl-3-(tri-*n*-butylstannyl)benzoate, 4164
- radiolabeled
  - augmented binding to melanoma cells, 2768
- radiolabeled antitumor
  - intravesical administration, bladder carcinoma, 724
- reactive to surface antigen
  - ovarian epithelial cancer cells, 4012
- recombinant/chimeric B72.3, 181
- <sup>186</sup>Re radioimmunotherapy
  - small cell lung carcinoma xenografts, 676
- sarcoma-associated antigens, 3768
- SN10
  - B leukemia-lymphoma, internalization into cells, 2985
- specific and control
  - uptake in subcutaneous xenografts, intratumor injection, 3251
- TAG-72 epitopes
  - colorectal cancer, 5378
- three-step tumor targeting
  - carcinoembryonic antigen-positive patients, 5960
- trichosantin conjugate
  - cytotoxicity, human hepatoma cells, 3353
- TURP-27 and HNK-1
  - neural cell adhesion molecules, prostate tumor-associated antigens, 2296
- Vinca* alkaloid immunoconjugate
  - solid tumor membrane antigen, antigen-antibody complexes, 2965
- yttrium-labeled anti-Ly1
  - radiotherapy, T cell lymphoma, 1883
- radiotherapy, graft-vs-host disease, 1891
- Monocytes
  - activated
    - elevated phosphatidylserine expression, human tumor cells, 3062
- blood
  - cytokine messenger RNA, lung cancer, 857
- derived macrophages
  - low-affinity Fc receptors, antibody-dependent tumor cell phagocytosis, 1117
- transcription of interleukin 1 gene
  - human melanoma cells, 3334
- Monokines
  - down-regulation by interleukin 4
  - tumorcidal state, human alveolar macrophages, 5526
- Mononitropyrenes
  - carcinogenicity, 2902
- Mononuclear cells
  - peripheral blood
    - class I MHC, interferon- $\alpha$ , 652
- Monooxygenase
  - flavin-containing
    - P-450-catalyzed binding of tamoxifen to proteins, 6052
- Monoterpene
  - geraniol
    - concentration-dependent increase, P388 and B16 doubling time, 37
- MOPC-315
  - advantages of adoptive chemoimmunotherapy
    - polyethylene glycol-cultured spleen cells, 4516
- Morphogenesis
  - neural rosette formation within *in vitro* spheroids
    - teratocarcinoma cell line, 2655
- Morphometry
  - human tumor cell line growth
    - drug sensitivity, soft agar culture, 1247
  - $\sigma$  opioid receptors
    - non-neural tumors, 6558
- Motility factor
  - receptor internalization
    - lung colonization capacity, melanoma cells, 2699
- Mouse mammary tumor virus
  - suppression
    - dietary restriction, normal parturition and lactation, 5123
- Mouthwash
  - use and oral conditions
    - risk of oral and pharyngeal cancer, 3044
- MS-073
  - circumvention of multidrug resistance, 2420
- Mucin
  - antigen recognition by monoclonal antibodies
    - human colon cancer cells, 331
  - breast tumor-associated antigen
    - monoclonal antibody 3E1.2, *N*-glycolylneuraminic acid, 5826
  - colon cancer-associated
    - accessible sugar epitopes, monoclonal antibody AM-3, 5342
  - human colonic sulfomucin
    - identification, specific monoclonal antibody, 5728
  - like carcinoma-associated antigen
    - relative operating characteristic analysis, breast carcinoma, 1904
  - like glycoprotein
    - epiglycanin, immunosuppressive activity, 1170
- protein core
  - cytotoxic T-lymphocytes, breast adenocarcinoma, 2908
- purified
  - pancreatic cancer-reactive monoclonal antibodies, 372
- Mucosa
  - nasal
    - metabolism of carcinogenic nitrosamines, diallyl sulfide, 1509
  - nonfamilial neoplasia of large intestine
    - rectal mucosal cell proliferation, 1917
  - normal
    - sex steroid and 1,25-dihydroxyvitamin D<sub>3</sub> receptors, 1227
- Müllerian inhibiting substance
  - inhibition of tumor growth, 2101
- Multidrug resistance: *see also* Drug resistance
  - buthionine sulfoximine effect
    - toxicity, verapamil and doxorubicin, 67
  - characterization of *MDR3* P-glycoprotein
    - recognition, P-glycoprotein-specific monoclonal antibodies, 2628
  - circumvention by MS-073, 2420
  - daunorubicin-resistant Ehrlich ascites tumor cells
    - decreased DNA topoisomerase II, 4213
  - etoposide and teniposide
    - mechanisms, colon and lung carcinoma, 5275
  - expression of gene product
    - tumor aggressiveness and lymph node metastasis, colon carcinoma, 2720
  - fluorescent dyes, 4665
  - gene in bone marrow
    - chemotherapy and chemosensitization, transgenic mice, 5417
  - low level
    - attenuated topoisomerase II content, Chinese hamster ovary cells, 6543
  - MDR1-mediated resistance
    - camptothecin, human KB carcinoma cells, 6039
  - modulation by cyclosporin A and verapamil
    - human leukemia cell lines, 1749
  - non-P-glycoprotein-mediated
    - small cell lung cancer, 3345
  - P-glycoprotein-mediated
    - circumvention, SDZ PSC 833, 4226
  - phenotype
    - <sup>31</sup>P nuclear magnetic resonance, 2-deoxyglucose toxicity, 1638
  - phenotype conferring selective resistance
    - lipophilic antifolates, Chinese hamster ovary cells, 2949
  - protein kinase C activity
    - trimetrexate resistance, lymphoblastic leukemia, 55
  - reversal with Solutol HS 15, 897
- Muscle
  - neural and striated cells
    - CD56 and CD57, 1300
  - specific gene expression
    - rhabdomyosarcoma, human fetal skeletal muscle development, 5100

# SUBJECT INDEX TO VOLUME 51

**Muscle, smooth**  
inhibition of tumor invasion  
recombinant human metalloproteinase  
inhibitor, 2151

**MX2**  
cellular pharmacology  
pleiotropic drug-resistant cells, 157

**myc**  
activation in human lung carcinoma  
heterotransplantation, nude mice,  
2566  
DNA amplification in tumors and cell  
lines  
combination chemotherapy regimens,  
small cell lung cancer, 1708

**Myeloid cells**  
chromosomal and growth factor abnor-  
malities  
leukemia, 2494

**Myeloma**  
immunoglobulin G  
sugar chains, antibody-lectin enzyme  
immunoassay, 5888  
multiple  
melphalan-resistant, development of  
cell line, 995  
no expansion of pre-B and B-cell com-  
partments, bone marrow patients,  
3224  
predictive value, interleukin 6 and  
neopterin, 6250

**Myoepithelial cells**  
luminal cell lines and  
coexpression of cytokeratins, rat mam-  
mary adenocarcinoma, 5943

## N

**Na<sup>+</sup>,K<sup>+</sup>-adenosine triphosphatase**  
accumulation of *cis*-diamminedichloro-  
platinum(II)  
ovarian carcinoma cells, 3677

**Nafenopin**  
role of oxidative stress  
age-dependent hepatocarcinogenesis,  
1789

**Na<sup>+</sup>/H<sup>+</sup> antiporter**  
modulation  
rat neutrophil-mediated tumor cyto-  
toxicity, 3212

**Naloxone**  
enhancement of colon carcinogenesis  
methionine enkephalin, azoxyme-  
thane, 785

**National Cancer Institute**  
roundtable on prostate cancer  
future research directions, 2498

**Natural cell**  
-mediated cytotoxicity  
increased immunogenicity and sensi-  
tivity, ultraviolet radiation, 5153

**Natural killer cells**  
-associated antigens CD56 and CD57  
human neural and striated muscle  
cells, 1300  
biological monitoring  
low-dose interleukin 2, cytokines and  
cell surface phenotypes, 6312  
interferon-induced inhibition  
spontaneous metastases, melanoma,  
1124  
monoclonal antibody 3.2.3 and

tissues from normal and tumor-bear-  
ing rats, 4931  
phenotype and function  
bronchogenic carcinoma, 5596  
target molecules  
transformation, oncogene-transfected  
fibroblast, 4250

**Navelbine**  
pharmacokinetic and preliminary meta-  
bolic fate  
high performance liquid chromatogra-  
phy, 2073

**Necrosis**  
induction by anti-G<sub>M12</sub> monoclonal anti-  
bodies  
G<sub>M2</sub>-rich cultures, human glioma cell  
line, 4643

**Neoplasia**  
breast and colon  
β1-6 branched oligosaccharides, tumor  
progression, 718  
stepwise  
nonrandom chromosome losses, uro-  
epithelial cells, 3323  
transforming gene  
reticulum cell sarcoma, 744

**Neoplastic progression**  
origin and development of cancer  
cellular adaptation, 2751

**Neoplastic transformation**  
hormonal carcinogenesis, 3626  
immortalization of normal bronchial epi-  
thelial cells  
human papillomaviruses 16 or 18,  
5370

induction of growth factor RNA expres-  
sion  
human malignant melanoma, 4815  
oncogenic mechanisms  
radiation-induced cancer, 2740

**Neopterin**  
interleukin 6 and  
predictive value, multiple myeloma,  
6250

**Nerve growth factor**  
-like protein  
paracrine interactions, human pros-  
tate, 3304

**Nervous system**  
developmental genetics and childhood  
cancer, 5435

**Neural cell adhesion molecule**  
messenger RNA splicing patterns  
lung cancer cell lines, 6019  
monoclonal antibodies  
prostate tumor-associated antigens,  
2296

**Neuroblastoma**  
accumulation of *m*-iodobenzylguanidine  
independent uptake and storage mech-  
anisms, 4342

cell differentiation  
inducible expression, calcyclin, 1733  
childhood  
models to predict outcome, ferritin  
and tumor histology, 1426  
chimeric anti-G<sub>D2</sub> antibody-mediated  
lysis, 144  
differential expression  
*bcl2* protooncogene, 6529  
differentiation induced by interferon  
retinoic acid, dibutyl cyclic adeno-

sine 3':5'-monophosphate, 3958  
DNA amplification and rearrangement  
*N-myc* gene region, 1946  
DNA ploidy index and *N-myc* genomic  
content, 33  
effects of 6-hydroxydopamine and hydro-  
gen peroxide  
ascorbic acid, DNA strand-breaks,  
6060  
expression of *N-myc*, 6338  
low frequency of *ras* gene mutations,  
1596

primary  
undifferentiated phenotype and prog-  
nosis, *N-myc* and *c-src* protoonco-  
genes, 3148

**Neuroectodermal neoplasms**  
low frequency of *ras* gene mutations,  
1596  
nonoxidative lysis  
polymorphonuclear leukocytes, mono-  
clonal antibody, 4865  
primitive  
loss of heterozygosity, 6q/16q/17p,  
639

**Neuroectodermal tissue**  
preferential expression  
*dbi* protooncogene, 4234

**Neurofibromatosis**  
hamster model  
*N-nitroso-N-ethylurea*, early lesion,  
434

**Neurogenesis**  
rosette formation within *in vitro* spher-  
oids  
teratocarcinoma cell line, 2655

**Neuromedin B**  
production and gene expression  
human lung tumor cell lines, 5205

**Neuropeptides**  
stimulation of clonal growth  
small cell lung cancer, 3621

**Neurotensin**  
stimulation of clonal growth  
small cell lung cancer, 3621

**Neutrophils**  
granulocyte colony-stimulating factor  
conjugation with polyethylene glycol,  
pharmacokinetics, 3710  
-mediated tumor cytotoxicity  
modulation by Na<sup>+</sup>/H<sup>+</sup> exchange,  
3212

**Nickel(II)**  
-dependent damage by hydrogen perox-  
ide  
DNA bases, human chromatin, 5837

**Nicotine**  
modulation of uptake and metabolism  
4-(methylnitrosamino)-1-(3-pyridyl)-1-  
butanone, hamster lung, 2009

**NIH-3T3 cells**  
confluence-mediated progression  
heterogeneity, 1003  
*H-ras*-transformed  
antipain-induced suppression, onco-  
gene expression, 4810  
induction of cisplatin resistance  
*c-Ha-ras*, 5903

**Nile blue**  
photosensitizers  
lysosomal localization and mechanism  
of uptake, tumor cells, 2710

- Nitrate**  
*N*-nitrosodimethylamine and elevated formation in woodchucks, hepatitis virus infection, 3925  
 plasma concentrations  
   antitumor effect, flavone-8-acetic acid and analogues, 77  
   urinary excretion in high-risk population stomach cancer, 190
- Nitric oxide**  
 differential synthesis  
   platelet aggregation, colorectal adenocarcinoma, 6073  
 lysis of tumor cells  
   cytokine-activated endothelial cells, 2531
- Nitroalkanes**  
 oxidative damage to liver, 3143
- N*-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide**  
*H-ras* mutations  
   bladder tumors, 3471
- Nitrogen mustard**  
 sensitive Burkitt's lymphoma cell lines  
   DNA cross-links, cell cycle and apoptosis, 6550  
 single interstrand  
   construction, human shuttle vector, 2268
- Nitropyrene**  
 metabolic activation and inactivation  
   liver, species differences, 3919  
   structurally related compounds and carcinogenicity, female rats, 2902
- 4-Nitroquinoline-*N*-oxide**  
 promoting effect of snuff, 4388
- Nitrosamine**  
 carcinogenic  
   metabolism by nasal mucosa, diallyl sulfide, 1509  
 chronic ingestion in rodents, 6470  
 -induced cancer  
   sequence selective repair and conformation, *O*<sup>6</sup>-methylguanine, 5843  
 -induced pancreatic cancer  
   inhibitory effect, RC-3095 and RC-160, 5980
- 9-Nitro-20(*S*)-camptothecin**  
*c-jun* expression  
   human myeloid leukemia cells, 6636
- N*-Nitrosobenzylmethylamine**  
 carcinogenesis  
   inhibitory effects of phenethyl isothiocyanate, rat esophagus, 2063
- N*-Nitrosobis(2-oxopropyl)amine**  
 high-fat diet and patterns of prostatic cancer  
   testosterone, 4757
- N*-Nitrosodiethylamine**  
*N*-nitrosodimethylamine and mechanistic and statistical insight, large carcinogenesis bioassays, 6409  
 tumor induction, liver and esophagus, 6452
- N*-Nitrosodimethylamine**  
 chronic ingestion  
   detailed dose-response study, 6415  
 nitrate and  
   elevated formation in woodchucks, hepatitis virus infection, 3925
- N*-Nitroso-*N*-ethylurea**  
 -induced hamster neurofibromatosis model  
   early lesion, 434
- N*-Nitrosoproline**  
 urinary excretion in high-risk population stomach cancer, 190
- Nitrous oxide**  
 maternal and perinatal risk factors  
   childhood leukemia, 3696
- Nocardia rubra***  
 cell wall skeleton  
   antitumor effect, syngeneically transplanted P388 tumors, 4038  
 cell wall skeleton and interleukin 2 synergistic effect, LAK cell induction, 5261
- Nonneural neoplasms**  
*sigma* opioid receptors, 6558
- Norepinephrine**  
 enhanced induction of gastric carcinogenesis  
   *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine, 3493
- Norethindrone**  
 scattering of silver-stained nucleolar organizer regions  
   Ishikawa cells, 5987
- Norway**  
 survival and causes of death  
   thyroid cancer, 1234
- Novantrone**  
 modulation of effects by caffeine, 3682
- Novobiocin**  
 2,4-dinitrophenol and modulation, amscarine-induced DNA lesions, 573  
 Phase I clinical trial, 510
- NR6 cells**  
 enhanced tumorigenesis  
   non-downregulating epidermal growth factor receptors, 6170
- NSC 628503: see Taxotere**
- Nuclear envelope**  
 differential expression of laminins A and C  
   differential expression, lung cancer cell lines, 581
- Nuclear magnetic resonance**  
<sup>31</sup>P  
   multidrug resistance phenotype, 1638  
<sup>31</sup>P and <sup>2</sup>H  
   tumors growing in irradiated bed, angiogenesis, 3289  
 tumor metabolism  
   *ex vivo* model, Morris hepatoma 7777, 841
- Nuclear magnetic resonance spectroscopy**  
<sup>19</sup>F  
   intratumoral metabolism, 5-fluorouracil, 5806  
 intratumoral metabolism  
   5-fluorouracil, 5821  
<sup>14</sup>N  
   tumors, 3378  
 pH-dependent uptake  
   5-fluorouracil, 5770  
 phosphorus  
   cellular energetics, multicellular tumor spheroids, 3831  
   radiation-induced fibrosarcoma-1 tumor metabolism  
   blood flow, glucose and mannitol effects, 3108
- Nuclear matrix proteins**  
 cancer and normal rat prostate, 6514
- Nucleic acid adducts**  
 stereoselective formation, 2,3-epoxy-4-hydroxynonanal, 137
- Nucleolar antigens**  
 P120  
   prognostic significance, breast carcinoma, 1973
- Nucleolar organizer regions**  
 argyrophilic  
   prognostic significance, esophageal carcinoma, 5339  
 prognostic indicator  
   stage I non-small cell lung cancer, 4008  
 silver-stained  
   norethindrone, Ishikawa cells, 5987
- Nucleotides**  
 major alterations in structure  
   DNA, cancer of female breast, 5430  
 metabolism in CCRF-CEM cells  
   (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid, 2291  
 uridine  
   regulation of deoxycytidine kinase, human leukemia cells, 2559

O

- Obesity**  
 body fat distribution and endometrial cancer, 568
- Okadaic acid**  
 differential activation and inhibition  
   lymphocyte proliferation, 82
- Oligodeoxynucleotides**  
 antisense  
   inhibition of protooncogene expression, 4505  
*c-myc* antisense  
   inhibition of proliferation, colon adenocarcinoma, 2897
- Oligonucleotide**  
 phosphorothioate antisense  
   inhibition of *c-myc* expression, breast cancer growth, 3996
- Oligosaccharides,  $\beta$ 1-6 branched**  
 marker of tumor progression  
   breast and colon neoplasia, 718
- Oltipaz**  
 protection  
   aflatoxin B<sub>1</sub>-induced hepatocarcinogenesis, 5501
- Oncogenes**  
*c-erbB-2*  
   estrogen receptor status and, prognostic significance in breast cancer, 3296  
   gp185, antigen shed from mouse tumors, 2593  
*c-Ha-ras*  
   induction of resistance to cisplatin, mouse NIH 3T3 cells, 5903  
   tumorigenic clones, epidermal morphogenesis and keratin expression, 4402  
*c-myc* gene-induced alterations  
   protein kinase C expression, 5514  
 differential expression  
   transforming growth factor- $\beta$ 1 gene, 3LL metastatic variants, 5491

**erbB2**

- accumulation of genetic alterations, progression of primary breast cancer, 5794
- immunoreactivity, gastric cancer, 1034
- expression in irradiated rat colon
- Bowman-Birk protease inhibitor, 4539

**HER-2/neu**

- amplification, primary breast cancer, 944
- normal bronchial epithelium, lung cancer, 400

**hormonal carcinogenesis, 3626**

**H-ras**

- antipain-induced suppression, NIH3T3 cells, 4810
- histopathology, salivary and mammary gland tumors, 3762
- induction of invasive phenotype, papillary transitional cell carcinoma cells, 4486
- inhibition, adeno-associated virus Rep78, 3373
- mutations, bladder tumors, 3471
- phorbol ester, interleukin 3 requirement in mast cell line, 632
- sequence selective repair and conformation, *O*-methylguanine, 5843
- inhibition of protooncogene expression antisense oligodeoxynucleotides, 4505

**K-ras**

- activation, premalignant and malignant epithelial lesions of the uterus, 5308
- loss of heterozygosity on 6q/16q/17p central nervous system primitive neuroectodermal tumors, 639
- mechanisms in radiation-induced cancer, 2740

**mouse pulmonary carcinogenesis, 450**

- myc* activation
- lung carcinoma, heterotransplantation, 2566

**neu**

- frequent induction, mammary carcinoma, 5649

**N-myc**

- DNA ploidy index, neuroblastoma, 33
- nuclear
- growth factors, hormone-related tumors, 4114

**origin and development of cancer**

- cellular adaptation, 2751
- overexpression of products
- tumor progression without parenchymal infiltration, brain, 3595

**pim-1**

- carcinogen-induced lymphomagenesis, transgenic mice, 958

**ras**

- staging of T-cell receptor  $\beta$  chain gene rearrangements, thymic lymphoma, 1627
- transformed fibroblasts, Thy-1 as negative growth regulator, 99

**ras or myc**

- 2-aza-2'-deoxycytidine, nontumorigenic fibroblasts, 324

**ras p21 expression**

- DNA ploidy, lung cancer, 6346
- SV40 DNA in milk epithelial cells
- loss of heterozygosity, short arm of

**chromosome 11, 294**

- transfected fibroblast
- transformation, natural killer target molecules, 4250
- transformed rat fibroblasts
- growth inhibition, cocultured normal cells, 5348

**v-Ha-ras**

- in situ* transfer, carcinoma induction, 2642
- mammary carcinoma suppressor gene, mammary epithelial cells, 5298

**Oncogenesis**

- platelet-derived growth factor
- autocrine transformation, 5087

**Oncology**

- clinical
- new developments, 5060s
- radiation
- past achievements, ongoing controversies, 5065s
- training in clinical research, 753

**Oral neoplasms**

- mouthwash use and oral conditions, 3044
- promoting effect of snuff
- 4-nitroquinoline-*N*-oxide, 7,12-dimethylbenz(*a*)anthracene, 4388

**Ornithine**

- polyamine metabolism and
- dietary arginine restriction, two-stage epidermal carcinogenesis, 2932

**Ornithine decarboxylase**

- activation in tracheal epithelial cells
- asbestos and oxygen species, 167
- heterogenicity
- mouse colon carcinogenesis, human colon tumors, 2069
- inhibition of induction by phorbol 12-myristate 13-acetate
- prostratin, mouse skin, 5355
- mucosal
- increased activity, gastric cancer, 1448
- suppression of activity in the elderly
- supplemental calcium, adenomatous polyps, 3416
- tumor promoter-induced activity
- tannic acid and other polyphenols, mouse epidermis, 2820

**Osteopontin**

- nonphosphorylated
- calcitriol induction, JB6 epidermal cells, 2144

**Osteosarcoma**

- human xenografts in nude mice
- inhibition of growth, suramin, 3585
- thrombospondin binding
- mediation, platelet-osteosarcoma cell interaction, 2621

**Oval cells**

- hepatic foci, nodules and carcinomas
- antigenic relationship, hepatocarcinogenesis, 1308
- progenitors
- cell lineages, liver development, 2611

**Ovarian neoplasms**

- antitumor activity of interferon- $\gamma$
- ascitic and solid tumor models, 6643
- c-erbB2* oncogene overexpression
- gp185, antigen shed from mouse tumors, 2593
- coexpression of different antigenic markers

**ers**

- CA 125 determinants, 468
- development of monoclonal antibodies
- reactivity to surface antigen, 4012
- cis*-diamminedichloroplatinum(II)
- ionizing radiation and, resistance patterns, 4523

**DNA damage**

- platinum, titanium and ruthenium complexes, 2943

**epithelial**

- overexpression, mutation of p53, 2979
- tumor-infiltrating lymphocytes, cisplatin-containing chemotherapy, 1934
- folate-binding protein marker, 5329
- frequent allelic losses and mutations
- p53* gene, 5171
- granulosa cell culture
- cell-cell communication, multistep transformation, 696

**human**

- alleleotype, 5118
- insulin-like growth factor I
- expression, binding proteins, 5107
- monoclonal antibody against *c-erbB-2* protein
- enhanced cisplatin cytotoxicity, 4575
- P-glycoprotein expression
- DNA topoisomerases, platinum/cyclophosphamide chemotherapy, 5915
- targeted T-cell antitumor responses
- host survival, murine xenograft model, 5716
- transforming growth factor- $\alpha$
- epidermal growth factor receptor autocrine growth mechanism, 5322, 5951, 5956

**Ovary**

- gonadal protection and fecundity rates
- cyclophosphamide-treated rats, 2124
- hormones

- 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, hepatocarcinogenesis, 1391
- human normal and tumor tissue
- O*-methylguanine-DNA methyltransferase, 4131

**malignant ascites**

- infiltrating lymphocytes, tumor cytotoxicity, 4257

**Ovine trophoblast protein-1**

- pregnancy recognition hormone
- antiproliferative activity, 5304

**Oxidative stress**

- protein induction
- mediated by porphyrin photosensitization, 6574

**Oxygenation**

- activation of ornithine decarboxylase
- tracheal epithelial cells, 167
- carcinomas of uterine cervix, 6098
- human tumors, 3316
- tumor
- interstitial hypertension, carcinoma of uterine cervix, 6695

**P**

**p21**

- histopathology of salivary and mammary gland tumors
- H-ras, transgenic mice, 3762

**p21<sup>ras</sup>**

- inhibition of protein isoprenylation  
dehydroepiandrosterone, colonic adenocarcinoma cells, 6563
- p53**  
chromosome 17p  
hepatitis B virus integration event, hepatocellular carcinoma, 49  
detection of aberrations  
alleles and gene transcript, single-strand conformation polymorphism analysis, 3356  
detection of gene mutations  
primary gastric cancer, 3056  
follow-up study of twenty-four families Li-Fraumeni syndrome, 6094  
frequent allelic losses and mutations ovarian cancer, 5171  
from gene to carcinogen  
rapid evolution, field of molecular epidemiology, 3617  
gene analysis  
human uterine carcinoma cell lines, 6506  
gene mutations  
abnormal retinoblastoma protein, radiation-induced human sarcoma, 6393  
Barrett's epithelium, esophageal cancer, 4495  
gastric cancer metastases, 5800  
primary human breast cancer, 6194  
genetic alterations  
malignant mesothelioma, 5410  
genetic analysis of human esophageal tumors  
high incidence geographic areas, 4102  
germ line mutation in exon 5  
extended cancer family, 6385  
increased levels of expression  
maturation, human hematopoietic cells, 4279  
infrequent gene mutations  
medulloblastoma, 4721  
loss of heterozygosity  
protein expression, colorectal carcinoma, 4436  
maintenance of alterations  
breast cancer progression, 2605  
mutant expression in melanoma, 5976  
mutations  
allelic loss on chromosome 17p, endometrial carcinoma, 5632  
carcinogens and, 6185  
colorectal tumors, familial polyposis coli, 2874  
human brain tumors, 6202  
overexpression and, epithelial ovarian cancer, 2979  
participation in cellular response  
DNA damage, 6304  
protein overexpression  
17p allelic deletions, Barrett's adenocarcinoma, 5482  
ras mutations and p53-heat shock protein complexes  
human lung carcinoma cell lines, 4090  
retinoblastoma genes and  
aberrations, hepatocellular carcinoma, 5520  
wild-type  
mutant proteins or, alterations and tumor development, 5232
- suppressed prostate cancer cell growth, mutant alleles, 4716
- P120**  
prognostic significance in breast carcinoma, 1973
- Pan carcinoma**  
monoclonal antibody CC49  
construction, binding properties, 6363
- Pancreas**  
differential binding and biological activities  
epidermal growth factor, transforming growth factor- $\alpha$ , 6243  
lipid-dependent proliferation, 3633
- Pancreatic islet cell neoplasms**  
allelic loss on chromosome 11  
familial multiple endocrine neoplasia type 1, 1154  
glucagon gene expression  
differential glucocorticoid regulation, 1196
- Pancreatic neoplasms**  
apomucin  
relationship, mammary and intestinal apomucins, 1026  
breast adenocarcinoma  
protein core of mucin molecule, cytotoxic T-lymphocytes, 2908  
nitrosamine-induced  
inhibitory effect, RC-3095 and RC-160, 5980  
-reactive monoclonal antibodies  
purified mucin, 372
- Papilloma**  
skin  
promoter independence, 1045
- Papillomavirus**  
DNA in anal intraepithelial neoplasia  
anal cancer, 1014  
human  
role in human cancer, 5019s  
type 16  
alteration of retinoid regulation by immortalization, ectocervical epithelial cell differentiation, 3982  
transformed keratinocytes, extracellular matrix, 5967  
type 16-derived proteins L1 and E4  
cervical secretions, HPV-related cervical disease, 4423  
type 16 or type 18  
immortalization, normal bronchial epithelial cells, 5370
- Paraneoplastic syndromes**  
squamous carcinoma and  
epidermal growth factor receptor pathway, 2438
- Parathyroid**  
allelic loss on chromosome 11  
familial multiple endocrine neoplasia type 1, 1154
- Parathyroid hormone**  
-like hormone peptide  
localization, rat fetus, 6351  
-like peptide expression and secretion  
dysregulation, keratinocyte model of tumor progression, 6521  
-related protein in breast cancer metastases  
localization, incidence in bone, 3059
- cis-Parinaric acid**  
cytotoxic effect
- cultured malignant cells, 6144
- Pazelliptine**  
ionizing radiation and  
additive and supraadditive interaction, 3204
- P388 cells**  
concentration-dependent increase in doubling time  
acyclic monoterpene geraniol, 37
- Pediatrics**  
developmental genetics and childhood cancer, 5435  
high-dose oral leucovorin plus 5-fluorouracil  
refractory cancer, 4871
- Penclomedine**  
preclinical antitumor activity, 1979
- Peptide G**  
laminin receptor complementary DNA-deduced synthetic peptide  
inhibition of cancer cell attachment, 5672
- Peripherin**  
expression of N-myc  
human neuroblastoma, 6338
- Peritoneal carcinomatosis**  
cytotoxic effects of acoustic cavitation, 3024
- Peritoneal cavity**  
intraperitoneal injection volume  
antibody protein dose, immunoglobulin G2a, 3434
- Peroxisomes**  
hepatocarcinogenesis by nafenopin  
aged rats, 666  
tumor necrosis factor/cachectin  
decrease in catalase activity, rat liver, 3990
- Perspectives in Cancer Research**  
acquired immunodeficiency syndrome  
non-Hodgkin's lymphoma, 4743  
carcinogenesis and cancer, 6215  
genetic errors  
cell proliferation, carcinogenesis, 6493  
inhibition of protooncogene expression  
antisense oligodeoxynucleotides, 4505  
inhibition of tumor growth by tumor mass, 2  
mutator phenotype  
multistage carcinogenesis, 3075  
origin and development of cancer  
cellular adaptation, 2751  
tumor transplantation and tumor immunity, 757
- P-glycoprotein**  
daunorubicin-resistant Ehrlich ascites tumor cells  
decreased DNA topoisomerase II, 4213  
drug-sensitive and multiple drug-resistant cells  
secretion, lysosomal enzymes, 1996  
expression and DNA topoisomerases  
platinum/cyclophosphamide chemotherapy, benign and malignant ovarian tumors, 5915  
glutathione-based detoxifying enzymes  
constitutive drug resistance, human colorectal tumors, 2092  
inhibition of expression by Activin A  
multidrug-resistant K562 cells, 2582  
local tumor aggressiveness

- lymph node metastasis, colon carcinoma, 2720
- MDR3**  
recognition, P-glycoprotein-specific monoclonal antibodies, 2628  
-mediated multidrug resistance circumvention, SDZ PSC 833, 4226  
-positive and -negative drug-resistant cell lines  
subcellular distribution, daunorubicin, 4955
- pH**  
L-ascorbic acid amplification  
bladder carcinogenesis,  $K_2CO_3$ , 2548
- Phagocytosis**  
antibody-dependent tumor cell  
low-affinity Fc receptors, monocyte-derived macrophages, 1117
- Pharyngeal neoplasms**  
mouthwash use and oral conditions, 3044
- Phenethyl isothiocyanate**  
inhibitory effects  
N-nitrosobenzylmethylamine carcinogenesis, rat esophagus, 2063
- Phenobarbital**  
liver tumor promotion  
protein kinase C translocation, 130
- Phenolic antioxidants**  
forestomach carcinogenesis  
N-methyl-N'-nitro-N-nitrosoguanidine, 824
- Phenoxazine**  
Nile blue derivatives  
photosensitization, bladder carcinoma cells, 1109
- 1-Phenylalanine mustard**  
conjugation with glutathione  
specificity of isozymes, hepatic glutathione S-transferase, 2410  
intercellular transfer of drug resistance, 1190
- Pheochromocytoma**  
low frequency of *ras* gene mutations, 1596
- Phorbin**  
immunologic quantitation of TIMP-1  
colon cancer, 6231
- Phorbol diester**  
induction of macrophage maturation  
human malignant histiocytosis, 5712
- Phorbol ester**  
activated H-*ras*  
interleukin 3, mast cells, 632  
differential activation and inhibition  
lymphocyte proliferation, 82  
-elicited tumor promotion  
dietary fat, mouse skin, 907  
epidermal growth factor and  
progression of G<sub>2</sub> phase, mitosis of HeLa cells, 4328  
-induced *fos* expression  
inhibition of cell proliferation, B859-35, 5821  
-induced transformation of JB6 cells  
synergistic inhibition, transforming growth factor- $\beta$  and retinoic acid, 1158  
-specific defect  
protein kinase C translocation, hepatocytes, 130
- Phorbol 12-myristate 13-acetate**  
ornithine decarboxylase  
inhibition of induction, prostratin, 5355  
stimulation of epithelial tumor cell motility  
tumor necrosis factor, 5315
- Phosphatidylinositol-3 kinase**  
associated p85 $\alpha$   
human gene, chromosome region 5q12-13, 3818
- Phosphatidylserine**  
elevated expression in outer membrane leaflet  
activated blood monocytes, human tumor cells, 3062
- Phospholipase C**  
recombinant membrane-acting immunotoxin, 465
- N-(Phosphonacetyl)-L-aspartate**  
sensitivity  
increases in tumorigenicity, human fibroblasts, 1855
- Phosphorothioate**  
antisense oligonucleotide  
inhibition of *c-myc* expression, breast cancer growth, 3996
- Phosphorus-31**  
nuclear magnetic resonance  
*ex vivo* model, tumor metabolism, 841
- Photodynamic therapy**  
porphyrin-mediated  
resistance, mouse tumor cells, 4243  
rapid cell death by apoptosis  
mouse lymphoma cells, 5993
- Photofrin**  
uptake by murine macrophages, 2251
- Photoimmunotherapy**  
human ovarian carcinoma cells, 4762
- Photosensitization**  
mechanism of  
microsphere-bound chlorin *e<sub>6</sub>*, bladder carcinoma cells, 4410  
phenoxazine Nile blue derivatives  
bladder carcinoma cells, 1109  
picket fence porphyrins, 1836  
release of von Willebrand factor  
cultured human endothelial cells, 3261
- Photosensitizers**  
Nile blue  
lysosomal localization and mechanism of uptake, tumor cells, 2710
- Phyllolitorin**  
-like peptide  
production of neuromedin B, human lung tumor cell lines, 5205
- Piroxicam**  
chemoprevention of colon carcinogenesis, 4528
- Plasma**  
adhesive proteins  
platelet aggregation, human melanoma cell line, 1286  
class I MHC enhancement by interferon- $\alpha$   
peripheral blood mononuclear cells, melanoma patients, 652  
homocysteine in children  
methotrexate, acute lymphoblastic leukemia, 828  
lipid and lipoprotein cholesterol changes  
weight changes, prior to cancer diagnosis, 3198
- pharmacokinetics**  
1- $\beta$ -D-arabinofuranosylcytosine, 1- $\beta$ -D-arabinofuranosyluracil, 4141
- platelet-derived growth factor B-chain**  
levels  
cancer patients, 4149
- Plasmacytoma**  
advantages of adoptive chemoimmunotherapy  
polyethylene glycol-cultured spleen cells, 4516
- Plasmid**  
reactivation in cisplatin-resistant cells, 601
- Plasminogen**  
activation system  
human colon cancer, 4067
- Plasminogen activator**  
receptor-bound  
malignant transformation, fibroblasts, 1221  
tissue-type  
induction by ionizing radiation, malignant melanoma cells, 5587
- urokinase-type**  
fibrinolysis pathways, neoplastic and nonneoplastic breast tissue, 354  
inhibition by antibodies, tumor dissemination, 274  
primary and metastatic tumors, pulmonary adenocarcinoma, 3522
- Platelet activating factor**  
antagonists  
cytotoxicity, human malignant cell lines, 43
- Platelet-derived growth factor**  
autocrine transformation, 5087  
B-chain levels  
cancer patients, 4149
- Platelet factor 4**  
analogue  
inhibition of tumor growth, angiostatic activity, 2077
- Platelets**  
aggregation  
differential nitric oxide synthesis, colorectal adenocarcinoma, 6073  
human melanoma cell line, 1286  
inhibitory effect of N,N,N-trimethylsphingosine, metastatic potential of B16 melanoma, 6138  
inhibition of aggregation  
monoclonal antibody, colon adenocarcinoma, 921  
-osteosarcoma cell interaction  
thrombospondin binding, human osteosarcoma cells, 2621
- $\beta$ -Platelets**  
-derived growth factor receptor gene structure and expression, human tumor cell lines, 5626
- Platinum**  
-cyclophosphamide chemotherapy  
P-glycoprotein expression, ovary, 5915  
1,25-dihydroxyvitamin D<sub>3</sub> and  
growth of MCF-7 cells, 2848  
-DNA adduct formation and removal  
cisplatin sensitivity, ovarian carcinoma, 4557  
titanium and ruthenium complexes  
DNA damage, ovarian tumor cells, 2943

# SUBJECT INDEX TO VOLUME 51

- Platinum(II)**  
trisubstituted  
antitumor agents, mechanistic studies, 1866
- Pleiotropic drug**  
-resistant cells  
cellular pharmacology, MX2, 157
- P388 neoplasms**  
syngeneically transplanted  
antitumor effect, *Nocardia rubra* cell wall skeleton, 4038
- Podophyllotoxin**  
glucoside to etoposide  
chemical and biological route, 5
- Poly(adenosine diphosphate-ribose) polymerase**  
inhibition by thymidine and thymidine analogues  
1,3-bis(2-chloroethyl)-1-nitrosourea, L1210 cells, 1586
- Polyamine analogue**  
-induced increases in spermidine/spermine *N*<sup>1</sup>-acetyltransferase  
polyamine pool deletion, melanoma, 3715
- Polyamines**  
1,2-dimethylhydrazine-induced colonic carcinogenesis  
modulation, dietary calcium and vitamin D, 5608  
metabolism  
dietary arginine restriction, two-stage epidermal carcinogenesis, 2932
- Polyethylene esters**  
12-hydroxystearic acid  
Solutol HS 15, reversal of multidrug resistance, 897
- Polyethylene glycol**  
chemical engineering of monoclonal antibody A7  
targeting of cancer chemotherapy, 4310  
conjugation with granulocyte colony-stimulating factor  
pharmacokinetics, 3710  
-cultured spleen cells  
advantages, adoptive chemoimmunotherapy for plasmacytoma, 4516
- Polymeric implants**  
vinorelbine-loaded  
local treatment, solid tumors, 5384
- Polyoma virus**  
-transformed cells  
FcγRII expression, 612
- Polypeptide**  
domains  
synthetic, carcinoembryonic antigen, 1876
- Polyphenols**  
tumor promoter-induced ornithine decarboxylase activity  
mouse epidermis, 2820
- Polyps**  
adenomatous  
dietary calcium, colonic ornithine decarboxylase, 3416
- Population ecology**  
issues in tumor growth, 2542
- Porfomycin**  
mitomycin C and  
potentiation of antitumor activity, interleukin 1α, 5454
- Porphyria**  
-mediated photodynamic therapy  
resistance, mouse tumor cells, 4243  
oxidative stress protein reduction, 6574  
picket fence  
photosensitizing activities, 1836
- Positron emission tomography**  
fluorine-18 labeled progestin  
progesterin receptor positive tumors, 1930
- Potassium chloride**  
inhibition of gastric carcinogenesis induction  
deoxycorticosterone acetate-NaCl hypertensive rats, 2863
- Pregnancy**  
maternal and perinatal risk factors  
childhood leukemia, 3696  
recognition hormone ovine trophoblast protein-1  
antiproliferative activity, 5304
- Preleukemic cells**  
induction by radiation leukemia virus, 2179
- Procarbazine**  
potentiation of cytotoxic action of mafosfamide  
*N*-isopropyl-*p*-formylbenzamide, 4170
- Procarcinogens**  
drug-metabolizing enzymes  
liver epithelial cells, 301
- Progesterone**  
binding analysis of estrogen receptor  
DNA target site, breast cancer, 3405  
gonadal protection and fecundity rates  
cyclophosphamide-treated rats, 2124  
receptor bound to R5020 and RU486  
DNA binding, 3938
- Progestin**  
evolution of resistance  
human breast cancer cells, 2051  
fluorine-18 labeled  
progesterin receptor positive tumors,  
positron emission tomography, 1930  
regulation of alkaline phosphatase  
breast cancer cell line, 4470  
regulation of transforming growth factor gene expression  
endometrial adenocarcinoma, 5476
- Prolactin**  
loss of dependency  
karyotypic changes, lymphoma cell cultures, 282
- Proliferating cell nuclear antigen**  
antibodies  
S-phase probes, flow cytometry, 4570
- Prostacyclin**  
urinary excretion and degradation products  
thromboxane, gestational choriocarcinoma, 4146
- Prostaglandin E<sub>2</sub>**  
arachidonate release from epidermal cells  
4β- and 4α-12-*O*-tetradecanoylphorbol-13-acetate, 850
- Prostaglandin synthetase**  
inhibitor indomethacin  
tumorigenesis, mammary carcinoma and diet, 2683
- Prostate**  
neoplastic epithelial cell line and stromal cells  
regulation of growth, nerve growth factor-like protein, 3304  
normal rat  
cancer and, nuclear matrix proteins, 6514  
-specific antigen and α<sub>1</sub>-antichymotrypsin complex  
prostatic cancer, 222  
-specific antigen messenger RNA  
hormonal regulation, prostatic adenocarcinoma, 3748  
spontaneous transformation of fibroblasts  
extracellular matrix, androgen receptor expression, 1910
- Prostatic neoplasms**  
acceleration of growth *in vivo*  
factors produced by prostate, bone fibroblasts, 3753  
androgen-dependent and -independent  
γ-interferon, tumor necrosis factor-α, 2329  
-associated antigens  
monoclonal antibodies, neural cell adhesion molecules, 2296  
biphasic action of androgens  
anti-proliferative effects, EM-139, 5165  
Dunning R3327 G model  
androgen-primed chemotherapy, 1760  
fatal  
tobacco use, 3067  
high-fat diet  
*N*-nitrosobis(2-oxopropyl)amine, testosterone, 4757  
high mobility protein I(Y)  
potential progression marker, 606  
hybrid human endogenous retrovirus  
calbindin, subtractive cloning, 4107  
individual foci  
image analysis, DNA ploidy, 4084  
National Cancer Institute roundtable  
future research directions, 2498  
nonproliferating androgen-independent  
programmed death, 4693  
peripheral hormone levels  
controls and patients, benign prostatic hyperplasia, 3445  
primary  
prevention of, *N*-(4-hydroxyphenyl)retinamide, 3610  
regulation of kinesin expression  
type IV collagenase secretion, 5866  
stimulation of apolipoprotein D secretion  
inhibition of cell proliferation, 4336  
suppressed growth by wild-type *p53*  
mutant *p53* alleles, 4716  
suppression of metastatic ability  
genetic factors, 3788
- Prostratin**  
inhibition of induction by PMA  
ornithine decarboxylase, mouse skin, 5355
- Protease**  
Bowman-Birk  
oncogene expression, irradiated rat colon, 4539  
tumor-associated trypsin  
cancer cell-mediated degradation, ex-

- tracellular matrix, 2107
- Proteasome**  
changes in gene expression  
renal cancer cells, 6677
- Protein**  
galactoside-binding  
molecular cloning, chromosomal mapping, 2173
- Proteinase inhibitors**  
differential release  
rat mammary adenocarcinoma variants, metastatic potential, 1318
- Proteinases**  
tumor invasion and metastasis  
positive and negative regulation, 5054s
- Protein I(Y)**  
potential progression marker  
prostate cancer, 606
- Protein kinase**  
cyclic AMP-dependent messenger RNA  
normal vs. neoplastic mouse lung epithelial cells, 6699  
down-regulation of *cdc2*  
senescent human and hamster cells, 6010  
effects of 8-Cl-cAMP and  $N^6$ -benzyl-cAMP  
kinetics, HL-60 leukemia cells, 6263  
inhibitors of differentiation  
Abelson murine leukemia virus and SV40 retrovirus, mouse megakaryoblastic cell line, 4649
- Protein kinase C**  
activator lyngbyatoxin A  
cellular sensitization, *cis*-diamminedichloroplatinum(II), 2511  
activity and multidrug resistance  
lymphoblastic leukemia, trimetrexate resistance, 55  
altered activity in biopsies  
human colonic adenomas and carcinomas, 205  
altered intracellular calcium regulation  
colorectal cancer, "normal" adjacent mucosa, 4492  
antitumor activity of UCN-01  
murine and human tumor models, 4888  
*c-myc* gene-induced alterations  
*myc-ras* gene complementation, 5514  
down-regulation  
correlation with melanocyte growth, 3281  
induction of agonist effects by staurosporine  
maturation, normal and neoplastic keratinocytes, 4677  
inhibition of cell proliferation  
B859-35, 5821  
inhibition of inositol phosphate formation  
hexadecylphosphocholine, 807  
isozymes  
various types, human leukemic cells, 4271  
mediation of tumor necrosis factor gene expression  
activation by ionizing radiation, 4565  
modulation of lymphocyte proliferation, 82  
phosphorylation  
12-*O*-tetradecanoylphorbol-13-acetate, *sn*-dioctanoylglycerol, 4624
- prostatin**  
nonpromoting phorbol ester, mouse skin, 5355
- translocation**  
reversible and phorbol ester-specific defect, 130  
vacuole formation and cytokeratin rearrangement  
teleocidin, hepatoma cells, 2677
- Protein serine kinase**  
human *PIM-1* gene product, 2486
- Protein tyrosine phosphatase**  
genetic approaches to study  
molecular basis of human cancer, 5015s
- Proteoglycan**  
melanoma-associated antigen  
monoclonal anti-idiotypic antibodies, 3183  
partial characterization  
neoplastic and nonneoplastic breast tissues, 1443
- Protooncogenes**  
acivicin-induced monocytoid differentiation  
mRNA expression, myeloid leukemia cells, 1202  
activation  
spontaneously occurring non-liver tumors, 1148
- bcl2***  
differential expression, neuroblastoma, 6529
- c-erbB-2***  
immunoscintigraphy, 990  
monoclonal antibody, cisplatin cytotoxicity in breast and ovarian tumor cell lines, 4575  
risk of recurrent disease, node-negative breast cancer, 556  
chemical and physical carcinogenesis, 5023s
- c-jun***  
camptothecin and its derivatives, human myeloid leukemia cells, 6636
- c-kit***  
transcript expression, small cell lung cancer, 2416
- c-kit* and *hst-1***  
expression, human testicular germ cell tumors, 1811
- c-raf-1* and *c-myc***  
bronchial epithelial cells, lung carcinogenesis model, 3793
- dbl***  
preferential expression, tumors of neuroectodermal origin, 4234  
genetic analysis of human esophageal tumors  
high incidence geographic areas, 4102  
genetic approaches to study  
molecular basis of human cancer, 5015s  
inhibition of expression  
antisense oligodeoxynucleotides, 4505
- K-ras***  
codon 12 mutations, cholangiocarcinoma, 3497  
specific inhibition by antisense RNA, lung cancer cells, 1744
- N-myc* and *c-src***  
undifferentiated phenotype and prognosis, primary neuroblastoma, 3148
- pS2**  
expression and response to hormonal therapy  
advanced breast cancer, 624
- Pseudomonas* exotoxin**  
chimeric protein  
high-affinity interleukin 4 receptors, murine sarcoma cells, 3011  
insulin-like growth factor I and recombinant fusion protein, cytotoxic activity, 174  
-interleukin 6 chimeric molecules  
human hepatocellular carcinoma in mice, 2831  
-monoclonal antibody conjugates  
therapy, cervical carcinoma, 4001  
-tumor growth factor- $\alpha$  fusion protein  
antitumor activity, 2808
- Psoralen**  
photoadducts  
differential introduction and repair, specific human genes, 2867  
ultraviolet A radiation and growth of melanoma cells, 5893  
5-(2-Pyrazinyl)-4-methyl-1,2-dithiole-3-thione  
protection  
aflatoxin B<sub>1</sub>-induced hepatocarcinogenesis, 5501
- Pyrazoloacridine**  
pharmacokinetics in Rhesus monkey, 5467
- Pyrrolidino-4-iodotamoxifen**  
4-iodotamoxifen and treatment of breast cancer, 5851

Q

- Quinoline derivative**  
MS-073  
circumvention of multidrug resistance, 2420

R

- Radiation**  
-induced cancer  
oncogenic mechanisms, 2740  
-induced fibrosarcoma-1  
<sup>14</sup>N nuclear magnetic resonance spectroscopy, 3378  
-induced fibrosarcoma-1 tumor metabolism and blood flow  
glucose and mannitol effects, nuclear magnetic resonance, 3108  
-induced human sarcoma  
*p53* gene mutations, abnormal retinoblastoma protein, 6393  
ionizing  
*cis*-diamminedichloroplatinum(II) and, resistance patterns, 4523  
G<sub>2</sub> block, cyclin B expression in HeLa cells, 5113  
pazelliptine and, additive and supraadditive interaction, 3204  
supercoiled DNA and, interaction within human cells, 3857  
tissue-type plasminogen activator, malignant melanoma cells, 5587  
topotecan and, synergistic cell killing, 5813

# SUBJECT INDEX TO VOLUME 51

- tumor necrosis factor gene expression, protein kinase C, 4565
- leukemia virus  
induction, preleukemic cells, 2179
- 193-nm  
DNA damage, mammalian cells, 288
- oncology  
past achievements, ongoing controversies, 5065s
- photon  
stem cell sensitization and then protection, interleukin 1 $\beta$ , 2280
- protection against late effects  
S-2-(3-aminopropylamino)-ethylphosphorothioic acid, 4125
- repair of damage  
autocrine effects of fibroblast growth factor, endothelial cells, 2552
- sensitivity  
local tumor control, melanoma xenografts, 4609
- therapeutic  
young age, secondary thyroid neoplasms, 2885
- tumor oxygenation and  
interstitial hypertension, carcinoma of uterine cervix, 6695
- uptake and distribution  
specific and control monoclonal antibodies, subcutaneous xenografts, 3251
- Radioconjugates**  
monoclonal antibody  
integrated microscopic-macroscopic pharmacology, 4821
- Radioimmunotherapy**  
generator-produced rhenium-188  
direct radiolabeling of monoclonal antibodies, 4594
- interferon enhancement  
colon carcinoma, 2335
- <sup>186</sup>Re  
small cell lung carcinoma xenografts, nude mice, 676
- Radioiodination**  
monoclonal antibodies  
improved efficacy, *N*-succinimidyl-3-(tri-*n*-butylstanny)benzoate, 4164
- Radionuclides**  
antibodies labeled with <sup>131</sup>I  
infusion, biodistribution and dosimetry, 5921
- monoclonal antibody conjugation to drugs  
induction of immunogenicity, 5774
- Radiosensitization**  
fluorodeoxyuridine-mediated modulation  
iododeoxyuridine incorporation, colon cancer, 3900
- Radiotherapy**  
factors influencing mutation  
*hprt* locus in T-cells, breast cancer, 6603
- improvement in therapeutic ratio  
indomethacin plus misonidazole, murine sarcoma, 3639
- yttrium-90-labeled anti-Ly1 monoclonal antibody  
graft-*vs*-host disease, major histocompatibility barrier, 1891
- T cell lymphoma, 1883
- ras**
- activated alleles  
human prostatic carcinoma, 1632
- carcinogen-induced lymphomagenesis  
*pim*-1 transgenic mice, 958
- codon 61 mutation  
thyroid tumors, iodide-deficient area, 2690
- inhibition of cell growth by lovastatin, 712
- low frequency of mutations  
neuroectodermal tumors, 1596
- ras p21**  
similarity of *smg* p21A  
low molecular weight G proteins, normal and malignant tissues, 2223
- RC-160**  
RC-3095 and  
inhibitory effect, nitrosamine-induced pancreatic cancer, 5980
- Receptors**  
androgen  
extracellular matrix, transformed prostate fibroblasts, 1910
- B16-F1 melanoma autocrine motility factor, 3507
- bound plasminogen activator  
malignant transformation, fibroblasts, 1221
- 1,25-dihydroxyvitamin D<sub>3</sub>  
human carcinomas, 2021
- prognosis, breast cancer, 239
- epidermal growth factor and insulin-like growth factor-I  
autocrine stimulation, esophageal carcinoma, 1898
- epidermal growth factor  
antitumor activity, transforming growth factor- $\alpha$ /PE40, 2808
- cellular growth response, colon carcinoma, 1452
- expression in human gliomas, 2164
- hematopoietic cell line, 150
- heterogeneity of cells, feline mammary carcinoma, 4028
- H-*ras* induction of invasive phenotype, papillary transitional cell carcinoma cells, 4486
- $\alpha$ -interferon, human epidermoid cancer cells, 1294
- $\alpha$ -interferon, renal carcinoma cells, 5881
- lack of down-regulation, tumorigenesis of NR6 cells, 6170
- negative tumors, estradiol receptor-positive primary breast cancers, 4544
- reactive monoclonal antibodies, 5471
- spontaneous melanoma metastasis, suppression in SCID mice, 2193
- squamous carcinoma, paraneoplastic syndromes, 2438
- transforming growth factor- $\alpha$  and, primary human ovarian cancer, 5322
- transforming growth factor- $\alpha$ , autocrine growth mechanism in ovarian cancer, 5951, 5956
- estrogen**  
antiestrogen with clinical potential, 3867
- binding to specific DNA target site, breast cancer, 3405
- c-erbB-2* and, prognostic significance in breast cancer, 3296
- constitutive transcriptional activity, breast tumor, 105
- ER-binding platinum complex, breast cancer, 3217
- hormone-dependent and hormone-independent Grunder strain mouse, 3843
- interleukin 1 $\alpha$ , MCF-7 cells, 1488
- prognosis, breast cancer, 239
- estrogen and progesterone  
normal female breast, 1817
- Fc**  
low-affinity, antibody-dependent tumor cell phagocytosis, 1117
- Fc $\gamma$ RII**  
polyoma virus-transformed cells, 612
- fibronectin  
increased tumorigenicity, Chinese hamster ovary cell variants, 1738
- glucocorticoid  
CCRF-CEM cells, 5224
- growth factor  
cytogenetic abnormalities, normal bronchial epithelium and lung cancer, 400
- insulin-like growth factor  
transcriptional mechanism, *c-myc*, 5997
- insulin-like growth factor I  
ovarian cancer, 5107
- interleukin 1  
interleukin 1 $\alpha$  and etoposide, melanoma cells, 769
- interleukin 2  
biological monitoring, cytokines and cell surface phenotypes, 6312
- interleukin 3  
inhibition of growth by monoclonal antibody, mouse leukemic cell lines, 4355
- interleukin 4  
lung tumors and normal lung, 261
- murine sarcoma cells, chimeric protein, 3011
- laminin**  
complementary DNA-deduced synthetic peptide, inhibition of cancer cell attachment, 5672
- M**, 80,000/105,000  
binding of thrombospondin, human carcinoma cells, 3648
- motility factor**  
lung colonization capacity, melanoma cells, 2699
- natural folates and antifolate compounds  
membrane transport, L1210 leukemia cells, 5507
- nicotinic cholinergic**  
uptake and metabolism, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 2009
- nuclear receptor subtype-selective activities  
retinoids, 4804
- platelet-derived growth factor  
autocrine transformation, 5087
- progesterone**  
DNA binding, R5020 and RU486, 3938
- prognosis, breast cancer, 239
- prostaglandin E<sub>2</sub>

- mammary tumor metastasis, 2047  
retinoic acid  
  abnormal expression and keratin 19,  
  oral and epidermal squamous cell  
  carcinoma, 3972  
*sigma* opioid  
  non-neural tumors, 6558  
soluble  
  increased serum levels, tumor necrosis  
  factor, 5602  
T-cell  
  CD3 complex, discordant gene and  
  surface expression, 6084  
  genes in T-cell neoplasms, acute lym-  
  phoblastic leukemia, 6103  
T-cell  $\beta$ -chain  
  methylation status, B precursor acute  
  lymphoblastic leukemia, 2917  
  *ras* oncogene mutations, thymic lym-  
  phoma, 1627  
T-cell V $\beta$  gene  
  tumor-infiltrating lymphocytes, pri-  
  mary and metastatic melanoma,  
  5565  
thrombospondin  
  distinct domains, human carcinoma  
  cells, 1645  
transferrin  
  immunotoxin, leukemic hematopoietic  
  progenitors, 536  
transforming growth factor- $\alpha$   
  activation pathway, human squamous  
  carcinoma cells, 6254  
truncated glucocorticoid  
  P1798 mouse lymphosarcoma, 2786  
urokinase  
  facilitation of extracellular matrix in-  
  vasion, colon cancer, 3690  
**Rectum**  
  mucosal cell proliferation  
  nonfamilial neoplasia, large intestine,  
  1917  
**Red blood cells**  
  rigidity  
  tumor blood flow, hyperglycemia,  
  2727  
**Renal neoplasms: see** Kidney neoplasms  
**Rep78**  
  inhibition of H-*ras* expression, 3373  
**Reproduction**  
  factors  
  colorectal cancer risk, Chinese fe-  
  males, 2307  
  hormones and  
  uveal melanoma, women, 1370  
**Respiration**  
  disruption of cellular energy balance  
  suramin, prostatic carcinoma, 6629  
**Respiratory disease**  
  lung cancer in women, 4893  
**Retinoblastoma**  
  aberrations of tumor suppressor p53  
  hepatocellular carcinoma, 5520  
  abnormal protein and p53 gene muta-  
  tions  
  radiation-induced human sarcoma,  
  6393  
  absence of protein expression  
  primary non-small cell lung carci-  
  noma, 2735  
  gene inactivation  
  human bladder and renal cell carci-  
  noma, 5736  
  locus  
  frequent loss of heterozygosity, human  
  esophageal cancers, 5766  
  molecular genetic alterations  
  human bladder cancer, 5405  
  *RB* gene-reconstituted cells  
  intraocular tumor suppression, 6381  
  reconstituted cells  
  intraocular tumor formation, 4481  
**Retinoic acid**  
  dibutyl cyclic adenosine 3':5'-mono-  
  phosphate and  
  differentiation of neuroblastoma, inter-  
  feron, 3958  
  synergistic inhibition  
  phorbol ester-induced transformation,  
  JB6 cells, 1158  
  12-*O*-tetradecanoylphorbol-13-acetate or  
  tumor progression, murine epidermal  
  cells, 4701  
**All-trans-Retinoic acid**  
  inhibition of growth  
  human rhabdomyosarcoma cells, 4882  
**Retinoids**  
  abnormal expression of retinoic acid re-  
  ceptors  
  oral and epidermal squamous cell car-  
  cinoma, 3972  
  alteration of regulation by immortaliza-  
  tion  
  ectocervical epithelial cell differentia-  
  tion, papillomavirus type 16, 3982  
  nuclear receptor subtype-selective activi-  
  ties, 4804  
  prevention of primary prostate cancer  
  *N*-(4-hydroxyphenyl)retinamide, 3610  
**Retrovirus**  
  hybrid human endogenous  
  calbindin and, prostate cell line PC3,  
  4107  
  *in situ* transfer of v-Ha-*ras*  
  carcinoma induction, mammary epi-  
  thelial cells, 2642  
  SV40 and Abelson murine leukemia vi-  
  rus  
  induction of differentiation, protein ki-  
  nase inhibitors, 4649  
**Rhabdomyosarcoma**  
  *dbi* protooncogene  
  preferential expression, 4234  
  human neural and striated muscle cells  
  CD56 and CD57, 1300  
  inhibition of growth  
  all-*trans*-retinoic acid, 4882  
  melphalan-resistant xenograft  
  therapeutic analysis, 3906  
  stages of human fetal skeletal muscle de-  
  velopment  
  muscle-specific gene expression, 5100  
**Rhenium-188**  
  generator-produced  
  direct radiolabeling of monoclonal an-  
  tibodies, radioimmunotherapy, 4594  
**Ribonucleotide reductase**  
  inhibition  
  2-chloro-9-(2-deoxy-2-fluoro- $\beta$ -D-ara-  
  binofuranosyl)adenine, 2386  
  gallium, murine leukemic L1210 cells,  
  6199  
**Ricin**  
  blocked  
  preparation of immunotoxin, thera-  
  peutic use, 6235  
**Ricin A chain**  
  deglycosylated  
  covalent binding of  $\alpha_2$ -macroglobulin,  
  1482  
  immunotoxins  
  potentiation, monensin in lipid emul-  
  sion, 4316  
  intracellular trafficking  
  ligand effects, anti-ricin hybridomas,  
  1689  
*M*, 30,000 form  
  pharmacokinetics and tumor localiza-  
  tion, immunotoxins, 4219  
  Phase I immunotoxin trial  
  B-cell lymphoma, 4052  
  <sup>90</sup>Y-labeled C110 anti-CEA antigen im-  
  munotoxin  
  preclinical assessment, colon cancer,  
  255  
**RIF-1 neoplasms**  
  combination therapy  
  lonidamine, hyperthermia and chemo-  
  therapy, 5910  
  5-fluorouracil metabolism  
  <sup>19</sup>F magnetic resonance spectroscopy,  
  1384  
**RNA**  
  antisense  
  specific inhibition of K-*ras*, lung can-  
  cer cells, 1744  
   $\alpha$ -fetoprotein  
  adult rat liver, 4656  
  growth factor  
  human malignant melanoma, 4815  
  inhibition of primer formation  
  fludarabine triphosphate, CCRF-CEM  
  leukemia cells, 1829  
  oxidative damage by nitroalkanes  
  liver, 3143  
  posttranscriptional regulation  
  SV40 T antigen, DNA polymerase- $\alpha$   
  genes, 1465  
**RNA, messenger**  
  acivicin-induced monocytoid differentia-  
  tion  
  myeloid leukemia cells, 1202  
  cathepsin B  
  stage-specific increases, colorectal car-  
  cinoma, 1137  
  control of carcinoembryonic antigen  
  gene family  
  differentiating colon carcinoma, 3526  
  cyclic AMP-dependent protein kinase  
  normal vs. neoplastic mouse lung epi-  
  thelial cells, 6699  
  cytokine  
  alveolar macrophages and blood  
  monocytes, lung cancer, 857  
  discordant gene and surface expression  
  T-cell receptor/CD3 complex, 6084  
  enhanced promoter activity  
  human *M*, 72,000 type IV collagenase  
  gene, metastatic cell line, 6190  
  hepatic  
  arylsulfotransferase IV, hepatocarcino-  
  genesis, 504  
  insulin-like growth factor receptor  
  transcriptional mechanism, *c-myc*,  
  5997  
   $O^6$ -methylguanine DNA methyltransfer-

ase activity  
streptozotocin/bis-chloroethylnitrosourea combination therapy in HT-29 cells, 1581  
novel gene sequences  
molecular subtraction, melanoma, 1418  
plasminogen activation system  
human colon cancer, 4067  
single 3.7-kilobase  
hybridization to immediate-early promoter-enhancer, cytomegalovirus in HL-60 and acute myeloid leukemia cells, 4724  
splicing patterns  
neural cell adhesion molecule, lung cancer cell lines, 6019  
tissue lipoprotein lipase activity  
tumor-induced alterations, 863  
type II inosine 5'-monophosphate dehydrogenase  
human leukemias, 3886  
**RNase**  
growth factor messenger RNA expression  
human breast fibroblasts, benign and malignant lesions, 4979  
lactoferrin and polymorphism  
normal leukocytes, leukemic cells and breast cancer, 3039  
**Rosette**  
neural formation within *in vitro* spheroids  
extracellular matrix components, teratocarcinoma cell line, 2655  
**RP 56976**: see *Taxotere*  
**RU486**  
R5020 and  
DNA binding, progesterone receptor, 3938  
**Ruthenium**  
platinum and titanium complexes  
DNA damage, ovarian tumor cells, 2943

S

**S 12363**  
preclinical antitumor activity, 2312  
**Salivary gland**  
histopathology of tumors  
H-ras oncogene, 3762  
**Salmonella abortus equi**  
Phase I trial  
cancer patients, 2524  
**Salmonella typhimurium**  
mutagenicity  
fjord- and bay-region diol-epoxides, 1659  
**Salt**  
enhanced induction of gastric carcinogenesis  
N-methyl-N'-nitro-N-nitrosoguanidine, 2863  
**Saporin**  
deliverance to lymphoma  
comparative mixtures, bispecific F(ab')<sub>2</sub> antibodies, 2353  
**Sapporo Cancer Seminar**  
tenth annual meeting, 745  
**Sarcoma**  
-associated antigens

monoclonal antibody identification, 3768  
**Ewing's**  
cell surface antigen, biochemical and genetic characterization, 336  
follow-up study of twenty-four families  
Li-Fraumeni syndrome, 6094  
high-affinity interleukin 4 receptors  
cytotoxicity, chimeric protein, 3011  
improvement in therapeutic ratio  
radiotherapy, indomethacin plus missonidazole, 3639  
increased glutathione peroxidase  
doxorubicin resistance, 521  
**Kaposi's**  
supernatants, endothelial cell chemotaxis and invasiveness, 2670  
promoting effect of snuff  
4-nitroquinoline-N-oxide, 7,12-dimethylbenz(a)anthracene, 4388  
radiation-induced  
p53 gene mutations, abnormal retinoblastoma protein, 6393  
reticulum cell  
transforming gene, neoplasia, 744  
**Schwann**  
-like cell lines  
inducible expression, calcyclin, 1733  
**SCID**: see *Severe combined immunodeficiency disease*  
**SDZ PSC 833**  
circumvention  
P-glycoprotein-mediated multidrug resistance, 4226  
**Selenite**  
dietary  
inhibition, 7,12-dimethylbenz(a)anthracene-induced mammary tumors and DNA adducts, 4613  
**Selenium**  
chemical form  
critical metabolites, cancer prevention, 595  
**Senescence**  
human and hamster cells  
down-regulation of cdc2, 6010  
**Serum**  
carcinoembryonic antigen  
tumor-associated glycoprotein-72 levels, interferons, 4155  
levels of dehydroepiandrosterone and its sulfate  
risk, development of bladder cancer, 1366  
small cell lung cancer-associated ganglioside  
immunochemical detection, 2879  
urinary androgens and  
risk of breast cancer, postmenopausal women, 2572  
**Severe combined immunodeficiency disease**  
antitumor activity of Fab' and IgG-anti-CD22  
human B lymphoma grown in SCID mice, 5876  
growth and metastasis  
fresh human melanoma tissue, 4937  
**Sex hormone-binding globulin**  
serum and urinary androgens  
risk of breast cancer, postmenopausal women, 2572

**Sex organs**  
accessory  
invasive carcinoma, rats, 1264  
**Shuttle vector**  
human  
construction, single nitrogen mustard interstrand, 2268  
N-methyl-N-nitrosourea-induced mutations  
O<sup>6</sup>-methylguanine-DNA methyltransferase-deficient cells, 6219  
**Sialic acid**  
N-glycolylneuraminic acid expression  
human cancerous tissues, avian lymphoma cell lines, 1242  
**Simian virus 40**  
immortalization of milk epithelial cells  
loss of heterozygosity, short arm of chromosome 11, 294  
retrovirus and Abelson murine leukemia virus  
induction of differentiation by protein kinase inhibitors, megakaryoblastic cell line, 4649  
**T-antigen**  
immortalized esophageal epithelial cells, 365  
posttranscriptional regulation, DNA polymerase- $\alpha$  gene, 1465  
**Sister chromatid exchange**  
induced chromosome damage  
individual susceptibility, genotoxic exposures, 5266  
metabolism and single-strand breaks  
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, vitamin A, 3846  
**Skin**  
carcinogenesis  
diet and calorie restriction, Sencar mouse model, 1851  
inhibition of induction  
phorbol 12-myristate 13-acetate of ornithine decarboxylase, mouse, 5355  
papilloma  
promoter independence, 1045  
phorbol ester-elicited tumor promotion  
dietary fat, 907  
progression of squamous carcinoma to spindle carcinoma  
H-ras alleles on chromosome 7, 4097  
tumor promoter-treated  
common genetic pathway, 1398  
formation, oxidized DNA bases, 4443  
**Skin neoplasms**  
altered O<sup>6</sup>-alkylguanine-DNA alkyltransferase  
cell strains, UV irradiation, 2425  
epidermal morphogenesis and keratin expression  
c-Ha-ras-transfected tumorigenic clones, 4402  
growth of melanoma  
local effect, ultraviolet radiation, 4176  
hairless mice  
discontinuation, ultraviolet irradiation, 979  
ultraviolet-irradiated shuttle vector plasmid  
point mutations, 3177  
ultraviolet radiation-induced, in *Mono-dphis domestica*  
photoreactivation, 6539

# SUBJECT INDEX TO VOLUME 51

- SN-38**  
intracellular roles  
antitumor effect, CPT-11, 4187
- Snuff**  
promoting effect  
4-nitroquinoline-*N*-oxide, 7,12-dimethylbenz(a)anthracene, 4388
- Sodium ascorbate**  
*H-ras* mutations  
bladder tumors, 3471
- Sodium butyrate**  
glycosylation and  
transcriptional regulation, germ cell alkaline phosphatase, 2058
- Sodium saccharin**  
AIN-76A diet  
lack, bladder tumor promoting activity, 1778  
*H-ras* mutations  
bladder tumors, 3471  
sodium ascorbate and  
bladder tumor promoting activity, 1766
- Solutol HS 15**  
reversal of multidrug resistance, 897
- Somatic cells**  
hybrids  
predominance of metastatic phenotype, murine melanoma, 6292
- Soy sauce**  
dietary  
inhibition, benzo(a)pyrene-induced mouse forestomach neoplasia, 2940
- Species differences**  
metabolic activation and inactivation  
1-nitropyrene, liver, 3919
- Spermidine**  
-spermine *N*<sup>1</sup>-acetyltransferase activity  
polyamine pool deletion, melanoma, 3715
- Spheroids**  
multicellular  
self-diffusion of water, magnetic resonance imaging, 4072  
multicellular tumor  
cellular energetics, phosphorus nuclear magnetic resonance spectroscopy, 3831
- Spleen**  
leukocytes  
cytokine gene expression, flavone acetic acid, 6596  
polyethylene glycol-cultured cells  
adoptive chemimmunotherapy, plasmacytoma, 4516
- Squamous cell**  
hyperplasia  
regression, forestomach lesions, 318
- SR-2508**  
cyclophosphamide and  
Phase I study, 1099
- SRI 62-834**  
modulation of tumor cell membrane permeability  
multiparametric flow cytometry, 799
- Starch**  
malabsorption  
fecal bile acids and neutral sterols, colonic carcinogenesis, 4238
- Staurosporine**  
induction of protein kinase C agonist effects
- maturation, normal and neoplastic keratinocytes, 4677
- Stem cells**  
initial sensitization and subsequent protection  
photon radiation, interleukin 1 $\beta$ , 2280
- Steroidogenesis**  
murine Leydig tumor cell  
effect of 4-hydroxyandrostenedione, 3663
- Steroids**  
contraceptive  
carcinogenicity, diethylstilbestrol, 3311  
1,25-dihydroxyvitamin D<sub>3</sub> receptors and human colorectal adenocarcinoma, normal mucosa, 1227  
influence of estrogens  
natural history, Sinclair swine cutaneous melanoma, 2025  
silver-stained nucleolar organizer regions  
norethindrone, Ishikawa cells, 5987  
stimulation of apolipoprotein D secretion  
inhibition of cell proliferation, prostate cancer cells, 4336
- Sterols**  
neutral  
starch malabsorption, colonic carcinogenesis, 4238
- Stomach neoplasms**  
urinary excretion of nitrate  
*N*-nitrosoproline, 3-methyladenine and 7-methylguanine, 190
- Streptozotocin**  
bis-chloroethylnitrosourea combination therapy  
*O*<sup>6</sup>-methylguanine DNA methyltransferase, messenger RNA levels in HT-29 cells, 1581
- Stroma**  
human breast fibroblasts  
growth factor messenger RNA expression, benign and malignant lesions, 4979  
regulation of cell growth  
nerve growth factor-like protein, human prostate, 3304  
tumor  
plasminogen activation system, human colon cancer, 4067
- N*-Succinimidyl-3-(tri-*n*-butylsilyl)benzoate**  
improved therapeutic efficacy  
radioiodination, monoclonal antibody, 4164
- Sugar**  
accessible epitopes  
colon cancer-associated mucins, monoclonal antibody AM-3, 5342
- Sugar chains**  
antibody-lectin enzyme immunoassay  
myeloma IgG, 5888
- Sulfomucin**  
colonic  
identification, specific monoclonal antibody, 5728
- Superantigens**  
elimination of V $\beta$ 2 bearing T-cells  
preneoplastic and neoplastic mammary lesions, 3331
- Superoxide dismutase**
- colon cancer  
gene expression, complementary DNA, 939
- Suramin**  
disruption of cellular energy balance  
prostatic carcinoma, 6629  
inhibition of growth  
human osteosarcoma xenografts, nude mice, 3585

## T

- TAG 72**  
coexpression of different antigenic markers  
CA 125 determinants, 468  
elevation of serum carcinoembryonic antigen  
interferons, 4155  
epitopes in colorectal cancer, 5378  
normal and transformed endometrium  
diagnosis, postmenopausal patients, 3001  
pan carcinoma monoclonal antibody  
CC49  
construction, binding properties, 6363
- Tamoxifen**  
factors influencing mutation  
*hprt* locus in T-cells, breast cancer, 6603
- ICI 182,780**  
antiestrogen with clinical potential, 3867  
metabolites and  
distribution in rat and human tissues, steady-state treatment, 4837  
P-450-mediated activation and irreversible binding  
proteins in rat and human liver, 6052  
pS2 expression and response  
advanced breast cancer, 624  
pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen  
treatment of breast cancer, 5851
- Tannic acid**  
tumor promoter-induced ornithine decarboxylase activity  
mouse epidermis, 2820
- Taxotere**  
experimental antitumor activity, 4865
- T-cells**  
autotumor-reactive clones  
tumor-infiltrating lymphocytes, liver metastasis of gastric carcinoma, 6153
- CD8<sup>+</sup>**  
positive selection from blood and lymph nodes, head and neck cancer, 3891
- curative effect**  
*N,N'*-bis[3-(ethylamino)propyl]-1,7-heptanediamine, L1210 leukemia, 62
- cytotoxic T-lymphocytes**  
protein core of mucin molecule, breast adenocarcinoma, 2908
- factors influencing mutation**  
*hprt* locus, breast cancer treatment, 6603
- fetal**  
*hprt* gene deletion, VDJ recombinase-like activity, 6001

# SUBJECT INDEX TO VOLUME 51

- genetic approaches to study  
molecular basis of human cancer,  
5015s
- immunization with haptenized tumor  
cells  
inflammation, melanoma metastases,  
2731
- interferon-induced inhibition  
spontaneous metastases, melanoma,  
1124
- neoplasms  
T-cell receptor gene configurations,  
6103
- peripheral blood  
adoptive immunotherapy, LAK cells  
and interleukin 2, 1494
- recognition  
HLA-A2 antigen, human melanoma  
cell lines, 3164
- targeted antitumor responses  
host survival, human ovarian carci-  
noma, 5716
- V $\beta$ 2 bearing  
elimination of, preneoplastic and neo-  
plastic mammary lesions, 3331
- Telocidin**  
differential activation and inhibition  
lymphocyte proliferation, 82  
vacuole formation  
cytokeratin rearrangement, hepatoma  
cells, 2677
- Tenascin**  
qualitative and quantitative changes  
fibronectin, lung fibroblast and lung  
tumor tissues, 4876  
secretion by human melanoma cells,  
4853
- Teniposide**  
camptothecin or 4'-(9-acridinylamino)-3-  
methanesulfon-*m*-aniside  
degradation of nuclear DNA, S phase  
of HL-60 cells, 1165
- etoposide and  
mechanisms of resistance, colon and  
lung carcinoma, 5275
- podophyllotoxin glucoside to etoposide  
chemical and biological route, 5
- Teratocarcinoma**  
cell line  
neural rosette formation within *in vitro*  
spheroids, 2655
- Terpenoids**  
nonintercalative  
heat-stable topoisomerase II-DNA  
cleavable complex, 2922
- Testis cells**  
topoisomerase II levels and chemosen-  
sitivity, 6592
- Testosterone**  
androgen-sensitive cancer  
thyroid hormone, 4323  
high-fat diet and patterns of prostatic  
cancer  
*N*-nitrosobis(2-oxopropyl)amine, 4757  
peripheral hormone levels  
prostatic cancer, benign prostatic hy-  
perplasia, 3445  
serum and urinary androgens  
risk of breast cancer, postmenopausal  
women, 2572
- Testosterone propionate**  
3,2'-dimethyl-4-aminobiphenyl and  
invasive carcinoma, accessory sex or-  
gans, 1264
- Tetrachloro-(*d,l*-trans)-1,2-diaminocyclo-  
hexaneplatinum(IV)**  
unexpected biotransformation pathway  
L1210 cell line, 969
- 12-*O*-Tetradecanoylphorbol-13-acetate**  
formation of oxidized DNA bases  
treated mouse skin, 4443  
induction of protein kinase C agonist ef-  
fects  
staurosporine, normal and neoplastic  
keratinocytes, 4677  
mechanism of G $_2$  inhibition  
HeLa cells, 4328  
retinoic acid or  
tumor progression, murine epidermal  
cells, 4701  
*sn*-1,2-dioctanoylglycerol and  
phosphorylation, protein kinase C,  
4624
- 4 $\beta$ -12-*O*-Tetradecanoylphorbol-13-acetate**  
**4 $\alpha$ -12-*O*-tetradecanoylphorbol-13-acetate**  
and  
arachidonate release, epidermal cells,  
850
- Tetrahydrofolate cofactor**  
highly glycosylated methotrexate mem-  
brane carrier  
K562 cells, 3420
- Tetrazolium**  
-based assays for cellular viability  
parameters, formazan production,  
2515
- Thermoresistance**  
loss of intrinsic heat resistance  
*M*, 70,000 expression, human x ham-  
ster hybrids, 2636
- Thermotolerance**  
HSP-28 and HSP-70 genes  
leukemic and nonleukemic human tu-  
mors, 6608
- Thioimidazolines**  
cytotoxicity  
human malignant cell lines, 43
- Thiol**  
cellular glutathione and  
surgically resected lung tumor, normal  
lung tissue, 4287  
melphalan-resistant multiple myeloma  
development of cell line, 995
- Thiopurinol**  
2,6-dithiopurine and  
inhibition of binding, benzo(*a*)pyrene  
diol epoxide to DNA in epidermis,  
4859
- Thiopyrimidines**  
cytotoxicity  
human malignant cell lines, 43
- Thiotepa**  
combined with ethacrynic acid  
Phase I study, 6059  
oxygenation by constitutive hepatic P450  
enzymes  
drug metabolism and clearance, P450-  
inducing agents, 2340  
Phase I/pharmacokinetic reevaluation,  
3171
- Threonine**  
mouse immunotherapy, 1406
- Thrombin**  
fibrinogen deposition  
primary breast cancer tissue, 349  
inhibitor desulfatohirudin  
murine melanoma experimental me-  
tastasis, 4549
- Thrombospondin**  
binding of human carcinoma cells  
*M*, 80,000/105,000 receptor, 3648  
binding to surface of human osteosar-  
coma cells  
mediation, platelet-osteosarcoma cell  
interaction, 2621  
distinct domains  
receptor expression, human carcinoma  
cells, 1645
- Thromboxane A $_2$**   
urinary excretion and degradation prod-  
ucts  
prostacyclin, gestational choriocarci-  
noma, 4146
- Thy-1**  
negative growth regulator  
*ras*-transformed fibroblasts, 99
- Thymidine**  
inhibition of poly(adenosine diphos-  
phate-ribose) polymerase  
1,3-bis(2-chloroethyl)-1-nitrosourea,  
L1210 cells, 1586  
uptake  
glucose transporter expression,  
Chinese hamster ovary cells, 4450
- Thymidylate synthase**  
inhibition  
cell death, 2'-deoxyuridine-5'-triphos-  
phate accumulation, 2346  
inhibitor  
ICI D1694, L1210 tumor cell growth,  
5579  
monoclonal antibodies  
cytoplasm, human cells and tissue,  
6668
- Thymocytes**  
topoisomerase II-reactive chemothera-  
peutic drugs  
induction of apoptosis, 1078
- Thyroid**  
human tissues  
 $\alpha$ -amylase isozymes, 3544
- Thyroid hormone**  
androgen- or basic fibroblast growth fac-  
tor-induced proliferation  
Shionogi carcinoma 115 mammary  
carcinoma cells, 4323
- Thyroid neoplasms**  
high rates of *ras* codon 61 mutation  
iodide-deficient area, 2690  
medullary  
low frequency, *ras* gene mutations,  
1596  
secondary  
therapeutic radiation, young age, 2885  
survival and causes of death, 1234
- TIMP-1**  
immunologic quantitation  
colon cancer, 6231
- Titanium**  
platinum and ruthenium complexes  
DNA damage, ovarian tumor cells,  
2943
- Tn antigen**  
mouse immunotherapy, 1406
- Tobacco**  
extract

- carcinogenicity, vitamin A-deficient Sprague-Dawley rats, 3018
- specific nitrosamine
- 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, microsomal  $\alpha$ -hydroxylation, 5495
- use of
- fatal prostate cancer, 3067
- Topotecan**
- ionizing radiation and synergistic cell killing, 5813
- Toxins**
- monoclonal antibody conjugation to drugs
- induction of immunogenicity, 5774
- Tracheal epithelial cells**
- ornithine decarboxylase activation and expression
- asbestos and oxygen species, 167
- Transcatheter arterial embolization**
- evaluation of nontumorous tissue damage
- hepatocellular carcinoma, 5667
- Transforming growth factor**
- gene expression
- regulation by progestins, endometrial adenocarcinoma cells, 5476
- growth factors in hormone-related tumors, 4114
- Transforming growth factor- $\alpha$**
- altered expression
- hereditary rat renal cell carcinoma, 2973
- autonomous growth
- androgen-independent prostatic carcinoma cells, 2780
- c-myc** and
- clonal cosegregation of tumorigenicity, liver epithelial cells, 5238
- establishment of quiescent state, colon carcinoma cells, 2256
- epidermal growth factor and differential binding, human pancreatic cancer cell line, 6243
- epidermal growth factor receptor autocrine growth mechanism
- ovarian cancer cell line, 5951, 5956
- primary human ovarian cancer, 5322
- expression in human gliomas, 2164
- pathway in squamous carcinoma cells, 6254
- Pseudomonas** exotoxin fusion protein
- antitumor activity, 2808
- Transforming growth factor- $\beta$**
- anchorage-independent growth
- murine epithelial cells, 5898
- cell death
- cultured rat hepatocytes, 2478
- cell resistance to tumor necrosis factor cytotoxicity
- growth arrest, G<sub>1</sub> phase of cell cycle, 2379
- growth of highly enriched hematopoietic progenitor cells
- normal human bone marrow, peripheral blood, 4828
- messenger RNA and its polypeptide
- human hepatocellular carcinoma, 4080
- release from gastric carcinoma cells
- contraction, collagen-matrix gels containing fibroblasts, 3550
- synergistic inhibition
- phorbol ester-induced transformation, JB6 cells, 1158
- Transforming growth factor- $\beta$**
- basic fibroblast growth factor and localization, human mammary gland, 4685
- differential expression of gene
- 3LL metastatic variants, 5491
- induction of cachexia and systemic fibrosis
- without an antitumor effect, nude mice, 3590
- resistance to growth inhibitory effects
- transformation, rat liver epithelial cells, 5929
- Transplantation**
- bone marrow
- induction of graft vs. leukemia effect, interleukin 2, 2015
- human prostatic carcinoma
- nude mice, Matrigel, 3814
- tumor
- immunity and, 757, 5433
- Trichosanthin**
- monoclonal antibody conjugate
- cytotoxicity, human hepatoma cells, 3353
- N,N',N''-Triethylenephosphoramidate**
- N,N',N''-triethylenephosphoramidate and interaction, cellular DNA, 4360
- Trimethylamine**
- <sup>14</sup>N nuclear magnetic resonance spectroscopy
- tumors, 3378
- N,N,N'-Trimethylsphingosine**
- derivatives
- cell membrane signaling, target in cancer therapy, 1613
- inhibitory effect
- metastatic potential, B16 melanoma, 6138
- Trimetrexate**
- combined with *cis*-diamminedichloroplatinum(II)
- pharmacokinetic study, 3080
- resistance of lymphoblastic leukemia
- protein kinase C activity, multidrug resistance, 55
- 1,4,5-Triphosphate**
- altered intracellular calcium regulation
- colorectal cancer, "normal" adjacent mucosa, 4492
- Trophoblast protein-1**
- pregnancy recognition hormone
- antiproliferative activity, 5304
- Trypsin**
- tumor-associated
- cancer cell-mediated degradation, extracellular matrix, 2107
- Tryptophan**
- ascitic and solid tumor models
- interferon- $\gamma$  antitumor activity, ovarian cancer, 6643
- Tubulin**
- polymerization
- 4 $\beta$ -arylamino derivatives, 4'-*o*-demethylipodophyllotoxin, 1755
- Tumor-associated antigen**
- cloning of
- monoclonal antibodies, folate binding protein, 6125
- cytotoxic T-lymphocytes
- protein core of mucin molecule, breast adenocarcinoma, 2908
- monoclonal antibody BCA 227
- breast carcinoma, 1537
- Tumor growth**
- inhibition by tumor mass, 2
- population ecology issues, 2542
- Tumorigenesis**
- dietary dehydroepiandrosterone for chemoprevention
- premalignant colonic epithelium, 476
- elimination of V $\beta$ 2 bearing T-cells
- preneoplastic and neoplastic mammary lesions, 3331
- histopathology of salivary and mammary gland tumors
- H-ras, transgenic mice, 3762
- inhibition by 2,6-dithiopurine and thio-purinol
- binding of benzo(a)pyrene diol epoxide to DNA, mouse epidermis, 4859
- 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
- inhibition by arylalkyl isothiocyanates, lung, 1846
- O<sup>6</sup>-methylguanine, mouse lung, 5557
- non-downregulating epidermal growth factor receptors, 6170
- participation of p53 protein
- cellular response, DNA damage, 6304
- role of chromosome rearrangements
- deletions, point mutations, 5440
- Tumorigenicity**
- clonal cosegregation
- c-myc and transforming growth factor- $\alpha$ , liver epithelial cells, 5238
- fibronectin receptor deficiency
- Chinese hamster ovary cell variants, 1738
- increases in
- sensitivity to cytotoxic agents, human fibroblasts, 1855
- loss
- Had-1, composition of glycolipids, 1701
- reduced
- $\gamma$ -interferon, murine tumor cells, 1185
- tumor invasion and metastasis
- positive and negative regulation, 5054s
- tumor necrosis factor sensitivity
- MCA102 tumor cell immunogenicity, ultraviolet irradiation, 6209, 6210
- Tumor markers**
- relative operating characteristic analysis
- group modeling, breast carcinoma, 1904
- Tumor necrosis factor**
- cachectin
- decrease in catalase activity, rat liver, 3990
- cell resistance
- growth arrest, G<sub>1</sub> phase of cell cycle, 2379
- effect of ultraviolet irradiation
- MCA102 tumor cell immunogenicity, 6209, 6210
- expression by human ovarian carcinoma, 4476
- gene expression
- mediation by protein kinase C, activation by ionizing radiation, 4565
- gene expression in tumor cells

# SUBJECT INDEX TO VOLUME 51

- reduced tumorigenicity and invasive-  
ness, 2229
- increased serum levels  
soluble receptors, cancer patients,  
5602
- inhibition of cytokine-induced lipogene-  
sis  
interleukin 4, 2803
- interleukin 2 and  
preclinical study, canine neoplasms,  
233
- liposomal-lipophilic  
preparation and characterization, 3362
- potentiation of antiproliferative effects  
interleukin 4, various tumor cell lines,  
4266
- resistance cells  
discrete types, derivation from same  
cell line, 2469
- separation of lethal and antitumor activi-  
ties  
induction of tolerance, 2366
- stimulation of epithelial tumor cell mo-  
tility, 5315
- tumor cell immunogenicity and sensitiv-  
ity  
ultraviolet irradiation, 1521
- Tumor necrosis factor- $\alpha$**   
 $\gamma$ -interferon and  
androgen-dependent and -independent  
prostatic tumors, 2329
- experimental model, cancer cachexia,  
2302
- $\gamma$ -interferon or  
interleukin 4, inhibition of cell growth  
in renal cell carcinoma, 5687
- interleukin 1 and  
tumor growth and development, can-  
cer cachexia, 415
- interleukin 2 and  
Phase I, advanced non-small cell lung  
cancer, 3669
- interleukin 4 and  $\gamma$ -interferon  
modulation, melanoma cells, 2002
- intravenous  
administration three times weekly,  
1651
- Tumor progression**  
allelotype study  
primary hepatocellular carcinoma, 89
- $\beta$ 1-6 branched oligosaccharides as  
marker  
breast and colon neoplasia, 718
- inhibition of *c-myc* expression  
phosphorothioate antisense oligonu-  
cleotide, growth of breast cancer,  
3996
- invasive and growth factor-independent  
cell variants  
primary human melanomas, 2205
- keratinocyte model  
dysregulation, parathyroid hormone-  
like peptide expression, 6521
- loss of prolactin dependency  
karyotypic changes, lymphoma cell  
cultures, 282
- murine epidermal cells  
12-*O*-tetradecanoylphorbol-13-acetate  
or retinoic acid, 4701
- mutator phenotype  
multistage carcinogenesis, 3075
- overexpression of oncogene products  
lack of parenchymal infiltration, brain,  
3595
- somatic allelic deletion  
*nm23* in human cancer, 2490
- Tumor promotion**  
ethyl phenylpropionate, 5642
- induced ornithine decarboxylase activity  
tannic acid and other polyphenols,  
mouse epidermis, 2820
- reversible and phorbol ester-specific de-  
fect  
protein kinase C translocation, 130
- skin  
common genetic pathway, promoting  
agents, 1398
- formation, oxidized DNA bases, 4443
- Tumors: see also specific type**  
**immunity**  
transplantation, 757
- solid**  
measurement, capillary filtration coef-  
ficient, 1352
- mitomycin C and porfiromycin, poten-  
tiation by interleukin 1 $\alpha$ , 5454
- toxicity, micelle-forming polymeric an-  
ticancer drug, 3229
- solid and ascitic**  
interferon- $\gamma$  antitumor activity, ovar-  
ian cancer, 6643
- Tumor suppressors**  
accumulation of genetic alterations  
progression, primary breast cancer,  
5794
- adeno-associated virus Rep78  
inhibition of *H-ras* expression, 3383
- allelotype of renal cell carcinoma, 820
- E*-cadherin expression  
squamous cell carcinoma, lymph node  
metastasis, 6328
- chemical and physical carcinogenesis,  
5023s
- genetic approaches to study  
molecular basis of human cancer,  
5015s
- loss of somatic heterozygosity  
hepatocellular carcinoma, 4367
- intraocular tumor suppression  
*RB*-reconstituted retinoblastoma cells,  
6381
- mammary carcinoma suppressor gene  
*v-H-ras* oncogene transfer, mammary  
epithelial cells, 5298
- molecular genetic alterations  
human bladder cancer, 5405
- origin and development of renal cell car-  
cinoma  
molecular analysis, 1071
- radiation-induced human sarcoma  
*p53* gene mutations, abnormal retino-  
blastoma protein, 6393
- Tyrosine**  
phosphorylation of *M*, 150,000 kDa pro-  
tein  
insulin-like growth factor I, metastatic  
colon cancer, 5859
- Tyrosine kinase**  
differential binding and biological activi-  
ties  
epidermal growth factor, transforming  
growth factor- $\alpha$ , 6243
- induction of differentiation by genistein  
erythroleukemia cells, 764
- Tyrphostins**  
antiproliferative effects  
squamous cell carcinoma, 4430
- U**
- Ubiquitin**  
changes in gene expression  
renal cancer cells, 6677
- U-937 cells**  
cytotoxic effect of *cis*-parinaric acid,  
6144
- UCN-01**  
antitumor activity  
murine and human tumor models,  
4888
- UDP-glucuronosyl transferase**  
inhibition of glucuronidation  
benzo(a)pyrene phenols, long-chain  
fatty acids, 4511
- Ultraviolet A**  
psoralen and  
growth of melanoma cells, 5893
- Ultraviolet irradiation**  
altered *O*<sup>6</sup>-alkylguanine-DNA alkyltrans-  
ferase  
cell strains, mouse skin tumors, 2425
- discontinuation  
development, skin tumors in hairless  
mice, 979
- DNA excision repair in cell extracts  
hypersensitivity, 3384
- increased immunogenicity and sensitivity  
natural cell-mediated cytotoxicity,  
5153
- induced murine tumors  
absence, UV-induced systemic tumor  
immunosuppression, 2773
- induced skin and eye tumors in *Mono-*  
*delphis domestica*  
photoreactivation, 6539
- induction of melanocytic tumors  
hairless mice, 4964
- local effect on melanoma growth  
immunological mediation, 4176
- MCA102 tumor cell immunogenicity**  
tumor necrosis factor sensitivity, 6209,  
6210
- tumor cell immunogenicity and sensitiv-  
ity  
tumor necrosis factor, 1521
- Ultraviolet light**  
-irradiated shuttle vector plasmid  
point mutations, xeroderma pigmento-  
sum, 3177
- sensitive mutants for excision repair  
formation, complementation groups 9  
and 10, 3965
- Urethane**  
quantitative analysis of genetic suscepti-  
bility  
liver and lung carcinogenesis, mice,  
6299
- Uridine**  
nucleotides  
regulation of deoxycytidine kinase, hu-  
man leukemia cells, 2559
- Urinary tract**  
disease  
bladder cancer, 629
- Urine**  
clonal growth of human bladder cancer

cell lines, 4631  
epidermal growth factor  
tumor-promoting effect, rat urinary  
bladder carcinogenesis, 5487  
frequency  
adduct formation, 4-aminobiphenyl,  
4371  
**Uroepithelial cells**  
nonrandom chromosome losses  
stepwise neoplasia, 3323  
**Urokinase**  
-type plasminogen activator  
inhibition by antibodies, tumor dis-  
semination, 274  
primary and metastatic tumors, pul-  
monary adenocarcinoma, 3522  
**Uterus**  
endometrial carcinoma  
allelic loss on chromosome 17p, p53  
mutations, 5632  
premalignant and malignant epithelial  
lesions  
K-ras activation, 5308

**V**

**Vacuole**  
formation and cytokeratin re-  
arrangement  
teleocidin, hepatoma cells, 2677  
**Vascular leak syndrome**  
normal and microvascular endothelium  
interleukin 2-induced leukocyte adhe-  
sion, dextran sulfate, 1561  
**Vasculature**  
microvascular architecture  
mammary carcinoma, 265  
**Vasopressin**  
stimulation of clonal growth  
small cell lung cancer, 3621  
**V79 cells**  
hypoxic and aerobic cytotoxicity  
Mitomycin C, 6622  
**VDJ recombination**  
-like activity  
hprt gene deletion, fetal T-cells, 6001  
**Verapamil**  
cyclosporin A and  
modulation of multidrug resistance,  
human leukemia cell lines, 1749  
doxorubicin and  
buthionine sulfoximine effect, multi-  
drug resistant cells, 67  
**Vinblastine**  
drug-sensitive and multiple drug-resist-  
ant cells  
secretion, lysosomal enzymes, 1996  
**Vinca alkaloids**  
derivative S 12363  
preclinical antitumor activity, 2312  
epidermal growth factor receptor-reac-  
tive monoclonal antibodies  
immunoconjugates, xenograft anti-  
tumor activity, 5471

mechanism of inhibition  
cell proliferation, 2212  
-monoclonal antibody immunoconjugate  
solid tumor membrane antigen, anti-  
gen-antibody complexes, 2965  
single and multiple dose clinical studies  
human immune response, LY256787  
and LY20378, 2286  
**Vinorelbine**  
-loaded polymeric bioresorbable implants  
local treatment, solid tumors, 5384  
**Vitamin A**  
-deficient Sprague-Dawley rats  
carcinogenicity, tobacco extract, 3018  
metabolism and sister chromatid ex-  
change  
4-(methylnitrosamino)-1-(3-pyridyl)-1-  
butanone, 3846  
**Vitamin D**  
calcium and colon cancer, 3069  
deficiency  
K-ras mutations, 1,2-dimethylhydra-  
zine-induced colonic tumors, 4305  
dietary calcium and  
colonic carcinogenesis, 5608  
**VLA-4**  
melanoma cell adhesion  
cytokine-activated endothelial cells,  
2239  
**von Willebrand factor**  
photosensitized release  
cultured human endothelial cells, 3261  
**VP-16: see Etoposide**

**W**

**Walker 256 cells**  
morphological and phenotypic analysis,  
1334  
**Water**  
self-diffusion  
multicellular spheroids, magnetic reso-  
nance imaging, 4072  
**Wick-in-needle technique**  
interstitial hypertension  
superficial metastatic melanoma, 6691  
**Wilms' tumor**  
histologic and clinical features  
correlation, chromosome abnormali-  
ties, 5937  
**Women**  
lung cancer, 4893  
**WR2721**  
S-2-(3-aminopropylamino)-ethylphos-  
phorothioic acid  
protection, late effects of radiation,  
4125

**X**

**Xenografts**  
antitumor activity  
epidermal growth factor receptor-reac-  
tive monoclonal antibodies, 5471  
ascitic and solid tumor models

interferon- $\gamma$  antitumor activity, ovar-  
ian cancer, 6643  
**A431 tumors**  
modification of growth rates, hypoxic  
fractions, 4111  
**colon tumor**  
hyperthermia,  $^{111}\text{In}$ -labeled hapten to  
bifunctional antibody, 1515  
**HT-29 human colon cancer**  
inhibition of growth, bombesin/gastrin  
releasing peptide antagonist, 6006  
**human cancer**  
complete growth inhibition, 20-(S)-  
camptothecin, 3052  
**human osteosarcoma**  
inhibition of growth, suramin, 3585  
**human tumor**  
microdistribution, rat monoclonal an-  
tibodies to mouse tissues, 1529  
**large-animal human brain tumor model**  
immunosuppressed cats, 2430  
**MDR1-mediated resistance**  
camptothecin, human KB carcinoma  
cells, 6039  
**melanoma**  
cellular radiation sensitivity, local tu-  
mor control, 4609  
**melphalan-resistant human rhabdo-  
myosarcoma**  
therapeutic analysis, 3906  
**monoclonal antibody-based therapy**  
 $^{177}\text{Lu}$ -labeled immunoconjugate,  
2889  
**ovarian carcinoma**  
malignant behavior, resistance to cis-  
platin, 6358  
**preclinical antitumor activity**  
penclomedine, mice, 1979  
**small cell lung carcinoma**  
 $^{186}\text{Re}$  radioimmunotherapy, nude mice,  
676  
**subcutaneous**  
uptake and distribution, specific and  
control monoclonal antibodies, 3251  
**targeted T-cell antitumor responses**  
human ovarian carcinoma, 5716  
**Xeroderma pigmentosum**  
clinical symptoms  
DNA repair characteristics, 3456  
**point mutations**  
ultraviolet-irradiated shuttle vector  
plasmid, 3177

**Y**

**Yttrium-90**  
C110 anti-carcinoembryonic antigen im-  
munotoxin  
preclinical assessment, colon cancer,  
255  
-labeled anti-Ly1 monoclonal antibody  
radiotherapy, graft-vs-host disease,  
1891  
radiotherapy, T cell lymphoma, 1883